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1 Summary 
Cationic peptides have shown their potency to efficiently enhance cellular uptake of 
covalently coupled molecules. In order to avoid their rapid degradation by peptidases, diverse 
classes of peptide mimics like peptoids, ß-peptides, and oligocarbamates were exploited. 
Polyamines, although bearing high density of positive charges at physiological pH, found 
only less regard for the purpose to act as covalently coupled drug delivery agents.  
To solve problems, which occurred during the synthesis of polyamines, a solid phase 
strategy was developed, which especially allows the generation of acid sensitive polyamine-
conjugates. On the strongly acid labile trityl linkers, which allow the mild cleavage from the 
resin, the Aloc group was introduced into polyamine chemistry, to serve for the permanent 
protection of the backbone amines. Fukuyama alkylation was identified as the method of 
choice for backbone elongation. Compatibility with the protection group strategy was 
demonstrated and the reaction conditions were optimised. Finally, Fukuyama alkylation 
allowed the introduction of a variety of functional groups, which could not be used with other 
frequently used alkylation methods. The  combination of trityl linker and Aloc-, o-Nosyl-, and 
Dde-protection groups allowed branching by introduction of side chains on particular amines 
of the backbone. For this, Reductive amination turned out to be the appropriate alkylation 
method. For the bioconjugation of polyamines, the Michael addition of thiols to maleimides 
was exploited, which already showed its utility to couple large molecules like 
oligonucleotides and peptides. After introduction of a maleimide to an immobilised 
polyamine, its reaction with different sulfides was investigated. It showed suitability to 
efficiently couple diverse sulfides of medium polarity on polystyrene resins. The vice versa 
strategy, integration of a thiol on the immobilised polyamine and coupling with maleimides 
was also investigated. The coupling with 2- iminothiolane showed to be superior to all other 
examined methods. An alkoxytrityl resins with even higher acid sensitivity than most 
commercially available resins, was prepared. On this resin, coupling with 2- iminothiolane 
allows the quick generation of polyamine conjugates under very mild conditions. The 
selectivity of 2- iminothiolane for primary amines supersedes the use of complex protection 
schemes. The synthetic methods were used to generate a variety of polyamine conjugates with 
nucleosides, fluorophores, porphyrin, Indomethacin, and a radical scavenger. Evaluation of 
some of these conjugates by fluorescence microscopy showed enhanced cellular uptake. 
Intensive investigation on the amphiphilic polyamine-porphyrin conjugate showed a 
mitochondrial localisation. Irradiation caused severe cell damage. Co-cultures of mammalian 
cells with tumour cells or bacteria, respectively, showed a beneficial differentiation between 
those cell types. As the uptake into tumour cells was faster than into bacteria, which was 
again faster than that into mammalian cells, the compound is a candidate for application in 
photodynamic therapy. Toxicological data for most of the tested compounds were determined 
by the MTT assay. 
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Zusammenfassung 
Kationische Peptide haben ihre Potenzial bewiesen, die zelluläre Aufnahmen kovalent 
gebundener Moleküle zu verbessern. Um ihren schnellen Abbau durch Peptidasen zu 
verhindern wurden unterschiedliche Klassen von Peptidmimetika, wie Peptoide, ß-Peptide, 
and Oligocarbamate untersucht. Polyamine, welcher ebenfalls eine hohe Dichte an positiven 
Ladungen bei physiologischem pH-Wert tragen, wurden bereits für die Komplexierung 
negativ geladener Moleküle wie beispielsweise DNA verwendet. Allerdings fanden sie zum 
jetzigen Zeitpunkt kaum Beachtung als kovalent gebundener Transporter für die zelluläre 
Aufnahme von Wirkstoffen.  
Um die Probleme zu lösen, die im Laufe der Polyaminsynthese gewöhnlich auftreten, wurde 
eine festphasengebundene Synthesestrategie entwickelt, die vor allem der Darstellung 
empfindlicher Polyaminkonjugate dienen soll. Während stark säurelabile Trityllinker eine 
milde Abspaltung erlauben, wurde die Alloc-Gruppe, welche als permanente Schutzgruppe 
für die Amine des Rückgrades fungiert, in die Polyaminchemie eingeführt. 
Fukuyama-Alkylierung wurde als Methode der Wahl für die Verlängerung des Rückgrades 
identifiziert. Die Kompatibilität mit der gewählten Schutzgruppenstrategie wurde gezeigt und 
die Reaktionsbedingungen optimiert. Zusätzlich wurde gezeigt, dass die 
Fukuyama-Alkylierung die Einführung unterschiedlicher funktioneller Gruppen erlaubt, deren 
Verwendung bei anderen Alkylierungsmethoden nicht möglich wäre. Die Kombination von 
orthogonalem Trityl-Linker, Aloc-, o-Nosyl- und Dde-Schutzgruppe erlaubte Verzweigung 
durch selektive Einführung von Seitenketten an bestimmten Aminen des Rückgrades. Hierbei 
zeigte sich Reduktive Aminierung als probate Alkylierungsmethode.  
Für die Biokonjugation von Polyaminen wurde die Michael-Addition von Thiolen an 
Maleimide gewählt, welche bereits ihre Verwendbarkeit für die Kupplung großer Moleküle 
wie Oligonucleotide und Peptide gezeigt hat. Nach Bindung eines Maleimides an das 
immobilisierte Polyamin wurde dessen Reaktion mit Sulfiden untersucht. Es zeigte sich, dass 
die Reaktion geeignet ist, Sulfide mittlerer Polarität an Polystorenharzen zu kuppeln. Die 
umgekehrte Strategie, Einführung eines Thiols an ein immobilisiertes Polyamin und Bindung 
an Maleimide wurde ebenfalls untersucht. Kupplung mit 2-Iminothiolan zeigte sich gegenüber 
allen anderen untersuchten Methoden als überlegen. Ein Alkoxytritylharz mit hoher 
Säurelabilität wurde hergestellt. An diesem Harz erlaubte die Kupplung mit 2-Iminothiolan 
eine schnelle Darstellung von Polyaminkonjugaten unter sehr milden Bedingungen 
durchzuführen. Die Selektivität von 2-Iminothiolan für primäre Amine macht die 
Verwendung von komplexen Schutzgruppen-Schemata überflüssig. Diese synthetischen 
Methoden wurden verwendet um Polyaminkonjugate mit Nucleosiden, Fluorophoren, 
Porphyrin, Indomethacin und einem großen aromatischen Radikalfänger darzustellen. 
Untersuchung einiger dieser Konjugate durch Fluoreszenzmikroskopie zeigte verstärkte 
zelluläre Aufnahme. Intensive Untersuchung des amphiphilen Polyamin-Porphyrinkonjugates 
in Fibroblasten, HeLa-, HepG2- und COS7-Zellen zeigte dessen mitochondriale 
Lokalisierung. Bestrahlung verursachte schwerewiegende Zerstörung der Zellen. Co-Kulturen 
von Säugetierzellen und Tumorzellen bzw. Bakterien zeigten eine vorteilhafte 
Differenzierung zwischen diesen Zelltypen. Da die Aufnahme in Tumorzellen stärker war als 
die in Bakterien und diese wiederum stärker als die in Säugerzellen, ist die Verbindung ein 
Kandidat für den Einsatz in der photodynamischen Therapie. Die toxokologischen Daten der 
meisten dargestellten Polyaminkonjugate wurden mit dem MTT-Test bestimmt. 
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2  Introduction 
2.1 Drug delivery 
2.1.1 The problem of restricted bioavailability 
A limiting factor in the application of drugs and biologically active target molecules is often 
their low uptake efficiency. Many drugs, which have shown their potency in in vitro assays, 
are restricted in their in vivo application by their low biodistribution after oral application. The 
efficiency of an in vivo treatment largely depends on the targeting of active compounds into 
specific organs, cell types, and even the right cellular compartments. Based on empirical data, 
the L´ipinski rule of five´ points towards the bioavailability of potential drug molecules.[1, 2] 
These rules are: 
· Five or less hydrogen bond dona tors (for example OH- or NH groups) 
· Ten or less hydrogen bond acceptors (for example oxygen or nitrogen) 
· A molecular mass below 500 g / mol 
· A partition coefficient (log P) of five or lower 
The number of potential drug molecules is strongly limited by such restrictions. In order to 
evolve the full potential of modern high throughput drug delivery strategies, it is of great 
interest to find ways to enhance the bioavailability of drug candidates. Especially the 
transfection of DNA and RNA into cells is crucial in the establishment of gene therapy. To 
reduce uptake problems, several invasive methods have been developed, for example 
electroporation[3-7], microinjection[8], and particle guns[9-18]. Encapsulation into liposomes[19-
24], micro- and nanoparticles, and supramolecular structures (cyclodextrins[29] and dendrimers) 
showed good results especially for the delivery of DNA or RNA-oligomers. Viral delivery is 
also an efficient method, but is restricted in its use, and clinical applications also showed 
severe side effects.[30] A relatively novel field in research is the covalent coupling of drugs to 
carrier molecules, which facilitate cellular uptake. Naturally occurring members are the so-
called ´cell penetrating peptides´ (CPPs). They are virtually ´pre-optimized´ by evolution and 
can thereby act as helpful templates for synthetic analogues with improved properties. A 
detailed introduction into all above-mentioned classes of delivery agents would go beyond the 
scope of this thesis. Thus, dendrimers, covalently bound carriers, and polyamines are 
discussed in more detail, as they all share one common motif: Their positive net charge seems 
to be of major importance for their ability to enhance cellular uptake. In the course of this 
work, ´cellular uptake´ will be used as a collective term to describe uptake into any cellular 
compartment. The term ´molecular transporter´ will not stand for intrinsic cellular system like 
the polyamine transport system. ´Molecular transporter´ will be used for molecules, which 
enhance cellular uptake after covalent attachment. 
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2.1.2 Dendrimers 
In contrast to linear polymers, dendrimers optimally have a perfectly branched structure. 
Unlike the classical polymerization process, which results in linear polymers of different 
sizes, the mode of dendrimers-preparation gives precise control over the molecular size, 
structure, and physical properties.[31-38] This is especially important for triggering of the 
water-solubility of dendrimers using different building blocks. Dendrimers of lower 
generations (0 – 2) have a highly asymmetric shape and consist of a more open structure 
compared to their higher generation relatives. As the chains grow longer and the branching 
increases, the structure of higher generation dendrimers becomes globular and more densely 
packed. After reaching a critical branch state, further growing is inhibited by the lack of 
space, a phenomenon known as the starburst effect.[39] In contrast to initial expectations, it 
became obvious in recent years that with growing density of the outer shells, the dendrimers 
reduce the tension in their outer shells. This is accomplished by backfolding of the outer 
dendrons into their interior to fill the gaps, which are existent in the core generations.[40] 
 
 
Figure 1 Molecular encapsulation of drugs by a polypropyleneimine-dendrimer. A globular dendrimer with a 
dense amino acid shell can hold four molecules of Rose Bengal (shown in red) and many smaller molecules (not 
shown) inside the dendrimer's flexible cavities. R = benzyl.[8] 
While the hydrophilic shell of the dendrimers ensures water solubility, the interior can be 
hydrophobic[40-45], enabling dendrimers to incorporate hydrophobic drug molecules and 
release them slowly (Figure 1).[42] The core of the dendrimer can also be hydrophilic and 
carry even large, highly polar molecules like DNA. Acidic drugs such as the cytostatics 
methotrexate[41] and adriamycin can be incorporated by dendrimers with a basic interior. 
Prominent examples of basic dendrimers, which are generated starting from polyamine 
building blocks, are polyamidoamines (PAMAM). Drug release systems with a hydrophobic 
shell cause problems in native systems due to aggregation and low solubility.[46] In addition, 
surface modification with poly(ethylene glycol) (PEG) yielded dendrimers with a 
biocompatible surface, since the polymer coating enhances circulation half- life by two orders 
of magnitude. After some of the widely used dendrimers had been shown to be toxic, 
biodegradable and biocompatible dendrimers were developed.[47] Cationic dendrimers 
displaying amino groups on the outer shell, which are protonated at lower pH values, are 
generally hemolytic and cytotoxic. Their toxicity is generation-dependent and increases with 
the number of protonated amines on the surface. The putative pathway for cellular entry of 
dendrimer-DNA complexes seems to be endocytosis.[48] The complexes are entrapped into 
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endocytic vesicles that originate from the invagination of the cell surface membrane. 
However, it is still unknown whether the complexes interact with the membrane surface or are 
simply captured with the extra-cellular fluid that is taken up by pinocytosis.[8] Once inside the 
cell, the endocytic vesicle fuses with the acid endosomal compartments.[49, 50] It is obvious 
that positive net charge is important for this uptake mechanism. 
 
2.1.3 Covalently bound carriers 
In contrast to dendrimers, liposomes, and other core shell architectures, covalent attachment 
of transport molecules to drugs can enhance the stability of coupled cargo.[8]  
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Figure 2 Known naturally and synthetic polycationic molecules, which can enhance cellular uptake of covalent 
coupled cargo.[51] 
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By covalent attachment, distinct structures with exact ratios of functional units are formed. 
This is especially beneficial in terms of identifying the pharmacokinetics of such 
conjugates.[52] Non-covalently bound delivering agents have to be formulated with the 
respective drug molecules and it his hard to predict the exact composition of such 
formulations. The procedures can cause inhomogeneities, whose effect on the outcome cannot 
be determined. A summary of some covalently bound uptake enhancers is shown in Figure 2. 
 
2.1.3.1 Cell penetrating peptides 
Cell penetrating peptides (CPPs), are structures provided by nature, which can serve as 
templates for the development of other peptido mimetica with improved cellular uptake. In 
the late 80ies, a novel class of protein domains was discovered that could enter the cells in a 
receptor and, as it was then believed, in an energy-independent fashion carrying the rest of the 
protein into the interior of the cells.[8, 53] In the past, this novel way of intracellular delivery 
was termed “protein transduction”, and the responsible peptide sequences from native 
proteins were referred to as protein transduction domains (PTD). In the following, the term 
CPPs will be used to describe both, protein transduction domains and cell penetrating 
peptides. 
 
Figure 3 Sequence of the active domain of the HIV-TAT protein. It mainly consists of the basic amino acids 
lysine (17) and arginine (20). Uncharged residues give HIV-TAT an amphiphilic overall structure.[8] 
It has been shown that isolated CPPs are able to introduce a variety of covalently bound 
cargo into almost all cell types.[54] As described for a variety of proteins, CPPs are well suited 
as fusion tags, which transport the rest of the protein through membranes. Prominent 
members of this family are the HIV-TAT domain, HSV VP22, penetratin, antennapedia, and 
transportan. It was shown that the enhancement of cellular uptake mainly depends on the 
integrity of short sequences of these CPPs, which mainly consist of basic residues (Figure 3). 
These short domains delivered several cargos into cells with nearly the same efficiency as the 
full CPPs. Consequently, short homooligomers of lysine (17),[55] ornithine (18)[56], and 
arginine (20)[56] were also shown to efficiently enhance cellular uptake of cargos. 
Development of optimized CPPs resulted in candidates, which are even more efficient than 
the naturally occurring CPPs. The amphipathic KLAL (HO-KLALKLALKALKAAKLA-
NH2) was one of the first synthetic peptides derived from naturally occurring peptides. In a 
comparison study with natural CPPs it showed to be more efficient in cargo transport than 
transportan, TAT48-60 and, penetratin. In the beginning of CPP research it was believed that 
these cationic amphipathic peptides enter the cells either in inverse micelles or by just flipping 
through the membrane after inserting the hydrophobic part into the membrane while bound to 
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negatively charged molecules on the surface of the cells. This theory has recently been proven 
wrong.[57-60] Due to a paraformaldehyde fixation of the cells after treatment, the CPPs are 
mislocalised to the nucleus of the cells leading to a misinterpretation of the mechanism of 
cellular entry. Revised experiments in live cells revealed that endocytosis is involved in the 
uptake of most of the CPPs.[57, 61-63] However, complete interruption of the endocytic 
pathways mainly inhibits but does not exclude the cellular uptake of CPPs. To date, it is 
believed that most of the CPPs bearing cationic residues enter the cells either by clathrin-
mediated endocytosis, macropinocytosis or caveolin-mediated endocytosis dependent on their 
charge, their lipophilicity, and their cargo, while binding with their cationic moiety to the 
negatively charged proteoglycans on the extracellular surface of the cellular membrane.[8] 
Proteoglycans contain sugar groups, which are modified with sialic acids and sulfates and are 
differently distributed on different cell types, which probably explains their different cellular 
uptake.[64-67] Mutant cells defective for glycosaminoglycan synthesis showed dramatically 
reduced penetratin-  or TAT-mediated cellular uptake confirming the role of these complex 
polysaccharides in CPP-mediated cellular uptake.[8] Moreover, it has been shown that the 
cellular uptake efficiency is dependent on the cellular differentiation status. After endocytosis, 
most of the CPPs are entrapped and accumulated in macropinosomes or endosomal vesicles, 
while being slowly released into the cytosol or transported to other organelles. However, there 
are still debates on the exact mechanisms of endosomal escape. Albeit their improved cellular 
uptake efficiency, CPPs just have limited potential for the application in whole organisms, 
since they are rapidly degraded in the bloodstream by proteases, before they can be taken up 
by the specified tissue. This leads to high doses and subsequent treatments. Furthermore, 
besides several successful treatment reports largely cationic CPPs such as the HIV-TAT 
peptide or octa-arginines have to be shown to exhibit strong toxicity. Therefore, peptide 
analogues have been examined to overcome those problems. The best-investigated analogues 
so far are ß-peptides, peptoids, and oligocarbamates bearing basic side chains. 
 
2.1.3.2 b-Peptides 
b-Amino acid oligomers (“b-peptides”) have extensively been studied in recent years[68]. 
They can adopt a broader range of well-defined protein- like secondary structures than a-
peptides [69-72], and several b-peptides with interesting biological activities have been reported. 
For example, synthetic b-peptides were found to perform functions, which are naturally 
carried out by a-peptides. They can act as antagonists for somatostatin receptor hsst4 and as 
inhibitors of cholesterol transport through Caco-2-cells.[73, 74] Metabolic stability was 
observed in most mammalian, insect, and plant-cell cultures. Slow biodegradation was only 
observed in human kidney and in a sample of microorganisms. In this case, decomposition 
was not accomplished by one organism, but symbiotically by a colony of microorganisms. 
None of them was able to grow with the offered b-tripeptide as only C- or N-source.[75, 76] 
Since b-peptides are resistant to degradation by proteases[76], and their secondary structure can 
be controlled, they are useful analogues to peptidic molecular transporters and may help to 
elucidate the mechanism of translocation.[77]  
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Figure 4 Optimized b-peptide transporter.[78] 
Successful uptake experiments were carried out with b-homoarginine[79], b-homolysine[80], 
and b-TAT[81]. Peptide uptake was not completely suppressed in experiments at low 
temperature, in the presence of endocytosis inhibitors, under cell-energy-depletion conditions, 
or with microorganisms (E. coli and B.megaterium).[78] This is consistent with prior reports 
about b-peptide TAT47-59, suggesting that cellular uptake does not exclusively depend on 
endocytosis. The uptake of b-oligopeptides strongly depends on their chain length. As b-
tetraarginines only adsorb to the cell surface, b-decaarginines migrate rapidly to the 
nucleoli.[73, 74] The membrane translocation activity is preserved in b-peptides despite a drastic 
alteration in the oligomer backbone (amide group spacing) in comparison to the a-peptides. 
Since b-peptides are easily programmed to adopt specific conformations, they represent a 
platform that can be used to explore the effects of conformational constraints on cellular 
uptake activity. 
 
2.1.3.3 Peptoids  
“Peptoids” (poly-N-substituted glycines) are a diverse family of non-natural oligomers with 
close similarity to natural polypeptides. Sequence-specific peptoid oligomers are easily 
assembled from various primary amines with different functionalities using the solid-phase 
submonomer method and offer particular advantages for the design of biomimetic 
materials.[82, 83]  These polymers, pioneered by Zuckermann, are protease resistant, which 
makes them suitable transporters for in vivo applications.  The achiral backbone of oligo-N-
substituted glycines or “peptoids” lacks hydrogen-bond donors, which effectively prevent 
formation of the regular, intrachain hydrogen bonds that stabilize peptide R-helical structures.  
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Scheme 1 Optimized peptoid transporter and its synthesis.[51] 
Since the guanidinium groups of TAT49–57 play a greater role in facilitating cellular uptake 
than rather charge or backbone structure, Wender al. designed and synthesized a class of 
polyguanidine peptoid derivatives (Scheme 1).[84] Remarkably, the subset of peptoid 
analogues containing a six-methylene spacer between the guanidine head group and backbone 
exhibited significantly enhanced cellular uptake compared to TAT49–57 and even to 
polyarginine. These studies led to a transporter, which is superior to TAT49–57, protease 
resistant, and more easily prepared. Several revisions of the submonomer method were 
developed that allow efficient incorporation of unprotected imidazoles, pyridines, pyrazines, 
indoles, quinolines, and thiol containing functionalities into oligomers of up to 15 
monomers[85-87]. The incorporation of novel side chains should enable the synthesis of 
peptoids with entirely novel properties. In general, cationic peptoid polymers and cationic 
lipitoid polymers (peptoid-phospholipid conjugates) are efficient gene transfer molecules. 
Measurements revealed that the biophysical properties of DNA-polymer complexes (size, z-
potential, ethidium bromide exclusion) varied with polymer structure and complex (+ / -) 
charge ratio, but were not directly predictive of transfection efficiency.[88] A versatile and 
efficient solid phase approach has been developed for the synthesis of these cell permeable 
peptoid oligomers. These peptoids consisted of monomer units derived from ethyl 
bromoacetate and protected 1,6-hexanediamine. A series of fluorescein conjugates were 
constructed (Scheme 2). Fluorescence microscopy and FACS analysis indicated that these 
materials possessed the ability to be successfully taken up the cells. The uptake efficiency of 
the peptoids 11 was dependent on the number of monomer units of the oligomer. The 
heptamer exhibited maximum internalisation (> 99% of cells labelled). Cellular uptake was 
concentration-dependent, although cellular enrichment was evident in all cases.[51]  
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Scheme 2 Optimized peptoid transporter and its synthesis. Reagents and conditions: (a) 9, PyBrOP then 
piperidine; (b) 1. N-Fmoc-6-aminocaproic acid, PyBrOP, 2. piperidine, 3. carboxyfluorescine, PyBrOP, 4. TFA 
or ß-mercaptoethanol then TFA.[51] 
These findings complement reports by other groups, who have also indicated an enhanced 
uptake rate for the larger oligomers.[82] First studies in cells showed that in contrast to CPPs, 
the uptake of peptoid transporters is ATP-dependent and can be completely inhibited by the 
addition of sodium azide to the cultured cells prior to exposure to the peptoids. The uptake 
rate was also decreased at 20 °C, whereas no internalization was observed at 4 °C. These 
temperature-dependent results suggest the involvement of an endocytic pathway, which has 
been implicated in the transport of small organic molecules by poly-L-lysine, which shares 
some structural similarities with the peptoids. None of the peptoids were found to be toxic at 
concentrations up to 400 µM of the concentrations tested, which qualifies the peptoids as 
delivery agents for in vivo studies.[8, 51] 
 
2.1.3.4 Oligocarbamates 
Since guanidine-rich peptides and peptoids with 1,4-spaced side chains are superior to TAT49-
57 in cellular uptake[8], Wender et al. explored whether the amide backbone common to 
peptide and peptoid transporters could be replaced with a carbamate, and whether the 
resulting increased spacing and enhanced flexibility (1,4 to 1,6) would enhance uptake into 
cells and tissues.[84] 
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Figure 5 Optimized oligocarbamate transporters.[89] 
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A series of novel guanidine-rich oligocarbamates was prepared. The synthesis was designed 
to produce an oligoamine, which upon perguanidinylation would be converted to the desired 
oligoguanidine (Figure 5). The oligocarbamate 5-, 7-, and 9-mers of 12 were synthesized on 
solid phase with an automated peptide synthesizer. The ability of the oligocarbamates to 
enable cellular uptake was determined by FACS analysis of Jurkat cells that had been 
incubated with fluoresceinated oligomers. The pentacarbamate and pentaarginine conjugates 
displayed very limited cellular uptake. In contrast, the hepta- and nonacarbamate conjugates 
had entered virtually all cells after 3 minutes. The rate of uptake increased with guanidine 
content (8 > 7) and concentration, which corresponds to the behaviour of other TAT-related 
transporters.[84, 89] Carbamate 9-mer translocated into cells 2.3 times faster than a-Arg9, which 
was taken up into cells 100 times faster than TAT, making it one of the best guanidine-based 
transporters studied to date. 
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2.2 Polyamines 
2.2.1 Distribution and function inside the cell 
Polyamines are aliphatic molecules, carrying two or more amino functions.[90] Although the 
pKa-values of the several amino functions differ, they are usually all protonated at 
physiological pH-values. Consequently, polyamines appear in organisms as highly positively 
charged molecules and their function mainly relies on those polycationic properties. Some 
prominent aliphatic polyamines are shown in Figure 6. 
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Figure 6 Four of the most abundant polyamines in nature. Usually, they are protonated at physiological pH.[91] 
Besides their biosynthesis, a high amount of polyamines are obtained from diet and bacteria 
residing in the gut.[91] These polyamines are transported through the mucosa, presumably by 
passive diffusion through the paracellular pathway, and reach the systemic circulation. 
Eventually, they are distributed throughout the body and are widely implicated in cell growth, 
development of tissues and tissue repair. They have been involved in the growth not only of 
normal tissue but also of malignant tumours.[91] Furthermore, it has been implied that they 
play an important role in the development of the gut and the repair of gastric and duodenal 
injuries, as well as in other wound healing processes. Increase in polyamine levels in several 
other tissues has been associated with the normal growth and hypertrophy of several tissues 
such as skin, breast, kidney, and heart.[91] Since polyamines are protonated under 
physiological conditions, they can interact with many negatively charged or zwitterionic 
biomolecules such as DNA, RNA, proteoglycans, and phosphate groups of phospholipids, and 
negatively charged amino acids of proteins such as aspartate and glutamate.[92] Especially, 
spermine (16) has been shown to condense the DNA and chromatin, thus stabilizing DNA 
conformations such as triplexes, allowing either modulation of protein-DNA interactions or 
protection of DNA from degradation. The hydrophilicity / hydrophobicity of most polyamines 
is balanced, allowing them to perform physiological functions by interacting with some of 
these anionic structures, without impairing the functionality of others.[92] In addition to the 
genuine aliphatic polyamines, numerous naturally occurring polyamine conjugates have been 
isolated and characterized, displaying a broad range of biological functions and activities. 
These range from potent immunosuppressive agents such as deoxyspergualin, over 
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antibacterial and broad-spectrum antibiotics such as squalamine (35), Edeine A, 
guanidospermidine, and glycinamoylspermidine, to alkaloids such as wasp toxins and spider 
venoms.[92] Due to their cationic properties, polyamine moieties were found to enhance water 
solubility and cellular uptake of many therapeutic molecules, making them potential drug 
delivery agents. For most of the properties of polyamines, the biological mechanisms are not 
well understood or still in debate. Therefore, current research on natural and synthetic 
polyamines requires the synthesis of those compounds, as well as many derivatives in order to 
investigate their function and to obtain novel mimics for therapeutic applications. 
 
2.2.2 Biosynthesis of Polyamines 
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Scheme 3 Biosynthesis of the three most often appearing polyamines putrescine (13), spermidine (15), and 
spermine (16).[90, 91] 
The common biosynthetic pathway of spermine (Spm) (16) and spermidine (Spd) (15) starts 
with putrescine (Put) (13) (Scheme 3). Putrescine (13) is alkylated with a 3-aminopropyl 
building block by spermidine synthase, leading to spermidine (15), which is again alkylated 
by the spermine synthase, yielding spermine (16). The exclusive 3-aminopropylation on the 
second amino group derived from cadaverine illustrates that polyamine-forming enzymes are 
highly regiospecific. The 3-aminopropyl group is transferred from S-adenosylmethionine, 
which was previously decarboxylated by the S-adenosylmethionine decarboxylase. This 
alkylation is rather uncommon, since S-adenosylmethionine usually acts as a methylating 
agent. Finally, all the building blocks for the polyamine biosynthesis derive from amino acids, 
which are decarboxylated and activated for alkylation. Thus, the polyamine biosynthesis has 
common points with the citric acid cycle. 
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Scheme 4 Biosynthesis of cadaverine / putrescine (13) starting from lysine (17) / ornithine (18) in mammalian 
cells.[90, 91] 
The diamines putrescine (13) and cadaverine (14) are derived by decarboxylation of 
ornithine (18) and lysine (17), respectively (Scheme 4). Putrescine (13) has a special 
regulatory function in the spermine (16) / spermidine (15) biosynthetic pathway. It inhibits the 
ornithine decarboxylase (ODC), acts as Co-factor for the S-adenosylmethionine 
decarboxylase, and as substrate for the spermidine synthase. Consequently, the inhibition of 
ODC is a major target for the down-regulation of polyamine biosynthesis. Difluoromethyl 
ornithine (19) (DFMO) was developed as a potent inhibitor of ODC with strong effect on 
global cellular polyamine levels. Further contributing factors are discussed in chapters 2.2.2 
and 2.2.3. 
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Scheme 5 Biosynthesis of putrescine (13) starting from arginine (20) in plant cells.[90, 91] 
Plants lack ODC and derive putrescine (13) from decarboxylation of arginine and 
subsequent hydrolysis (Scheme 5). The unstable multifunctional enzyme putrescine synthase 
that combines the activities of agmatine iminohydrolase, putrescine transcarbamylase, 
ornithine transcarbamylase, and carbamate kinase, was purified from Lathyrus sativus. The 
catabolism of aliphatic polyamines is dominated by acetylation and oxidative deamination 
reactions (Scheme 6). The degradation of spermine (16) leads back to putrescine (13) via 
spermidine (15). The N1-position of either spermine (16) or spermidine (15) is acetylated by 
the acetyl-CoA dependent spermidine-N1-acetyltransferase. The ubiquitous FAD-containing 
polyamine oxidase (PAO) is capable of degrading the acetyl-derivative to 
3-acetamidopropanal and spermidine (15) or putrescine (13) respectively. 
N8-acetylspermidine is not oxidized by polyamine oxidase, also showing the regioselectivity 
of catabolic enzymes. It is noteworthy that the polyamine oxidase also degrades non-
acetylated polyamines, but with a significantly lower activity. The oxidative degradation of 
putrescine (13) represents an alternative route for the biosynthesis of c-butyric acid (GABA), 
which can replace the decarboxylation of L-glutamate by the pyridoxal phosphate (PLP)-
depending glutamic acid decarboxylase (GAD). Consequently, the inhibition of GAD 
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markedly increases ODC-activity, while decreasing S-adenosylmethionine decarboxylase, 
despite a rise in putrescine concentration.[93] 
 
1 = Ornithine decarboxylase (ODC) 
2 = S-Adenosylmethione decarboxylase (SAMDC)  
3 = Spermidine synthase 
4 = Spermine synthase 
5 = AcetyI-CoA: polyamine acetyltransferase (cytoplasmic) 
6 = Acetyl-CoA: spermidine NS-acetyltransferase (nuclear) 
7 = Polyamine oxidase (PAO) 
8 = Monoamine oxidase 
9 = Diamine oxidase (or other copper-containing amine oxidases)  
10 = Ornithine-2-oxoacid aminotransferase 
11 = 4-Aminobutyrat e: 2-oxoacid aminotransferase (GABA-T) 
12 = Glutamate decarboxylase (GAD) 
Scheme 6 The polyamine metabolism in human. (Image taken from Cohen, A guide to the polyamines, 1998)[94] 
Putrescine (13) is accepted by the acetyl CoA-dependent spermidine-N8-acetyltransferase 
for acetylation to N1-acetylputrescine, which is then oxidized to GABA by the monoamine 
oxidase. By systematic fractionation of rat urinary metabolites of radiolabelled putrescine 
(13), spermidine (15), and spermine (16), a lot of other metabolites were obtained.[95] 
Prominent members are 2-pyrrolidone, GABA, 2-hydroxyputrescine (from putrescine (13)), 
putreanine, isoputreanine, monacetylated polyamines (from spermidine (15)), spermic acid, 
and N8-(2-carboxyethyl)spermidine (from spermine (16)). Several catabolic intermediates 
deriving from the action of acetylases, oxidases and lactam forming cyclases were identified 
in mammalian tissues and sera.  
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Scheme 7 Biosynthesis of hypusine from lysine in eIF-5A.[91] 
Interestingly, the synthesis of the amino acid hypusine directly links the spermidine 
metabolism to the expression of the Eukaryotic translation initiation factor 5A (eIF-5A, see 
Scheme 7). The modification, consisting in the alkylation of the e-amino function of lysine by 
a 4-aminobutyl moiety and their subsequent hydroxylation in the ß-position appears to be 
posttranslational. Simultaneously, spermidine (15) is degraded to 1,3-diaminopropane (24).[91] 
 
2.2.3 Polyamine transport system 
Besides the rate of biosynthesis, the action of the polyamine transport system (PTS) has a 
great influence on the cellular concentration of polyamines. Although the rate of biosynthesis 
is high to maintain the level of polyamines in cells, it can be largely substituted by active 
transport into cells. This is supported by the failure of DFMO (19) to solely inhibit the 
compensatory growth of organs and tumours in vivo.[96-100] Likewise, the lifetime of mice 
incubated with mutant L1210 leukemia cell line deficient in polyamine transport was 
extended by 60 – 70% compared to mice incubated with the parental cells.[101] Nearly all cells 
are able to take up and secret polyamines. Tissues with a high demand, like prostate glands, 
tumours, and normal but rapidly proliferating cells take up polyamines in large amounts from 
the environment.[102-106] Polyamine uptake characteristics can vary, depending on the state of 
cellular growth and maturation of the organism. Nevertheless, several general features of the 
polyamine transport are common. Transport is 
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· energy and temperature dependent 
· saturable,  
· activated by Na+. 
The saturation suggests a carrier-mediated transport of the polyamines. Experiments in the 
absence of sodium suggest that in some cell lines, also a Na+ independent transport exists.[107] 
However, most cells seem to have only one polyamine transporter with growing affinity for 
increasing number of positive charges.[107] As it is least selective for putrescine (13), some 
cells also have an additional transport system for putrescine (13). Finally, little is known 
about the biochemical components, which are involved in the polyamine transport and several 
models exist for uptake mechanism.[52, 108, 109] Three important aspects of the polyamine 
transport system are of special interest to understand polyamine analogue effects on 
mammalian cells. The transporter has high affinity for spermidine (15) and spermine (16), the 
velocity of uptake is quite substantial and the transport system is feedback-regulated. The 
specificity of the transporter is not stringent.[112, 113], as it tolerates multiple analogues with 
methyl and ethyl substituents on the amines or in a-position.[114-117] In contrast, benzyl 
modifications on the amines appear to be too bulky to be transported by the uptake system of 
naturally occurring polyamines. However, experimental evidence exists that anti malaria 
active bis(benzyl)polyamine analogues are transported by a different mechanism.[118, 119] 
Especially the putrescine moiety of all polyamines seems to be tolerant as it can be replaced 
by cyclohexyl rings or unsaturations and bear free amino groups.[120-122] Aminooxy analogues 
are also taken up as well as fluorinated analogues.[123, 124] The uptake system is also shared by 
structurally only weakly related compounds like N,N´-dimethyl-4,4´-bipyridylium (Paraquat) 
(27) [125], mimicking 1,6-diaminohexane, and methylglyoxal-bis(guanylhydrazone) (MGBG) 
(28) [126-128], mimicking spermidine (15) (Figure 7). MGBG (28) also acts potent inhibitor of 
the S-adenosylmethionine decarboxylase.[129] 
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Figure 7 Compounds sharing the polyamine uptake system. 
Enhanced polyamine uptake is often coupled to increased de novo biosynthesis of 
polyamines. Factors, enhancing the formation of polyamines often also increase their uptake 
from environment. In E. coli, the genes coding for ODC and the putrescine transporter protein 
coexist on 16 min of the same chromosome.[130] Cells overexpressing ODC are unable to 
downregulate uptake and thus accumulate exogenous polyamines to toxic concentrations.[131-
133] Both, uptake and de novo biosynthesis of the polyamines are feedback-regulated by the 
cellular concentrations of the polyamines. The arginine (20) rather than the ornithine (18) 
concentration seems to have a strong influence on putrescine uptake.[134-136] At supra-normal 
concentrations of polyamines, antizyme proteins are expressed, which inactivate ODC 
complex formation and thus block de novo biosynthesis of polyamines at the biosynthetical 
starting point.[137-140] 
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Figure 8 Control of cellular polyamine levels by antizyme.(Image taken from Mitchell, Biochem. Soc. Transac., 
2007)[109] 
Antizyme also showed to have influence on the feedback control of polyamine uptake, 
unless the mechanism is not yet understood (Figure 8). Especially this feedback control of 
uptake is important, as the polyamine transporter is highly active and would otherwise over-
accumulate polyamines inside the cell. Cells of higher eukaryotes posses an antizyme-binding 
protein, termed antizyme inhibitor (AzI) that appears to be involved in lowering antizyme 
activity and closely interacts with polyamine levels.[143] Consequently, some tumour cell lines 
over-express antizyme inhibitor to enable accumulation of polyamines required for their 
aggressive growth.[144] Thus, exposure of cancer cells lines to antizyme stimulating polyamine 
analogues can efficiently suppress polyamine transport.[145] Besides lowering de novo 
biosynthesis and restricting uptake of polyamines, cells can also react by enhanced release of 
polyamines and acetylpolyamines. This export appears to be carrier mediated.[146] Uptake and 
export of polyamines are mediated by different transport systems, for which spermine (16) as 
well as spermidine (15) rather than putrescine (13) or other diamines seem to act as signalling 
compounds. However, spermine (16) is usually only released in minimal amounts.[147-149] It is 
either degraded to spermidine (15) or exported as its N1-acetyl derivative (Figure 9). 
Likewise, spermidine (15) is largely converted to putrescine (13) or its acetyl derivatives 
before excretion. The preferentially excreted polyamine derivative strongly depends on the 
environment. As the polyamine metabolism is linked to the amino acid metabolism, 
conversion into their oxidative deamination products displays another possible route for their 
degradation. However, since the required enzymes are not ubiquitously present, this way is 
restricted to selected tissues.[150] A coherence of polyamine transport and Ca2+ concentration 
is also described.[52, 151, 152] Exposure of cultured cells to putrescine (13) and spermidine (15) 
increased intracellular Ca2+. On the other hand, calmodulin antagonists inhibit ODC and 
polyamine uptake, suggesting a role of polyamines in the regulation of transmembrane 
signalling pathways as well as participation of Ca2+ in polyamine uptake mechanism.[152-154] 
Besides calcium ions, Mn2+ is an activator of polyamine uptake. Other divalent cations like 
Ba2+, Sr2+, Co2+, Ni2+, and Cu2+ also have either a weaker or opposite effect. 
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Figure 9 Major polyamine transport ways through the cell membrane their interconnection to the mayor 
biosynthetic pathways. The polyamines are mainly taken up in their native form. However, only putrescine (13) 
is released in significant amounts. Spermidine (15) and spermine (16) are converted to their acetyl-derivatives by 
SSAT prior excretion. (Image taken from Hahn, Schepers, in Combinatorial Chemistry on Solid Supports, 
2007)[92] 
 
2.2.4 Therapeutic applications of polyamines 
The described properties of polyamines make them suitable candidates for therapeutic use. 
The applications can be classified into five major groups:  
· DNA recognition and binding  
· Natural products of toxins and venoms  
· Polyamine conjugates with antibiotic, bactericidal, or antiparasitic properties 
· Cancer therapy 
· Drug delivery 
In all cases the efficacy of polyamines is either based on their high charge density, which 
enables strong interaction with negatively charged DNA, RNA, proteoglycans, and 
phospholipids, or it is based on the highly amphiphilic nature of polyamine conjugates with 
hydrophobic moieties. 
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2.2.4.1 DNA recognition and binding 
A number of studies have suggested that DNA is a major target of polyamines. As already 
described above, aliphatic polyamines have shown to either condense or bend DNA by 
binding to the nucleic acid via strong salt bridges, or disturb the DNA structure by introducing 
intercalating conjugates. Polyamine-DNA interactions play a pivotal role in DNA 
conformational transitions, condensation / decondensation, and stabilisation.[155, 156] 
Stabilisation of specific DNA conformations may be important for nucleosome formation, 
chromatin condensation, and gene expression. The binding of the polyamines alters the DNA 
structure from the common B-helix to the A and Z forms.[157] It also leads to aggregation at 
higher concentration. Such an effect might be important for the DNA physiology, as a tight 
correlation exists between the acquisition of the Z-Form and the transcriptional activity on 
DNA. The stability of the double helix increases with the ratio of the positively charged 
amino groups to the negatively charged phosphate groups.[158] Direct binding of polyamines 
to DNA and their ability to modulate DNA-protein interactions appear to be important in the 
molecular mechanisms of polyamine action in cell proliferation. Therefore, DNA-binding 
polyamines have the potential to exert anticancer activity. Interactions of polyamines with 
DNA were thoroughly studied in order to allow for the selective design of anticancer drugs by 
the synthesis of a series of analogues. Recent studies indicated that programmed cell death 
might be a common characteristic for polyamine analogue- induced cytotoxicity in cancer 
cells.[159-161] Interesting DNA-interacting polyamine analogues are naphthalimides and bis-
naphthalimides, N1-(anthracene-9-carbonyl)-spermine and N1,N12-bisaziridinyl-spermine, 
which have been shown to intercalate into the DNA backbone.[162-167] 
 
2.2.4.2 Natural products of toxins and venoms  
In the last couple of years research was focused on the synthesis of polyamines present in 
spider and wasp toxins such as Nephilatoxin-643 (NPhTX-643), philanthotoxin-433 (PhTX-
433) (33) and many other analogues. These natural products are mainly present in the venom 
glands of the spider or wasp and serve as a paralyzing toxin (Figure 10).[168, 169] Most of the 
polyamine toxins show a high degree of structural similarity, implying that the polyamine part 
of the toxin has an important function. The interest in these acylpolyamines arises from their 
ability to act as potent antagonists of the mammalian neuroexcitatory or ionotropic glutamic 
acid receptors (iGluR), or as inhibitors of the nicotinic acetylcholine receptors. The family of 
the iGluR comprises the N-methyl-D-aspartate (NMDA), the 2-amino-3-(3-hydroxy-5-
methyl-4- isooxazolyl)-propionic acid (AMPA), and the kainaite receptor. These are partially 
blocked by the polyamine toxins in an open cationic channel conformation.[169] Attempts have 
been made to exploit this interaction for the therapy or prevention of neurotoxicity, epilepsy, 
and neurodegenerative diseases.[170, 171] As described, for many polyamine toxins, the 
polyamine moiety is coupled via an amide bond to an aromatic moiety, mostly consisting of 
2,4-dihydroxyphenylacetyl, N-butoryl-tyrosine, or indol-3-acetyl moieties.  
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Figure 10 Naturally occurring spider and wasp toxins containing polyamine backbones.[169] 
 
2.2.4.3 Polyamine conjugates with antibiotic, bactericidal, or antiparasitic properties 
The emergence of multidrug resistant microorganisms such as the methicillin- resistant 
Staphylococcus aureus, vancomycin resistant Enterococcus, and drug resistant 
Mycobacterium tuberculosis, pushes the pharmaceutical industry to expand their research on 
novel classes of antibiotics.[172-174] Lipopolyamines are of particular interest. They are 
characterized by the presence of long-chain acyl- or alkyl substituents on polyamine scaffolds. 
Members of the lipopolyamine class bind lipo-polysaccharide (LPS), are effective in 
preventing endotoxic shock in animal models, and yet appear to be non-toxic both in vitro and 
in vivo.[175] Recent reports indicate a correlation between antiendotoxic and antibacterial 
activity in lipoamines with stable amide- linked acyl groups and in cationic amphipathic 
peptides[176-178]. Recent reports proved the interactions of a series of N-acylated homologated 
spermine compounds with LPS.[179] Importantly, they are also non-toxic due to their 
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biodegradation to physiological substituents (polyamine and CoA-fatty acid esters).[175, 180] In 
recent years, an interesting broadband antibiotic, squalamine (35) (3-b-N-1-(N-[3-(4-
aminobutyl)]-1,3-diaminopropane)-7-a-24-z-dihydroxy-5-a-cholestane-24-sulfate), has been 
isolated from the dogfish shark Squalus acanthias (Figure 11). Squalamine (35) is a cationic 
steroid characterized by a condensation of an anionic bile salt intermediate with spermidine 
(15) and exhibits potent antibiotic and microbiotic activity against both gram-negative and 
gram-positive bacteria, as well as against fungi.[174, 181] 
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Figure 11 Structure of Squalamine (35).[181] 
In addition, squalamine (35) induces osmotic lysis of protozoa and show antiangiogenic 
activity, making it useful for the treatment of different diseases such as lung, ovarian, brain 
and other cancers, as well as age-related macular degeneration (AMD) and the control of body 
weight in human.[181, 182] Its amphiphilic structure, derived from the hydrophilic spermidine 
chain and the hydrophobic sterol scaffold, enables squalamine (35) to interfere with 
membrane lipids, thus enhancing cellular uptake. Moreover, some of the squalamine mimics, 
as well as related compounds based on the squalamine structure, effectively permeabilise the 
outer membranes of gram-negative bacteria, thus sensitizing these organisms to hydrophobic 
antibiotics.[183]  
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Figure 12 Squalamine-based umbrella transporter.[184] 
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A kinetic analysis of the membrane activity of squalamine analogues in discharging pH 
gradients across liposomal membranes supported a model in which a monomer and a non-
covalently- linked dimer coexist in equilibrium. Based on this model, molecular umbrella 
molecules were generated, in which two molecules of squalamine (35) or its derivatives are 
covalently linked to form dimers (Figure 12). These dimers can be coupled with a variety of 
cargo and drug molecules, for which cellular uptake is enhanced. Coupled molecules range 
from small molecules such as amino acids up to ATP, AMP, glutathione, anti HIV drugs, and 
even oligonucleotides.[184-187] 
Other polyamines such as pseudokeratidine[188-190], which is used in antifouling paints are 
secondary metabolites from marine sponges with antimicrobial activity. The majority of those 
alkaloid polyamines contains a spermidine moiety such as Ptilomycalin A (37) (Figure 
13).[191] 
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Figure 13 Structure of Ptilomycalin A (37). The molecule contains a spermidine- and a guanidinium moiety, 
which are separated by an ester linked long chain aliphatic, hydrophobic region, and a polycyclic non-aromatic 
region.[191, 192] 
It was long known that cytotoxic properties of many polyamine analogues depend on the 
number of nitrogen atoms in the chain, and therefore the charge distribution of these 
molecules at physiological pH, the distance between the nitrogen atoms, and the nature of the 
terminal alkyl substituents. Anticancer derivatives of oxa-polyamines and bis-oxy-
naphtalimides are examples for cytotoxic polyamines with strong effects. While the parent 
oxa-spermine and spermidine do not show biological activity, their sulfonamide derivatives 
exhibit cytotoxicity against a broad panel of malignant and proliferating cells.[193-199] In recent  
years, many synthetic polyamine conjugates have been synthesized in which the polyamine 
moiety is covalently coupled to cytotoxic compounds such as chlorambucil or porphyrins.[200] 
The polyamine enhances the solubility and the cellular uptake of the cytotoxic compounds. 
 
2.2.4.4 Polyamines in cancer therapy 
A large body of data indicates that the polyamine pathway can be a molecular target for 
therapeutic intervention in several cancer types (see chapter 2.2.1).[201] The last two decades 
have seen an increasing interest in the cytotoxic response to agents that do not directly inhibit 
the metabolic enzymes in tumour cells, but rather the regulation of the polyamine 
metabolism.[202] This interest resulted in the generation of a variety of polyamine analogues 
and conjugates displaying effective cytotoxicity (see chapter 2.2.3). Having a similar structure 
to natural polyamines, these analogues efficiently enter the cells via the polyamine transport 
and uptake machinery. However, they also have a better specificity for cancer cells exhibiting, 
thus lower toxicity to normal cells, as well as a better metabolic stability. The cytotoxicity of 
these analogues for cancer cells has been attributed to various mechanisms such as the 
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induction of the catabolic enzymes or the reduction in the activity of the anabolic enzymes. 
Both mechanisms serve to reduce the polyamine content of the cell. Once in the cell, they can 
mimic intracellular polyamines that serve as anti-metabolites, displacing the natural 
polyamines from their binding sites but not substituting their growth promoting properties.[202] 
They lower the polyamine level below the level necessary for cell survival. Some of these 
polyamine analogues are also able to interfere with the polyamine uptake from nutrition, as 
well as to accelerate the degradation and the export of the natural polyamines.[203-206] 
 
2.2.4.5 Polyamines in drug delivery 
Since polyamines are highly positively charged at physiological pH, they can interact with 
biological membranes that mainly contain zwitterionically- and anionically charged 
phospholipids, proteins, and proteoglycans.[91] Electrostatic interaction with membranes often 
leads to internalization of the bound molecules via endocytic mechanisms. Additionally, 
many organisms have an active, but largely unknown polyamine uptake system.[52, 108] When 
covalently bound to a therapeutically active drug, polyamines and polyamine conjugates with 
lipophilic anchors can be used as drug delivery moieties. The polyamine moiety often serves 
as a solubilising agent for very hydrophobic drugs in the aqueous environment, additionally 
increasing the electrostatic interaction with the biological membrane. Further, the polyamine 
moiety can serve as a complexion agent to neutralize negatively charged drugs, which would 
otherwise not interact with a mainly negatively charged membrane, and therefore be excluded 
from endocytic uptake. To date, polycationic moieties are used for a variety of drugs to 
enhance their cellular uptake (Figure 14).  
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Figure 14 Polyamines used for transfection of DNA and nucleotides.[92] 
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Polyamine scaffolds have been chosen as precursors for DNA delivering agents since they 
display some important features. Prerequisites for delivery of DNA across the cellular 
membrane are the condensation of the DNA and the masking of the negative charges of the 
nucleotide backbone as described by polyamines.[207] Conjugates of polyamines with long 
aliphatic chains[208], bile acids[208], cholesterol and steroids[209-212], as well as other lipid 
moieties[180, 213], have been recently developed as gene delivery agents (Figure 14).The 
attachment of hydrophobic residues, such as a lipid moiety, further enhances the condensation 
and the crossing of the hydrophobic membrane part.[214-216] The mechanism by which these 
compounds mediate cellular uptake is still poorly understood. It was proposed that the 
polyamines still interact with the phospholipids head groups of the membrane lipids, leading 
to close neighbourhood of the DNA and the membrane. The complex eventually will be taken 
up by endocytosis and delivery into the endosomes. There are many proposed mechanisms 
such as the proton sponge theory or the retrograde transport of DNA via the Golgi 
apparatus.[217-219] Combinatorial approaches on solid phase have been used to synthesize 
amphiphilic polyamine conjugates as non-viral gene delivery agents. The highest activity was 
detected with compounds, which contain two guanidinium head-groups and only one aliphatic 
or hydrophobic chain. While nearly the entire steroid conjugates showed poor DNA binding 
and transfection efficiency, some of the straight aliphatic chain conjugates displayed good 
transfection activities. 
 
2.2.5 Polyamine synthesis  
Polyamine chemistry often encounters problems regarding the selective protection or the 
directed reaction of the various secondary and primary amino functionalities. However, only 
few possibilities for the  direct derivatization of particular amines in a polyamine are known. 
Selectivity is mostly achieved by the use of complex protection group schemes, which 
differentiate between primary amines and secondary amines (see chapter 2.3.4.1). For a 
modification of the primary amine it is necessary to orthogonally protect the secondary amine 
and re-liberate the primary amine (Scheme 8).[220, 221] 
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Scheme 8 Schematic description of the differentiation between primary and secondary amines in 42 by the use 
of a protection group, which is selective for primary amines.[92] 
To accomplish derivatization between the secondary amines, a modular construction of the 
polyamine backbone allows the introduction of orthogonal protection groups for each 
secondary amine (Scheme 9).[225] This strategy results in complex synthetic schemes and is 
limited by the number of orthogonal amino protection groups, which are compatible with the 
alkylation method. Introduction of the branching before finishing generation of the backbone 
allows the reuse of the respective protection group. 
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Scheme 9 Schematic description of the orthogonal protection of secondary amines. Primary amine 48 is 
alkylated with a building block that contains a protected primary amine. The resulting secondary amines in 49 
are protected with an orthogonal protection group. The number of orthogonal sets of amino protection groups, 
which can be applied, limits this strategy.[92, 225] 
The reversible reaction of 1,3-diaminopropylgroups and formaldehyde in the presence of 
other diamine fragments with different methylene group spacers leads to selective formation 
of an aminal. This reaction is a valuable tool for the diversification of unsymmetrical 
polyamines such as spermidine (15) (Scheme 10).[228, 229] As it is a stoichiometric reaction, it 
is suitable for the solution phase preparation of building blocks. However, it is not appropriate 
for a solid phase methodology.  
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Scheme 10 Schematic description of the differentiation between 3-aminopropyl and other amino-alkylgroups 
with different length of the methylene group spacer. 1,3-Diaminopropyl groups form an aminal 55 and increase 
the alkylation state of the involved amines. This can be used for differentiation from unmodified amines. The 
ring closure is reversible and therefore serves as quasi-selective protection for the three carbon spacer.[228, 229] 
 
2.2.6 Work-up of polyamine conjugates 
The tediousness of the purification procedures is also an important issue in polyamine 
syntheses and analytics. Work-up is complicated by the high polarities of even the protected 
polyamines. For elution on silica gel, high amounts of polar solvents such as water and 
methanol are necessary to shorten elution times. This increases the amount of impurities 
resulting from disintegration of the silica gel. The use of vacuum liquid chromatography 
(VLC) can improve separation, however it does not principally solve this problem.[220] The 
protected polyamines often appear oily and therefore purification methods such as 
recrystallisation and precipitation are excluded. On the other hand, the fact that partially 
protected polyamines can change their solubility behaviour depending on their protonation 
state, is advantageous.[220] If several free amines are present, the protonated building blocks 
are often soluble in water, while at basic pH, they are non-protonated, less polar, and can thus 
be extracted with organic solvents. Unprotected polyamines are highly polar and reversed 
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phase instead of silica gel materials are generally suitable for their separation. For those 
reasons, it is highly desirable to immobilize the substrate to a resin. This allows the removal 
of excess-reagents by simple washing steps after each reaction. After cleavage from the resin, 
the final products can then be separated by chromatography, if necessary in multiple runs.[220] 
As mentioned above, many polyamine conjugates have rather non-polar regions that confer a 
high amphiphilicity to the overall structure. This attribute can drastically complicate the 
purification procedure.[200] If the final conjugates have more than two amines, their migration 
on silica gel is often too slow to allow separation. On the other hand, the non-polar parts of 
the molecule can interact too tightly with standard C8 / C18 RP-material. This is not crucial 
with small aromatic systems, aliphatic rings, and short aliphatic chains. Philanthotoxins for 
example have an amphiphilic structure but can be separated by HPLC on C18-columns 
because the hydrophobic parts are below the size limit. Larger aromatic systems as well as 
longer aliphatic chains avoid migration, even if the positively charged parts of the molecule 
show nearly no interaction with the RP-column material.[200] In the context of this work, a 
procedure was applied, which solves problems during work-up of amphiphilic conjugates by 
the use of solid phase synthesis (work-up of compound 217 in chapter 4.2.1). For these 
reasons, it is highly desirable to reduce the number of polyamine synthesis steps and transfer 
as many as possible to the solid phase.  
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2.3 Polyamine solid phase synthesis 
2.3.1 Solid phase synthesis 
Merrifield’s pioneering work on the synthesis of the tetrapeptide L- leucyl-L-alanylglycyl-
L-valine, which he published in 1963 can be viewed as origin of solid phase synthesis.[233] He 
used the substrate immobilization onto a cross- linked polystyrene polymer (Merrifield resin 
(56), Figure 15), to synthesise a peptide backbone. The revolutionary development of this 
method was the minimisation of the purification steps and the acceleration of the whole 
synthetic procedure. Simple washing steps, which remove the reagents from the resin after 
every reaction cycle substitute recrystallisation, column chromatography and other tedious 
purification steps. The diffusion- inhibition of the reactions that was caused by the shift of the 
reaction to the inside of the resin beads was efficiently overcome by the use of high excess of 
the reagents. After esterification of a protected monomer to the solid support, the procedure 
consists of the following, repetitive steps: 
1. Deprotection of the amino group 
2. Peptide bond formation with the next protected monomer 
3. ´End-capping´ of the remaining free amines 
After final deprotection, the peptide is removed from the polymer. Although the synthetic 
scheme of solid phase peptide synthesis (SPPS) was optimized in the course of time to enable 
the synthesis of longer polypeptides with biological activity, which are often sensitive to the 
harsh deprotection and cleavage conditions or necessitate further modifications. As solid 
phase synthesis uses the reaction of immobilised substrates, some modifications are important 
compared to solution phase chemistry. As usually more than 90% of the reaction sites are 
located inside the resin beads, only solvents can be applied, which swell the resin. For 
polystyrene resins, the most commonly used swelling solvents are N,N-dimethylformamide, 
N-methylpyrrolidone, tetrahydrofuran, dichloromethane, and toluene. Cycloalkanes, alkanes, 
diethylether, ethylacetate, acetonitrile, dimethylsulfoxide, and water collapse the resin and 
reactions in those solvents usually only proceed to a minor degree. Due to the sensitivity of 
the resin to mechanical stress, some reaction conditions like high temperatures or aggressive 
reagents, which destroy the matrix are excluded. The monitoring of a reaction is more 
difficult than in solution phase chemistry, as the substrate is immobilized and techniques like 
thin layer chromatography (TLC) are not directly accessible. There are some methods for the 
qualitative or quantitative detection of the reaction progress on the immobilized compound, 
for example IR-spectroscopy, ´on bead´-mass spectrometry, solid state NMR, or colorimetric 
assays. A rather beneficial effect of the immobilization is the distinctly higher quasi-
molecular mass of immobilized substrates. Thus it is possible to handle even minimal 
amounts of substance. The possibility to automatise all working steps makes solid phase 
synthesis an ideal technique for combinatorial approaches. Polyamine chemistry uses some of 
the established methods of peptide solid phase synthesis. Both share the use of some linkers 
(see chapter 2.3.2), protection groups (see chapter 2.3.3), and peptide bond forming 
methods.[92] In the last couple of years, solid phase chemistry of polyamines afforded 
methods, which take more advantage on their special needs. 
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2.3.2  Resins and Linkers 
Some of the linkers, which were used in solid phase peptide synthesis as well as solid phase 
organic synthesis are shown in Figure 15.[92] 
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Figure 15 Some linker groups, which were used for solid phase synthesis. 
The original Merrifield resin 56 liberates its substrate after treatment with strong acids 
(> 90% TFA in CH2Cl2, HBr in HOAc) or under basic saponification conditions.[233] As these 
conditions are not suitable with most substrates, many linkers were developed, which can be 
cleaved under milder and more selective conditions (Figure 15). For example, substituted 
benzyl- linker (30 – 80%), trityl- linker (0.1 – 10%) and triazene- linker (< 10%) can be cleaved 
with distinctly lower concentrations of TFA in CH2Cl2.[234, 235] For polyamine chemistry, more 
recently linkers were used, which take care of the attributes of polyamines. A variety of 
polyamine linkers were developed by Bradley et al.[234, 236, 237] They mainly used an 
aminomethylated polystyrene resin. The polyamine was coupled via a urethane linkage, which 
was cleavable using 10 equiv. of trifluoromethanesulfonic acid-trifluoroacetic acid (TFMSA-
TFA). However, the cleavage of many polyamine-coupled biomolecules such as DNA, which 
are hydrolyzed when treated with high concentrations of TFA requires mild conditions.  
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Figure 16 Trityl linkers, applied for the synthesis of polyamine on solid support.[238-240] 
Byk et al. have developed a solid phase methodology, which allows a quick and easy access 
to a high number of mono-functionalized geometrically varied polyamines. They used mild 
cleavage methods of a trityl tethered resin 60, cleavable using low concentrations of TFA (see 
chapter 2.3.4.1).[238] The family of trityl-derived linkers has since then frequently been used 
for polyamine synthesis on solid phase (Figure 16). It unites several advantages as selectivity 
for primary amines and mild cleavage conditions. It is important to note that trityl linkers are 
stable against all alkylation procedures, which were developed for polyamine synthesis. 
Especially the reductive methods like BH3·THF-reduction of amides and imine reduction with 
borohydrides were successfully executed on solid phase.[231, 241, 242] Fukuyama alkylation has 
also been shown to be unproblematic.[243] A mentionable improve for the synthesis of acid 
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sensitive conjugates is the alkoxytrityl resin 61, developed by Fukuyama (Figure 16). It is a 
cheap alternative to obtain large amounts of a resin (Scheme 53), which is even more acid 
labile than the usually applied trityl- or 2-chlorotrityl resins.[239] The enhanced acid lability is 
caused by the +M-effect of the ether-bridge that couples resin and linker. Most of the solid 
phase syntheses that are performed to date take advantage of these types of resin with 
derivatised trityl linkers. In this work the trityl-based linkers are used for the same reasons 
described above (4.3.6.1). Various other linker systems, e.g. FMOP (4-formyl-3-methoxy-
phenoxymethyl-polystyrol) linker, immobilize amines by Reductive amination in benzylic 
position (Scheme 27). The cleavage conditions are milder than that for the Merrifield resin, 
but generally harsher than those of trityl resins. They additionally lack the bene ficial 
selectivity for primary amines and hence their use in the ´conventional´ synthesis of 
polyamines is rather seldom.  
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Figure 17 DNA conjugation to polyamines on ArgoGel-NH2 as reported by Kim and Diamond.
[244, 245] 
Nevertheless, they found application on the externally controlled cleavage of covalently 
linked prodrugs, proteins, or solid-phase formulation vehicles, which offers potential 
advantages for controlled drug or gene delivery. Diamond and co-workers tested a series of o-
nitrobenzyl ester compounds that allow a systematic study of resins with linkers for 
polyamine synthesis expressing a photolability for mild cleavage of the polyamine conjugate 
(Figure 17).[244, 245] With this linker system, DNA-loaded solid phase 64 is assumed to be 
exploited for spatially, temporally, or dose-controlled release of DNA-polyamine complexes, 
at extracellular or intracellular sites. To avoid acidic cleaving conditions, Bycroft and 
colleagues developed a linker, which bases on the same reactivity as the Dde protecting group 
(cleavage with hydrazine hydrate or primary amines).[246] It is fully orthogonal with Boc and 
Fmoc protection groups. So, it enabled discrimination between primary and secondary amines 
during the loading step and served as linker for polyamine synthesis on solid supports in 
several examples (see Scheme 20 in 2.3.4.4). 
 
2.3.3 Protection groups 
The discrimination between the respective amino-functionalities is highly desired to allow a 
directed synthesis of polyamine. This requires an extensive and well-planned protection group 
strategy.[92, 247] The polyamine synthesis uses the pool of common amino-protection groups 
from peptide synthesis, like the butyloxycarbonyl group (Boc), the allyloxycarbonyl group 
(Aloc), the triphenylmethyl group (trityl, Tr), and with restrictions the 
9H-fluoren-9-ylmethoxycarbonyl group (Fmoc).[248] Special needs of polyamine chemistry 
force the expansion of the set of orthogonal protection groups in polyamine synthesis (Table 
1). 
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Table 1 Prominent protection groups, which were used for polyamine syntheses.[248] 
 
The Boc-group, Trt-groups, the p-Nosyl-group and the Phthaloyl group (Pht) allow 
differentiation between primary and secondary amines if the protection group is introduced in 
stoichiometric amounts or in low excess.[249-253] Their selectivity arises from sterical demands 
of the protection group or by the much quicker reaction of primary amines with the 
introducing agent compared to secondary amines. An exclusive selectivity is observed for the 
Dde-group 67 (Figure 18) and the Tfa-group 68.[220, 222-224, 230, 254-256]  
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Figure 18 The Dde-protected primary amine is stabilized by a hydrogen bond that forms a six membered 
ring.[248] 
In case of Dde, the readily protected primary amines 67 are stabilized by hydrogen bonds, 
which were not present in the protected secondary amines. The Tfa group 68 can be 
selectively introduced at primary amines, if ethyl trifluoroacetate is used instead of the 
anhydride. Selectivity for a-monosubstituted primary amines in the presence of a-di- or 
trisubstituted primary amines is also observed. Alkylation methods, which include the use of 
specific protection groups make use of the Z-group, the Pht-group and the Nosyl-groups.[257-
260] Due to the bulky phenyl moiety, primary amines are selectively mono-protected by 
benzylbromide in the presence of weak bases. The resulting secondary amine can be alkylated 
with electrophiles in a simple SN2-reaction. After deprotection, secondary amines are 
selectively obtained. The harsh acidic deprotection conditions of the Z-group are rarely 
compatible with the commonly used resins in polyamine SPS. Pht-group and the Nosyl-
groups play a key role in the selective formation of primary / secondary amines. In both, the 
pKS-value of the activated N-H is distinctly lowered and in the presence of bases the 
hydrogen can be abstracted to obtain much higher rates in halogen displacement-reactions or 
Mitsunobu-reactions.[225, 239, 261-263] After their relatively mild deprotection, the liberated 
Protection group Deprotection conditions 
Z, Boc, Trt, MMTr, DMTr acidic 
Tfa, Fmoc basic 
Aloc Pd0 
o-Nosyl, p-Nosyl, d-Nosyl thiolates 
Dde, Pht N2H4·H2O 
Teoc F- 
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amines are selectively obtained. Since they play an important role in the present work some 
protection groups are specified. 
 
2.3.3.1 The Dde group 
The Dde-group is introduced by reaction of primary amines with 2-acetyldimedone 191 and 
weak bases in polar solvents.[223, 224] Unlike during the introduction of most other protection 
groups, the mechanism contains an aza-Michael-addition followed by elimination of water. 
The protected state is stabilized by hydrogen bonding and can be disturbed by other primary 
amines. Thus, selective protection of only one of several primary amines is not possible as 
transamination to all present primary amines would take place and quickly decompose the 
monoprotected compound.[92] On the other hand this mechanism is used for the mild 
deprotection with primary amines. Since Fmoc is also affected by the primary amine the use 
of hydrazine-hydrate is more popular. The reaction occurs quickly without any affection of 
the Fmoc-group (Figure 19).[264, 265] 
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Figure 19 Deprotection of the Dde group.[248] 
The formation of the 3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indazole (71) is 
irreversible. Its strong UV-absorption at 270 or 290 nm can be used for quantitative 
monitoring of the deprotection. If carried out with hydrazine hydrate, the orthogonality 
between Dde- and Aloc groups is not fully given as hydrazine partially reduces the Aloc 
group to the corresponding propyl carbamate. Addition of 100 equiv. of allyl alcohol avoids 
this side reaction without the necessity of higher excess of hydrazine or elongating the 
reaction time.[266] 
 
2.3.3.2 The Aloc group 
Allyl type protection groups have extensively been used for the protection of amines, 
carboxylic acids, phosphates and ethers. [267, 268] Aloc is introduced by N-acylation with allyl-
chloroformate under Schotten-Baumann conditions or with diallyl dicarbonate in the presence 
of bases.[248] It features a remarkable stability during removal of other protection groups. 
Likewise, Aloc deprotection occurs under extremely mild conditions, which make it 
orthogonal to nearly all other amino protection groups. During deprotection, the allyl moiety 
is transferred to a Pd0 species, Pd(PPh3)4 or Pd(II) that is reduced in situ. After protonation, 
the carbamic acid decomposes under loss of carbon dioxide to give the free amine (Figure 
20).[268] 
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Figure 20 Deprotection of an Aloc-protected amine 72.[268] 
The destruction of the Pd-allyl complex (step two in Figure 20) is crucial. This has to appear 
quickly by nucleophilic attack of a scavenger, as the liberated amine will act itself as a 
scavenger for the allyl cation. The variety of scavengers is broad and enables flexible use, 
depending on the presence of susceptible functions in the molecule.[248, 269-275] 
Table 2 Classes of scavengers, which were previously applied for Aloc deprotection.[268] 
 
Nevertheless, some scavengers only suppress the formation of ally amines but do not 
completely avoid it. For carboxylic acid salts, it is crucial that the formed allyl-carboxylate is 
less stable than the allyamines. Thus, the trapping process is irreversible and both, the amine 
and the carboxylic acid salt compete for the allyl cation.[248] Acidic scavengers reprotonate the 
amine to such a far extend that trapping of the allyl cation is excluded. Tin hydrides, silanes, 
Class of scavenger Substitute 
Allylamine 
formation 
Carboxylic acids No  
Carboxylic acid salts Yes 
HOBt No  
Oxygen nucleophiles 
N-Hydroxysuccinimide No  
Morpholine Yes 
Pyrrolidine Yes 
Piperidine Yes 
N-Methylaniline Yes 
Nitrogen nucleophiles 
Me2NH Yes 
Dimedone No 
N,N´-Dimethyl barbituric acid No Carbon nucleophiles 
Dimethyl malonate No 
Sulfur nucleophiles 2-Thiobenzoic acid No 
R2NSiMe3 No 
Silylating derivatives 
Me3SiN3 / Bu4NF No 
Formic acid No 
HSnBu3 No 
Borohydrides No 
Hydride donors 
Silanes No 
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boron hydrides, and silylated derivates of nucleophiles inactivate the amine by converting the 
carbamate to the corresponding (semi-)metalated carbamates 75 (Figure 21). The (semi)-metal 
can be exchanged under weakly acidic conditions and give the deprotected amine 73 after 
subsequent decarboxylation of the carbamic acid 76. The use of dry solvents during the allyl 
transfer is highly recommended as traces of water can prematurely destroy the silylated 
carbamate.[276, 277] 
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Figure 21 Pd-mediated allyl-transfer in the presence of (semi)-metal hydrides or silyl donors results in the 
formation of the respective carbamates 75. After protonation and decarboxylation, the deprotected amine 73 is 
obtained. Representatively, the reaction with HSnBu3 is shown.
[248, 268] 
The Pd-catalyzed rearrangement of allyl carbamates to allylamines is a common method for 
the selective mono-allylation of amines.[268] 
 
2.3.3.3 The Nosyl group 
The Nosyl group is introduced by reaction of amines with the respective sulfonyl chloride in 
the presence of weak nitrogen bases. 2-mono- (o-Nosyl), 4-mono- (p-Nosyl), and 2,4-di-
nitrophenylsulfonyl (d-Nosyl) groups are reported. Due to the much lower costs of the 
respective sulfonyl chloride, the o-Nosyl group is usually applied.[248, 278, 279] The formed 
sulfonamide 79 is stable and can be smoothly removed under mild conditions. Due to its 
electron deficiency, the phenyl ring can be readily attacked by thiolates. Those are usually 
generated in situ by reaction of a thiol and a base (Scheme 11).[261] 
 
R1 NH2 + NO2
SO2Cl
NO2
SO2N
H
R1
Base, R2-Hal or
Mitsunobu with R2-OH
NO2
SO2NR1
R2
Base, R3-SH NO2
SO2NR1
R2
SR3
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R1 NH
R2 NO2
S
R3
+
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Scheme 11 General mechanism of Fukuyama alkylation  and subsequent removal of the o-Nosyl group. After 
introduction of the Nitrobenzenesulfonyl-protecting group, an N-alkylsulfonamide 79 is obtained in which the 
acidity of the NH-proton is significantly enhanced. After deprotonation of the sulfonamide, it can displace a 
halide or an alcohol in a Mitsunobu reaction. Thereby, the former activating group changes its function to a 
protecting group. Thiolates form a Meisenheimer complex 81 with the electron deficient ring of the Nosyl-group, 
which decomposes under loss of SO2 and nitrophenyl thioether 82 to release the secondary amine 73.
[261] 
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The choice of the thiol seems to be of low importance. Different examples such as 
b-mercaptoethanol, thiophenol and 2-mercaptoacetic acid are reported.[239, 279] Usually, bases 
are carbonate and DBU, whereas DBU significantly accelerates the reaction compared to 
carbonate. The use of readily prepared thiol salts, for example sodium thiomethylate, is also 
reported. Compared to other sulfonamides, which are usually removed under strongly basic 
aqueous alkaline, these deprotection conditions are very mild and predestine the Nosyl group 
for use in polyamine solid phase chemistry. In analogy to other sulfonamides, Nosyl does not 
only function as a protection group for primary and secondary amines. It can also act as an 
activation group for primary amines (see Scheme 11 and chapter 2.3.4.3). This possibility to 
discriminate between primary and secondary amines and to selectively alkylate masked 
primary amines makes it one of the most frequently used protection groups in polyamine 
chemistry.[261] 
 
2.3.4 Strategies for Polyamine Solid Phase Synthesis 
In the last ten years, many efforts were undertaken to generate reliable methods for 
polyamine solid phase synthesis. In general, solid phase synthesis of polyamines and their 
conjugates can be pursued by two strategies.[247, 280] The first is based on the stepwise or 
modular elongation of the backbone with small building blocks. The second consists in the 
coupling of larger partially protected polyamine building blocks in order to rapidly elongate 
the backbone. The preference for one of these methods depends on the functional properties 
of the building blocks. Finally, both require a combination of solution and solid phase 
methods. Although the first strategy allows the introduction of more diversity in the aliphatic 
backbone between two amino groups and in the side chains, it is limited by the fact that every 
elongation step decreases the yield. Furthermore, the smaller building blocks have to be 
prepared in at least one solution phase step, making the modular approach less favourable for 
the generation of longer backbones. For the synthesis of longer backbones it is more 
economical to prepare building blocks, which can be coupled to the support in one step. This 
method is especially advantageous for commercially available backbones such as spermine 
(16). However, this requires an efficient protection of the primary and secondary amino 
groups in a solution phase synthesis step.[232, 236, 247, 259, 260, 280, 281] For high throughput library 
productions and large-scale SPS large quantities of highly stable and partially or fully 
protected polyamine building blocks are required. They should be asymmetrically protected to 
exclude cross- linking reactions that would severely decrease yields and purities of the solid 
phase synthesis. The substitution should also allow direct access to a variety of different 
polyamine structures without laborious conversions after coupling to the solid support. The 
necessity of building up a polyamine backbone by alkylation instead of acylation is an 
additional concern. Usually, alkylation conditions are harsher than those for peptide bond 
formation. They therefore restrict the range of tolerated functional- and protection groups. 
The transfer of such alkylation procedures to the solid phase and the compatibility to several 
protection groups has been extensively studied. Ultimately, there is no generally applicable 
alkylation and protection scheme, and the final choice of the methods strongly depends on the 
desired structure of the product.  
First solid phase syntheses of polyamines were reported by Sergheraert and co-workers in 
1994.[282] The synthesis of trypanothione disulfide involved the selective protection of the 
primary amines of spermidine (15) with tertbutyldiphenylsilyl chloride followed by coupling 
the disilyl derivative to a methylchloroformylated Merrifield polystyrene resin. After 
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deprotection and assembly of the peptidic chain the product was cleaved from the resin with 
HF. Oxidation and purification afforded the product in 38% yield. In the following years, 
many efforts were undertaken to improve polyamine solid phase synthesis, especially in terms 
of linkers, alkylation methods, and protection groups, which allow diversification between the 
particular amines. Development of milder reaction conditions than those mentioned in the 
example of Sergheraert is also an important point. 
 
2.3.4.1 Direct attachment of protected polyamines 
An early example is the first mention of a solid phase synthesis of PhTX-343 published by 
Bycroft et al in 1996 (Scheme 12).[240] They attached unmodified spermine (16) to a 2-
chlorotrityl resin (60) and used Dde- and Boc-group to differentiate between primary and 
secondary amines. Investigation of the crude product after Dde-protection showed no bis-
Dde-spermine (89f), proving the selectivity of trityl linkers for primary amines under these 
conditions. 
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Scheme 12 Synthesis of PhTX-343 using Dde- and Boc-protecting group. Reagents and conditions: (a) 
Spermine, CH2 Cl2; (b) 2-acetyldimedon, DMF; (c) Boc2O, DiPEA; (d) 2% N2H4 in DMF; (e) Fmoc-L-
Tyr(OtBu)-OH, HBTU, HOBt, DiPEA, DMF; (f) 20% piperidine in DMF; (g) Fmoc-L-Tyr(OtBu)-OH, HBTU, 
HOBt, DiPEA, DMF.[240] 
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Protecting groups, which enable the primary-secondary amine-differentiation were 
described in chapter 2.3.3. They were previously used to prepare some valuable, protected 
polyamine derivates, shown in Figure 22.[92, 247] 
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Figure 22 Some synthetically useful polyamine building blocks.[92] 
One example for the selective protection of secondary amines, which served as a template 
for the reactions in chapter 4.1.1.1, is shown in Scheme 13.[220, 230, 283] Differentiation is 
accomplished by an indirect method after blocking of the primary amines. Therein, the Tfa 
group partially or fully protects spermine (16) at its primary amines and the remaining amines 
are saturated with Boc-groups. After cleavage of the Tfa group with aqueous NaOH, different 
Boc-spermines are obtained.  
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Scheme 13 Exemplary synthesis of di- and tri-Boc protected spermine. The Tfa -group is used for temporary 
blocking of the primary amines. Di- and tri-Boc-spermine are obtained in 18% and 43% yield after 
chromatographic workup by vacuum liquid chromatography (VLC); Reagents and conditions: (a) 1.2 Equiv. 
TfaOEt, MeOH, -50 °C; (b) Boc2O, MeOH, 0 °C; (c) NaOHconc / H2O.[230] 
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By choosing the excess of ethyl-trifluoroacetate, the amounts of di-  and tri-Boc-spermines 
94 and 95 can be controlled. Both products are useful building blocks for solution as well as 
for solid phase chemistry. An asymmetrically protected building block was applied in the 
synthesis of PhTX-343 (Scheme 14).[221] After immobilisation of the Fmoc-protected and Pfp-
activated tyrosine moiety on a trityl bromide resin, amide generation with an asymmetrically 
protected spermine building block 91a resulted in PhTX-343 (34) in 43% overall yield. 
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Scheme 14 Synthesis of PhTX-343. Reagents and conditions: (a) DiPEA, HODhbt; (b) 20% piperidine in DMF; 
(c) C3H7COOPfp, DiPEA, HODhbt; (d) TFA in CH2Cl2.
[221] 
 
2.3.4.2 SN2-Alkylation 
SPS approaches for both, amine and electrophile bound to the resin have been reported. The 
latter one is superior, due direct alkylation of primary amines can easily lead to 
overalkylation.[284] However, this strategy is also not sufficient in all cases. It has to be taken 
care of cross linkage between solid phase bound electrophiles and primary amines, which 
leads to the formation of tertia ry amines and significantly lowers yield and purity. Thereby 
common SN2-alkylation is mostly limited to the homo-dialkylation of primary amines and 
monoalkylation of secondary amines. Appropriate electrophiles are halides and sulfonates 
(mesylates, tosylates and nosylates).[284]  
An example that starts the synthesis of polyamine toxins from a central amino group 
immobilized on a Merrifield resin (55) is shown in Scheme 15. The backbone is elongated by 
alternate coupling of benzyl-protected amines and bromides.[257, 258] Due to the protection 
group strategy, consisting of orthogonal Boc-, benzyl- and phthalimides it is possible to 
synthesize polyamines from centre to tail with high control over the amino substitution. 
Unfortunately the overall yield after three alkylation steps is only 30%, which drops the 
overall yield to 10 – 30%. Besides the incompleteness of the bromine displacement caused by 
the use of hindered N-benzylamines, this probably arises from the two steps in which 
symmetrical building blocks serve for the elongation of the polyamine in steps b and c. Both 
steps probably suffered from cross- linking. 
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Scheme 15 Asymmetric synthesis of polyamine starting from an internal amino functionality. Reagents and 
conditions: (a) N-Boc-diaminopropane, DiPEA; (b) dibromopropane, DiPEA; (c) N1,N5-
dibenzyldiaminopropane, DiPEA; (d) N1-benzyl-N5-phthaloyldiaminopropane.[257, 258] 
In a detailed study on SN2 alkylation by Jaroszewski et al, similar results were obtained for 
the alkylation of immobilized bromides and iodides generated from alcohols if the reaction is 
carried out on a trityl resin.[285] Interestingly, the change to a p-nitrophenylcarbonate-activated 
Argopore Wang resin resulted in significantly higher overall yields for both steps. Again, the 
formation of side products by cross-linking is problematic. This obstacle could not be solved 
by the use of higher excess of amine or electrophile. Use of only partially loaded resins with 
loadings about 0.5 mmol / g was suggested to largely suppress the cross- linking. The 
2-nitrophenylsulfonate leaving group was examined in the alkylation of cyclic secondary 
amines.[286] However, the overall yield (26%) of this synthesis containing two alkylation steps 
is low, as the cyclic amines are sterically demanding. If only one piperidine moiety is 
introduced, the overall yield rose up to 60%, confirming that the alkylation step is crucial. 
Nevertheless, the O-o-Nosyl-group seems to be the leaving group of choice, because the use 
of the appropriate mesylate revealed no product. Finally, mesylates found an application in 
the solid phase synthesis of polyamine conjugates with imidazole and usnic acid, both 
published by Uriac et al. (Scheme 16).[287, 288] They showed that the use of longer reaction 
times (32 h) and higher temperatures (70 °C) produces good yields for the alkylation of 
secondary amines. Primary amines are alkylated in much shorter time (6 h) and at lower 
temperatures (50 °C). 
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Scheme 16 Syntheses of Polyamine-Imidazole Conjugates. Reagents and conditions: (a) Aminoalcohol, CH2 Cl2, 
2 h, r.t.; (b) Methanesulfonyl chloride, pyridine, 30 min, r.t.; (c) 109, DMSO, 32 h, 70 °C; (d) 110, DMSO, 5 h, 
50 °C; (e) 50% TFA in CH2Cl2, 1 h, r.t.; (f) NaOH then CH2Cl2, chromatography; (g) 20% Pd(OH)2 / C, H2, 
MeOH, 4 h; (h) water, HCl / EtOH, 3 h, 0 °C then r.t.[288] 
 
2.3.4.3 Fukuyama alkylation 
The Fukuyama alkylation is a special case of SN2-reaction with activated amines. It was 
developed by Fukuyama et al. in 1995 for solution phase synthesis and found its first mention 
for solid phase chemistry in 1997 by Nguyen et al.[279, 289] It is particularly useful for the 
selective monoalkylation of primary amines under mild conditions. This is a major advantage 
over other alkylation methods used for the generation of polyamine backbones. Several Nosyl 
groups with different nitro substitution patterns can be applied (see chapter 2.3.3.3).[278, 279] 
One advantage of d-Nosyl over mono-Nosyl is the greater rate in sulfonamide formation. By 
the enhanced electron withdrawing effect of the second nitro-group the amide-proton of the d-
Nosyl amide has an additionally lowered pKa-value leading to higher rates in alkylation 
reactions.[278] On the other hand this makes it even more susceptible to the basic deprotection 
conditions used for o-Nosyl. This enables o-Nosyl and d-Nosyl to be used as fully orthogonal 
protecting groups. Otherwise, this also limits the scope of the d-Nosyl group. Weak bases like 
n-propylamine, and higher temperatures partially deprotect the amine, which makes the use of 
d-Nosyl problematic. By all means it is not possible to keep the protecting group on the resin 
for multiple alkylation steps. Alkylation with tosyl- and trifluoroacetamides has also been 
reported but due to their harsh deprotection conditions, they were not suitable for solid phase 
chemistry of polyamines.[290] 
After publishing a mixed solution-solid phase synthesis of polyamine toxin HO-416b in 
1999, Fukuyama et al. demonstrated the versatility of the Ns-strategy for the complete 
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synthesis of longer polyamines on solid phase in 2002 by the synthesis of PhTX-343 (34) 
(Scheme 17).[239] The product was isolated in 75% yield. A possible source of loss in this 
synthesis is the expectable cross- linking in the attachment of unprotected diaminopropane to 
the resin and in step a. 
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Scheme 17 Synthesis of PhTX-343 using o-Nosyl group and primary bromides for synthesis of the polyamine 
backbone. Reagents and conditions: (a) 1,4-Dibromobutane, K2CO3, DMF, 60 °C; (b) N
1-Nosyl-N3-Aloc-1,3-
diaminopropane, K2CO3, DMF, 60 °C; (c) Pd(PPh3)4, pyrrolidine, DMF, r.t.; N-Butyryl-O-acetyl-L-tyrosine-p-
nitrophenol ester, CH2Cl2, r.t.; (d) K2CO3, MeOH; mercaptoethanol, DBU, DMF, r.t.; TFA in CH2Cl2, r.t.
[239] 
This problem is circumvented by the use of monoprotected diamine building blocks or 
amino alcohols that can be alkylated under Mitsunobu conditions. Hone et al. showed the 
utility of this method in the synthesis of spider toxin HO-416a (123) in 2000 (Scheme 18).[225] 
The whole 16-step reaction sequence revealed HO-416a (123) in 88% yield and 94% purity. 
Herein, the d-Nosyl group is used and it is obvious that the instability of d-Nosyl requires 
multiple transprotection steps during each alkylation step. 
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Scheme 18 Synthesis of Agel 416 using d-Nosyl-amide alkylation as central tool.  Reagents and conditions: (a) 
2,4-Dinitrobenzenesulfonyl chloride, 2,6-lutidine, CH2Cl2, 3 h; (b) 1. N-Dde-butanolamine or 
N-Dde-propanolamine, PPh3, DEAD, THF, 3 h; 2. mercaptoacetic acid, DiPEA, CH2 Cl2, 3 h; 3. Boc2O, DiPEA, 
CH2Cl2,  3 h; (c) hydrazine-hydrate (2% in DMF), 30 min; 2,4-dinitrobenzenesulfonyl chloride, 2,6-lutidine, 
CH2Cl2, 3 h; (d) hydrazine-hydrate (2% in DMF), 30 min; indole-3-acetic acid, HOBt, DIC, CH2Cl2, 1h; (e) 5% 
TFA in CH2Cl2, 5 min; 4M HCl in dioxane, 3 h.
[225] 
The alkylation of amines using Mitsunobu-Fukuyama conditions has since then extensively 
been studied and applied in the synthesis of polyamines (Scheme 19). Stromgaard et al. 
investigated reagent concentration, excess, reaction time, number of reaction cycles and order 
of reagent addition. It appeared that a reagent-concentration of 200 mM, reagent addition in 
the order tributyl phosphine (TBP) followed by 1,1'-(azodicarbonyl)dipiperidine (ADDP), and 
reaction times of three times three h yielded 100% conversion for the first alkylation step.[291] 
After one further alkylation and acylation, PhTX-433 analogues are obtained in overall yields 
of 23 – 40%. This suggests a distinct loss of conversion in either the second alkylation or the 
acylation steps. 
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Scheme 19 Mechanism of the Mitsunobu reaction. The essential compounds are a phosphane and a 
diazocompound, which are able to generate the oxophosphonium intermediate 130. The SN2 reaction in step III 
is the rate determinant step. The outcome of the reaction strongly depends on the sterical environment of the 
alcohol 128 and the acidity of 125. In this case the traditional Mitsunobu reagents diethylazodicarboxylate (124) 
(DEAD) and triphenylphosphane are shown as participants.[92] 
A further study of the reaction by Olsen et al. tested the influence of base addition, different 
solvent systems and Mitsunobu reagent pairs.[263] The use of diethylazodicarboxylate (124) in 
combination with PPh3 or PEt3 seems favourable, however with an obvious dependence on 
the substrate type. Efforts to synthesize curtatoxins with more than 5 amino groups did not 
give the desired product. This loss of yield is probable due to the necessity of four 
components to act together during Mitsunobu-reaction, which is rather disadvantageous for a 
solid phase reaction, as the concentration of the activated species inside the resin beads 
remains low.  The results for the alkylation with secondary alcohols were even worse. In 
agreement with the work of Stromgaard this shows that the scope of Fukuyama-Mitsunobu 
alkylation with protected amino alcohols is limited to less steps, if acceptable yields are 
demanded. A study on the optimization of the reaction conditions for conventional Fukuyama 
alkylation with electrophiles comes again from Stromgaard et al.[243] They showed that halides 
are best leaving groups, that DMF is the solvent of choice and that the outcome of the reaction 
strongly depends on the applied base, more than on the temperature. The reaction is carried 
out in three cycles of 3 h applying 6 equiv. of both, base and halide. HBTU gave slightly 
better results than DBU, while carbonate and tertiary nitrogen bases gave low or no 
conversion under these conditions. Those results were the background for the study on 
conventional Fukuyama alkylation with halides in chapter 4.1.2.4 in which it was emphasized 
to suggest conditions that allow the more economic incorporation of more diverse building 
blocks than the simple iodoalkanes or protected amino iodides in Stroomgaard’s example. 
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2.3.4.4 Reductive amination 
Reductive amination was the earliest of the here described amine forming methods for solid 
phase.[292, 293] Then, it was used for the alkylation of Somatostatin Octapeptide analogues. 
Due to the early development of this alkylation method it found entry into the synthesis of 
diverse substance classes like N-terminal modified peptides, carbohydrate mimetics[294], 
glycopeptides[295, 296], oligonucleotides[297] and of course polyamines. For the same reasons as 
the Amide reduction approach, it is suitable to be used in library formations. 
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Scheme 20 First use of Reductive amination in the solid phase preparation of a PhTX-334 by Chhabra et al. 
Reagents and conditions: (a) 1. N-Fmoc-3-aminopropanal, 1% AcOH / DMF, 1.5 h; 2. Na(CN)BH3, 1% 
AcOH / DMF, 10 min; (b) 1. Boc2O, DiPEA, DMF, 20 h; 2. 20% piperidine in DMF; (c) 1. 
N-Fmoc-3-aminopropanal, 1% AcOH / DMF, 1.5 h; 2. Na(CN)BH3, 1% AcOH / DMF, 10 min.
[246] 
The first time that this approach was used for the synthesis of a polyamine backbone was in 
2000 by Bycroft and co-workers during the synthesis of PhTX-334 (137) (Scheme 20).[246, 298] 
After attachment of 1,4-butanediamine to a Dde resin, the asymmetric backbone of the 
polyamine moiety was established stepwise. N-Fmoc-3-aminopropanal building blocks were 
used for elongation, with Na(CN)BH3 / HOAc as reducing agent. Protection group conversion 
and repetitive chain elongation gave immobilised tetraamine 136. Finally, PhTX-334 (137) 
was obtained in 65% overall yield and in 90% purity. A drawback for the general use of 
Reductive amination in polyamine synthesis is that to date all attempts to generate N-protected 
C4- and C5-aminoaldehydes failed. This limits the application of Reductive amination to the 
elongation with less than four or more than five methylene group spacers. Remarkable 
syntheses were published by Jönsson. A complex protection strategy, which makes us of the 
slightly varying acid labilities of 4-methoxy dityl- (Mmd) and 4,4´-dimethoxy dityl (Dod) 
groups, in combination with Reductive amination enabled the directed synthesis of branched 
polyamines (Scheme 21). The staggered acid lability of Mmd and Dod arises from their 
different number of methoxy substituents and enables the selective removal of the Dod group 
in the presence of the Mmd group. The intermediate protection with these two alkyl-type 
protection groups avoids overalkylation during Reductive amination. However, this strategy is 
not compatible with the use on highly acid labile trityl linkers. Finally, the products were 
obtained in > 80% purity and 75 – 80% overall yield. 
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Scheme 21 Synthesis of PhTX-233 by Jönsson. Reagents and conditions: (a) 1. N-Fmoc-3-amino-
aminopropanal; 2. Na(CN)BH3, 3% AcOH, NMP, 40 °C; (b) 1. piperidine in DMF; 2. Dod-Cl, DiPEA, CH2Cl2; 
3. 5% TFA; 4. N-Fmoc-2-aminoacetaldehyde; 5. Na(CN)BH3, 3% AcOH, NMP; (c) 1. 5% TFA in CH2Cl2; 
2. n-butyraldehyde or 3-phenylpropionaldehyde; 3. Na(CN)BH3, 3% AcOH, NMP, 40 °C. 
In another example, overalkylation during Reductive amination was circumvented by the 
choice of appropriate excess of aldehyde.[299] 
 
2.3.4.5 Reduction of Amides 
The first works on solid phase dealing with the reduction of amides were published by 
Schultz et al. for the synthesis of N,N-dialkylated oligocarbamates.[300] They used diborane, a 
milder reducing agent compared to LiAlH4, which had been used in solution phase. Due to its 
harshness against several other reducible groups and linker systems, BH3*THF is favoured in 
the recent literature.[301-303] The method itself is high yielding for the formation of secondary 
amines. In combination with the large number of commercially available acylation reagents it 
opens access to a broad range of structurally diverse polyamines. Scheme 22 shows the 
supposed mechanism for the reduction of amides by BH3.[304] The reaction proceeds well via 
exhaustive complexation of the boron by three amides and subsequent elimination of B2O3, 
giving tris-aminoborane 145. Unfortunately its complexation with three additional equivalents 
of borane to 146 occurs faster than the reduction of further amides, which requires extra 
excess of BH3·THF for complete reduction. 146 is stable and can only be transformed to 147b  
at high temperatures (110 °C in toluene). The aminoborane is converted to the secondary 
amine 148 by acidic, aqueous workup. As these conditions are not suitable for solid phase 
chemistry on the most acid labile resins, a different work-up procedure is necessary. If 
reduction is the terminal step of a synthesis, complex 146 can be destroyed during the 
cleavage from the resin with strong acids. Alternative decomplexation conditions are the use 
of DBU in NMP : MeOH (9 : 1)[300], piperidine[241, 305] and ones known from solution phase 
like e.g. exposure to refluxing methanol[306] and basic hydrolysis with hydrochloric acid or 
saturated ammonium chloride[307]. However, those conditions are often not suitable with either 
resin requirements, commonly used linker systems and amino-protection groups. 
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Scheme 22 Supposed mechanism of Amide reduction  by BH3 and subsequent liberation of the resulting 
amino-borane complex.[304] 
Hall et al. developed a milder method employing iodine in an i-Pr2NH / HOAc buffered 
solution for polyamine synthesis on a trityl linker.[304] In this approach it is believed that the 
acetate anion is able to rapidly cleave the covalently bound aminoborane unit in 146 (Scheme 
22). The hydrides in 147a can successively be removed by iodine, which can be displaced by 
another acetate ion in a simple SN2-reaction. Back bonding of the oxygen weakens the boron-
nitrogen bond and the complex decomposes irreversible after protonation of the resulting 
amine. Karigiannis et al. used Amide reduction in the synthesis of Kukoamine isomers 
(Scheme 23).[301] The spermine backbone is established by amide formation of diaminobutane 
(13) and trityl protected respectively trityl-resin bound b-alanine. The amide groups are 
reduced with BH3 and kukoamine C (154) is obtained in 65% overall yield after further 
modification. There was no mention about, how the amine-borane complex was destroyed. 
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Scheme 23 Synthesis of Kukoamine C (154). Reagents and conditions: (a) DIC / HOBt, diaminobutane; (b) 
N-Trt-3-aminopropionyl-succinate, Et3N; (c) BH3, THF; (d) O,O´-benzylcaffeyl chloride, Et3N; (e) 1. TFA, 
Et3SiH, 2. H2 / Pd-C.
[301] 
The synthesis of chiral polyamines by reduction of the precursor amides was also shown to 
work without loss of optical activity (Scheme 24).[304] Stepwise coupling of L-amino acids 
and following reduction of the triamide 156 gives the polyamine backbone. The aminoborane 
complex is destroyed by the above mentioned iodine procedure and the resulting secondary 
amines were again acylated. The products were obtained in nearly quantitative yield and with 
high purity. A comparison study with the piperidine  workup showed that the iodine workup is 
superior. Analysis of the products showed no racemisation at the stereogenic centres. 
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Scheme 24 Synthesis of chiral polyamine by coupling of amino acids and subsequent reduction. Reagents and 
conditions: (a) 1. BH3, THF, 24 h, 65 °C; 2. I2, (1 : 2 : 7) i-Pr2 EtN / AcOH / THF, 4 h, r.t.; 3. neutralisation; (b) 
1. Ac2O, Et3N, DMF; 2. 5% TFA / CH2Cl2.
[304] 
The possibility to introduce branching was also investigated. It showed that yields dropped 
drastically, if the secondary amines were acylated and the resulting amides were reduced with 
BH3·THF. Due to the sluggish reduction of the tertiary amide, this led to many only partially 
reduced side products, even after 5 d of reaction at 65 °C. The problem was satisfactorily 
solved by Reductive amination with aldehydes.  
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Finally, the advantages of the amide-formation / BH3-reduction strategy are numerous. The 
well- investigated methods for amide formation known from peptide synthesis facilitate the 
generation of polyamine backbones in high overall yields. The great amount of commercially 
available acyl-building blocks enables the generation of large compound libraries, if the 
relatively harsh reduction conditions are tolerated.[92, 284] Examples for such libraries come 
again from Hall et al. and especially from Houghten et al., who based their ´Libraries from 
libraries´ concept on Amide reduction.[308-320] In this concept, the polyamines are only 
intermediates en route to other functional groups. The number of their published examples is 
extraordinary and so one should be mentioned as representative for the whole concept 
(Scheme 25).[320] N-alkylated tripeptide 163 was synthesised and reduced. After cleavage 
from the solid support, the free amines were converted to nitrosamines. 
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Scheme 25 Amide reduction in ´Libraries from libraries´. Polyamines are intermediates in the conversion to 
nitrosamines. Reagents and conditions: (a) 1. N -Boc-AA-OH, peptide coupling; 2. 5% TFA in CH2Cl2; (b) 1. 
TrtCl, DiPEA, CH2Cl2; 2. CH3I, tBuOLi, DMSO; (c) 1. 2% TFA in CH2Cl2; 2. 5% DiPEA in CH2Cl2; 3. 
N-Fmoc-AA-OH, peptide coupling; 4. 20% piperidine in DMF; (d) R3COOH, DIC, HOBt, DMF; (e) BH3?THF, 
65 °C; (f) HF / anisole, 0 °C; (g) EtONO, CH2Cl2.
[320] 
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3 Aims 
As displayed above, there is a need for improved methods of cellular delivery. Especially 
the covalently bound CPPs and their mimics are of interest (see 2.1.3). Polyamines previously 
found entry into the field of drug delivery as complexing-agents, but they were rather 
unattended as covalently bound carriers.[209, 218, 321] Their backbones are positively charged at 
physiological pH, making them potential candidates for drug delivery (see chapter 2.1.1 and 
chapter 2.2.4.5). As polyamines are also abundantly present in nearly all organisms, it can be 
expected that the toxicity of their conjugates is rather low compared to non-natural 
compounds.[52, 108]  
One probable reason for the less-regard of polyamines as covalently bound carriers is the 
limited scope of their synthesis. Polyamine syntheses are ideally carried out on solid phase. 
While rational solid phase strategies for the synthesis of a- and b-peptides, peptoids, and 
oligocarbamates are already established and can be automatised for combinatorial use, 
polyamine syntheses are much more difficult to unitise.[92, 169, 284] The necessity to use 
alkylation instead of acylation reactions for the generation of the backbone is disadvantageous 
as alkylation conditions are usually harsher than the conditions for peptide bond formation. 
Consequently, Amide reduction of short oligopeptides is the only established alkylation 
method for polyamine synthesis that has ever been applied in the formation of larger 
polyamine libraries (see chapter 2.3.4.5).[316, 322] However, the harsh conditions of the 
reduction make it unsuitable in the presence of sensitive groups, requiring a milder method for 
backbone elongation. The choice of an appropriate protection group strategy is also important. 
It should tolerate the method of backbone elongation, coupling to other molecules, and allow 
the introduction of branches into the backbone. 
To address the depicted points, the following aims were selected for of this thesis: 
 
Aim 1: Development of a suitable protection strategy for the mild solid phase synthesis of 
sensitive polyamine conjugates 
Aim 2: Development of coupling methods for the formation of sensitive polyamine-drug 
conjugates 
Aim 3: Synthesis of conjugates, which can be tested for their biologic activity 
Aim 4: Initial biological testing of the derived polyamine-conjugates concerning their 
potential to enhance cellular uptake 
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3.1 Aim 1: Development of a suitable protection strategy for the 
mild solid phase synthesis of acid sensitive polyamine 
conjugates 
As a prerequisite, trityl resins were chosen as solid support for the syntheses. It allows the 
liberation of the conjugates by such a mild acidic treatment, which is compatible with nearly 
all protection- and functional groups (see chapter 2.3.3.2). Otherwise, it is known that trityl 
resins are stable during the usual conditions of polyamine syntheses.[92] According to previous 
experiments in which fluorescence labelled derivatives of diverse polyamines were compared 
in terms of their uptake efficiency, spermine (16) was chosen as the scaffold for the 
polyamine backbones.[323] Thus, partially protected building blocks derived from spermine 
(16) should be prepared and loaded onto the trityl resin. The choice of the protection groups 
should allow a direct access to backbone elongation and side chain modification of the 
polyamine. An alkylation method, which converges with the protection groups strategy and 
allows efficient elongation of the backbone under mild conditions, should be identified. 
 
3.1.1 Protection strategy and synthesis of the building blocks 
Since the final conjugates in this work should derive from spermine (16), it is obvious to 
prepare protected entities based on the 3-4-3 polyamine skeleton. One pot procedures for the 
selective N4,N9-protection of spermine (16) with Boc-, Bn- and Tr-groups were reported, but 
the use of these protection groups was not suitable reach the aims of this thesis.[230, 251] Since 
Bn- and Boc-groups are removed with high concentrations of TFA in CH2Cl2, they cannot be 
used with highly acid labile trityl resins. After attachment to the resin the secondary amines 
would be blocked and their modification would no longer be possible. Additionally, the 
deprotection conditions are too harsh for the synthesis of highly acid labile polyamine 
conjugates. On the other hand, the synthesis of N4,N9-bis-tritylspermine 90c suffers from low 
yields and the huge sterical demand of the trityl groups prohibits the attachment to a bulky 
trityl linker.[251] Application of base labile protection groups such as Fmoc is excluded, as 
other amino functionalities, even if only temporarily liberated, can effect partial Fmoc-
deprotection. Indeed, the fluoride sensitive Teoc group fulfils the constraints in terms of 
orthogonality and mild removal. However, the reagents for its introduction (usua lly 4-
nitrophenyl 2-(trimethylsilyl)ethyl carbonate or the respective chloride) are too expensive for 
a large scale synthesis.[248] The Aloc group circumvents the above-depicted drawbacks. It can 
be introduced under modified Schotten-Baumann conditions using allyl chloroformiate.[248] 
Aloc protection is stable during cleavage of most other amino protection groups and linkers 
and it can gently be removed with Pd0 species.[268] The range of reported allyl-scavengers is 
broad and can be adjusted to different substrate susceptibilities. 
 
3.1.2 Alkylation procedure for backbone elongation 
There are four established methods for the elongation of polyamine backbones, SN2-
displacement, Fukuyama alkylation, reduction of amides and Reductive amination. All of 
these methods display certain limits for their applicability on solid phase (see chapter 2.3.4.3 
and chapter 2.3.4). The use of Aloc protection and the above-depicted drawbacks exclude the 
use of SN2-alkylation and reductive methods and thus, the Fukuyama alkylation is chosen. It is 
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selective for the generation of secondary amines and compared to the reductive methods all 
steps can be carried out under milder conditions.[92, 284, 324] Although particular efforts have 
been made to optimize the Fukuyama-Mitsunobu alkylation, it showed to be unsuitable for the 
generation of longer backbones.[263, 291] As Mitsunobu-conditions are also highly sensitive to 
air and humidity, the more robust reaction with halides should be applied.[243] A broad range 
of halides is commercially available or can easily be obtained from the corresponding 
alcohols by reaction with PPh3, iodine and imidazole.[243] There were only few examples of a 
conventional Fukuyama alkylation with halides on solid phase.[239] The above-mentioned 
study of Stromgaard et al. gave first information on the reaction and should be further 
investigated and optimised to allow the introduction of diverse functionalities and building 
blocks.[243] 
 
3.1.3 Introduction of side chain modifications 
Besides the generation of a polyamine backbone, it is important to achieve modifications of 
the backbone in order to introduce side chains. Efficient alkylation procedures for secondary 
amines were necessary. Fukuyama alkylation is not suitable, as it is restricted to the formation 
of secondary amines. Remaining approaches from the set of methods were SN2-alkylation, 
Reductive amination and Amide reduction after acylation of the secondary amines. These 
methods shall be explored for their potential to introduce side chain modifications. 
 
3.2 Aim 2: Development of coupling methods for the formation of 
acid sensitive polyamine-drug conjugates 
For the coupling of polyamines to acid sensitive molecules it is important to have methods, 
which allow a mild, quick, selective, and high yielding reaction. In the last years, some 
reactions for the chemoselective Bioconjugation emerged, which exhibit high selectivity and 
are sufficiently mild for the use with sensitive biomacromolecules (Table 3).[325-327] Such 
reactions enable the site-specific labelling and cross- linking of biomolecules.  
Sulfides and maleimides are frequently involved in such bioconjugation reactions (Table 3). 
This often origins in the fact that sulphur is a soft centre. It preferentially reacts with other 
soft centres like iodides, sulfenyls, or the b-position of a,b-unsaturated carbonyls (Entries 1, 
3, and 4 in Table 3).[328] Maleimides are also common; they specifically react with sulfides in 
a Michael addition or with 1,3-dienes in a Diels-Alder reaction. In both cases, the driving 
force is the reduction of the strong ring strain by conversion of the double bond forming 
carbons from sp2-hybridisation to sp3-hybridisation.[327] More recently, azides received 
emerged attention. Their reaction with alkynes is probably one of the most cited examples of 
the concept of Click chemistry, introduced by Sharpless in 2002.[325, 329, 330] This is due it 
perfectly suits the terms of this concept, namely a high driving force (1,3-dipolar 
cycloaddition), high selectivity, non-air and non-water sensitive educts, and simple reaction 
conditions. The traceless Staudinger ligation also found increasing attention for the same 
reason as the 1,3-dipolar cycloaddition between azides and alkynes.[331, 332] Bioconjugation 
via the Michael addition of a thiolate, often from the side chain of a cysteine residue, to a 
maleimide to form a succinimidyl thioether is especially common. The addition proceeds 
rapidly and in high yield in neutral aqueous solutions at room temperature, making it ideal for 
biological applications. It has been frequently used for the coupling of oligonucleotides, 
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peptides, and other large molecules.[333-337] Its advantages are the formation of a stable, non-
reducible thioester bond and the quick reaction in high yield. The reaction does not need any 
catalyst and is traceless. For the generation of a polyamine with a maleimido-binding site, a 
compound that allows the introduction of the maleimide under avoidance of cross- linking on 
the resin should be prepared. Finally, the coupling reaction should be investigated with some 
model compounds and integrated into the established synthetic scheme (Aim 1, see chapter 
3.1). 
Table 3 Some common bioconjugation reactions. 
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3.3 Aim 3: Synthesis of conjugates and tests of their biologic 
activity  
After development of the synthetic methods, the derived knowledge should be used to 
synthesise polyamine conjugates, which can be tested for their biological activity. Cargo 
molecules are: 
1. Fluorophores 
2. Porphyrins and radical scavenger 
3. Indomethacin 
4. Oligonucleotides 
 
3.3.1 Fluorophores 
Incubation with fluorophore-labelled compounds is one possible approach to determine the 
uptake of polyamines and their conjugates into cells.[78, 82, 84] If cells are incubated with 
polyamino-fluorophores, the migration and accumulation of the latter can be investigated by 
fluorescence microscopy of the living cells. This method is very demonstrative for the 
temporal and spatial resolution of the uptake process. Co- localisation experiments with 
fluorescent sub-cellular markers will enable the assignment compartments, reached by the 
fluorophore.  
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Figure 23 Structures of the fluorophoric compounds rhodamine B and NBDCl. 
In similar experiments with peptoids, which were executed in the group, rhodamine B 167 
was used for the labelling and showed good results in cell tests (Figure 23).[82] Another 
prominent fluorescent marker is 7-nitro-1,2,3-benzoxadiazole-4-yl (NBD) 168.[338-341] Due to 
the electron-deficient ring system of NBDCl the chlorine can be displaced in an SNAr reaction 
with an amine. In both cases the amine used for the coupling is no longer charged at 
physiological pH. In case of NBD, aniline with three electron-withdrawing substitutions on 
the ring is generated by this reaction. The pKb value of aniline is 9.34 and as basicity is 
distinctly decreased by the substitutions of the phenyl ring, it is not protonated under 
physiological conditions.[342] As it is known that enhanced lipophilicity improves the uptake 
of cationic conjugates by tightening them to the membrane, polyamine with lipophilic parts 
should be synthesised. A schematic illustration of such a lipophilic conjugate is shown in 
Figure 24.  
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Figure 24 Schematic description of the NBD-labelled polyamines with lipophilic modifications. 
Although NBD allows transversal diffusion, it is a polar moiety and would therefore be 
pushed out of the bilayer to the aqueous media. Thus, it should be attached to the polar part of 
the molecules. 
 
3.3.2 Porphyrins and radical scavenger 
Photodynamic therapy (PDT) is an important application in the treatment of age-related 
macular degeneration, various skin disorders, and an increasing number of cancers.[343-347] 
Photosensitizers are administered to initiate a light-activated destruction of a variety of 
tissue.[348-352] The porphyrin is excited by light of a certain wavelength. In the presence of 
oxygen, this excited state of the porphyrin is relaxed by excitation of triplet- into singlet 
oxygen. This singlet oxygen is a highly reactive di-radical species, which readily reacts with 
unsaturated molecules.[349, 351] DNA, RNA, aromatic amino acids, and especially unsaturated 
fatty acids are target for these oxidation- and peroxidation reactions.[351] It is known that 
peroxidised fatty acids play a role as mediators of apoptotic cell death. If delivered into the 
right cellular compartments, cell death can specifically induce apoptosis and not necrosis.[353-
355] 
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Figure 25 Schematic description of excitation and relaxation of a porphyrin. Two processes can be initiated by 
irradiation with particular wavelengths. Either leads to red fluorescence, while excitation at longer wavelength 
promotes the porphyrin to a level from which it can return by inter system crossing followed by transfer of its 
energy to an oxygen molecule (if present), or fluorescence at a longer wavelength. 
A highly lipophilic porphyrin should be coupled to the polyamine. This lipophilicity is 
especially important, as the efficiency of porphyrins in PDT mainly depends on the 
environment of the tetrapyrrole ring. Lipophilic porphyrins are able to penetrate deeply into 
the membrane in order to generate cytotoxic singlet oxygen in direct neighbourhood to 
unsaturated fatty acids and to cause membrane destabilisation. This localisation inside the 
membrane strongly enhances the phototoxic efficiency of porphyrins. 
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Figure 26 Structure of a lipophilic porphyrin, kindly provided by the group of Prof. Dr. T.S. Balaban. This 
porphyrin should be coupled to a polyamine. The conjugates can be visualised for live microscopy by the 
fluorescence of the porphyrin at 420 nm. Depending on the wavelength, the porphyrin can also be excited to 
generate singlet-oxygen, which will cause local cell damage. This could finally be used for therapeutic 
applications. 
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Water solubility and a potential site for interaction with the outer membrane should be 
provided by the polyamine modification. The polyamine should be coupled to only one side 
of the porphyrin via an appropriate spacer, assigning it a highly amphiphilic structure. The 
introduction of a linker should allow the porphyrin to maintain flexibility once the polyamine 
part has attached to the membrane. Polar porphyrins are not able to penetrate into membranes 
and there, they only evolve minimal parts of their photodynamic potential. However, unpolar 
porphyrins are only poorly soluble in water and they are not easy to apply to aqueous media. 
The described polyamine-porphyrin conjugate should supersede these drawbacks of both, 
polar and unpolar agents. Besides the knowledge about the temporal and spatial effects of 
porphyrins in PDT, it is interesting to enable its deactivation. This could be achieved by 
delivery of a compound, which aborts its efficacy. The polycyclic compound 170 shown in 
Figure 27 is able to quench singlet oxygen by transforming it into the less detrimental triplet 
oxygen.[356] 
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Figure 27 Structure of a radical scavenger, kindly provided by the group of Prof. Dr. K. Müllen. The molecule is 
able to quench singlet oxygen and transform it into the less detrimental triplet oxygen.  
As it bears a maleimido group, binding to a polyamine via the above-mentioned maleimido 
thiol chemistry should be possible (Aim 2, see chapter 3.2). 170 is unstable to various 
conditions and thus, the conditions for coupling and liberation of the product should be mild. 
3.3.3 Indomethacin 
Indomethacin (171) is a non-steroidal anti- inflammatory drug, which was discovered in 
1963 and first approved for use in the U.S. in 1965 (Figure 28). It is commonly used to reduce 
fever, pain, stiffness, and swelling. Its mode of action, elucidated in 1971, consists of 
inhibition of the prostaglandin biosynthesis.[357-360] 
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Figure 28 Structure of Indomethacin, a methylated indole derivative, which acts as COX-2 inhibitor. 
Aims 
 59
It inhibits the cyclooxygenase, COX-1 and COX-2, which catalyse the formation of 
prostaglandins from arachidonic acid. In contrast to COX-1, which produces the baseline 
levels of prostaglandins, COX-2 is responsible for the prostaglandins biosynthesis through 
stimulation. Especially enhanced COX-2 activity often mediates inflammatory processes. As 
prostaglandins induce uterine contractions in pregnant women, indomethacin is also an 
effective tocolytic agent. However, it is highly recommended to prescribe indomethacin only 
in lowest doses, as it shows several adverse effects. Those are for example peptic ulcers, 
edema, hyperkalemia, hypernatremis, hypertension (the latter four caused by retention of 
alkali metal ions), renal damage, and skin reactions. Thus, it is desirable to enhance the 
efficiency of Indomethacin-uptake in order to reduce the required dose and the adverse 
effects. Evidence was presented that the carboxylic acid of indomethacin (171) is not essential 
for the activity of indomethacin to act as COX-inhibitor.[361] Esters as well as primary or 
secondary amides of indomethacin (171) have shown to be equally well or superior 
COX-inhibitors, which beneficially show improved activity against COX-2 compared to 
COX-1, if related to indomethacin (171).[362] Tertiary amides were less active than carboxylic 
acid of indomethacin (171). Furthermore, it was shown that the 4-chlorophenyl and the 2-
methyl group are essential for the activity of both, indomethacin (171) and its carboxylic acid 
derivatives. Modification on them should hence be avoided. Thus, conjugates of indomethacin 
(171) and polyamines should be prepared. A primary amine should serve for the coupling to 
the carboxylic acid of Indomethacin. The conditions during the synthesis should be 
sufficiently mild to avoid side reactions, especially as the 4-chlorobenzamide of indole is 
sensitive.  
 
3.3.4 Preparation of polyamino-oligonucleotide conjugates 
For modern medicinal approaches like gene therapy, reliable methods for the delivery of 
DNA into cells are important.[8] Complexes of lipo-polyamines and DNA have already shown 
to be efficient delivery systems for genetic material.[92] However, the lipophilic polyamines 
showed strong toxicity after longer treatment at higher doses.[91] Covalently coupled 
polyamines could reduce this problem. In analogy to the promising results that were obtained 
with conjugates of CPPs and their mimics, one to one-polyamine-oligonucleotide conjugates 
should be prepared. The strong electrostatic interactions between polyamines and highly 
negatively charged oligonucleotides complicate the development of such conjugates. As 
already mentioned in the introduction, the biological function of spermine (16) involves 
complexation of DNA.[91, 92, 247] This is expected to cause difficulties in the selected formation 
of 1 : 1-conjugates between polyamines and DNA. 
Two approaches should be investigated in the course of this work (Figure 29). One is the 
direct coupling of modified polyamines with oligonucleotides bearing a specific binding site. 
In this approach, the strategy comprises a complete protection and mild deprotection after 
coupling. The coupling / deprotection process should be established on solid phase as the 
terminal step after the synthesis of the polyamine. The second approach is the attachment of a 
polyamine to nucleotides and the subsequent enzymatic integration of the triphosphate into an 
oligonucleotide. This method gives more flexibility in terms of the positioning of the 
modification in the DNA-strand.[363, 364] However, it would either be suitable for modification 
with smaller polyamines, since the enzymatic integration does not tolerate too bulky 
substrates. The methods for modification should be mild with respect to the sensitivity of 
triphosphates.[365] 
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Figure 29 Schematic descriptions of the strategies for the formation of polyamino-oligonucleotide conjugates. 
 
3.3.4.1 The bioconjugation approach 
The maleimido-thiol coupling should be tested for its feasibility in the formation of 
polyamino-oligonucleotides. Thiol-modified oligonucleotides are commercially available and 
can be readily inserted into the reaction with immobilised polyamino-maleimides. 
 
3.3.4.2 Preparation of polyamino-modified nucleotides and attachment to DNA-
oligomers  
For the incorporation of polyamine modification to the terminus of a DNA strand it is 
necessary to synthesize linker-modified nucleoside-triphosphates, which enable an efficient 
coupling. This approach is based on a previously reported strategy from Taira et al., in which 
a modified cytidine 331, bearing a maleimido group linked to the base moiety of the 
nucleoside, was synthesised.[364] The derivatised nucleoside was then triphosphorylated and 
attached to the 3’-terminus of a DNA-strand by a terminal desoxy transferase (tdT). 
Eventually, the oligonucleotide was coupled to the free cysteine of an oligopeptide by a 
Michael addition. Variation of the order of triphosphorylation, introduction of binding site 
and coupling to the polyamine moiety shall allow the transfer of this concept from peptides to 
polyamines. Additionally, other nucleosides / nucleotides, also bearing maleimido binding 
sites, should be prepared and coupled to polyamines. 
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3.4 Aim 4: Preliminary biological testing of the derived 
polyamine-conjugates 
All conjugates (Aim 3, 3.3) should be tested with regard to the potential of covalently 
coupled polyamines to act as delivery agents. For the four classes of conjugates, the following 
testing should be executed: 
 
3.4.1 Fluorophores 
The conjugates should be studied by fluorescence microscopy of living cells. Special 
attention should be paid to the subcellular localisation of the conjugates. Several fluorescent 
sub-cellular markers are available, which can be used to determine the intracellular fate of the 
rhodamine B- or NBD-labelled polyamines. The toxicity of the conjugates should also be 
determined. 
 
3.4.2 Porphyrins and radical scavenger 
In analogy to the fluorescent dyes, cells should be incubated with the polyamine-porphyrin 
conjugate. The localisation of the conjugates inside mammalian cells should be determined by 
co-localisation with subcellular markers and subsequent fluorescence microscopy of the living 
cells. The effect of irradiation should be investigated to get at least qualitative information 
about the phototoxic efficiency. Co- incubation of different cell types and following 
incubation should reveal information about uptake preference for certain cells. The dark 
toxicity of the conjugates should be determined. Fina lly, this should illuminate the suitability 
of the polyamine-porphyrin conjugate to be used for PDT. The conjugate of polyamine and 
170 should also be tested for its ability to enter cells. In order to test the facility to achieve 
temporal control over the potency of photodynamic treatment, this conjugate should be co-
incubated with polyamine-porphyrin conjugate. The influence on the action of 217 should be 
determined. 
 
3.4.3 Indomethacin 
The influence of polyamine homologation should be investigated by comparison of the 
effects of polyamine- indomethacin conjugates with indomethacin (171). The toxicity of the 
conjugates should be determined and compared with the respective values of indomethacin 
(171) in order to find out, if effects in toxicity go hand- in-hand with the uptake properties.
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4 Results 
4.1 Development of a suitable protection strategy for mild solid 
phase synthesis of polyamines 
4.1.1 Solution phase syntheses of the building blocks 
4.1.1.1 Symmetric building blocks 
For the introduction of different protection groups onto secondary and primary amines, a 
procedure with Boc as permanent protection group for the secondary amines and Tfa as 
temporary protection group for the primary amines was adapted and slightly modified 
(Scheme 26).[230] Spermine was selectively protected at the primary amines with ethyl 
trifluoroacetate. The second protection groups were introduced with the respective chloride in 
the presence of equimolar amounts of a base to remove the released HCl. The Tfa groups 
were removed by addition of aqueous sodium hydroxide and N4,N9-bisprotected building 
blocks 179a and 179b were obtained in good to excellent yield (Scheme 26). 
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b
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R1 = H or COCF3
R2 = H or PG  
Scheme 26 Synthesis of spermine building blocks. Reagents and conditions: (a) F3C-COOEt, MeOH, –80 °C; 
(b) Aloc-Cl and Et3N or o -Nosyl-Cl and DiPEA, 0 °C to r.t.; (c) NaOHconc / H2O, r.t. 
Depending on the initial excess of ethyl trifluoroacetate, the ratio between bis- and tris-
protected spermine could be regulated (Table 4). Symmetric (178 and 180) or asymmetric 
(179 and 181) building blocks were obtained (Figure 30). The yields for the o-Nosyl protected 
spermine derivates 180 and 181 were lower than those of the Aloc protected building blocks 
178 and 179 (Table 4). TLC-monitoring during the reaction showed that this arose from 
slower reaction of the second and third amine with the o-Nosyl chloride, which hinders the 
overall protection of all amines. This slower reaction of o-Nosyl chloride with secondary 
amines has previously been used for the quasi-selective protection of primary amines in the 
presence of secondary amines with equimolar amounts of o-Nosyl chloride (see chapter 
2.3.3).[366] Additionally, the o-Nosyl group is not fully stable against the basic conditions of 
the Tfa deprotection.[248] 
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Table 4 Control of the ratio of symmetric and asymmetric building blocks by variation of the excess of TfaOEt.  
Excess of 
TfaOEt 
Excess of 
chloridea 
Reaction 
timeb 
Yield of bis-protected 
building block 
Yield of tris-protected 
building block 
Aloc protected building blocks 
1.2 equiv. 6 equiv. 17.5 h 44% 23% 
1.2 equiv. 14 equiv. 22 h n.d. 24% 
1.1 equiv. 6 equiv. 7.5 h 27% 49% 
2 equiv. 6 equiv. 3 h 54% n.d. 
1.9 equiv. 6 equiv. 26 h 21% n.d. 
2.8 equiv. 5 equiv. 8.5 h 85% n.d. 
3.0 equiv. 5 equiv. 26 h 99% n.d. 
3.5 equiv. 5 equiv. 1.5 h 72% n.d. 
o-Nosyl protected building blocks 
1 equiv. 15 equiv. 41.5 h 7% 29% 
a Equimolar or higher amounts of a tertiary nitrogen base were used. 
b As reaction control by TLC indicated that the final deprotection with aqueous NaOH was complete in each 
case, the reaction time is given for the introduction of the protection groups starting from spermine (16). 
Addition of Tfa-OEt was accomplished during the first 30 min in each case. 
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Figure 30 Building blocks obtained from the reaction sequence in Scheme 26. 
The symmetric building block 178 was coupled to a conventional 2-chlorotrityl resin 
(loading: 1.3 mmol/g)[367-369] and an alkoxytrityl resin (loading approximately 0.4 mmol/g)[239, 
261] by slowly adding the resin to a large excess (up to 50 equiv) of 178 according to 
previously published solid phase polyamine syntheses.[230] However, further derivatization 
and cleavage from the resin revealed a large portion of non-derivatised educt 178,  due to 
cross- linking of the symmetric spermine building block, which seemed to be independent 
from the excess, as long as more than 10 equiv. were applied (Figure 31). Those results 
indicate that once the polyamine is immobilized, the second primary amine reacts with higher 
rate than the free, mobile diamines. Probably, this is induced by the proximity of multiple 
trityl linkers to the immobilised primary amine as well as by the hindered diffusion of 
diamines from the outside of the resin beads. 
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Figure 31 Loading of trityl resins with diamines building blocks. The reaction (a) is dimished by the 
cross-linking of two amines with the resin (b). 
Cross-linking is a major problem, which frequently occurs during coupling of polyamines 
with two terminal primary amino groups.[287] It leads to a decrease of the resin loadings and to 
contamination of the final coupling product with the polyamine after cleavage from the resin. 
In most cases the impurities are hard to separate and reduce the advantage of solid phase 
synthesis. Previously, resin cross- linking during further derivation of already- loaded 
polyamines was prevented by lowering the  capacity of the resin. This was done by blocking 
about 50% of the linker binding sites.[285, 370] However, there are only a few reports on 
crosslinking during the polyamine loading steps[287], although decreased yields indicate 
similar problems.[220] To avoid crosslinking, one of the primary amines was protected to 
ensure an unambiguous course of the reaction, which is more efficient than considerably 
lowering the resin capacity. 
 
4.1.1.2 Asymmetric building blocks 
Symmetric building block 178 was monoprotected with an o-Nosyl- or a Dde group, 
respectively (Scheme 27), by reaction with a substoichiometric amount of acetyldimedone or 
o-Nosyl chloride in the presence of a base. The asymmetric building blocks 186 and 187 were 
obtained in 54% and 79% yield related to the onset of acetyldimedone or o-Nosyl chloride. 
The best results with respect to the avoidance of the fully protected spermine derivates were 
obtained, if the acetyldimedone or o-Nosyl chloride was slowly added to a solution of 178 and 
the base. In this case, large portions of the initially applied 178 were recovered and could be 
reused in further reaction cycles. Unfortunately, TLC showed the appearance of two 
additional spots already after short agitation of pure mono-Dde-bis-Aloc-spermine 186 in 
solution. While the 1H NMR remained identical, two signals in the mass spectra emerged, 
which were consistent with transamination of the Dde group. In contrast, 187 was stable to 
aqueous solutions of pH-values from 1 to 14, 15 M ammonia solution, and temperatures up to 
80°C. 
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Scheme 27 Protection of one primary amine with orthogonal protection group. Reagents and conditions: (a) 0.6 
Equiv. Dde-OH, 0.6 equiv. DiPEA, MeOH, 16 h, r.t.; (b) 0.6 equiv. o-Nosyl-Cl, 1 equiv. collidine, CH2Cl2, 20 h, 
r.t. 
This stability of Aloc- and o-Nosyl group to aqueous acidic conditions greatly facilitates the 
workup procedure. While the bis-protonated form of 178 and collidine could be extracted 
with half concentrated HCl, the mono-protonated form of 187 completely remained in the 
organic layer. After removal of collidine from the combined aqueous layers in high vacuum, 
178 was recovered in high purity. This acidic treatment is the key-step in the workup-
procedure and is not compatible with Boc or Mmt-protection groups, which are sensitive to 
aqueous solutions with a pH below 5.[248] Hydrolysed o-Nosyl chloride was removed by 
quickly washing the organic layers with NaOH (0.5 M). The resulting crude mixture primarily 
contains 187 and traces of the bis-nosylated side product, which can easily be separated by 
filtration over a short bed of silica gel. The bis-nosylated side product is also a useful building 
block for polyamine synthesis, making the whole procedure very atom-economic. Finally, all 
of the inserted spermine (16) was converted into valuable entities. 
 
NH2H2N NH
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Scheme 28 Synthesis of a small asymmetrically protected building block derived from 1,3-diaminopropane. 
Reagents and conditions: (a) 0.6 Equiv. o-Nosyl chloride, 1 equiv. collidine, CH2Cl2, 19.5 h, r.t. 
Diaminopropane (24) was monoprotected with o-Nosyl using the conditions described 
above (Scheme 27). The stoichiometric reaction revealed 188 in 47% yield related on the 
onset of o-Nosyl chloride. (Scheme 28) 
 
4.1.1.3 Building block for backbone elongation 
For the modification and elongation of the backbone by Fukuyama alkylation another 
asymmetric building block was required, which should contain an electrophile and a protected 
amine. Amino alcoho ls are the ideal starting material for this purpose as they are less 
expensive and both functional groups can easily be distinguished for modification of the 
building block. The amino group in 3-aminopropanol was protected with Dde 191 in analogy 
to Scheme 27. Dde was chosen as it can quickly be removed with hydrazine hydrate. Likewise 
it was previously shown that it is compatible with the conditions of Fukuyama-Mitsunobu 
alkylation. 
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Scheme 29 Synthesis of an N-protected aminoiodide starting from dimedone. Reagents and conditions: (a) 1.5 
Equiv. acetylchloride, 1.1 equiv. pyridine, CHCl3, 30 min, r.t.; (b) 2 equiv. AlCl3, CHCl3, 1 h, r.t.; (c) 2 equiv. 
3-aminopropanol, 1.2 equiv. DiPEA, MeOH, 6.5 h, r.t.; (d) 1.1 equiv. PPh3, 1.2 equiv. I2, 1.5 equiv. imidazole, 
CH2Cl2, 30 min, 0°C to r.t.
[225] 
2-Acetyldimedone 191 was prepared by acetylation of dimedone 189 with acetylchloride 
and subsequent rearrangement with AlCl3 giving 51% yield over two steps (Scheme 29).[371] 
The Dde group 191 was reacted with an excess of 3-aminopropanol in presence of DiPEA 
resulting in protection of the amine of 3-aminopropanol in 78% yield.[225] Conversion of the 
hydroxyl group into the iodide was accomplished by a modified Appel reaction with PPh3, I2, 
and imidazole.[243] Finally, 82% yield in this step led to an overall yield of 33% for a four step 
synthesis of 193 starting from 2-acetyldimedone.[372] 
 
4.1.1.4 Building block for maleimide introduction 
For the introduction of a maleimide onto a polyamine, a building block 196 was prepared, 
which bears the carboxylic acid function pre-activated as NHS-ester (Scheme 30). This should 
prevent a potential side reactions between maleimide and amines, which can take place, if the 
peptide bond formation is slow. The building block is prepared by reaction of 3-
aminopropioinic acid (194) with 1.2 equiv. of maleic anhydride, followed by 2.4 equiv. of 
DCC and 1.5 equiv. of NHS.[373, 374] 
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Scheme 30 Synthesis of the activated building block 196 for the introduction of maleimides. Reagents and 
conditions: (a) 1.2 Equiv. maleic anhydride, DMF, 120 min, r.t.; (b) 2.4 equiv. DCC, 1.5 equiv. 
N-hydroxysuccinimide, DMF, 150 min, 0 °C then 16 h, r.t.[374] 
All building blocks were stable during storage at -20°C. In the case of building block 196, 
moisture was avoided to avoid slow hydrolysis of the ester linkage. Due to the risk of 
oxidation and addition of carbon dioxide to the free amines, they were kept under argon 
during all reactions. The reproducible yields of alkylation reactions with the iodide (Table 7) 
indicate that it does not significantly suffer from hydrolysis under those conditions. 
Results 
 67
4.1.2 Reactions on solid phase 
4.1.2.1 Optimisation of loading conditions  
To find the optimal conditions for the attachment of building block 187 to a trityl resin, with 
respect to an easy recovery of 187, the use of different bases, solvents, and excess of building 
block 187 was investigated. 100 mg of an alkoxytrityl resin 61 were activated with SOCl2 and 
subsequently reacted under the conditions depicted in Table 5.  
Table 5 Attachment of 187 to a Fukuyama-trityl resin. 
N
H
N
N
H
N
Aloc
Aloc
Conditions from 
Table 5, r.t., 3h
o-Ns
+ 187
OH
Alkoxytrityl resin
61 197
 
 
Entry Base  Solvent Excess (equiv.) Loading (mmol/g)a 
1 - CH2Cl2 10  0.240 
2 Pyridine / CH2Cl2 (1:1)  10  - 
3 DMAP (0.2 equiv)  Pyridine 10  0.012 
4 Et3N (5 equiv) CH2Cl2 10  0.426 
5 DiPEA (2.5 equiv) CH2Cl2 5  0.355 
6 DMAP (1 equiv) CH2Cl2 5  0.351 
7 Pyridine (2 equiv) CH2Cl2 5  0.354 
8 DiPEA (2.5 equiv) CH2Cl2 10  0.424 
a Loadings were calculated by addition of 1,4-dioxane as a quantitative NMR standard. 
 
10 equiv of building block 187 and 2.5 equiv DiPEA in dichloromethane provided the best 
loadings. The addition of a base seemed to be necessary to get feasible loadings within a short 
time. The choice of the base was of minor importance, although it should be mentioned that 
large excess of Et3N and pyridine partially blocked the linker. Longer reaction times than 3 h 
did not produce significantly higher loadings. After loading of the resin, excess of building 
block 187 could easily be recove red by the removal of solvent and Hünig’s base in vacuum or 
by extraction of DiPEA with diluted hydrochloric acid from the filtrate. Recovered building 
block 187 could be reused in further reactions. 
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4.1.2.2 Aloc deprotection 
During deprotection of the Aloc-groups the formation of the stable allylamines was 
constantly observed (Table 6). This was probably due to the close proximity of the liberated 
amines, which could themselves act as allyl-scavenger during deprotection.[248] 
Table 6 Aloc deprotection with different scavengers.a 
N
H
N
N
H
N
Aloc
Aloc
o-Ns
198
Conditions 
from Table 6
N
H
N
H
H
N
H
N
o-Ns
2-Chlorotrityl resin
199  
 
a If not indicated, the reactions were carried out at room temperature. 
b Amounts were calculated from the Aloc-corresponding integrals in the 1H NMR spectra of the crude product 
relative to those in 187. The b-amino / carbamoyl-methylene groups of the spermine backbone between 1.3 and 
2.1 ppm were set to be 8.0. 
 
Scavenger 
Excess of 
scavenger 
(equiv.) 
Amount of 
Pd(PPh3)4 
(mol%) 
Reaction 
time 
Deprotection 
in%b 
Allylamine 
formation 
in%b 
Pyrrolidine 10 50 20 h > 99% 33 
 20 20 16 h > 99% 10 
 20 5 21 h 27 0 
 20 1 21 h 0 0 
PhSiH3 9 20 3 h > 99% 20 
 10 5 1.5 h > 99% 12 
 20 1 2 h 0 0 
Me3SiN3 10 15 17 h 83 10 
 8 10 17 h 68 1 
Dimedone 10 15 17 h 4 0 
 8 10 17 h 29 0 
 8 10 0.5 h 0 0 
DMBA 10 10 2 h / 35°C 99 < 1 
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Higher amounts of the Pd-catalyst as well as decreasing levels of scavenger enforced the 
allylamines formation, while in the vice versa situation the deprotection was incomplete even 
after long reaction times. Basic scavengers, hydride donors, and azides combined with a 
silylating agent did not sufficiently suppress the allylamine formation. From those results, it 
can be concluded that some scavengers, which are usually known to prevent allylamines 
formation during Aloc deprotection, are not efficient during their use with polyamines. 
Usually, the carbamate, which is liberated after transfer of the allyl moiety to the palladium 
catalyst, is directly converted to the respective silyl-carbamate in cases of phenylsilane or 
trimethylsilyl azide and allylation is avoided.[268] The consequent use of anhydrous conditions 
and application of high excess of scavenger, make it improbable that the side reaction simply 
arises from partial hydrolysis of the silyl-oxygen bond. It is more likely that allylamines 
formation derives from a spontaneous elimination of CO2, which is known to proceed quicker 
on secondary amines than on primary amines, and a subsequent destruction of the proximate 
silyl-carbamates by the liberated secondary amines.[268] Indeed, dimedone reprotonated the 
deprotected amine to some extend and thereby avoided this problem but resulted in only poor 
deprotection even after 17 h. Usually, Rh- or Ni-catalysts are used to remove allylamines.[248] 
Due to their costs and the fact that heavy metal complexes are hard to separate from the resin, 
their use did not display an elegant solution of the problem. In solution phase, it was reported 
that allylamines can be removed at a slightly raised temperature in presence of Pd-catalyst 
using N,N’-dimethylbarbituric acid as scavenger (Table 6).[375] Finally, reaction with 10 equiv 
of scavenger and catalyst loading of 10 mol% for 2 h at 35°C resulted in full deprotection 
without allylamine formation. The o-Ns-protection remained unaffected under those 
conditions.  
 
4.1.2.3 Versatility of the protection group strategy - synthesis of HO359b 
To prove the versatility of the Aloc- / o-Nosyl protection strategy, resin 198 was used for 
the solid phase synthesis of philanthotoxin analogue HO359b (203) (Scheme 31), which so far 
has only been synthesized in solution phase.[376, 377] The o-Nosyl group was removed from 
198 with b-mercaptoethanol / DBU. It was visible by the rapid yellow colouration of the 
suspension that the o-Nosyl deprotection proceeded quickly. 2-Indoleacetic acid was coupled 
to the free primary amine of 200 by peptide bond formation. Complete removal was 
accomplished either by triple treatment with 10 equiv. of ß-mercaptoethanol and 5 equiv. of 
DBU for 15 min or by treatment with 20 equiv. of both over night. Three methods for peptide 
bond formation were examined. Attempts with pivaloylchloride / DiPEA and PyBrOP / 
DiPEA for activation did not result in satisfactory coupling. In contrast, the use of DCC in 
combination with HOBt led to full acylation of all free primary amines, as monitored by the 
Kaiser Test. After Aloc-deprotection as described above (Table 6) and cleavage from the 
resin, HO359b (203) was obtained in 90% yield and 93% purity, demonstrating the suitability 
of this protection group strategy. 
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Scheme 31 Synthesis of philanthotoxin analogue HO359b. Reagents and conditions: (a) 10 Equiv. 
b-mercaptoethanol, 5 equiv. DBU, DMF, 3 * 30 min, r.t.; (b) 5 equiv. indoleacetic acid, 5 equiv. DCC, 5 equiv. 
HOBt, DMF, 16 h, r.t.; (c) N,N -´dimethylbarbituric acid (10 equiv), Pd(PPh3)4 (0.2 equiv), CH2Cl2, 35°C; (d) 
TFA (5%) / CH2Cl2.
[324] 
 
4.1.2.4 Investigation on Fukuyama alkylation 
As mentioned above, there was one initial attempt to investigate conventional 
Fukuyama alkylation. The use of different solvents, leaving groups, bases, temperatures, and 
numbers of reaction cycles was investigated.[243] However, the suggested reaction conditions 
were only applied to simple alkyliodides and N-protected aminoiodides and thus, this gives no 
information on the tolerance of other functional groups. After all, the method requires 
18 equiv. of the respective iodides. To confirm the versatility of the chosen protection group 
strategy with the conditions of Fukuyama alkylation and to explore the possibility to 
incorporate functional groups and structural elements into the polyamine skeleton, the 
reaction was investigated with various halides under two sets of conditions (Table 7). The 
first set was oriented on the original Fukuyama conditions (electrophile (20 equiv.), K2CO3 
(20 equiv.), 60°C or room temperature, 18 h), which were milder but, due to the weak base, 
resulted in lower deprotonation and hence lower displacement rates. As the originally applied 
20 equiv. could be critical for the use of valuable and expensive halides, the reaction was 
tested with 13 equiv. of either of them. The second set of conditions (electrophile (6 equiv), 
DBU (6 equiv), r.t., 3 – 5 h) gives higher deprotonation rates but provokes side reactions due 
to the stronger basicity of DBU. 
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Table 7 Conversion of halides in the Fukuyama alkylation. 
N
H
N
N
H
N
Aloc
Aloc
o-Ns
N
H
N
N N
Aloc
Aloc
o-Ns
R
R = alkyl moiety 
of the halides
K2CO3 or DBU, 
halide, DMF
198
204
 
 
Entry Halide Base  Reaction time Temperature  Conversion in%
a 
1 BrCH2  
K2CO3 
DBU 
DBU 
DBU 
18 h 
18 h 
8 h 
3 h 
r.t. 
r.t. 
r.t. 
r.t. 
20 
98 
100 
97 
2 BrCH2 NO2  
K2CO3 
DBU 
DBU 
10 h 
18 h 
8 h 
60°C 
r.t. 
r.t. 
30 
80 
59 
3 BrCH2 CF3  
DBU 
DBU 
DBU 
30 h 
5 h 
3 h 
r.t. 
r.t. 
r.t. 
93 
78 
66 
4 BrCH2 SMe  
DBU 
DBU 
5 h 
3 h 
r.t. 
r.t. 
95 
84 
5 
BrCH2
Br
 
DBU 
DBU 
5 h 
3 h 
r.t. 
r.t. 
87 
95 
6 
BrCH2 CO2Me
O2N
 
DBU 3 h r.t. 37 
7 ClH2C OMe  DBU 3 h r.t. 86 
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8 Br  DBU 3 h r.t. 97 
9 I  DBU 3 h r.t. 91 
10 Br
Br  DBU 3 h r.t. 92 
11 Br 12 
K2CO3 
DBU 
18 h 
3 h 
r.t. 
r.t. 
89 
38 
12 Br 2 Br  
K2CO3 
K2CO3 
DBU 
18 h 
18 h 
3 h 
60°C 
r.t. 
r.t. 
57b 
68 b 
45 b 
13 Br
2
S
O
 
K2CO3 8 h 60°C 93 
14 
Br  
K2CO3 
K2CO3 
DBU 
8 h 
18 h 
3 h 
60°C 
r.t. 
r.t. 
97 
48 
2 
15 Br O 
K2CO3 
DBU 
18 h 
3 h 
r.t. 
r.t. 
44 
20 
16 Br
OMe
O  
K2CO3 
DBU 
18 h 
3 h 
r.t. 
r.t. 
75 
22 
17 Cl  
K2CO3 
K2CO3 
DBU 
DBU 
18 h 
18 h 
3 h 
3 h 
60°C 
r.t. 
r.t. 
r.t. 
47 
6 
1 
1 
18 Cl SiMe3  
K2CO3 
DBU 
DBU 
18 h 
3 h 
3 h 
r.t. 
r.t. 
r.t. 
< 5 
< 5 
0 
19 
I O
O
 
K2CO3 
DBU 
18 h 
3 h 
r.t. 
r.t. 
86 
35 
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20 I N
H
Dde
 
K2CO3 
DBU 
18 h 
3 h 
60°C 
r.t. 
98 
3 
a After cleavage from the resin, the conversions were determined by the RP-HPLC peak integration of the 
product peak in comparison to remaining educt and side products (UV-detection at 254 nm). 
b The amount of 1,4-dibromobutane was raised to 20 equiv in order to minimize cross-linking of the resin. The 
yield of the cross-linked product was found in 17% (for K2CO3, 18 h, 60 °C), 14% (for K2CO3, 18 h, r.t.) and 
20% yield (for DBU, 3 h, r.t.). 
 
The results from Table 7 can be summarized as follows:  
Benzyl- and allylhalides require DBU as a base. In the presence of K2CO3, the conversion was 
low in each case. Benzyl bromide shows the best result, while electron-rich are superior to 
electron-deficient benzyl compounds (Entries 1 – 10). In some cases, extension of the reaction 
time to five hours or more accomplished desirable conversions of 95% or more. In crucial 
examples (Entries 2 and 3), it should be possible to achieve nearly quantitative conversion by 
slightly raising the temperature or by repetitive treatment of the resin with 6 equiv. of 
DBU / halide. Finally, Entry 6 revealed no alkylation product according to Fukuyama. 
Instead, the formed Fukuyama-product 205 showed deprotonation at the benzyl position of 
the electron-deficient ring system. Subsequent nucleophilic addition in ipso-position of the 
o-Nosyl group and SO2 elimination resulted in 208 (Scheme 32). 
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Scheme 32 Isolated product in Entry 6 of Table 7. 
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Most aliphatic halides produced low conversion rates with DBU (Entries 11 – 20), 
especially when the substrates were susceptible to b-elimination (Entry 14). In the presence of 
carbonate, the conversions were distinctly higher. However, raising the temperature was 
necessary to achieve higher conversion rates after one reaction cycle. While bromides and 
iodides reacted equally well (Entries 11 – 16, 19, 20), chlorides showed only poor 
conversions even after long reaction times or after addition of NaI (1 equiv) (Entries 17 and 
18). As expected, the purities in the reaction with the symmetric dibromide (Entry 12) are 
diminished by the formation of a side product. This is due to the cross- linking reaction of both 
halides with two immobilized sulfonamides. Although this reaction was carried out with 20 
equiv of the bromide, the amount of side product was still significant. In Entries 15 and 19 the 
products were obtained as the hydrolysed compounds. As no ether- formation was found, it 
could be concluded that hydrolysis of epoxide and acetal exclusively happened during 
cleavage from the resin and purification of the crude product. The reaction with building 
block 193 in Entry 20 proceeded very well showing that elongation of the backbone is 
efficiently accomplished with conventional Fukuyama alkylation. In contrast Fukuyama-
Mitsunobu alkylation only afforded conversions of lower than 30% during elongation of 
backbones with comparable length.[263, 291] 
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4.2 Synthesis of polyamine conjugates 
All syntheses started with the universal resin 198. Variations in the synthetic schemes arose 
from different numbers of charges and length of the backbones of the final products as well as 
incompatibility of some deprotection conditions with the cargo molecules. 
 
4.2.1 Synthesis of spermidine derivatives 
All conjugates use spermine (16) as scaffold but some of them can be regarded as 
spermidine derivates as one terminal charge is depleted (Scheme 33). 
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Scheme 33 Synthesis of polyamine conjugates derived from spermidine (15). Reagents and conditions: (a) 
10 Equiv. b-mercaptoethanol, 5 equiv. DBU, DMF, 1 * 30 min + 2 * 15 min, r.t.; (b) 5 equiv. indomethacin or 
rhodamin B, 5 equiv. DCC, 5 equiv. HOBt, DMF, 16 h, r.t.; or 3.3 equiv. NBDCl, 1.7 equiv. K2CO3, DMF, 16 h, 
r.t.; (c) 10 equiv. N,N’-dimethylbarbituric acid, 20 mol% Pd(PPh3)4, CH2 Cl2,  6 - 8 h, 40 °C; (d) 10% TFA in 
CH2Cl2, 3 * 1 min, r.t. 
In each case, resin 198 was o-Nosyl group deprotected and the respective effector molecule 
was coupled to the primary amine. After Aloc deprotection, the products were cleaved from 
the resin and purified by preparative RP-HPLC.  
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Scheme 34 Synthesis of a polyamino-porphyrin conjugate with C6-spacer. Compound 215 was kindly provided 
by the group of Prof. Dr. T.S. Balaban. Reagents and conditions: (a) 20 Equiv. b-mercaptoethanol, 20 equiv. 
DBU, DMF, 20 h, r.t.; (b) 3 equiv. N -Fmoc-6-aminocaproic acid, 2 equiv. PyBrOP, 4 equiv. DiPEA, DMF, 20 h, 
r.t. (c) pyrrolidine / DMF (1:4 (v / v)), 3 * 2 min, r.t.; (d) 2 equiv. carboxyporphyrin 215, 3.4 equiv. HOBt, 
5 equiv. DCC, CH2Cl2 / DMF (1:1, (v / v)), 5 d, r.t.; (e) 10 equiv. N,N’-dimethylbarbituric acid, 20 mol% 
Pd(PPh3)4, CH2 Cl2, 3 h, 40 °C; (f) 10% TFA in CH2Cl2, 3 * 1 min, r.t.
[200] 
For the synthesis of the polyamine-porphyrin conjugate 217, two additional steps were 
added. In those caproic acid, which acted as a C6-spacer between hydrophilic polyamine and 
hydrophobic porphyrin, was inserted (Scheme 34). The carboxyporphyrin was coupled to the 
Fmoc deprotected amine by reaction with DCC / HOBt and the resin was extensive ly washed, 
until clearance of the filtrate, to remove any remains of the bulky, hydrophobic porphyrin. 
After Aloc deprotection and an extensive washing of the resin for the complete removal of the 
Pd-catalyst, the compound was cleaved from the resin and the solvents were removed. As all 
non-polar compounds were already separated from the resin, the polar truncated fragments 
were removed by partitioning between an aqueous solution of K2CO3 (pH = 10) and CHCl3. 
Repetitive washings with aqueous solutions removed all polar compounds, while the large 
hydrophobic moiety guarantees that the product stays in the organic layer (visualized by its 
strong green fluorescence). After removal of the solvents and drying under HV, a dark solid 
was obtained in 96% yield and high purity as determined by 1H NMR spectroscopy. The high 
hydrophobicity of the undecanyl chains of 217 prevented HPLC chromatography. (see 
chapter 2.2.6)  
Taken together, in all four cases the cargo molecules were stable to the mild conditions of 
the Aloc deprotection. This showed that the Aloc group is suitable for the permanent 
protection of secondary amines during synthesis of sensitive conjugates. 
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4.2.2 Synthesis of spermine conjugates 
The synthesis of spermine derived conjugates with four positive charges required one 
elongation step that incorporated one additional amino group into the backbone. 
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Scheme 35 Synthesis of the spermine-rhodamine conjugate. Reagents and conditions: (a) 13 Equiv. 193, 
13 equiv. K2CO3, DMF, 18 h, 60 °C; (b) 10 equiv. N2H4*H2O, 100 equiv. allylalcohol, DMF, 3 * 15 min, r.t.; (c) 
5 equiv. rhodamine B, 5 equiv. DCC, 5 equiv. HOBt, DMF, 16 h, r.t.; (d) dimethylbarbituric acid (10 equiv), 
Pd(PPh3)4 (0.2 equiv), CH2 Cl2, 35 °C; (d) TFA (5%) / CH2Cl2; (e) 10 equiv. b-mercaptoethanol, 5 equiv. DBU, 
DMF, 3 * 30 min, r.t.; (f) TFA (5%) / CH2 Cl2. 
For the rhodamine derivative, the synthesis started with resin 198, which is alkylated with 
building block 193 according to Entry 20 of the study on Fukuyama alkylation (Table 7). The 
resulting resin 218, bearing three amino protection groups was used for investigation on their 
orthogonality. After exposure to the respective removal conditions, the products were cleaved 
from the resin and analyzed by 1H NMR spectroscopy. The results indicated that all three 
protection groups are orthogonal. Dde was removed and rhodamine B 167 was coupled to the 
free primary amine, visualized by the strong pink colour of the resin. The remaining 
protection groups were removed in the order Aloc- and then o-Nosyl-group to avoid a 
potential formation of allylamines. The product was cleaved from the resin and purified by 
RH-HPLC. The whole synthesis was carried out in 31% yield and with 26% purity after 
cleavage from the resin. If the synthesis is carried out with NBD- or indomethacin instead of 
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rhodamine B, no products were obtained. It was concluded that the cargo molecules are 
unstable to the deprotection conditions of the o-Nosyl group. An SNAr reaction of the sulfide 
analogously to the o-Nosyl removal or in case of NBD a reduction of the nitro function seems 
to be plausible, as all three molecules contain electron deficient aryl systems. 
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Scheme 36 Synthesis of spermine conjugates with NBD and Indomethacin. Reagents and conditions: (a) 
13 Equiv. 193, 13 equiv. K2CO3, DMF, 18 h, 60 °C; (b) 10 equiv. b-mercaptoethanol, 5 equiv. DBU, DMF, 
3 * 30 min, r.t.; (c) 5 equiv. allyloxycarbonyl chloride, 5 equiv. Et3N, CH2 Cl2, 16 h, r.t.; (d) 10 equiv. 
N2H4*H2O, 100 equiv. allylalcohol, DMF, 3 * 15 min, r.t.; (e) 5 equiv. Indomethacin, 5 equiv. DCC, 5 equiv. 
HOBt, DMF, 16 h, r.t.; or 4 equiv. NBDCl, 4 equiv. DiPEA, THF, 16 h, r.t.; (f) dimethylbarbituric acid 
(10 equiv), Pd(PPh3)4 (0.2 equiv), CH2Cl2, 35 °C; (g) TFA (5%) / CH2Cl2. 
The syntheses of the NBD- and indomethacin conjugates were therefore modified by the 
exchange of the o-Nosyl- against Aloc-group previous to Dde removal and coupling (Scheme 
36). After coupling, the Aloc groups were smoothly removed and the product was cleaved 
from the resin. Purification by RP-HPLC resulted in 24% yield in case of NBD derivative and 
in 99% yield in case of the indomethacin derivative. The purities of the crude compounds 
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after cleavage from the resin were 25% for the NBD derivative and 67% for the indomethacin 
derivative. After this, conjugates were evaluated in biological tests (see chapter 4.4). 
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4.2.3 Synthesis of lipophilic putrescine conjugates 
As mentioned in the introduction (see 2.2.4.5), it is known that lipophilic modifications on 
cationic moieties improve cellular uptake.[8, 92] Thus, conjugates with lipophilic building 
blocks were synthesized. These modifications were thought to improve cellular uptake by 
tighter anchoring into the membrane.[378-380] As preliminary evaluations of the 
NBD-conjugates 212 and 230 showed good uptake (see chapter 4.4.1), it was reasoned that 
the number of positive charges could be reduced to two per molecule. Finally, the products 
are named putrescine conjugates. In contrast to the conjugates without lipophilic 
modifications, the syntheses of those higher substituted polyamines could not be entirely 
executed on solid phase. Due to the instability of NBD to various reaction conditions and 
light, the polyamines were usually first derivatised with the respective modification and 
finally labelled with NBD after cleavage from the resin. The higher substitution of the 
conjugates mostly led to more complex syntheses than in the case of unmodified polyamine 
backbones.  
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Scheme 37 Synthesis of a conjugate with two charges and terminal lipophilic substitution. Reagents and 
conditions: (a) 10 Equiv. b-mercaptoethanol, 5 equiv. DBU, DMF, 3 * 30 min, r.t.; (b) 8 equiv. 
1-adamantyl carboxylic acid, 8.2 equiv. DCC, 5.1 equiv. NHS, DMF / THF, r.t.; (c) 10% TFA in CH2Cl2; (d) 2.9 
equiv. NBDCl, 3 equiv. K2CO3, THF, 18 h, r.t.; (e) 9.7 equiv. dimethylbarbituric acid, 10 mol% Pd(PPh3)4, 
CH2Cl2, 2.5 h, 40 °C. 
The conjugate from Scheme 37 has an amphiphilic structure in which the hydrophobic and 
the hydrophilic parts are separated. The synthesis comprises of two solid- and two solution 
phase steps (Scheme 37). Resin 198 was de-nosylated and an adamantyl-moiety was 
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introduced by peptide bond formation using DCC / HOBt / adamantyl carboxylic acid. 
Qualitative monitoring of the reaction by the Kaiser Test indicated completion of the reaction. 
After cleavage from the resin with 10% TFA in dichloromethane, the liberated amine was 
labelled with NBD by reaction with excess of NBDCl and K2CO3. After workup, Aloc was 
removed with Pd(PPh3)4 / N,N´-DMBA. After purification, the bis-acetic acid salt of (4-{3-
[(Adamantane-1-carbonyl)-amino]-propylamino}-butyl)-[3-(7-nitro-benzo[1,2,5]oxadiazol-4-
ylamino)-propyl]-amine (234) was obtained in 66% yield. 
The conjugate 239 shows increased lipophilicity in the backbone, which derived from a 
substitution of the secondary amines with allyl groups and acetylation of the terminal amino 
group of 236 (Scheme 38). The introduction of the allyl groups was obtained by 
transallylation from Aloc-groups to allylamines. It was accomplished by treatment of the resin 
198 with 1 equiv. of Pd-catalyst and 0.3 equiv. of allyliodide, in the absence of an 
allyl-scavenger. The higher amount of Pd(PPh3)4 was necessary to accelerate the reaction to 
completion over night. After removal of the o-Nosyl group, the free amine was acylated with 
acetic anhydride and Et3N. After cleavage from the resin, the primary amine was labelled with 
NBD. Purification by RP-HPLC afforded the pure bis-TFA salt of 
N1-Acetyl-N5,N10-bis-allyl-N12-NBD-4,9,12-tetraazatetradecane (239) in 27% yield. 
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Scheme 38 Synthesis of a conjugate with two charges and allyl side chain modifications. Reagents and 
conditions: (a) 1 Equiv. Pd(PPh3)4, 0.3 equiv. allyliodide, CH2Cl2, 16 h, r.t.; (b) 10 equiv. b-mercaptoethanol, 
5 equiv. DBU, DMF, 3 * 30 min, r.t.; (c) 4 equiv. Ac2O, 4 equiv. Et3N, DMF, 16 h, r.t. (d) 10% TFA in CH2 Cl2, 
r.t.; (e) 1.5 equiv. NBDCl, 2 equiv. K2CO3, THF, 18 h, r.t. 
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Expansion of the side chain modifications to octyl-chains is shown in Scheme 39. The 
o-Nosyl group was removed from 198 and the amine was acylated. After removal of the Aloc 
groups, the backbone amines were alkylated by SN2 reaction with octylbromide and K2CO3 at 
elevated temperature. The reaction was qualitatively followed by the Kaiser test. After 
cleavage from the resin, 243 was labelled with NBD to give N1-Acetyl-N5,N10-bis-octyl-N12-
NBD-4,9,12-tetraazatetradecane (244) in 8 % yield. The low overall yield was referred to the 
loss during the terminal step (see 4.2.4). 
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Scheme 39 Synthesis of a conjugate with two charges and octyl side chain modifications. Reagents and 
conditions: (a) 10 Equiv. b-mercaptoethanol, 5 equiv. DBU, DMF, 3 * 30 min, r.t.; (b) 5 equiv. acetic acid, 
5 equiv. DCC, 5 equiv. NHS, DMF, 16 h, r.t.; (c) 10 equiv. dimethylbarbituric acid, 0.2 equiv. Pd(PPh3)4, 
CH2Cl2, 20 h, 35 °C; (d) 20 equiv. 1-octylbromide, 20 equiv. K2CO3, DMF, 72 h, 50 °C; (e) 10% TFA in 
CH2Cl2, r.t.; (f) 4 equiv. NBDCl, 7 equiv. K2CO3, THF, 18 h, r.t. 
The synthesis of conjugates with both, larger head groups and side chain modifications is 
shown in Scheme 40. After deprotection of the primary amine, 200 is expediently acylated 
with adamantyl carboxylic acid / DCC / NHS. The secondary amines in 231 were liberated 
and alkylated by Reductive amination with benzaldehyde / capronaldehyde as described above 
until the Kaiser test was negative. After cleavage from the resin, the free amine was labelled 
with NBDCl and K2CO3 in THF. After purification, N1-adamantylcarbonyl-N5,N10-bis-hexyl-
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N12-NBD-4,9,12-tetraazatetradecane (249) was obtained in 53% yield. Only traces of N1-
Acetyl-N5,N10-bis-benzyl-N12-NBD-4,9,12-tetraazatetradecane (248) were found in the crude 
mixture. 
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Scheme 40 Synthesis of conjugates with bulky, terminal adamantyl group and different side chain modifications. 
Both modifications were introduced by Reductive amination. Reagents and conditions: (a) 10 Equiv. 
b-mercaptoethanol, 5 equiv. DBU, DMF, 3 * 30 min, r.t.; (b) 5 equiv. adamantyl carboxylic acid, 5 equiv. DCC, 
5 equiv. NHS, DMF, 16 h, r.t.; (c) 10 equiv. dimethylbarbituric acid, 0.2 equiv. Pd(PPh3)4, CH2Cl2, 20 h, 35 °C; 
(d) (10 equiv. benzylbromide, 10 equiv. K2 CO3, DMF, over night, 40 °C then 6 equiv. benzaldehyde, 6 equiv. 
Bu4N(BH4), 3% HOAc in DMF, 2 * 30 min 1 * over night) for 248, (40 °C;  6 equiv. capronaldehyde, 6 equiv. 
Bu4N(BH4), 3% HOAc in DMF, 2 * 30 min 1 * over night, 40 °C) for 249; (e) 10% TFA in CH2Cl2, r.t.; (f) 
(4 equiv. NBDCl, 7 equiv. K2CO3, THF, 17 h, r.t.) for 248, (3 equiv. NBDCl, 4 equiv. K2 CO3, THF, 17 h, r.t.) 
for 249. 
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Syntheses of conjugates with expanded lipophilic tail were also accomplished (Scheme 41). 
According to 4.1.2.4, the resin 198 was exhaustively alkylated by Fukuyama alkylation with 
benzylbromide. After removal of the o-Nosyl group, the liberated amine was acylated with 
lauroyl chloride / pyridine. Monitoring by the Kaiser Test showed that the reaction was 
completed after 18 h, which suggests that the proximity to the bulky trityl linker was the 
major obstacle for the incomplete acylation of the N4-amino group in some cases (see 
chapter 4.2.4). 
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Scheme 41 Synthesis of a conjugate with expanded lipophilic tail and side chain modifications. Reagents and 
conditions: (a) 20 Equiv. benzylbromide, 20 equiv. DBU, DMF, 16 h, r.t.; (b) 10 equiv. b-mercaptoethanol, 
5 equiv. DBU, DMF, 3 * 30 min, r.t.; (c) 20 equiv. lauroyl chloride, pyridine / CH2Cl2
 (1:2), 18 h, r.t.; (d) 
dimethylbarbituric acid (10 equiv), Pd(PPh3)4 (0.2 equiv), CH2Cl2, 20 h, 35 °C; (e) 6 equiv. capronaldehyde, 
3% HOAc in DMF, 40 °C, 3 min, then 6 equiv. NBu4BH4, 2 * 30 min, 1 * 16 h; (f) 10% TFA in CH2Cl2; (g) 
3 equiv. NBDCl, 4 equiv. K2CO3, THF, 17 h, r.t. 
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The Aloc groups were removed and the free amines were exhaustively alkylated by 
Reductive amination with capronaldehyde. After cleavage from the resin, the primary amine 
was labelled with NBD and the product was purified by flash chromatography on silica gel. 
After treatment with HOAc in CHCl3, pure bis-acetic acid salt of ((N-benzyl)-N1-
docecanamidyl)-N4,N9-bis-hexyl-12-NBD-4,9-diazadodecane 256 was obtained in 91% yield. 
Further expansion of the hydrophobic moiety was accomplished by substitution of the 
benzyl- by the bulkier adamantyl group, which was connected via a short linker to provide 
some flexibility to the end group (Scheme 42). Resin 198 was alkylated with building block 
193. After o-Nosyl deprotection, N13 of 224 was selectively acylated with lauroyl chloride in 
pyridine / dichloromethane. The Kaiser Test showed that the branching proceeded 
quantitatively. The primary amine of 257 was liberated by short treatment with hydrazine 
hydrate in DMF in the presence of a large excess of allylalcohol. The peptide bond formation 
with adamantyl carboxylic acid / DCC / NHS in DMF / THF proceeded quantitatively as 
indicated by the Kaiser Test. After Aloc deprotection, the internal secondary amines were 
alkylated by Reductive amination with n-hexanal. After cleavage from the resin the remaining 
primary amine of 262 was labelled with NBDCl and K2CO3 in THF. After workup and flash 
chromatography, N1-adamantylcarbonyl-N4-docecanoyl-N8,N13-bis-hexyl-N17-NBD-
1,4,8,13,17-pentaazaoctadecane (263) was converted into its bis-acetate salt by treatment with 
5% HOAc in CHCl3 for 10 min. The product was obtained in 89% yield. 
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Scheme 42 Synthesis of a conjugate with expanded hydrophobic tail and unpolar side chain modifications. 
Reagents and conditions: (a) 13 Equiv. 193, 13 equiv. K2CO3, DMF, 18 h, 60 °C; (b) 10 equiv. 
b-mercaptoethanol, 5 equiv. DBU, DMF, 3 * 30 min, r.t.; (c) 20 equiv. lauroyl chloride, pyridine / CH2Cl2 
(1 : 2), 18 h, r.t.; (d) 10 equiv. N2H4*H2O, 100 equiv. allylalcohol, DMF, 3 * 15 min, r.t.; (e) 5 equiv. 
1-adamantyl carboxylic acid, 5 equiv. DCC, 5 equiv. HOBt, DMF / THF (1:1), 20 h, r.t.; (f) dimethylbarbituric 
acid (10 equiv), Pd(PPh3)4 (0.2 equiv), CH2Cl2, 20 h, 35 °C; (g) 10 equiv. C13H27CHO, 3% HOAc in DMF, 
40 °C, 3 min, then 10 equiv. NBu4BH4, 2 * 30 min, 1 * 16 h; (h) TFA (5%) / CH2Cl2; (i) 4.7 equiv. NBDCl, 
4.7 equiv. Et3N, THF, 16 h, r.t. 
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4.2.4 Experimental findings 
Efforts were undertaken to synthesize a large number of conjugates with modifications at 
the terminus or the backbone amines (Figure 32). In groups a, b, c, and e the number of the 
protonable amines in the backbone was limited to two. The terminal amine was acylated to 
prevent protonation. The groups a to e differ in the size of this hydrophobic tail group, 
opposite to the NBD group. Inside the groups, the conjugates differ in the lipophilicity of their 
backbone modifications. Group d (271 – 275) displays longer backbones. Although these 
syntheses were not successful, valuable synthetic information, especially about the 
possibilities of backbone modification, was obtained. Finally, this enabled the synthesis of the 
lipophilic putrescine conjugates. The sources for the failure of those syntheses are differing. 
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Figure 32 Structures of products of attempted syntheses. The compounds are displayed in groups of similar 
substitution patterns. 
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4.2.4.1 NBD-labelling 
A problem, which could be easily prevented during further syntheses, was the unreliability 
of the NBD labelling. This was crucial in the syntheses of conjugates 264, 265, 269, 270, and  
273. Therein, the identity of the precursors was correct. However, no final product and only 
traces of the educt could be isolated after the labelling step. Recovery of the precursor was 
also not possible. The initial protocol used NBDCl (168) together with K2CO3 in THF. 
However, this procedure did only work during some the syntheses. Often a compound was 
isolated, which showed only two aromatic protons in the 1H NMR spectra. Unlike NBDCl 
(168), it was insoluble in CDCl3 and soluble in polar solvents like MeOH or water. It was 
assumed that the NBDCl (168) is either largely hydrolyzed or reacted with the high excess of 
K2CO3 to form this polar compound. Alternatively, the use of Et3N in DMF showed to be 
more reliable. 
 
4.2.4.2 Alkylation of secondary amines 
A general synthetic problem was the modification of the secondary amines in the backbone. 
The established method of Fukuyama alkylation was not suitable as it is restricted to the 
formation of secondary amines. Remaining approaches from the set of alkylation methods 
were SN2-alkylation, Reductive amination and Amide reduction. All three methods were 
applied, but the outcome differed strongly. Table 8 shows some representative moieties and 
the investigated methods for their introduction. 
Table 8 Methods and conditions for the modification of secondary amines  
Modification Alkylation Method 
 10 Equiv. allyliodide, 10 equiv. K2CO3, DMF, 16 h, r.t. 
 
6 / 10 Equiv. capronaldehyde, 3% HOAc in DMF, 40 °C, 
3 min, then 6 / 10 equiv. NBu4BH4; 2 * 30 min, 1 * over 
night 
 20 Equiv. bromooctane, 20 equiv. K2CO3, DMF, 3 d, 50 °C 
 
20 Equiv. lauroyl chloride, pyridine / CH2Cl2 (1 : 2), r.t.; 
1 M BH3·THF, 16 h, 60 °C, then pyrrolidine, 16 h, 60 °C 
2  
20 Equiv. allyliodide, 20 equiv. K2CO3, DMF, 16 h, 40 °C 
 
4 Equiv. 1-adamantyl carboxylic acid, 4 equiv. PyBrOP, 
4 equiv. DiPEA, DMF / THF (1 : 1), 20 h, r.t. 
1 M BH3·THF, 16 h, 60 °C, then pyrrolidine, 16 h, 60 °C 
 
20 Equiv. benzylbromide, 20 equiv. K2CO3, DMF, 16 h, 
40 °C 
10 Equiv. benzaldehyde, 3% HOAc in DMF, 40 °C, 3 min, 
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then 10 equiv. NBu4BH4, 2 * 30 min, 1 * 16 h; 
4.2.4.2.1 SN2 alkylation 
The SN2 alkylation was efficient for the monoalkylation to tertiary amines, if sterically less 
demanding moieties were exploited. Allyl groups were easily introduced by simple 
decarboxylation of the Aloc groups with Pd(PPh3)4 in the absence of an allyl-scavenger at 
room temperature. The SN2-reaction with the bulkier n-octyl group needed activation by 
raising the temperature to 50 °C and elongation of the reaction time to 72 h.[257, 258] The 
introduction of benzyl groups using benzylbromide / K2CO3 was not quantitative, even after 
reaction at higher temperatures not all secondary amines were saturated, indicated by the 
Kaiser test.[238] Attempts to overalkylate the tertiary amines to generate permanent charges 
with more unpolar neighbourhood were not successful. The introduction of octyl groups 
stopped at the level of tertiary amines and bis-alkyl-bis-allylammonium ions could not 
exhaustively be introduced even after prolonged reaction at elevated temperatures. The 
resulting crude product contained a mixture of various compounds with different degrees of 
alkylation and therefore this approach was discarded.  
 
4.2.4.2.2 Amide formation / amide reduction 
The attempts using amide formation with subsequent reduction were even less successful. 
Yet, the peptide bond formation was crucial. Although acid chlorides are one of the strongest 
activated forms of carboxylic acids, the reaction with lauroylchloride / pyridine resulted in 
insufficient amide formation. Similar to the results of SN2-alkylation, this indicates that the 
secondary amines are much less reactive and would need even higher activation to complete 
the reaction. A possible solution would be to raise temperature. However, resins suffer strong 
mechanical damage at temperatures above 60°C. For the introduction of 1-adamantyl 
carboxylic acid, the use of different activation methods was investigated. As expected, the 
degree of acylation increased from carboxylic acid / DCC / HOBt over 
carboxylic acid / DCC / NHS to carboxylic acid chloride / pyridine and 
carboxylic acid / PyBrOP / DiPEA, qualitatively and quantitatively monitored by TLC and 
RP-HPLC. However, 1H NMR of the final products revealed that peptide bond formation 
stopped at the level of monoacylation. This additional decrease can be explained by the high 
steric demand of the adamantyl group, which presumably prevents a sufficient approximation 
to the N4-amine. The trityl linker probably shields this secondary amine. Similar results are 
reported for solution phase syntheses, in which trityl protected amines also shielded the entry 
site, drastically decreased reactivity, and lowered the yield of modification on secondary 
amines with a distance of only three methylene groups from the trityl group.[253] It is likely 
that this effect is even more prominent for immobilized substrates, in which the diffusion of 
reactants is additionally hindered. On the other hand, this differentiation between the 
backbone amines could be used to distinguish them, if a smaller entity should be introduced at 
the N4-position. After finishing the reaction sequence, it was also obvious that the subsequent 
reduction of the amides was incomplete and would also require very long reaction times. This 
finding is confirmed in the literature and seems to be a general phenomenon.[241, 304] Examples 
in which Amide reduction was used for the generation of tertiary amines suffered from low 
yields. Finally, the amide formation / -reduction approach is limited to the generation of 
tertiary amines with sterically less demanding rests.[304] 
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4.2.4.2.3 Reductive amination 
Finally, Reductive amination solved the problem of incomplete reaction. Monitoring of the 
reaction progress by the Kaiser Test during treatment with capronaldehyde in 3% 
HOAc / DMF at 40 °C and subsequent reduction with NBu4BH4 showed that the reaction was 
complete after cycles of 2 * 30 min and 1 * over night. This was confirmed by the absence of 
products that would derive from incomplete alkylation of the secondary amines after labelling 
with NBD. In the synthesis of conjugate 263, the excess of capronaldehyde and hydride had 
to be elevated to 10 equiv. to achieve complete substitution of all secondary amines. The 
proximity of both, trityl linker and adamantyl group hindered the reaction. For the 
introduction of benzyl groups, a mixed approach consisting of previous partial benzylation 
with benzylbromide / K2CO3 and subsequent Reductive amination with 
benzaldehyde / NBu4BH4 was successfully applied. The pretreatment with benzylbromide was 
necessary because it was previously reported that in similar systems the reaction with 
benzaldehyde led to formation of cyclic aminals from two neighboured amines and 
benzaldehyde, which were not released during the repetitive reaction cycles.[304] 
 
4.2.4.3 Conclusion 
In conclusion, it was shown that Reductive amination is the method of choice for the 
selective alkylation of secondary amines in the presence of trityl linkers. SN2-alkylation is 
only suitable, if the respective building block and the other substituents have low sterical 
demands. An exhaustive overalkylation could not be achieved by using this approach. Amide 
formation / reduction is not suitable due to sometimes insufficient amide bond formation and 
generally incomplete reduction.[304] The problem of incomplete acylation could be reduced by 
the choice of a different linker with less sterical demand. 
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4.3 Development of a coupling method for bioconjugation 
4.3.1 Introduction of a maleimide 
For the introduction of a maleimide onto a polyamine, building block 196 was applied 
(Scheme 30).[373, 374, 381] Resin 198 was de-nosylated and the liberated amine was acylated 
with MPS / DiPEA (Scheme 43). Unfortunately, the loading of the resin dropped from about 
0.4 mmol / g to values of about 0.2 mmol / g during this step. As reported, activated acyl 
compounds like carboxylic acid chlorides can effect partial detachment from trityl- linkers.[243] 
It is likely that the activated carboxylic acid of the relatively small and motile N-MPS acted 
accordingly. 
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Scheme 43 Introduction of a maleimido-binding site onto immobilized spermine (200). Reagents and conditions: 
(a) 20 Equiv. b-mercaptoethanol, 20 equiv. DBU, DMF, 16 h, r.t.; (b) 6 equiv. 196, 6 equiv. DiPEA, DMF, 16 h, 
r.t.[381] 
 
Figure 33 1H NMR spectrum of cleaved 277.  
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The 1H NMR spectrum of the compound directly after cleavage from the resin is shown in 
Figure 33. Besides the various a- and ß-azamethylene protons, especially the singlet at 
6.68 ppm, displaying the aromatic protons of the maleimido double bond, is characteristic. 
 
4.3.2 Conditions for the Michael addition 
To investigate the suitability of the Michael addition for solid phase synthesis, ethylsulfide 
was chosen as small model compound (Table 9). Reaction of 277 with an excess of 1.2 equiv. 
of ethylsulfide in DMF in absence of any catalyst showed complete disappearance of the 
characteristic maleimido-singlet after 6 h. 
 
Figure 34 1H NMR spectrum of the Michael addition product of 1.2 equiv. ethylsulfide after 3 h. The spectrum 
is measured in CDCl3. The singlet of the maleimide is visible at 6.69 ppm and is overlaying with an unidentified 
impurity that was only present in this spectrum. The signals of the arising side product are found at 4.21 ppm and 
1.41 ppm. 
After 3 h, a no further determined side product was generated. Therefore, the excess of 
sulfide was slightly increased to 1.5 equiv (Figure 34). After 3 h, 94% conversion was 
detected without formation of any side products, demonstrating that the reaction is suitable for 
its use on solid phase. An investigation with a small library of sulfides is shown in Table 9. 
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Table 9 Tested sulfides in the addition of thiol to immobilized maleimide a 
N
H
N
N
H
N
O
N
Aloc
Aloc
O
O
R-SH
N
H
N
N
H
N
O
N
Aloc
Aloc
O
O
Ha
S R
Hb
Hb´
277
278  
Entry Sulfide Excess Solvent Reaction time 
Conversion 
in % 
1 SH  1.5 DMF 3 h 94 
2 HO
SH
 1.5 DMF 3 h >99 
3 +H3N
SHCl
-
 
1.5 DMF 3 h >99 
4 
N
H
SH
O OMe
O
 
1.5 DMF 3 h 93 
1.5 DMF 3 h >99 
5 
N
H
SH
O OH
O
 5 DMF 3 h 99 
1.5 DMF 3 h >99 
6 
+H3N
SH
O OMe
Cl-
 5 DMF 3 h >99 
1.5 DMF 3 h 89 
7 
H2N
SH
O OH
 5 DMF 3 h 63 
1.5 DMF / buffer-pH 4.0 3 h 96 
8 
+H3N
SH
O OH
Cl-
 5 DMF / buffer-pH 4.0 3 h >99 
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1.5 DMF 3 h < 5 
5 DMF 3 h 28 
1.5 DMF / H2O 3 h 30 
1.5 DMF / buffer-pH 4.0 3 h 34 
9 NH
NH2
HO
O
O
NH
HO
O
O SH
 
1.5 DMF / H2O 18 h >99 
10 
SH
 
1.5 DMF 3 h 93 
1.5 DMF 3 h 0 
11 
SH
 1.5 THF 3 h 0 
12 SH
 
1.5 DMF 3 h 0 
a The conversion was calculated by the disappearance of the maleimido corresponding singlet at 6.8 ppm. 
 
With respect to the instability of some of the products during purification on HPLC and the 
fact that the thio-Michael product is hard to separate from the side product of the 
aza-Michael-Addition the conversions in the crude mixture were determined by 1H NMR.  
 
a  
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Figure 35 Spectra of some addition products. (a) Addition of ethylsulfide after 1 h. The spectrum was measured 
in CDCl3 and the dd of the maleimido-Ha  collapsed with the t of the a-maleimido methylene group. The 
maleimido singlet at 6.71 was decreasing while the t of the terminal methyl group was occurring. (b) Addition of 
b-mercaptoethanol after 3 h reaction. The characteristic protons of the 3-S-succimidyl moiety are indicated. The 
dd of Ha was switched to 3.96 ppm in CD3OD and did not collapse with the t of the a-maleimido methylene 
group. The shifts of Hb and Hb  ´ differed by 0.7 ppm and they could be identified by their coupling constants, 
which were in accordance with the expected values for AB2 systems along a bond with fixed confirmation. (c) 
Addition of phenylsulfide after 3 h. The shifts of the AB2 system were nearly similar and the coupling constants 
were almost identical. (d) Addition of N-acetyl-L-cysteine methyl ester after 3 h. 
The NMR-spectra of 278 showed a very characteristic singlet at 6.70 ppm in CDCl3  
(6.81 ppm in MeOD) (Figure 33), which decreased with proceeding addition of the thiol to 
the double bond and therefore indicated the progress of the reaction (Figure 35). Meanwhile a 
dd occurred at 3.96 ppm (in MeOD; in CDCl3, the dd collapses with the t of the a-maleimido 
methylene group) that corresponds to Ha in 278 and is characteristic for the addition of a 
sulfide to the maleimide while addition of an amine would give a dd at approximately 
4.5 ppm. The other signals in the spectrum were in accordance to the structure. The particular 
characteristic signals in the 1H-NMR are less anisochronic to measure their integrals. Thus, 
the ratios of the diastereomers, which were formed in the reaction with chiral cysteine- and 
glutathione derivatives, could not be determined. However, it could be expected that racemic 
mixtures were obtained. The identity of the compounds was additionally confirmed by ESI-
HRMS. The reaction with the small molecules in Entries 1 – 6 and Entry 10 proceeded well, 
leading to conversions of > 90% after short incubation. Surprisingly, the hydrophobic thiols in 
Entries 12 and 13 did not react. A change to better swelling, less polar solvents such as THF 
did not improve the reaction. While it is reasonable that the bulky trityl group could prevent 
the approximation of thiol and maleimide, the source of the low reactivity of dodecanethiol is 
not clear. As ethylsulfide reacts well, it must be caused by the elongated alkyl chain. The 
polar substrates in Entries 7 – 9 were only poorly soluble in DMF and required addition of 
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10% water to allow sufficient conversion. Analysis of the products from Entries 3 and 
Entries 7 - 10 showed that the aza-Michael-Addition of the primary amine was competing 
with the desired addition of the sulfide, once the amine was unprotonated. This was also 
visible, if acidic buffer was added instead of water to minimize the amount of free amines. 
Only if ammonium salts were applied in pure DMF, the side reaction was avoided (Entry 3). 
This side reaction led to complex product mixtures arising from cross- linking and 
concomitant addition of the primary amine. The markedly quicker reaction with cysteine 
compared to glutathione suggests that the size of the polar thiols has a strong influence on the 
rate of the reaction carried out on polystyrene resins. Standard conditions (1.5 equiv.; 3 h) 
resulted in low conversion rates. Carrying out the reaction over night resulted in full 
conversion, while increasing the excess of thiol to 5 equiv. provided conversion of only 28% 
after 3 h. Elongation of the reaction time is thus more efficient for improving the conversion 
than insertion of additional thiol building block. 
 
4.3.3 Compatibility of maleimido-thiol coupling and Aloc protection 
strategy 
4.3.3.1 Aloc removal after maleimido-thiol coupling 
The stability of the 3-thiosuccimidyl linkage during Aloc deprotection was proven by the 
sequence shown in Scheme 44. N-Acetyl-L-cysteine methyl ester was coupled to the 
maleimide of 277 to generate the 3-thiosuccimidyl moiety and subsequently the Aloc groups 
were removed with Pd(PPh3)4 and N,N´-DMBA under the conditions established above 
(see 4.1.2.2). 1H NMRs were recorded after cleavage from the resin and subsequent 
purification by RP-HPLC. It was apparent that the Aloc groups were completely removed and 
the thioether is still intact indicating that the thioether does not interfere with the Pd catalyst. 
The ESI-HRMS spectrum was also fully consistent with the structure of 280. 
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Scheme 44 Deprotection of Aloc groups in the presence of the 3-thiosuccinimide. Reagents and conditions: (a) 
5 Equiv. N -acetyl-L-cysteine methyl ester, DMF, 6 h, r.t.; (b) 10 mol% Pd(PPh3)4, 10 equiv. 
N,N -´dimethylbarbituric acid, CH2Cl2, 15 h, 40 °C then 10% TFA in CH2Cl2. 
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4.3.3.2 Deprotection of Aloc in the presence of maleimides 
The vice versa strategy for coupling-deprotection was also explored. Aloc removal in the 
presence of the maleimides is especially challenging as the double bond could either interact 
with the palladium catalyst or could be attacked by the mainly nucleophilic or reductive allyl-
scavenger.[248, 268] In a first approach, the stability of the maleimide against several 
representatives of different classes of allyl scavenger was examined (Scheme 45; Table 10). 
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Scheme 45 Synthesis of a small model system for the examination of maleimide stability against several Aloc 
deprotection conditions. Reagents and conditions: (a) 10 Equiv. N-o-nosyl-diaminopropane, 2.5 equiv. DiPEA, 
CH2Cl2, 16 h, r.t.; (b) 20 equiv. b-mercaptoethanol, 20 equiv. DBU, DMF, 12 h, r.t.; (c) 6 equiv. MPS, 4 equiv. 
DiPEA, DMF, 17 h, r.t.; For conditions of the last step see Table 10. 
In summary, the presence of Pd-catalyst was not harmful, if the reaction time is short or if 
the amount of the catalyst is low. All nitrogen nucleophiles are generally incompatible 
scavengers, as well as N,N´-DMBA and hydride donors in the presence of HOAc. Previously, 
it had been shown that the addition of HOAc drastically enhances Aloc deprotection rate of 
peptides with Pd(PPh3)4 / HSnBu4[268], however, it is not necessary to get a protection at all. 
The maleimide remained largely unreactive against dimedone, oxygen nucleophiles, and 
hydride donors (in the absence of proton sources). Surprisingly, dimedone and N,N´-DMBA 
showed different behaviour, although they are structurally closely related. 
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Table 10 Conditions for the removal of Aloc groups applied to resin 282.a 
a The integrity of then maleimide was determined from the 1H NMR spectra of the crude product directly after 
cleavage from the resin. 
b Aza-Michael addition 
c Cleavage of the 3-N -maleimidopropionate. The mechanism was not further investigated. 
d Ring opening of the maleimide. 
e Complete reduction of the maleimide to the succinimide. 
 
Further, the ability to remove Aloc groups in the presence of a maleimide was investigated 
on immobilized lysine bearing both functionalities as a model system (Scheme 46). 
Commercially available N-(a)-Fmoc-N-(e)-L-lysine was loaded onto a chlorotrityl resin 60 as 
described by Barlos et al.[368, 384] The Fmoc group was removed with pyrrolidine in DMF and 
the maleimidopropionate was coupled to the liberated amine of 284 (see chapter 4.3.1).[381] 
The functional scavengers from Table 10 were applied to resin 286 (Scheme 46). Finally, only 
hydride donors showed suitability. The removal with oxygen nucleophiles and dimedone was 
very sluggish requiring high amounts of Pd-catalyst. Even though, the deprotection was 
Scavenger Excess of scavenger 
Amount of 
Pd(PPh3)4 in 
mol% 
Solvent Reaction time in min 
Stability of 
the 
maleimide 
Catalyst 
- - 4 / 10 / 40 THF 30 Yes 
- - 40 THF 120 No 
Nitrogen nucleophiles 
Pyrrolidine[239] 10 equiv. 20 THF 30 Nob 
NaN3[274, 382] 5 equiv. 10 DMF 30 Noc 
Carbon nucleophiles 
Dimedone[248] 8 equiv. 10 THF 30 Yes 
N,N’-DMBA[248] 10 equiv. 15 CH2Cl2 60 Nod 
Hydride donors 
PhSiH3[264] 6 equiv. 10 THF 30 Yes 
Bu3SnH[275] 7 equiv. 20 CH2Cl2 30 Yes 
Bu3SnH / HOAc[268] 3 / 3 equiv. 8 CH2Cl2 5 No 
Oxygen nucleophiles 
HOBt[273] 6 equiv. 10 DMF 30 Yes 
NHS[383] 8 equiv. 20 THF 30 Yes 
HOAc[269] 20 equiv. 20 THF 30 Yes 
Water[270] 50 equiv. 20 THF 30 Yes 
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mostly incomplete. If the Aloc group was removed with PhSiH3-scavenger, some allylamines 
formation was observed. However, HSnBu3 tracelessly remove the Aloc group without 
formation of side products. After cleavage from the resin, the product was obtained in 92% 
purity. The relatively high amounts of required catalyst indicate, that the maleimide interacts 
with the catalyst and reduces its efficiency. This interaction seems to be not necessarily 
detrimental as the maleimide is recovered intactly after cleavage from the resin. 
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Scheme 46 Exchange of Fmoc-group against a maleimidopropionyl group and subsequent removal of the Aloc 
group. Reagents and conditions: (a) Pyrrolidine / DMF (1 : 3), 3 * 15 min, r.t.; (b) 7.2 equiv. MPS, 4 equiv. 
DiPEA, DMF, 17 h, r.t.;(c) 120 mol% Pd(PPh3)4, 8 equiv. HSnBu3, THF, r.t. 
If the conditions were transmitted to resin 277 it turned out that although the maleimide 
stayed intact and the Aloc groups were disintegrated, the formation of allylamines was 
significant (Scheme 47). Increasing the excess of tributyltin hydride did not improve this 
result. This is in accordance with the findings from chapter 4.1.2.2: If scavengers, which 
usually avoid or largely suppress the formation of allylamines are used in the deprotection of 
Aloc-protected polyamines, they can still be inefficient avoiding this side reaction. 
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Scheme 47 Removal of Aloc from 277 and subsequent cleavage from the resin. 
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Previous reports showed that besides the excluded carbon nucleophiles the scavenger-
combination of formic acid / nitrogen base / NHS, PhSiH3 / silylating agent, and 2-
mercaptobenzoic acid efficiently avoid allylamine formation.[268] As sulfides are the binding 
partners of the maleimides, the latter was not used. Alternatively, tritylsulfide, which does not 
add to the maleimide (Table 9), was used as trapping agent. However, its use inactivated the 
Pd-catalyst. Similar results occurred with the use of both other combinations of scavengers: 
The maleimide was stable, but no deprotection was observed. If a combination of HSnBu3 and 
N,N´-DMBA was used, the results were similar. Finally, it can be concluded that the Aloc 
deprotection in the presence of maleimides is possible for protected primary amines, if 
HSnBu3 is used together with high amounts of Pd catalyst. Secondary (poly-)amines are prone 
to allylamines formation, which could neither be efficiently suppressed by the use of known 
scavengers nor by the use of rather unusual combinations of scavengers and carbamoyl-
trapping agents. The necessity to use wasteful amounts of catalyst (>1 equiv.) to achieve a 
deprotection, makes the whole approach unsuitable. However, the above demonstrated 
approach to remove Aloc groups after the conjugation allowed the combined use of the 
Aloc-based strategy for the synthesis of the polyamine and the maleimido-thiol coupling for 
the (bio-)conjugation. 
 
4.3.4 Application of the reaction for bioconjugation 
The results of Table 9 showed that the reaction is suitable for the coupling of thiols and 
immobilized maleimides. The thiol building block can be completely recovered for a further 
reaction cycles. The reaction excellently proceeded for substrates of medium and well for 
substrates of higher polarity. In the latter case it was necessary to elongate the reaction time 
and to add small amounts of water to achieve full conversion. The reaction is selective for 
thiols in the presence of several functional groups; only amines are competing. It is already 
known that the  addition of amines appeared if the coupling is carried out on solution phase to 
a minor degree.[333-337]  In case of the solid phase reaction, it is likely that the side reaction is 
enforced by a similar mechanism that caused the cross- linking during loading of the resin 
(see chapter 4.1.1.1). A solution for this problem would be to use thiol building blocks with a 
similar amino protection group as the polyamine or with a protection group that is prone to 
the cleavage conditions of the linker. In both cases, the deprotection of the building blocks 
and cleavage from the resin could take place simultaneous, avoiding a further step.  This is 
especially compatible with the chosen protection strategy for the polyamine synthesis, which 
comprises a permanent protection of the amines by Aloc groups and attachment to the resin 
via trityl linker. Both, Trt- and Aloc-group are common protection groups for the basic side 
chains in automated peptide synthesis and a prepared maleimido-peptide could directly be 
inserted, superseding its separate deprotection.[248] In case of oligonucleotides, the 
combination of trityl- and allyl type groups for permanent protection of phosphonates and 
amino groups during the synthesis is also reported, but is not typically used.[271] In both cases, 
the lowered polarity compared to the unprotected building blocks would be advantageous for 
the reaction on polystyrol resins. While the use of amino-deprotected oligopeptides is 
excluded, it should be possible to use unprotected, thiomodified oligonucleotides. Due to their 
lower nucleophilicity the amino groups of the bases are relatively unreactive against 
maleimides.[364] However, oligonucleotides are very poorly soluble in DMF and also on 
mixtures of minor degrees of water in DMF. Polystyrol resins usually show decreased 
swelling if the degree of water in the solvent exceeds a certain concentration. A test series in 
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which resin 282 was reacted with glutathione, as model for a water soluble, polar substrate in 
increasing proportions of water in DMF, showed that the reaction did not take place if the 
amount of water was higher than 20% and had its maximum at 10% water. The solution for 
this problem was the use of resins, which exhibit good swelling properties in water or solvent 
mixtures with a high water content. Tentagels and other resins with scaffold modifications 
were developed (see chapter 6.2). The synthesis of the polyamine-maleimide, shown in 
Scheme 43, was carried out on such a Tentagel resin. Unfortunately, analysis of the crude 
mixture after cleavage from the resin showed only minor degrees of the demanded product. 
The ESI-MS spectrum indeed showed the product peak, but NMR analysis revealed the 
occurrence of many side products. Those probably arose from oxidative cleavage of the 
PEG-linker of the resin scaffold. This degradation is a well-known problem during the use of 
Tentagel resins and in further studies, special care should be taken avoiding air contact. 
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4.3.5 ´On resin´-introduction of a thiol 
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Scheme 48 Introduction of a single thiol to a polyamine avoiding a loss of charge. Reagents and conditions: (a) 
20 Equiv. dibromobutane, 20 equiv. K2CO3, DMF, 18 h, r.t.; (b) 10 equiv. KSAc, DMF, 3 d, r.t.;(c) 10 equiv. 
HSTr, 10 equiv. DBU, DMF, 17 h, r.t.; (d) 20 equiv. b-mercaptoethanol, 20 equiv. DBU, DMF, 3 d, r.t.; (e) 
6 equiv. 3-nitropyridinyl-2-sulfenyl chloride, HOAc / CH2Cl2, 15 h, r.t. 
To avoid a loss of charge, the thiol function should be introduced by alkylation to the 
terminal amine of spermine (16). Therefore, the above-mentioned Fukuyama alkylation was 
used to introduce an electrophile (Scheme 48). The bromide of 288 was displaced by reaction 
with either potassium thioacetate or tritylsulfide and the protection groups were removed.[85] It 
was apparent that the o-Nosyl groups were stable during treatment with KSAc and that the 
bromine displacement proceeded well. Analysis of the crude product by 1H NMR and mass 
spectroscopy showed that the concomitant deprotection of acetyl- and o-Nosyl groups led to a 
removal of both. Displacement of the bromine by tritylsulfide also proceeded well, while 
simultaneously the o-Nosyl groups were removed. This is in accordance with reports, which 
describe that removal of the o-Nosyl group is extremely tolerant against many functional 
groups or bulky substituents of the thiolate.[261, 279] Removal of the trityl group in 290 with 
3-nitropyridinyl-2-sulfenyl chloride and subsequent cleavage of the disulfide bridge with 
b-mercaptoethanol / DBU showed the successful removal of the trityl group.[85] However, 
both approaches resulted in impure products. To shorten the reaction sequence and to 
minimize possible cross- linking, the synthesis was modified (Scheme 49).  
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Scheme 49 Attempt to introduce a thiol onto a polyamine. Reagents and conditions: (a) 0.6 Equiv. KSAc, DMF, 
21 h, r.t.; (b) 13 equiv. 294, 13 equiv. K2CO3, DMF, 8 h; 60 °C; (c) 10 equiv. NaSMe, DMF, 18 h, r.t. 
An asymmetric building block bearing a protected sulfide and bromine was prepared by 
reaction of dibromobutane and KSAc in DMF in 57% yield. Coupling of the halide to resin 
287 proceeded well (see chapter 4.1.2.4). While the removal of acetyl- and o-Nosyl group 
with sodium thiomethylate failed, it was successful with mercaptoethanol / DBU (Scheme 
48). Finally, there were still relevant amounts of impurities.  
2-Iminothiolane (296) (Traut’s reagent) is a popular cross- linking agent for peptides and it 
has frequently been used for the conversion of the lysine side chain amino groups into thiols 
297.[385-389] Since it discriminates between primary and secondary amines and preserves the 
charge of the primary amine by transformation to an amidite, it is interesting for polyamine 
chemistry (Figure 36). It is commercially available or can easily be generated in large 
portions. 
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Figure 36 Reaction of 2-iminothiolane with primary amines and subsequent coupling to a maleimide. 
The reaction between 2- iminothiolane (296) and a primary amine consists of a nucleophilic 
attack of the amine on the electrophilic carbon (Figure 36). The tetrahedral transition state is 
disintegrated by ring opening, results in an amidite and liberates a thiolate that can react with 
a maleimide. Since a previous experiment with immobilized spermine and phenylmaleimide 
provided good conversion the reaction was optimized for the use on solid phase. 
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Scheme 50 Loading of the resin, subsequent deprotection, and reaction with 296. Reagents and conditions: (a) 
10 Equiv. N-o -nosyl-diaminopropane, 2.5 equiv. DiPEA, CH2Cl2, 16 h, r.t.; (b) 20 equiv. 2 mercaptoethanol, 
20 equiv. DBU, DMF, 12 h, r.t.; (c) 2 equiv. 2-iminothiolane, varying solvents and additives, see text below.[390] 
To efficiently convert the reaction to the solid phase, a model system with a short diamine 
was prepared (Scheme 50). 2-chlorotrityl resin (1.3 mmol/g) was loaded with building block 
188 in order to avoid cross- linking of the symmetrical diamine. The o-Nosyl group was 
removed with b-mercaptoethanol / DBU in DMF and the free primary amine was reacted with 
an excess of 2- iminothiolane hydrochloride. The reaction was usually carried out in DMSO or 
in aqueous buffers at pH values above 7.0.[391-394] However, both solvents are less suitable for 
reactions on polystyrene resins. Therefore, some other solvent systems were additionally 
investigated. 2- iminothiolane was added to the pre-swollen resin in the respective solvent. 
After 15 h the resin was washed and the cleaved crude product was analyzed by 1H NMR 
spectroscopy and mass spectrometry. As expected, the resins showed only minimal swelling 
in phosphate buffer (pH 8.0) and DMSO and the reaction between the 2- iminothiolane (296) 
and the primary amine was prevented. Likewise, the reaction in THF was very poor, probably 
due to the low solubility of 2-iminothiolane (296). Although the solubility in DMF was 
higher, even after 15 h not all primary amines were reacted. The addition of 2 equivalents of 
DiPEA in order to accelerate the reaction did not markedly improve the conversion. However, 
complete reaction was observed if 2-iminothiolane (296) was dissolved in water and was 
added to a suspension of the resin in THF, giving a solvent mixture of water / THF (1 : 9). 
The liquid phase was clean indicating that the 2- iminothiolane was entirely solvated, while 
the resin was sufficiently swollen. 
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Scheme 51 Side reaction of 299 leading to restitution of a N-substituted iminothiolane 300.[390] 
Analysis of the crude mixture indeed showed the absence of diaminopropane but also the 
presence of a second compound. The mass spectra showed a peak at [M – 16]+ (159.1 u) 
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additionally to that of the expected product (Scheme 51). This fragment of 17 u is due to the 
loss of ammonia as already reported previously. The formation of this side product arises 
from the nucleophilic attack of the liberated thiolate onto the amidite giving the N-substituted 
iminothiolane 300. 
Table 11 Optimization of conditions for the reaction with three comp onents.[390] 
H
N
H
N
NH2+Cl-
S
Addition of 296 and 
ethylmaleimide
N
O
O
H
N
H
N
N
O
O
303
304
155
 
 
Ratio Reaction 
time 
Amount and times of 
addition of 2- iminothiolane 
Amount and times of 
addition of ethylmaleimidea 5 8 9 
15 h 2 / 0 5 / 780 1.69 0 1 
15 h 2 / 0 5 / 2 0.13 0.47 1 
15 h 
1 / 0 
1 / 5 
1 / 0 
1 / 5 
0.10 0.10 1 
15 h 
1 / 0 
1.5 / 1 
1 / 1 
0.3 / 2.5 
0.08 0.10 1 
15 h 
0.5 / 0 
1.5 / 2 
1.3 / 2 0.10 0.31 1 
15 h 3 / 0 2 / 1 0.06 0.04 1 
a Amount in equiv., Times of addition in min, 1 / 5 means: Addition of 1 equiv. after 5 min 
b The ration between 300 and 304 was determined by peak integration of the characteristic triplets at 3.7 and 
3.4 ppm. 
c The ratio of 303 and 304 was determined by integration of the characteristic dd at 4.5 and 3.9 ppm in MeOD. 
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If the reaction was carried out over night in the presence of a weak base, only this side 
product could be detected by 1H NMR. After addition of excess (5 equiv.) of ethylmaleimide 
2 h prior cleavage from the resin, no coupling could be observed indicating the absence of 
free thiols and also the irreversibility of the ring closure. After standing in a protic solvent and 
purification on preparative HPLC, the compound further showed severe decomposition 
arising from attack of primary amines to the N-substituted iminothiolane 301. This attack 
seems to occur intra- as well as intermolecular, indicated by 1H NMR and ESI-MS. To avoid 
the formation of this side product and to optimize the protocol for the maleimido-thiol 
coupling, the respective maleimide and 2- iminothiolane were simultaneously added to resin 
155. Although this mainly prevented the formation of the cyclisation product, the 
simultaneous coupling reaction of the amine to the maleimide resulted a second side 
product 303. The reaction time, excess and times of addition were varied to both side 
reactions (Table 11). 
Finally, the desired product after cleavage of resin 304 could be obtained in 95% purity after 
short reaction with 3 equiv. of 296 and 2 equiv. of ethylmaleimide. The formation of both side 
products could be suppressed by adding the whole maleimide two minutes after the addition 
of 2- iminothiolane, since the recyclization proceeded slower then the coupling reaction. 
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Scheme 52 Immobilized secondary amines do not react with 296. 
After establishing the conditions, the reaction was carried out using immobilized, mono-
protected spermine 199. Treating 199 with 4 equiv. of 296 for 4 h and subsequent analysis 
confirmed the selectivity for primary amines (Scheme 52).  
 
4.3.6 Application of 2-iminothiolane protocol for the mild coupling 
After optimisation of the conditions, which should allow the mild solid phase coupling of 
maleimides and polyamines via 2-iminothiolane, the reaction should be applied to some 
maleimides.  
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4.3.6.1 Synthesis of a suitable resin 
In order to allow the synthesis of very acid sensitive conjugates, the syntheses should be 
carried out on a very acid labile trityl resin. This was prepared as described in Scheme 53.[239] 
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Scheme 53 Synthesis of a 4-hydroxytrityl alcohol and subsequent attachment to a Merrifield resin. After 
activation with thionyl chloride, the resin can be used for SPS. Reagents and conditions: (a) 1 Equiv. AlCl3, 
1 equiv. phenol, CS2, 3 h, 50 °C; (b) 1 equiv. K2CO3, 5 mol% Merrifield resin, DMF, 22 h, 60 °C; (c) 2 equiv. 
SOCl2, CH2Cl2, 2 h, r.t.
[239] 
Starting from a,a-diphenyldichlormethane (305), 4-hydroxytrityl alcohol (306) was 
prepared by a Friedel-Crafts alkylation giving 87% yield. The trityl alcohol (306) was 
coupled to a Merrifield resin by reaction with K2CO3 in DMF for 22 h. After thoroughly 
washing the resin 307 to remove all remains of the reagents, the resin was activated by 
chlorination with thionyl chloride. The final loading of the resin 308 was in the range of 0.6 –
 0.8 mmol / g.[239] 
 
4.3.6.2 Synthesis of maleimides 
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Scheme 54 Synthesis of a maleimido building block. Reagents and conditions: (a) 3 Equiv. 196, 3 equiv. 
DiPEA, THF / DMF (1 : 1), 2 d, r.t. 
One maleimido building block was prepared, starting from N-o-Nosyl-monoprotected 
diaminopropane (188). Reaction with 3 equiv. of 196 in the presence of 3 equiv. of DiPEA 
gave product 309 in 47% yield. 
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Scheme 55 Synthesis of a maleimido-modified 2 -´desoxycytidine. Reagents and conditions: (a) 1 Equiv. Ac2O, 
2 equiv. Et3N, DMF, 6 h, r.t. then 1.3 equiv. DMTrCl, pyridine, 6 h, r.t.; (b) 0.7 equiv. K2CO3, MeOH, 24 h, r.t.; 
(c) 1.7 equiv. N-maleimidopropionic acid, 1.7 equiv. DCC, 1.7 equiv. HOBt, 0.17 equiv. DMAP, 1.7 equiv. 
Et3N, CH2Cl2, 240 min, r.t.
[364] 
A 2´-desoxycytidine was maleimido-modified at the 4-amino group of the base (Scheme 
55).[364] Commercially available 2´-desoxycytidine (310) was N-acylated with Ac2O / Et3N in 
DMF and 5´- protected with DMTrCl in pyridine without isolating the intermediate 
monoprotected nucleoside. The bis-protected 2´-desoxycytidine 311 was isolated in 74% 
yield. The acetyl protection group was selectively removed by treatment with a mild base in 
78% yield. The liberated amine of the nucleobase was coupled to 3-N-maleimidopropionic 
acid. Due to the low reactivity of the amine, the reaction required the use of 
DCC / HOBt / DMAP / Et3N to strongly activate the carboxylate and accelerate the reaction. 
The last step resulted in 49% yield giving an overall yield of 28% five steps.  
Likewise, maleimido-modified thymidine 319 was synthesised (Scheme 56). Starting from 
thymidine, the 3´-hydroxy group was transferred into a leaving group that could be attacked 
by the 2´-oxygen of the base leading to a six membered ring in 63% yield. The 3´-position 
could be attacked by an azide, which was eventually reduced to an amine with palladium on 
carbon under hydrogen atmosphere in 74% yield.[395] Peptide bond formation with building 
block 196 resulted in the 3´-(3-N-maleimidopropionyl) modified thymidine 319 in 16% 
overall yield. 
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Scheme 56 Synthesis of a maleimido modified thymidine. The first four steps were performed together with 
Henning Breyhan during his diploma thesis. Reagents and conditions: (a) 4 Equiv. diphenylsulfite, 0.2 equiv. 1-
methylimidazole, DMAP, 60 min at 150 °C; (b) Et3N / water (1 : 2), 40 min, 0 °C to r.t.; (c) 2 equiv. NaN3, 0.3 
equiv. NH4 Cl, DMF, 18 h, reflux; (d) 2 mol% Pd / C, H2-atmosphere, MeOH, 3 h, r.t.; (e) 2.2 equiv. MPS, 2.2 
equiv. DiPEA, DMF, 16 h, r.t.[395] 
 
4.3.6.3 Reaction of maleimides and 2-iminothiolane on immobilised, non cross-linked 
spermine 
The alkoxytrityl resin was loaded with tris-Aloc-spermine 179 and cleanly deprotected with 
Pd(PPh3)4 / N,N´-DMBA giving immobilized, non cross linked spermine. Subsequently, a 
variety of maleimides was coupled using the protocol developed from the results of Table 11. 
The alkoxytrityl resin was chosen due to its extremely mild cleavage conditions that allow the 
solid phase synthesis of acid and base labile conjugates. After one hour, the resin was washed 
and the product was cleaved from the resin with 1% TFA in dichloromethane and purified by 
preparative HPLC. 
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Table 12 Regioselective synthesis of spermine conjugates.[390] 
H
N N
N N
H
Aloc
Aloc
Aloc
H
N
H
N
N
H
NH2
N,N'-Dimethylbarbituric acid, 
Pd(PPh3)4, CH2Cl2
H
N
H
N
N
H
N
H
296, maleimide, 
THF / water (9 : 1)
NH2+Cl-
S
N
O
O
R
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Entry Maleimide: (Mal-R) Yield (%) Purity (%)a 
1 N
O
O  
75 93 
2 N
O
O  
82 94 
3 N
O
O
HOOC
 
72 98 
4 
H
N
H
N
S
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NO2
O
N
O
O  
76 99 
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63 55c 
a The purities were calculated by integration of the relative peak area of the HPLC with UV-detection at 280 nm. 
b Only 1.7 equiv. of the maleimide were applied. 
c The high amphipilicity of the conjugate prevents purification on RP-C18 as well as on silica gel. The conversion 
was calculated from 1H NMR spectra of the crude product. 
 
As shown in Table 12, the coupling efficiently proceeds with a variety of structurally 
diverse maleimides. The small maleimides from Entries 1 – 3 reacted smoothly and the 
products were obtained in high purity. Entries 4 – 7 showed that also bulkier maleimido 
building blocks with a broad variance in polarity are tole rated. More polar substrates seem to 
react better than less polar. The lower excess of the maleimide 170 can explain the poorer 
conversion rate in Entry 7. Entries 5 and 6 of Table 12 show tha t coupling of spermine (16) to 
the maleimido-modified nucleosides via 2- iminothiolane (296) worked successful. In 
summary, the introduction of a thiol and coupling to maleimides is most efficiently carried 
out using 2- iminothiolane. Although the reaction is also principally possible by the more 
conventional route from Scheme 49, the mild conditions, the broader tolerance for functional 
groups and the higher flexibility in the synthetic strategy favour the use of 2- iminothiolane 
(296). 
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4.3.7 Preparation of polyamino-nucleotides 
4.3.7.1 Triphosphorylation of coupling product 
The next step after successful coupling between polyamine and nucleoside was the 
triphosphorylation. A standard procedure was described from Kovacs and Ötvös (Scheme 
57).[396]  
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Scheme 57 Triphosphorylation of 323. The reaction only proceeded to the formation of the monophosphate. 
Reagents and conditions: (a) 2.3 Equiv. POCl3, 3 equiv. ´proton sponge´, Me3PO4, 2 h, 0 °C; (b) 4.3 equiv. 
(Bu3N)1.6H4PO4, kat. Bu3N, DMF, 1.5 min to 2 h, 0 °C; (c) (Et3N)H2CO3, 20 min, r.t.
[396]  
The nucleoside was first reacted with phosphoryl chloride in trimethylphosphate in the 
presence of ´proton sponge´, which led to the 5 -´dichloromonophosphate 324 of the 
respective nucleoside as the main intermediate. After addition of tributylammonium 
pyrophosphate and tributylamine in DMF a cyclic metaphosphate 325 was supposed to form, 
which is hydrolysed to the triphosphate by addition of aqueous buffer. However, reaction with 
substrate 323 did not produce the desired triphosphate. Analysis of the crude product by ESI-
(-)-MS, 1H NMR and 31P NMR revealed that the reaction stopped on the level of the 
monophosphate. Elongation of the reaction time in the second step (from 1.5 min to 120 min) 
did not improve this result. It is known that the addition of the pyrophosphate is crucial during 
the Kovacs / Ötvös procedure, because the transition state is fragile and sensitive to disruption 
by sterically demanding substituents.[397] Usually modifications of the base are less affecting 
than modifications of the ribose, but in the case of the polyamino-nucleoside it can be 
assumed that the polyamine interferes with the transition state.  
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4.3.7.2 Triphosphorylation of 2´,3´-Dideoxy- N4-(3-N-maleimidopropionyl)-cytidine  
To avoid disturbance by both, the base substituent and the 3 -´hydroxyl group, the 
2´-deoxycytidine 310 was additionally deoxygenated at the 3´-position. The coupling to the 
polyamine should be carried out after the triphosphorylation (Scheme 58). 2´-Desoxycytidine 
310 is protected as described in Scheme 55 and the 3´-hydroxyl group was removed by a 
Barton-McCombie reaction. Therefore the 3´-hydroxyl group was transferred into a 
thiocarbonate 327 by reaction with phenylchlorothioformiate / DMAP. Short reaction at 
120°C with HSnBu3 and catalytical amounts of AIBN resulted in 46% yield over two steps. 
The best results were obtained, if the intermediate 327 was not isolated but the crude product 
was directly inserted to the next step after removal of the solvent. If the thiocarbonate 327 was 
purified by column chromatography, the yield for both steps were 32% and 59% giving an 
overall yield of only 19%. The crucial step was the formation of the thiocarbonate, which was 
instable during purification on silica gel. The following steps were carried out as previously 
presented in Scheme 58, resulting in improved yields. This could be explained by the absence 
of interactions with the 3´-OH group. Removal of the DMTr group gave 77% yield after quick 
reaction of 330 with 1% TFA in dichloromethane.[364] 
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Scheme 58 Synthesis of a maleimido-modified 2´,3´-didesoxycytidine. Reagents and conditions: (a) 1 Equiv. 
Ac2O, 2 equiv. Et3N, DMF, 6 h, r.t. then 1.3 equiv. DMTrCl, pyridine, 6 h, r.t.; (b) 1.2 equiv. 
phenylchlorothioformiate, 2 equiv. DMAP, MeCN, 20 h, r.t.; (c) 3 equiv. HSnBu3, 0.38 equiv. AIBN, toluene, 
50 min, 120 °C; (d) 0.7 equiv. K2CO3, MeOH, r.t.; (e) 1.7 equiv. N-maleimidopropionic acid, 1.7 equiv. DCC, 
1.7 equiv. HOBt, 0.17 equiv. DMAP, 1.7 equiv. Et3N, CH2 Cl2, 120 min, r.t.; (f) 1% TFA in CH2Cl2, 2 min, r.t. 
[364] 
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The 1H NMR spectrum of the product recorded immediately after purification is shown in 
Figure 37. 
 
Figure 37 1H NMR spectrum of 331 in MeOD. The spectrum was measured directly after purification, because 
the compound decomposed quickly. 
The overall yield starting from 2´-desoxycytidine was 18%, which is improved if compared 
to the literature result (11% overall yield). As the final product is unstable, even if stored at 
temperatures of –20°C, it was in each case deprotected in appropriate amounts shortly before 
insertion into the next step. The triphosphorylation of 331 was executed by the 
Kovacs / Ötvös procedure as also described by Taira et al. Although the steric hindrance was 
considerably minimized compared to substrate 323, the results were similar to those 
previously obtained. No higher phosphorylated product than the monophosphate could be 
achieved, even if the default conditions were varied like described for the 
2´-monodeoxygenated cytidine-spermine construct. Another approach that was investigated 
came from Ahmadibeni and Parang (Scheme 59).[398] The method based on the preparation of 
a triphosphorylation agent that could be used to couple nucleosides after attachment to the 
solid phase. Eventually this leads to the respective triphosphates after oxidation, deprotection 
and cleavage from the resin. The preparation of the triphosphorylating agent started from 
phosphorous trichloride (332), which was transferred into a dichloride 333 by reaction with 
3-hydroxypropionitril. After partition, two third were reacted with diisopropylamine and were 
hydrolyzed with equimolar amounts of water. After reuniting the condensation should yield a 
triphosphane 336, which can be attached to a hydroxyl- resin. 
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Scheme 59 Synthesis of triphosphates on solid phase.[398] 
Unfortunately it was not possible to reproduce the synthesis of the triphosphorylating agent. 
The 31P-NMR spectra did not show any signals corresponding to P(III) or higher phosphate 
species than monophosphates. This probably resulted from a quick rearrangement reaction of 
335 to the pentavalent 337. This reaction can be classified as an analogue of an 
Arbuzov rearrangement (a in Scheme 60).[399, 400] In both depicted mechanisms, the P(+III) is 
transferred into a P(+V). The driving force is the formation of the phosphorous-oxygen 
double bond and the oxidation of the phosphorous to +V. Isolated hydroxyl-P(+III) species 
like 346 are only rarely found in literature. Mostly, their formation leads to the further 
reaction to analogous products as described in row b of Scheme 60. Moreover, this 
rearrangement is sometimes suggested as optimal route to such hydrido-phosphorazanes like 
348, starting from phosphodiazanes or chlorophosphazanes.[401, 402] There is only one example 
in which a molecule like 348 could be isolated.[403] However, in this case the amino group was 
substituted by a sulfonamide, which lowers the basicity of both, phosphorous and nitrogen. 
This could avoid or decelerates the proposed mechanism. 
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Scheme 60 Mechanism of the Arbuzov rearrangement (a) and the putative mechanism of the side reaction (b). 
In both cases, the P(+III) is transferred into a P(+V).[400] 
Finally, these facts question the whole procedure. A personal communication from the 
authors of the publication suggested carrying out the reaction in the absence of humidity, what 
was adhered strictly. However, as the key intermediate is prepared by reaction with water, this 
did not lead to an improved result. To minimize the side reaction, the original protocol was 
then modified. Diisopropylamine was added directly to the undivided solution of 233. After 
stirring, water was added in small portions to keep the concentration of 335 low and favour 
the further reaction with 333 against the rearrangement. However, the outcome of this 
approach was identical to the original experiment. Further efforts to directly phosphorylate the 
nucleoside were not undertaken. 
 
4.3.7.3 Introduction of a maleimide onto triphosphates 
As the triphosphorylation seemed to be crucial, it was tried to avoid this step. 
Phosphorylated analogues were applied in the reaction with maleimido building block 196. 
2´-Desoxycytydine monophosphate, 2 -´desoxyadenosine monophosphate and 
2´-desoxyadenosine triphosphate were reacted with 3-N-maleimidopropionyl succinimide 
under various conditions (Scheme 61). Like for nucleoside 329, it was necessary to strongly 
activate the carboxyl compound to enable considerable peptide bond formation (Scheme 61). 
It was reported that imidazole ester are sufficiently activated to be used for this reaction. In 
this case the succimidyl ester was applied and the imidazole ester was formed in situ by 
addition of 3.2 equiv. of imidazole to the reaction mixture. While neither the conditions a nor 
b gave any detectable amounts of product 350, reaction under condition c yielded a mass peak 
that could correspond to the product and was present before and after purification on 
RP-HPLC. Unfortunately the 1H NMR could not confirm the proposed structure, but showed 
a crude mixture of compounds. 
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Scheme 61 Attempts for the introduction of a maleimide to phosphorylated nucleosides. The conditions are 
depicted in the scheme. 
It could only be speculated that the product is unstable, keeping in mind that compound 319 
is also prone to quick degradation. Analysis of the crude product showed that large amounts 
of the monophosphorylated educt were recovered showing that it remains unchanged during 
the reaction. However, the activated maleimido-propionate was not recovered and instead the 
respective acid was present after reaction. It is probable that the activated ester was quickly 
hydrolysed and the peptide bond formation did not take place. For the other nucleotides, the 
result was identical. 
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4.4  Biological evaluation of the compounds 
To evaluate the potential of the different polyamine structures to serve as molecular 
transporters, they were applied in in vivo tests. Therefore, the polyamine moiety was labelled 
with fluorophores to allow a monitoring of their temporal and spatial uptake and cell 
specificity by live imaging and fluorescence detection. Common fluorophores such as 
rhodamine B, NBD, and also a porphyrin moiety, which can also serve as a phototoxic drug in 
Photodynamic Therapy (PDT) were chosen, since they all were suitable for most of the 
microscope filter sets and could be coupled to the terminal primary amino group. 
Co-incubation with subcellular markers and subsequent live imaging should also reveal a 
more detailed picture of the intracellular localization and migration of the fluorescent 
molecules.  
 
4.4.1 Fluorophore conjugates 
Initially, rhodamine B with excitation / emission wavelength at 562 / 573 nm was chosen to 
label the polyamine moiety (Figure 38).  
 
+H3N N
H2+
H2+
N
H2+
N
H
N
C
O5* TFA
ON N++H3N N
H2+
H2+
N
H
N
C
O4* TFA
ON N+
223
211
 
 
Figure 38 Structures of spermidine-rhodamine 211 and spermine-rhodamine 223.  
However, only minimal fluorescence was observed in live imaging experiments suggesting 
an interference with the polyamine moiety. 
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Figure 39 Structures of spermidine-NBD 212 and spermine-NBD 230. 
The NBD conjugates 212 and 230 are soluble in water, facilitating their application in cell 
culture (Figure 39). Calculations of the behaviour of molecule 230 in water showed that the 
polyamine chain is mostly existent in a stretched form. Only the NBD moiety adjacent to 
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NBD is bended, probably to optimise the hydrophobic interactions of NBD and the non-
charged part of the chain. Finally, all charges of the backbone are accessible for interaction 
with negatively charged groups on the cellular membrane (Figure 40). 
 
Figure 40 Calculation of the arrangement of spermine-NBD conjugate in water. (Molecular dynamics 
calculations using AMBER-software; in collaboration with J. Setzler, W. Wenzel, KIT Karlsruhe) 
Incubation of human primary fibroblasts with both spermidine-NBD 212 and 
spermine-NBD 230 revealed a strong punctuate fluorescence inside the cells (Figure 41), 
suggesting an accumulation in vesicular structures.  
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Figure 41 Live imaging of human primary fibroblasts incubated with spermidine- (a, b) and spermine-NBD 
(c, d). The cells were incubated with 1 µM or 10 µM of conjugates 212 and 230 (a, b) and y (c, d) for 24 h.[404] 
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Figure 42 Fluorescence confocal microscopy of living human primary fibroblasts, incubated with spermidine-
NBD conjugate 212 (a-d) or spermine-NBD conjugate 230 (e-h). a / b and e / f were incubated with 1 µM, c / d 
and g / h were incubated with 10 µM of the compound. The cells were co-incubated for 1 h with 150 nM 
LysoTracker Red to label the endosomal-lysosomal compartment (b, d, f, and h).[404] 
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The live images showed a pronounced uptake of the spermine conjugate 230 compared to 
the spermidine conjugate 212, while the latter is still considerably taken up. It was concluded 
that the efficiency of intracellular accumulation depends on the number of positive charges as 
already observed for the CPPs.[8] The intracellular fate of the NBD derivatives 212 and 230 
was determined by co- localisation studies with organellar markers. Co-incubation with 
LysoTracker Red for staining of the endosomal / lysosomal compartments and MitoTracker 
Red for the staining of mitochondria revealed a clear overlap with the endosomal / lysosomal 
compartment and therefore the uptake via the endocytic pathway for both polyamine moieties 
(Figure 42). 
In order to test, whether either the cellular uptake can be increased or the intracellular 
routing of the polyamine can be directed to different organelles, the lipophilicity of the 
polyamine moiety was increased as described above (see chapter 4.2.3). After labelling with 
NBD, the lipophilic polyamines shown in Figure 43 were tested in cell culture.  
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Figure 43 Structures of four lipophilic polyamines, which were labelled with NBD. These were also investigated 
by live-imaging. 
Molecular dynamics calculations in collaboration with W. Wenzel (KIT, Karlsruhe) 
revealed that in contrast to the spermine conjugate 230 (Figure 40), the backbone of 249 is 
curved to minimise the steric interaction between the large hydrophobic substituents (Figure 
44). The aliphatic C6-side chains are mostly orientated to the same side of the backbone. 
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Figure 44 Calculations of lipophilic putrescine conjugate 249 arrangement in water. (Molecular dynamics 
calculations using AMBER-software; in collaboration with J. Setzler, W. Wenzel, KIT Karlsruhe) 
HepG2 cells (human hepatic tumour), HeLa cells (human cervix tumour), and human 
primary fibroblasts (Figure 45) were incubated with these conjugates and evaluated by live 
imaging as described for the spermine- and spermidine conjugates. The intracellular 
distribution was determined by co- localisation studies using LysoTracker Red and others. All 
conjugates were efficiently taken up in human primary fibroblasts (Figure 45). The 
accumulation appeared to be mainly in vesicular structures, which are distributed in the entire 
cytosol. Co-incubation with LysoTracker Red for endosome / lysosome staining resulted in an 
overlap with the NBD fluorescence, indicating an endosomal distribution as observed for the 
more hydrophilic NBD-polyamines 212 and 230. 
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Figure 45 Fluorescence microscopy of living human primary fibroblasts. a to d show the cells after treatment 
with 239 (a), 256 (b), 249 (c), and 263 (d) (1 µM). One hour prior microscopy, the cells were co-incubated with 
150 nM LysoTracker Red to label the endosomal-lysosomal compartment (e to h).[404] 
However, the intracellular routing of the polyamines in tumour cells is different than in the 
non-tumourous fibroblasts. HepG2 and HeLa cells showed good uptake of the conjugates 
(Figure 46). While the localisation in the HeLa cells seems to be mainly vesicular in the 
perinuclear region, the accumulation in HepG2 cells occurred in larger compartments (Figure 
47). The identity of those compartments is currently under investigation. First experiments in 
HepG2 cells pointed towards a colocalization with lipid droplets due to lipophilicity of the 
polyamines. 
 
 
Figure 46 Fluorescence microscopy of HepG2 cells (a to d) and HeLa cells (e to h). The cells were incubated 
with 1 µM of 239 (a and e), 256 (b and f), 249 (c and g), and 263 (d and h) for 24 h.[404] 
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Figure 47 Accumulation of 239 in large compartments of the HepG2 cells.[404] 
To quantify the cellular uptake of all polyamine moieties, the intracellular content of the 
NBD-polyamine conjugates was determined by a fluorescence-based assay.[404] HepG2 and 
HeLa-cells were incubated with 0.1, 1, 10, 20, and 100 µM of the respective conjugates. After 
2, 24, 48, and 72 h the cellular surface bound polyamines were removed by trypsination and 
high salt washes and the fluorescence was determined and normalized to the number of living 
cells. The uptake of conjugates 239, 256, 249, and 263 into HeLa cells is shown in Figure 48. 
The assays showed a concentration (a – f) and time dependent (e, f) uptake (Figure 48). 
At higher concentrations up to 100 µM, the uptake is also markedly higher. Although the 
fluorescence is easily detectable by fluorescence microscopy in almost all cases, the uptake is 
not very high. HPLC determination of the intracellular content revealed that only up to 2 – 3% 
of spermine-NBD were taken up after 24 h.[404] However, the assays suggested a saturation of 
the cells, which has been also shown for other polyamine conjugates such as the spermidine-
porphyrin conjugate 217 (see chapter 4.4.2).  
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Figure 48 Uptake of conjugates 212 (a), 230 (b), 239 (c), 256 (d) , 249  (e), and 263  (f) into HeLa cells. To 
determine the NBD-polyamine concentration, fluorescence emission was read at 464 / 512 nm 
(excitation / emission) after 2, 24, 48, and 72 h by using a Thermo Scientific Varioskan plate reader. The 
emissions of n = 3 experiments were quantified and normalized to the viability of cells, previously determined 
by the MTT assay and the SD was calculated.[404] 
For the application of the polyamine-conjugates as `molecular transporters´ it was 
additionally important to determine the toxicology of the polyamine moiety and the respective 
conjugates with potential drugs. Therefore, a classical colorimetric viability assay, the MTT 
assay was used. The MTT assay is based on the reduction of the tetrazoliumsalt MTT (355) to 
the purple, water insoluble formazan (356) in the mitochondria of living cells (Figure 49).[405] 
The reduction occurs by the mitochondrial succinate-dehydrogenase, which belongs to the 
respiratory chain of the mitochondria and is active only in metabolically active cells.  
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Figure 49 Reduction of MTT (355) to formazan (356).[405] 
 
 
Figure 50 Time-and concentration dependent toxicity of conjugates 212 (a), 230 (b), 239 (c), 256 (d), 243 (e), 
and 263 (f). The toxicity was measured after 2, 24, 48, and 72 h upon incubation with varying concentrations of 
the compounds. The viability of the cells was measured using the Cell Titer 96 assay from Promega. 
T / C [%] = test over control (value for the viability of cells). SD was calculated from the n = 3 experiments.[404] 
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In analogy to the uptake assays, the cellular viability was measured in a time (2, 24, 48, 
72 h) and concentration (0.1, 1, 10, 20, 100 µM) dependent manner (Figure 50). Most 
compounds showed a proliferative effect after 2 – 24 h in accordance with the proliferative 
effects reported for many other polyamines and their analogues.[52, 91, 92, 108] After longer 
treatments, the more lipophilic compounds bearing the adamantyl modification 
(compounds 249 and 263) showed increased toxicity compared to the hydrophilic spermine 
and spermidine-NBDs 212 and 230 even in lower concentrations (Figure 50). The IC50 (Tox) 
values after 72 h treatment were ranging from 4 µM to 80 µM as depicted in Figure 51. 
Again, compound 243 showed the highest toxicity, while compounds 212, 230, and 263 were 
in a similar range as well as compound 239 and 256. 
 
 
Figure 51 Concentration-dependent application of the toxicity of conjugates 212 (a), 230 (b), 239 (c), 256 (d), 
243 (e), and 263 (f). The toxicity was measured after 72 h upon incubation with varying concentrations of the 
compounds. The viability of the cells was measured using the Cell Titer 96 assay from Promega. T / C [%] = test 
over control (value for the viability of cells). SD was calculated from the n = 3 experiments.[404] 
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At 100 µM, all conjugates showed a severe toxicity, which was also correlated with the 
amount of cellular uptake as depicted in Figure 48. It could be concluded that the toxicity of 
the conjugates is related to the amount of uptake. The stronger toxicity of conjugate 243 is 
again apparently, while it is visible that the increased toxicity goes along with stronger uptake 
of the compound from the medium. Further studies on the uptake and toxicity in other cell 
types are ongoing.  
 
 
Figure 52 Compilation of the uptake and the toxicity of all NBD labelled conjugates. The toxicity of the 
conjugates is related to the amount of uptake (212 (a), 230 (b), 239 (c), 256 (d), 243 (e), and 263 (f)). To 
determine the NBD-polyamine concentration, fluorescence emission was read at 464 / 512 nm (excitation / 
emission) by using a Thermo Scientific Varioskan plate reader. The emissions of n = 3 experiments were 
quantified and normalized to the viability of cells, previously determined by the MTT assay and the SD was 
calculated. The toxicity was measured after 72 h upon incubation with varying concentrations of the compounds. 
The viability of the cells was measured using the Cell Titer 96 assay from Promega. T / C [%] = test over control 
(value for the viability of cells). SD was calculated from the n = 3 experiments.[200] 
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4.4.2 Porphyrin-conjugate 217 
To test, whether the polyamine moieties are capable to enhance uptake of therapeutic drugs 
into cells and tissues, the cellular uptake and biophysiological properties of the polyamine 
conjugates with porphyrin and Indomethacin (171) were further determined.   
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Figure 53 Structure of the spermidine porphyrin-conjugate.[200] 
The polyamino-porphyrin conjugate 217, which is shown in Figure 53, was well 
investigated during this work. The polyamine is separated from the porphyrin by a C6-spacer 
that should allow a separation between the hydrophilic and the hydrophobic parts of the 
molecule (see chapter 4.2.1). Solubility studies with 217 showed that the protonated form is 
well soluble in polar alcohols such as methanol, ethanol and 50% methanol as well as in polar 
solvents like DMF or DMSO. Furthermore, it is poorly soluble in water, dichloromethane, 
and chloroform and insoluble in unpolar solvents like diethylether or cyclohexane. Therefore, 
the conjugate was solved in 50% methanol to reveal a stock solution of 20 mM allowing a 
low methanol content of the final incubation media. The UV spectra of solutions of 217 in 
water, containing low amounts of alcohol, showed the integrity of the typical porphyrin 
bands. This shows, that the conjugate is really solvated and that no unspecific aggregation 
occurs on the molecular level (see chapter 6.7 in the experimental section). On the other hand, 
carboxyporphyrin x was insoluble in water, poorly soluble in methanol and well soluble in 
chlorinated solvents. The highest concentration, which could be observed in methanol was 
below 40 µM. Finally, this required high percentages of methanol (more than 10%) in the 
media to achieve a final concentration of 5 µM after dilution. Such high methanol contents 
make it unsuitable for the use in PDT under physiological conditions. 
COS-7 cells, HeLa cells, and fibroblasts were incubated for 24 h in the absence of light with 
concentrations of 217 ranging from 0.01 to 100 µM (Figure 54). Live imaging, which avoids 
artefactual diffusion due to membrane perforation during fixation[57, 61-63], showed that the 
conjugate is taken up into vesicle like structures in the perinuclear region. A nuclear or 
cytosolic accumulation was not observed. Removal of the incubation media and washing of 
the cell-surface with trypsine ensured that the conjugate is no longer attached to the outside of 
the plasma membrane.  
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Figure 54 Treatment of COS-7, HeLa-cells and human fibroblasts with spermidine-porphyrin 217: A, after a 4 h 
treatment with high doses (50 µM) of spermidine-porphyrin 217, the majority of cells was killed in the presence 
of light. B, 24 h treatment with carboxy porphyrin 215 in the absence of light. C, 24 h treatment with 
concentration of 5 µM of spermidine-porphyrin 217 in the absence of light.[200] 
As opposed to 215 that could not be detected inside the cells at a concentration of 5 µM, 
217 exhibited a highly improved cellular uptake at the same concentration (Figure 54) as well 
as an increased uptake with the incubation time. Equivalent treatment of cells with 217 and 
10% methanol concentration still showed efficient uptake but also decreased the cell viability 
to lower than 50%. Cellular uptake of 217 could be observed by fluorescence microscopy and 
fluorometric determination for concentrations as low as 0.5 µM. In almost all cells, uptake 
increased with time and concentration, implying a slow uptake of the membrane-attached 
compound. Studies on the dose and time dependent cellular uptake were performed in HeLa 
cells (Figure 55).  
Figure 55 shows the time and concentration dependent quantification of the uptake. The 
amount of internalized spermidine-porphyrin was related to the amount of cellular protein 
after removal of the incubation media and cell- lysis. The treatment of cells with 215 at 5 µM 
did not show any significant uptake or accumulation. Although 217 is already rapidly taken 
up by the cells in low concentrations, the uptake reaches a saturation after 16 – 24 h 
depending on the initial concentration. At higher concentrations, the fluorescence seemed to 
saturate in the cells at 13 nmol / mg protein, and no further increase was found after longer 
exposure times. It is not clear, whether this saturation is due concentration quenching or real 
saturation of the compound. However, this result is similar to these of some NBD-conjugates 
presented in chapter 4.4.1.  The proliferative effect that was obtained after feeding of some 
polyamine conjugates might be responsible for the dilution and the following quasi-stationary 
state (see Figure 60 and chapter 4.4.1). 
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Figure 55 Time and concentration dependent uptake of polyamine-coupled porphyrin 217 in HeLa cells. HeLa 
cells were treated with different concentrations (0.5, 1, 5, and 10 µM) of 217 and 5 µM of 215 and harvested at 
different time points as described (see chapter 6.8 in the experimental section). To determine the 
polyamine-porphyrin concentration, fluorescence emission was read at 420 / 650 nm (excitation / emission) by 
using a Thermo Scientific Varioskan plate reader. The emissions of n = 4 experiments were quantified and 
normalized to the amount of the total protein and the SD was calculated.[200] 
Co-localisation studies with cellular markers such as LysoTracker Green, 
MitoTracker Green, NBD-C6-ceramide for Golgi staining and DAPI for nuclear staining were 
performed to investigate the cellular fate of 217 (Figure 56). Staining with Lysotracker did not 
reveal any co- localisation, even though the punctuate pattern is indicating vesicular structures. 
Co-incubation experiments with MitoTracker Green, however, showed a mitochondrial 
localisation of the amphiphilic porphyrin and often a strong vesicular accumulation in the 
perinuclear region especially in tumour cells (e-h in Figure 56). At higher doses or after 
prolonged incubation time, the vesicular structures in perinuclear region became more 
pronounced. However, these structures could not be co- labelled with LysoTracker green or 
MitoTracker green and their identity has to be determined in further studies. In hepatic 
tumour cells (HepG2), there are preliminary indications that the perinuclear vesicles are 
derived from lipid droplet fusion.  
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Figure 56 Fluorescence confocal microscopy of living COS-7 cells (a, b), human primary fibroblasts (c, d), 
HeLa cells  (e, f), and HepG2 cells  (g, h). The images show cells after co-incubation with compound 217 (a, c, e: 
5 µM, g : 1 µM) and MitoTracker Green (b, d: 150 nM) or LysoTracker Green (f, h: 150 nm). 
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For PDT, a mitochondrial localisation is desired to exhibit a stronger phototoxic effect and 
to induce not only necrosis but also apoptosis. It has recently been shown that amphiphilic 
cations including guanidyl-poprphyrins[378, 380, 406] are rapidly delivered to mitochondria due to 
their highly negative membrane potential. The hydrophobic moiety is believed to help with 
the integration into the lipid bilayer.[378, 380]Previously, a photodynamic approach has been 
reported for the killing of bacteria on the skin analogous to PDT for cancer.[407] A variety of 
compounds with photoactive properties have been tested against gram-negative and gram-
positive bacteria.[408, 409] Anionic porphyrins showed no activity against either gram-positive 
or gram- negative bacteria due to their impaired uptake or interaction with the bacterial cell 
wall. As it is well known that both E. coli and gram- positive bacteria interact with positively 
charged peptides, the positively charged spermine–porphyrin 217 was tested for its phototoxic 
effect on E. coli and gram-positive lactobacillus. The aim of this study was to find in vitro 
conditions for the killing of bacteria in presence of eukaryotic cells as a model for a later 
treatment of bacterial infection in vivo. Polyamine-porphyrin 217 showed efficient uptake in 
all tested organisms such as tumour and primary cells, gram-positive and gram-negative 
bacteria, and yeast (a-c, f in Figure 57). However, in a co-culture of bacteria and tumour cells, 
tumour cells preferentially bound and took up the conjugate, while in a co-culture of bacteria 
and primary cells, the uptake into bacteria was preferred after 2 h. After 15 min irradiation, all 
of the bacteria were found dead and no re-growth could be detected even after 72 h 
cultivation. 
Likewise, a co-culture of tumour cells and primary cells revealed a preferential uptake of the 
217 in tumour cells when the cells are treated with low concentrations and for short 
incubation times (i in Figure 57) This phenomenon is probably due to the density of negative 
charges on the outer membranes, which is increasing from primary cells over bacteria to 
tumour cells. It is not clear, whether the different uptake efficiency will rely on the interaction 
of the spermine moiety with the proteoglycans or negatively charged lipids on the surface of 
the different cells and organisms or whether it depends on an active transport system such as 
the polyamine transporter. Nevertheless, this assumes that 217 might be a potent candidate for 
PDT in vivo with less risk for the damage of healthy tissue. Further studies with multiresistant 
Staphylococcus aureus strains are ongoing. 
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Figure 57 Gram-(-) (E. coli) (a, b = DAPI counterstain) and gram-(+) (lactobacillus) (c) bacteria as well as yeast 
(f) revealed excellent uptake of 217 (1µM) after 2 h while 215 was not taken up. Irradiation of 15 min and 
24 - 72 h incubation at 37 °C did not show any bacterial regrowth in a colony-forming assay. Simultaneous 
treatment of a co-culture of tumour cells (HeLa) and gram-(+) bacteria (e)  or primary cells (human fibroblasts) 
and gram-(+) bacteria (h) showed a competition between the cells and the bacteria compared to non infected 
cells (d for HeLa; g for fibroblasts). Likewise, HeLa cells take up 217 faster than fibroblasts when incubated for 
1 h After 24 h both cell lines show equal uptake. H= HeLa cell, F= fibroblast. a-c, f confocal images. d,e g-i, 
Nomarski images were merged with the fluorescent images of 217 (red).[200] 
In vivo studies in mouse model showed an accumulation of conjugate 217 in the liver while 
a peptoid-conjugate bearing the same porphyrin moiety is targeted to lung and heart (Figure 
58).[410] In comparison with the peptoid-derivative, the emission of both conjugates differed 
when excited at the same wavelength. The peptoid conjugate is still detected at 680 nm, while 
the polyamine-porphyrin is detected at 800 nm. A similar effect was observed for the 
rhodamine derivatives (see chapter 4.4.1). 
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Figure 58 Comparison of a peptoid-porphyrin conjugate[82] and polyamine-porphyrin conjugate 217.[200] 
Although they bear the same lipophilic porphyrin, their emission after excitation at the same wavelength is 
different (first row). After injection into mice, the conjugates accumulate in different organs (second and third 
row). While the peptoid conjugate appears mainly in the lungs, the polyamine conjugate was mainly found in the 
liver.[410] 
As already mentioned, many porphyrins exhibit a strong phototoxicity and are suitable for 
Photodynamic Therapy (PDT). Their phototoxic efficacy depends on the chemical 
modification and their intracellular localisation. As shown in Figure 59, spermidine-porphyrin 
treated cells could be destroyed by irradiation with visible light. The mitochondrial 
accumulation of 217 suggested a very efficient phototoxicity, which would only require low 
concentrations of conjugate 217 to induce apoptosis and necrosis. The cells show severe 
necrosis already 2 min after visualization in the combined fluorescence and transmission light 
mode of the microscope. The membrane structure of the cells seemed to be disrupted and a 
release of the fluorescent material is observed indicating necrosis (A). After a 24 h incubation 
post photo- irradiation, many cells display nuclear fragmentation indicating apoptotic cell 
death (B). In both cases, the Nomarski images were merged with the fluorescent images of the 
porphyrin 217 labelling 
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Figure 59 Live imaging of primary fibroblasts treated with 1 µM of 217 after photo-irradiation with visible light 
(A, B).[200] Quantification of the phototoxic effect of 217 on HeLa cells. Cells were incubated with 0.1, 1, and 
5 µM of 217 and 5 µM of 215 for 4 h and 24 h. Eventually, the cells were irradiated with 650 nm laser light for 
various times. Quantification of dead and necrotic cells was performed after staining with propidium iodide and 
trypan blue. The irradiation of cells in absence of photosensitisers did not trigger cell death. The cells were 
counted in 3 x 4 random fields framed with the Axiovision software and the readout was evaluated by the 
student’s test. SD was calculated from the n = 5 experiments for the following conditions: 217, 5 µM, 4 h; 217, 
0.1 µM, 4 h; 215, 5 µM, 4 h. The data (217, 0.1 µM, 24 h; 217, 1 µM, 24 h) were taken from single 
experiments.[200] 
A more detailed investigation on the course of cell death is shown in Figure 59. It is visible 
that carboxyporphyrin 215 has only minor effects. The minimal cell death, even after 30 min 
irradiation, indicates a very constricted uptake. For 217, which was incubated for 4 h and 24 h 
in concentrations of 0.1, 1, and 5 µM, the experiment shows that severe phototoxicity was 
already visible after 5 min of irradiation with 650 nm light. When cells are treated with 5 µM 
of 217 for 4 h, about 70% of the cells were killed, while no cells survived the treatment for 
15 min. In lower concentrations, the compound has to be enriched for a longer incubation 
period to induce efficient cell death. Only in case of very low dose (0.1 µM) and short 
incubation time of 4 h, the incubation did not suffice to kill all the cells within 15 min. 
Comparison with the results from Figure 55 yield that once an inner-cellular concentration of 
6.5 nmol / mg protein was reached, the cells could be entirely killed after 10 min irradiation.  
Thereby, cell death correlated with intracellular saturation of the compound and irradiation 
time, while non- irradiated cells were not affected. The effective dose (ED50) for irradiation 
seems to be dependent on the total amount of the internalized or membrane bound compound. 
The dark toxicity of 217 was measured 72 h after addition (Figure 60). While exhibiting a 
strong phototoxic effect, the dark toxicity of 217 was low but not as low as reported for 
porphyrin derivatives coupled to polycationic peptides, which accumulate in the endosomal 
compartment.[406] It is assumed that the mitochondrial localization of 217 is responsible for 
the higher toxicity, as it has been shown for other mitochondria localized porphyrin 
derivatives.[406] The IC50 values of the dark toxicity were estimated as 81,2 µM for HeLa cells 
and 98,4 µM for primary fibroblasts (c in Figure 60) making the compound well suited for the 
application as a photosensitiser.  
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Figure 60 Dark toxicity of spermine-porphyrin 217 in primary human fibroblasts (a) and HeLa cells (b). The 
dark toxicity was measured after 24, 48, and 72 h upon incubation with varying concentrations of 217. The 
viability of the cells was measured using the Cell Titer 96 assay from Promega. (c). Concentration dependent 
dark toxicity after 72 h in HeLa cells (dashed line) and primary human fibroblasts (full line). T / C [%] = test 
over control (value for the viability of cells). SD was calculated from n = 3 experiments.[200] 
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4.4.3 Indomethacin conjugate 
It can be expected that Indomethacin-polyamine conjugates bear high toxicity, as even the 
intrinsic indomethacin is toxic and an improved uptake would enhance its effect. This can be 
tolerated, if the refinement of the impact is equal or higher than that of the toxicity.  
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Figure 61 Structures of spermidine-indomethacin 213 and spermine-indomethacin 229. 
The toxicity was determined by the SRB assay. The sulforhodamine B test was used to stain 
cellular proteins can be stained by sulforhodamine B in weakly acidic media as all basic side 
chains are sufficiently protonated to be complexed by the sulfonate groups. The dye can be 
removed from the proteins under basic conditions. Finally, it can be measured photometrically 
at 570 nm. 
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Figure 62 In slightly acidic medium, Sulforhodamine B 357 stains the basic side chains of proteins by 
complexation with its sulfonate groups.[411, 412] 
The results from Figure 63 show that spermidine-indomethacin conjugate 213 and 
spermine-indomethacin conjugate 229 show strong toxicity for concentrations above 1 µM. 
The toxicity for both follows the trends of spermidine (15) and spermine (16), with the 
conjugates being slightly more toxic than the particular polyamines. Indomethacin (171) is 
less toxic than both, the conjugates and the polyamines. Compared to 
spermidine- indomethacin 213, the toxicity of spermine- indomethacin conjugate 229 is 
slightly increased. The same correlation exists between the unmodified polyamines. 
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Figure 63 SRB assay of spermidine (15) (a), spermidine-indomethacin conjugate 213 (b) , spermine (16) (c), 
spermine-indomethacin conjugate 229 (d) , indomethacin (171) (e), and NH4(F3COO) (f). The test was performed 
with HT29 cells and the incubation time was 72 h. The average values and standard deviations were related to 
the control value of cell growth in medium spiked with 1% DMSO. (in collaboration with J. Pelka, D. Marko, 
KIT Karlsruhe) 
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5 Conclusion and outlook 
A variety of symmetric and  asymmetric spermine building blocks were prepared. The 
combination of o-Nosyl- and Aloc group was advantageous, because it greatly facilitates the 
work-up and gives stable entities. The asymmetric building blocks 179, 181, and 187 were 
applied for solid phase chemistry as they afford loading of resins under avoidance of 
cross- linking. Especially building block 187 was useful as it additionally allows the 
differentiation of primary and secondary amines. Furthermore, it also permits the direct 
elongation of the backbone by Fukuyama alkylation without requiring trans-protection. Thus, 
2-chlorotrityl resin (60) loaded with 187 was chosen to act as universal starting point for most 
of the following solid phase syntheses. The versatility of the novel protection group system 
for polyamine solid phase chemistry was consistently demonstrated. Problems occurring 
during the Aloc deprotection were successfully solved. Finally, the first solid phase synthesis 
of the spider toxin HO359b (203) proved that the protection group combination is equal to 
previously established combinations. Fukuyama alkylation with halides was identified as the 
method of choice for backbone elongation and modification. A detailed study revealed 
optimised reaction conditions for different substrate types. Those allow the introduction of 
several functional groups and are more economical in terms of inserted halide than previously 
published examples.[289] The combination of o-Nosyl / Aloc protection and 
Fukuyama alkylation for backbone elongation is selective and milder than many previously 
reported examples. Thus, it allows the synthesis of structurally more diverse molecules on 
trityl linkers. In contrast to examples, in which Boc- or Nosyl groups served for the 
permanent protection of backbone-secondary amines, Aloc groups can be selectively removed 
and allow further modification of the liberated amines. It showed that Reductive amination is 
able to mono-alkylate the backbone amines, allowing their substitution with 
aldehyde-building blocks. SN2-alkylation is restricted to sterically less hindered building 
blocks. The use of other resins, which do not bear a rigid trityl linker, could improve this 
result and allow the introduction of such bulky groups as for example adamantyl groups. 
For the development of coupling methods, the Michael addition between maleimides and 
thiols was chosen. Starting from resin 198, the o-Nosyl group was removed and a 
maleimidopropionyl group was introduced avoiding cross-linking, by reaction of the free 
amine with pre-activated building block 3-N-maleimidopropionyl succinate (196). The 
reaction conditions for addition of ethylsulfide to the maleimide were optimised and the 
reaction was applied to a small library of sulfides. The reaction showed to be suitable for the 
coupling of thiols of medium polarity, but not suitable for unpolar thiols. For coupling of 
polar thiols, it is necessary to add raising amounts of water into the solvent, in order to 
achieve sufficient solubility of the thiol. This collides with the swelling properties of 
polystyrene resins, which only tolerate low doses of protic solvents before they collapse. It 
was assumed that the solution would be the use of resins with better swelling properties in 
polar solvents. This is suited by PEG-modified resins, which are commercially available. 
Transfer of the reaction conditions of the synthesis of resin 277 to a Tentagel resin gave the 
product in only poor yield and purity. As it is known that Tentagel resins are difficult to 
handle, oxidation of the PEG scaffold upon air contact during synthesis could be responsible 
for this. For further studies, it would be necessary to optimise the preparative conditions. 
Once established, the coupling of polar thiols, particularly thiol-modified oligonucleotides, 
avoiding undesired electrostatic interactions, should be possible. It was shown that Aloc 
deprotection takes place and the formed thioether is not detrimental to the Pd-catalyst. The 
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chosen protection strategy would also converge with the coupling of peptides or DNA, 
because both are stable during Aloc deprotection.  
The vice versa strategy, introduction of a thiol on solid phase and subsequent coupling to 
maleimides was also examined. For this, the introduction of 2- iminothiolane proved to be 
especially promising. After successful suppression of diverse side reactions, the developed 
protocol showed to work excellently for the cross- linking reaction. If used with extremely 
acid labile alkoxytrityl resins, sensitive conjugates like polyamino nucleosides and spermine 
conjugate 360 could be successfully synthesised (see end of this chapter). The selectivity of 
2-iminothiolane for primary amines supersedes the use of complex protection schemes to 
allow regioselective introduction. The precursor maleimides 313 and 319 were prepared 
starting from the 2 -´deoxynucleosides in four or five steps giving 28% or 16% yield, 
respectively. A triphosphorylation of the conjugate 323 was not successful following the 
standard protocol of Kovacs and Ötvös. To exclude that a negative interaction with the 
3´-hydroxy group or the huge polyamine substituents was the reason for this, 
2´,3´-dideoxy-N4-3-maleimidopropionylcytidine (331) was synthesised. Reaction over seven 
steps gave an overall yield of 18%. As the triphosphorylation in analogy to Kovacs / Ötvös 
was again not successful, a more recent protocol from Ahmadibeni / Parang was applied on 
modified dideoxycytidine 331. These attempts also did not result in the desired triphosphate. 
Taken together, the synthesis of a maleimido-modified triphosphate was not successful. The 
most promising point of contact for further studies could be the isolation of the 
monophosphorylated nucleoside from the method according to Kovacs and Ötvös and use of 
another method for its conversion into the triphosphate. Alternatively another coupling 
method could be used, which does not require the synthesis of maleimido-modified 
nucleotides, which are susceptible to quick degradation. Finally, two methods were afforded 
for the introduction of a thiol to a polyamine from which one was further elaborated and 
showed to be useful for the synthesis of sensitive conjugates between maleimides and 
polyamines. 
Several conjugates of polyamines with fluorescent dyes, porphyrins and indomethacin were 
successfully synthesised. The above described protection system (see chapter 4.1.2) was 
extended in the way that it finally consists of the orthogonal use of trityl linker and Aloc-, 
o-Nosyl-, and Dde-protection group, and enabled the synthesis of natural product HO359b, 
conjugates with porphyrins, fluorescent dyes, and Indomethacin. Most of the conjugates 
found entry into biological evaluation (see chapter 4.4). The yields of the syntheses ranged 
from 8% to 99%. Problems during the labelling with NBDCl were the main reason for the low 
yields in some cases. 
Several of the synthesised conjugates were evaluated for their biological activity. 
Toxicological data were collected for all compounds. Fluorescence live imaging of incubated 
cells was used to gain information on their uptake into mammalian cells. The cellular uptake 
of polar NBD-derivatives 212 and 230 as well as lipophilic NBD conjugates 239, 249, 256, 
and 263 into HeLa cells, HepG2 cells, and fibroblasts was investigated by live imaging. It 
showed that the cells efficiently took up the conjugates. Two positive charges seem to be 
sufficient to achieve this uptake. The NBD-spermidine 212 and NBD-spermine 230 were 
taken up into endosomal and lysosomal compartments. The lipophilic NBD conjugates were 
also found in vesicular compartments in fibroblasts. In HeLa cells and even more distinct in 
HepG2 cells, the conjugates also appeared in larger compartments. The experiments for the 
exact determination of these intracellular compartments are ongoing. The rhodamine 
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derivatives could not be detected after excitation with the fixed wavelength of the 
fluorescence microscope.  
Porphyrin conjugate 217 was the most intensively studied conjugate. Fluorescence 
microscopy of incubated COS-7 cells, HeLa cells, HepG2 cells, and human fibroblasts 
showed a strong uptake compared to the non-modified, anionic carboxyporphyrin 215 (Figure 
54). Co-incubation with vesicular cellular markers in fibroblasts, HeLa cells, HepG2 cells, 
and COS-7 cells suggested a final accumulation in mitochondria (Figure 56 and 
chapter 4.4.2). A time dependent determination of the uptake showed that 217 is readily 
internalised and after longer incubation, the concentration of the conjugate inside the cell ends 
in a saturation. The time, when this plateau is reached depends on the concentration of 217 in 
the incubation medium. The reason for this saturation is not clear. Possibly, the cells take up 
huge amounts of the conjugate during their growth state and after this, the uptake is slowed 
down. This would be in accordance with the finding that most of the polyamine conjugates 
showed a slight proliferative effect in the first 24 h of the incubation. Another possibility is 
that cells actively regulate the content of porphyrin conjugate 217. Finally, a fluorescence 
quenching effect is also imaginable. However, the latter is rather improbable as the effective 
concentration in the cell lysate during fluorescence measurement is low. Consequently, 
illumination of HeLa cells showed strong phototoxicity already after short irradiation for 
10 min after previous incubation with 0.1 µM of 217 for 24 h. Incubation with higher 
concentrations up to 5 µM showed the same result, however already after 4 h. This strong 
effect is in accordance with the fact that oxidative stress in the mitochondria is especially 
harmful for the cell.[406, 413] In contrast, the dark toxicity of porphyrin conjugate 217 is low in 
fibroblasts, and in HeLa cells even a slight proliferative effect is observed during the first 
48 h. Co-cultures of different cell types with spermidine-porphyrin 217 showed very 
beneficial results. The rate of uptake increased in the line from fibroblasts over bacteria to 
tumour cells. After short ir radiation of a pre- incubated culture of bacteria, no re-growth of the 
bacteria could be observed even after 72 h of further incubation. This assumes the use of 217 
to act in photodynamic therapy of dermal disorders, skin-deep infections, and skin cancer. 
Further studies with multi- resistant Staphylococcus aureus strains and mouse models are 
ongoing.  
The toxicology of the indomethacin conjugates 213 and 229 was tested by an SRB assay. 
Both compounds showed increased toxicity compared to indomethacin and the particular 
polyamines. The toxicity of the conjugates is in both cases more similar to the polyamine 
toxicity than to indomethacin. The increased toxicity gets significant for values above 5 µM 
for the spermidine- indomethacin conjugate 213 and for values above 2.5 µM for the 
spermine-indomethacin conjugate 229, indicating a higher toxicity of the spermine conjugate. 
The next steps would be to determine the uptake efficiency of the conjugates and determine 
the effective dose ED50. Comparison with the toxicity will show, if polyamine homologation 
is of benefit for application of Indomethacin. 
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6 Experimental section 
6.1 General 
Materials 
Starting materials were obtained from commercial suppliers and were used without further 
purification (Acros, Aldrich, Fluka, Merck, Riedel de Haen, Sigma). 2-Chlorotrityl chloride 
resin (100 – 200 mesh, cross-linked with 1% divinylbenzene; loading: 1.3 mmol / g) and 
NovaSyn® TGT alcohol resin (100 – 200 mesh, cross-linked with 1% divinylbenzene; 90µm 
beads, loading: 0.27 mmol / g) were obtained from Novabiochem (Switzerland), 
Merrifield resin (75 – 150 mesh, 0.97 mmol / g) was obtained from Polymer Laboratories. 
Solvents were purchased dry and stored over molecular sieve (0.3 nm pore). Et3N, 
diisopropylamine, and acetanhydride were distilled prior to use. VLC and flash 
chromatography were performed using Merck silica gel 60, 40 – 63 µm, preparative RP-flash 
chromatography was performed on LiChroPrep-C18. 
 
HPLC 
Analytical HPLC was performed on a Pharmacia SMART-HPLC-system, using a CGE 
Bioscience C18 (2) 3ì column (150 × 4.6 mm) eluted at a rate of 0.1 mL / min and evaluated 
using SMART-Manager software. Preparative HPLC was performed on an Amersham-
Pharmacia-Biotech ETTAN-LC-system, using a VarioPrep 250 / 10 NUCLEODUR 100 – 
5 C18 ec, eluted at a rate of 2 mL / min and evaluated using UNICORN 4.0 software. Mobile 
phases were gradients of eluant A (MeCN - H2O - TFA 10 : 90 : 0.1) and eluant B 
(MeCN - H2O - TFA 80 : 20 : 0.1), eluant A (MeCN - TEAA (0.05 mmol, pH 6.5) 5 : 95) and 
eluant B (MeCN - TEAA(0.05 mmol, pH 7.3) 95 : 5), and eluant A (MeCN - H2O - HOAc 
5 : 95 : 0.01) and eluant B (MeCN - H2O - HOAc 95 : 5 : 0.01). The purities determined from 
HPLC were calculated from the values of the peak integrals. 
 
Reactions 
If not otherwise stated, all reactions were carried out at room temperature, 1.013 bar, and 
under argon atmosphere. Reactions in flasks were heated using an oil bath. Vials were heated 
with a Reacti-Therm (Pearce). All solid-phase reactions were performed in glas frits or glas 
vials. Suspensions of the resins were agitated on a Janke and Kunkel KS 501 D shaker. 
Solution phase syntheses were, depending on the reaction volume, carried out on glass flasks 
or in glass vials. Dry solvents were transferred by plastic coatings and steel cannulae. The 
washing steps were usually carried out on air. For the reactions, dry solvents were used and 
the first washing steps were usually carried out with solvents of technical grade, while the 
terminal washing was carried out with absolute, puriss.-grade solvent. The reactions were 
carried out in sealed glass frits or sealed glass tubes. Cooling mixtures:  
· 0 °C:  ice in water 
· –80 °C: dry ice in acetone 
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Large volumes of solvents were removed in a rotary evaporator. Compounds were dried at 
possibly low temperature in high vacuum. Compounds were dried with a vacuubrand 6 
oilpump. Column chromatography was doen in analogy to the procedure from Still.[414] The 
yields were given for products with purities above 95%. Otherwise the purities were stated. 
 
Thin layer chromatography 
To control the completion of a reaction or to monitor column chromatography samples of 
the reaction mixture, chromatography fractions are analyzed by thin layer chromatography 
(TLC) on silicagel-aluminium plates (2.5 x 6.5 cm or 7 x 5 cm respectively). Prior to each 
run, the liquid phase was allowed to equilibrate in the TLC chamber to obtain an atmosphere 
saturated with the applied solvents. TLC plates were dried and evaluated either under 
UV-light or by staining with Seebach reagent or 10% ninhydrin in EtOH. 
 
Analysis of the compounds 
In solid phase reactions, the substances were cleaved from the resin and are either directly 
analyzed by HRMS and 1H NMR spectroscopy or first purified by RP-HPLC or flash 
chromatography. If sufficient amounts of substances were available, also 13C NMR spectra 
were also recorded. 1H NMR and 13C NMR spectra were recorded at 400.14 MHz and at 
100.6 MHz on a Bruker DP 400 using CDCl3 or CD3OD as solvents and TMS as internal 
standard. The solvent residual peaks were chosen as 3.31 ppm for CD3OD and 7.26 for 
CDCl3. Coupling constants (J values) are given in hertz (Hz). Multiplicities of 1H NMR 
signals are reported as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; b, 
broad signal. ESI mass spectra and high-resolution mass spectra (HRMS-ESI) for exact mass 
determination were recorded with a Bruker ESI-Micro-Q-TOF (70 eV). FAB (fast atom 
bombardment) mass spectra were recorded in meta-nitrobenzoic acid (mNBA) matrix on a 
Kratos MS 50 (70 eV) instrument, Thermo Quest Finnigan MAT 95 XL. EI (electron impact 
ionization) spectra were recorded on a Kratos MS50 (I) instrument, ThermoQuest Finnigan 
MAT 95 XL (II). MALDI (Matrix assisted laser desorption ionization) spectra were obtained 
with a HiResMALDI FT-ICR (Ionspec, Lake Forrest, CA; 7 T magnet, pulsed laser 337 nm). 
 
6.2 Resins 
Applied resins 
Three resins were used for the solid phase syntheses, which all bear trityl linker. Those are 
2-chlorotrityl resin, alkoxytrityl resin (Fukuyama resin), and TGT alcohol resin (Table 
13).[239] They differ in swelling properties and cleavage conditions. 2-Chlorotritylchloride 
resin and TGT alcohol resin were purchased from commercial suppliers. 
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Table 13 All three applied resins bear a trityl type linker. 
 
2-Chlorotrityl 
chloride resin 
p-Alkoxytrityl resin NovaSyn® TGT resin 
Structure  Cl
Cl
 
OHO
 
PEG N
H
O
OH
 
Cleavage 
AcOH / TFE / CH2Cl2, 
> 1% TFA or HFIP in 
CH2Cl2 
< 1% TFA in CH2Cl2 
AcOH / MeOH / 
CH2Cl2, 
0.5% TFA or HFIP in 
CH2Cl2 
Activation 
Available in the 
activated form, 
recyclable without loss 
of loading 
Activation with 1.5 
equiv. SOCl2, 
recyclable under slight 
loss of loading 
Activation with 1.5 
equiv. SOCl2, 
recyclable without loss 
of loading 
Loading in 
mmol / g 
1.3 0.8 0.2 
 
Preactivation of TGT alcohol resin 
TGT alcohol resin required pre-activation with SOCl2. Therefore, the resin was swollen and 
three times washed with CH2Cl2. Two equiv. of SOCl2 in CH2Cl2 were added and the resin 
was agitated for 60 min. After three times washing with CH2Cl2, the resin was instantly 
loaded with the respective building block. 
 
Preparation of alkoxytrityl resin 308 
(4-hydroxyphenyl)-diphenylmethanol 
Alkoxytrityl resin was prepared in accordance with the reported procedure from Fukuyama 
et al.[239] To a solution of 13.44 g (100.79 mmol; 1 equiv.) AlCl3 suspended in 30 mL carbon 
disulfide was added under stirring 19 mL (100.08 mmol; 1 equiv.) of 
diphenyldichloromethane in 10 mL carbon disulfide. The colour of the solution changed to 
red and 9.47 g (100.74 mmol; 1 equiv.) of phenol in 40 mL carbon disulfide were slowly 
added. After addition of further 10 mL of carbon disulfide, the suspension was refluxed at 
50 °C for 3 h and then the reaction was quenched with 200 mL ice water. The reaction 
mixture was extracted with 200 mL Et2O and the solvent was removed from the united 
organic layers. The remaining yellow solid was dissolved in 350 mL of a 1 N aqueous 
solution of KOH. The product was precipitated by liberation of CO2, achieved by addition of 
KHCO3 and slow addition of HClconc followed by the addition of dry ice. The solid was 
extracted with Et2O. After drying of the organic layer on Na2SO4, the solvent was removed 
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and the remaining oil was dried on HV. 24.15 g of the pure product are obtained as a yellow 
solid giving 87%. 
 
OHHO
C19H16O2
1
2 3
2´ 3´
4
5
5´
6´´ 6´´´
6 6´
7 7´
7´´ 7´´´
8
8´
9
 
 
Rf = 0.63 (CHCl3 : MeOH - 10 : 1 (v/v)); 1H NMR (400 MHz, CD3OD) d (ppm): 6.69 (d, 
J = 8.47 Hz, 2 H, 3-H 3´-H); 7.02 (d, J = 8.47 Hz, 2 H, 2-H 2´-H); 7.18 – 7.23 (m, 10 H, 6-H 
6´-H, 6´´-H, 6´´´-H, 7-H, 7´-H, 7´ -´H, 7´´ -´H, 8-H, 8´-H); 13C NMR (75 MHz, CD3OD), 
d (ppm): 155.96 (Cquart, C-1) , 147.68 (Cquart , C-5 C-5´), 138.37 (Cquart , C-4), 129.13 (+, C-3 
C-3´), 127.74 (+, C-7 C-7´ C-7´´ C-7´´´), 127.06 (+, C-6 C-6´ C-6´´ C-6´´´), 126.34 (+, C-8 
C-8´), 113.81 (+, C-2 C-2´), 81.27 (Cquart, C-9); MS (ESI) (10 eV/z) [m / z (%)]: 575.18 (100) 
[2 M + Na]+; 299.06 (95) [M + Na]+; 259.08 (37) [M – OH]+; 245.06 (15) [M – 2 OH]+. 
 
To a suspension of 23.2 g (84.20 mmol) (4-hydroxyphenyl)-diphenylmethanol 306 and 
4.41 g (4.27 mmol) Merrifield resin in 80 ml DMF, 5.80 g (420 mmol) K2CO3 were added. 
The suspension was stirred and heated to 60 °C for 22 h. After cooling to room temperature, 
the solvent was removed and the resin was washed with H2O, H2O / THF (1:10), 
CH2Cl2 / MeOH, and CH2Cl2. After drying in HV, the pink resin 306 was obtained. The 
loading was calculated by the weight difference before and after binding of the linker. 
Usually, values of 0.6 – 0.8 mmol / g were obtained. For activation, the resin was treated with 
a solution of 2 equiv. of SOCl2 in CH2Cl2 and agitated for 2 h. After washing with CH2Cl2 
and drying in HV, a yellow resin 308 is obtained.  
 
Recycling of the resins 
The 2-chlorotrityl resin was recycled by the following procedure: 
1. The resin was treated with 10% TFA / CH2Cl2 and agitated for 30 min. 
2. The solvent was removed and the resin was agitated with 10% 0.001 M aqueous 
NaOH / THF (3 * 5 min) 
3. The resin was washed with dry THF (3 * 2 min) and dry CH2Cl2 (3 * 2 min) 
4. The resin was activated as described above. 
 
Kaiser Test 
For the qualitative determination of amino functionalities on immobilized substrates the 
Kaiser Test was applied.[238, 415] It is basically an adoption of the Ninhydrin Assay for the 
determination of amines on TLC plates. It provides the possibility to distinguish between 
primary and secondary amines, because in contrast to primary amines, secondary amines only 
show a positive reaction if the test is carried out at elevated temperatures.[238] A small portion 
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of the resin is placed in a small tube and is washed three times with MeOH. Subsequently, 
few drops of the following solution are added: 
1. 0.5 g ninhydrine in 10 mL EtOH 
2. 80 g phenol in 20 mL EtOH 
3. 0.4 mL 0.001 M aqueous KCN in 20 mL pyridine 
In the presence of primary amines the resin beads quickly adopt an intensive dark blue 
colour. The detection of secondary amines requires heating with a blow drier for 30 seconds. 
In the absence of amino groups the resin keeps its initial colour or turns to slight brown. 
 
Swelling of the resins 
The resin is placed in the reaction vessel, the swelling solvent is added in a way that 
disperses the solid and it is shortly shaken until the entire polymer is suspended. The resin is 
abandoned for at least five minutes and the solvent is removed. 
 
Washing of the resins 
The solvent is added to the resin and the suspension is agitated for two minutes. The solvent 
is removed by suction. Washing with one solvent consists of three repetitive of those steps. 
Swelling and collapsing solvents are used alternatingly after every of those steps. The 
solvents are applied in the order of decreasing polarity and the washing sequence is usually 
terminated with CH2Cl2. The removal of DMF is sluggish and thus one washing step with 
water and addition of 10% water to the following solvents is necessary to achieve complete 
removal. 
 
Cleavage from the resins 
Alkoxytrityl resin: 100 mg of the resin are treated with a solution of 1% TFA in CH2Cl2  
(3 * 3 min). The drained cleavage mixture is combined with washings of CH2Cl2 and MeOH 
and the solvent is removed in vacuum. 
2-Chlorotrityl resin: 50 mg of the resin are treated with a solution of 5% TFA in CH2Cl2  
(3 * 3 min). The drained cleavage mixture is combined with washings of CH2Cl2 and MeOH 
and the solvent is removed in vacuum. 
PEG-trityl resin: 100 mg of the resin are treated with a solution of 2% TFA in CH2Cl2  
(3 * 3 min). The drained cleavage mixture is combined with washings of CH2Cl2 and MeOH 
and the solvent is removed in vacuum. 
 
Determination of resin loading 
After all impurities were washed from the resin it is dried until all solvent is removed. The 
compound is cleaved from the resin, the solvents are removed, and the compound is dried on 
high vacuum in a 25 mL flask. The dry compound is etched with 0.1 mL of CDCl3 and 
0.5 mL of a reference solution of 1,4-dioxane in CDCl3 are added (86 µmol dioxane / ml 
CDCl3). The solution is transferred into a NMR tube and the remaining compound in the flask 
is transferred into the tube with CDCl3. For polar compounds CD3OD is used instead of 
CDCl3 for etching and transferring to ensure solubility of the compound in the reference 
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solution. For determination of the amount of compound the integral of the singlet from 
dioxane appearing at 3.8 ppm in the 1H NMR is set to 8. The quantity of material is calculated 
by the intensity of the protons of the internal methylene groups 6 and 7 appearing at 1.5 ppm 
in the 1H NMR spectra. The conversion factor was obtained by measuring four defined 
amounts of spermine (16) in the dioxane / CDCl3 NMR solvent. 
 
6.3 Synthesis of the building blocks 
 
1,12-diamino-4,9-bis-(allyloxycarbonyl)-4,9-diazadodecane (178) 
4.91 g (24.3 mmol; 1 equiv.) of spermine (16) were dissolved in 400 mL MeOH, cooled to –
80 °C and stirred under argon. 10.0 mL (84.0 mmol; 3.5 equiv.) of TfaOEt in 20 mL MeOH 
were slowly added through a syringe during 90 min, whereas a white solid precipitates. 
Stirring was continued for further 50 min. The suspension was warmed to 0 °C and 16.8 mL 
(121 mmol; 5 equiv.) of Et3N and 12.9 mL (121 mmol; 5 equiv.) of allylchloroformate were 
added in two portions. Stirring of the clear solution was continued for 5 h at room 
temperature. After addition of 62 mL of a mixture of NaOHconc / H2O (4 : 3) a white solid 
precipitated and stirring was continued for 1 d. The MeOH was removed under reduced 
pressure. The resulting clear aqueous solution was diluted to a five-fold volume with H2Odist 
and was ten times extracted with CHCl3. After removal of the solvent, Et3N was removed 
from the mixture by heating on high vacuum. The product 178 was obtained as colourless, 
hygroscopic syrup (8.89 g; 24.0 mmol) in 99% yield. 
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Rf = 0.39 (CH2Cl2 : MeOH : NH3(aq) (25%) - 6 : 1 : 0.1); 1H NMR (400 MHz, CDCl3) d 5.90 
(ddt, J1 = 17.2 Hz, J2 = 10.5 Hz, J3 = 5.5 Hz, 2 H, 8-H 8´-H), 5.27 (ddt, J1 = 17.2 Hz, J2 = 1.5 
Hz, J3 = 1.5 Hz, 2 H, 9-Ha 9´-Ha), 5.19 (ddt, J1 = 10.5 Hz, J2 = 1.5 Hz, J3 = 1.5 Hz, 2 H, 9-Hb 
9´-Hb), 4.57 (ddd, J1 = 5.5 Hz, J2 = 1.5 Hz,  J3 = 1.5 Hz, 4 H, 7-H 7´-H), 3.15 – 3.34 (m, 8 H, 
3-H 3´-H 4-H 4´-H), 2.68 (t, J = 6.9 Hz, 4 H, 1-H 1´-H), 1.65 (tt, J1 = 7.0 Hz, J2 = 6.9 Hz, 4 
H, 2-H 2´-H), 1.51 (m, 4 H, 5-H 5´-H), 1.29 (bs, 4 H, N-H); 13C NMR (75 MHz, CDCl3) d 
156.2, 156.1 (Cquart, C-5), 133.2 (+, C-8), 117.4, 117.2 (–, C-9), 65.9 (–, C-7), 47.0, 46.5 (–, 
C-4 C-4´), 44.6, 44.4 (–, C-3 C-3´), 39.4, 39.2 (–, C-1 C-1´), 32.5, 31.8 (–, C-2 C-2´), 25.9, 
25.4 (–, C-5 C-5´); HRMS (EI) [M + H]+ calc. 370.2580, found 370.2582; FAB-MS: 371.2 
(100) [M + H]+, 393.2 (43) [M + Na]+. 
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1,12-diamino-N4,N9-bis-(allyloxycarbonyl)-4,9-diazadodecane (178) / 12-amino-1-
allylcarbamyl-N4,N9-bis-(allyloxycarbonyl)-5,10-diazadodecane (179) 
3.00 g (14.8 mmol; 1 equiv.) of spermine (16) were dissolved in 150 mL MeOH, cooled to –
80 °C and stirred under argon. 1.94 mL (16.3 mmol; 1.1 equiv.) of TfaOEt in 18 mL MeOH 
were slowly added through a syringe during 30 min, whereas a white solid precipitates. The 
suspension was warmed to 0 °C and stirring was continued for 60 min. 5.14 mL (74.1 mmol; 
5 equiv.) of Et3N and 9.45 mL (88.96 mmol; 6 equiv.) of allylchloroformate were added in 
one portions. Stirring of the clear solution was continued for 6 h at room temperature. After 
addition of 38 mL of a mixture of NaOHconc / H2O (11 : 8) a white solid precipitated and 
stirring was continued for 5 d at 0 °C. The MeOH was removed under reduced pressure. The 
resulting precipitate was between H2O and CHCl3 and the aqueous layer was eight times 
extracted with CHCl3. The organic layers were dried over Na2SO4. After flash 
chromatography on silica gel (CHCl3 : MeOH : NH3aq) (10 : 1 : 0.1) to 
(CHCl3 : MeOH : NH3aq) (2.5 : 1 : 0.1) 3.32 g (7.31 mmol) of 13-amino-1,5,10-
tri-(allyloxycarbonyl)-1,5,10-triazatridecane 179 (49% yield) and 1.49 g (4.01 mmol) of 
1,12-diamino-4,9-bis-(allyloxycarbonyl)-4,9-diazadodecane 178 (27% yield), both as highly 
viscose syrups were obtained. 
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Rf = 0.30 (CH2Cl2 : MeOH : NH3(aq) (25%) - 10 : 1 : 0.1); 1H NMR (400 MHz, CD3OD) 
d 5.96 (ddt, J1 = 17.3 Hz, J2 = 10.6 Hz, J3 = 5.3 Hz, 2 H, 15-H 15´-H), 5.92 (ddt, J1 = 17.3 Hz, 
J2 = 9.9 Hz, J3 = 5.4 Hz, 1 H, 12-H), 5.30 (ddt, J1 = 17.3 Hz, J2 = 1.7 Hz, J3 = 1.4 Hz, 3 H, 
13a-Ha 16-Ha 16´-Ha), 5.21 (ddt, J1 = 10.6 Hz, J2 = 1.7 Hz, J3 = 1.4 Hz, 2 H, 16-Hb 16´-Hb), 
5.18 (d, J = 9.9 Hz, 1 H, 13-Hb), 4.57 (ddd, J1 = 5.3 Hz, J2 = 1.7 Hz, J3 = 1.4 Hz, 4 H, 14-H 
14´-H), 4.52 (d, J = 5.4 Hz, 2 H, 11-H), 3.34 (t, J = 6.8 Hz, 2 H, 3-H), 3.33 – 3.26 (m, 6 H, 
4-H 7-H 8-H), 3.11 (t, J = 6.9 Hz, 2 H, 10-H), 2.68 (t, J = 6.8 Hz, 2 H, 1-H), 1.74 (tt, J1 = 
6.9 Hz, J2 = 6.8 Hz, 4 H, 2-H 9-H), 1.59 – 1.52 (m, 4 H, 5-H 6-H); FAB-MS: 455.2 (100) [M 
+ H]+, 495.2 (63) [M + K]+. 
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Figure 64 1H NMR and 13C NMR of 178, both measured in CDCl3. Some of the signals corresponding to the 
backbone methylene groups are splitted due to rotational isomerism of the tertiary carbamates. 
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Figure 65 1H-1H-COSY-Spectrum of 178, measured in CDCl3. The signal at 2.7 ppm corresponds to the 
methylene group 1. This was confirmed by the fact that solely this multiplet changes distinctly to lower field 
after protonation of the amino group in its trifluoroacetic acid salt. 1 and 3 show a correlation with multiplet 2 
indicating that those three conform to the terminal methylene group spacer. The correlation between methylene 
groups 4 and 5 is also slightly visible. The shift of the NH-protons is depending on then concentration. It is  
1.6 ppm in this spectrum and 1.2 ppm in a lower concentrated probe. 
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Figure 66 2D-1H-13C HMQC-Spectrum of 178, measured in CDCl3. The signals of the 
13C NMR spectra are 
broadened / splitted. This is due to dynamic effects that result from hindered rotation along the bonds of the 
backbone. 
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Figure 67 2D-1H-13C HMBC-Spectrum of 178, measured in CDCl3. 
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1,12-diamino-4,9-bis-(2-nitrophenylsulfonyl)-4,9-diazadodecane (180) / 12-amino-5,10-
bis-(2-nitrophenylsulfonyl)-1-(2-nitrophenylsulfonamido)-5,10-diazadodecane (181) 
500 mg (2.47 mmol; 1 equiv.) of spermine (16) were dissolved in 25 mL MeOH, cooled to  
–78 °C and stirred under argon. 0.29 mL (2.47 mmol; 1.0 equiv.) of TfaOEt in 4 mL MeOH 
were slowly added through a syringe during 30 min, whereas a white solid precipitates. The 
suspension was warmed to 0 °C and stirring was continued for 60 min. 6.35 mL (37.1 mmol; 
15 equiv.) of DiPEA and 9.860 g (44.5 mmol; 18.0 equiv.) of 2-nitrophenylsulfonyl chloride 
were added in one portions. Stirring of the clear solution was continued for 40 h at room 
temperature. A mixture of NaOHconc / H2O (1 : 1) was added in several portions until the pH 
was constantly adjusted above 12 and stirring was continued for 16 h. The MeOH was 
removed under reduced pressure. The resulting precipitate was separated between 5% 
aqueous NaHCO3 and CH2Cl2 and the aqueous layer was three times extracted with CH2Cl2. 
The solvents were removed and after flash chromatography on silica gel ((CHCl3 : MeOH : 
NH3(aq)(25%)) (20 : 1 : 0.1) to (CHCl3 : MeOH : NH3(aq)(25%)) (2 : 1 : 0.1)), 94 mg (160 
µmol) of 1,12-diamino-4,9-bis-(2-nitrophenylsulfonyl)-4,9-diazadodecane (180) (7% yield) 
and 535 mg (712 µmol) of 12-amino-5,10-bis-(2-nitrophenylsulfonyl)-1-(2-
nitrophenylsulfonamido)-5,10-diazadodecane (181) (29% yield), both as yellow solids were 
obtained. 
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Rf = 0.60 (CH2Cl2 : MeOH : NH3(aq) (25%) - 3 : 2 : 0.5); 1H NMR (400 MHz, CDCl3) d 8.03 
– 7.97 (m, 2 H, 8-H 8´-H), 7.83 – 7.69 (m, 6 H, 9-H 9´-H 10-H 10´-H 11-H 11´-H), 3.35 (t, 
J = 7.2 Hz, 4 H, 3-H 3´-H), 3.32 – 3.28 (m, 4 H, 4-H 4, -´H), 2.67 (t, J = 7.1 Hz, 4 H, 1-H 1´-
H), 1.72 (tt, J1 = 7.2 Hz, J2 = 7.1 Hz, 4 H, 2-H 2´-H), 1.55 – 1.49 (m, 4 H, 5-H 5´-H); FAB-
MS: 573.1 (78) [M + H]+. 
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Rf = 0.87 (CH2Cl2 : MeOH : NH3(aq) (25%) - 3 : 2 : 0.5); 1H NMR (400 MHz, CD3OD / 
CDCl3) d 8.07 – 7.95 (m, 3 H, 13-H 13´-H 13´´-H), 7.86 – 7.68 (m, 9 H, 14-H 14´-H 14´´-H 
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15-H 15´-H 15´´-H 16-H 16´-H 16´´-H), 3.35 (t, J = 7.3 Hz, 2 H, 3-H), 3.32 – 3.24 (m, 6 H, 
4-H 7-H 8-H), 3.02 (t, J = 6.8 Hz, 2 H, 10-H), 2.66 (t, J = 7.0 Hz, 2 H, 1-H), 1.79 – 1.67 (m, 
4 H, 2-H 9-H), 1.54 – 1.44 (m, 4 H, 5-H 6-H); 13C NMR (75 MHz, CDCl3) d 149.2, 149.1 
(Cquart, C-12 C-12´ C-12´´), 135.0, 134.8 (+, C-15 C-15´ C-15´´), 133.7, 133.5 (Cquart , C-11 
C-11´ C-11´´), 133.0 (+, C-14 C-14´ C-14´´), 131.4, 131.2 (+, C-16 C-16´ C-16´´), 125.8, 
125.2 (+, C-13 C-13´ C-13´´), 48.1, 47.9 (–, C-4 C-7), 46.1, 45.9 (–, C-3 C-8), 41.5 (–, C-10), 
39.2 (–, C-1), 30.5 (–, C-2), 29.6 (–, C-9), 25.9 (–, C-5 C-6); FAB-MS: 758.1 (51) [M + H]+, 
742.1 (6) [M – NH]+, 573.1 (4) [M – o-Nosyl]+. 
 
 
1-Amino-12-(1-(4,4-dimethyl-2,6-dioxocyclohexyliden)-ethylamino)-4,9-bis-
(allyloxycarbonyl)-4,9-diazadodecane (186)  
200 mg (0.54 mmol; 1 equiv.) of 178 were dissolved in 10 mL MeOH and 55 µl (0.32 
mmol; 0.6 equiv.) of DiPEA were added.  A solution of 60 mg (0.32 mmol; 0.6 equiv.) of 
Dde-OH 191 in 5 mL MeOH was slowly added during 30 min and stirring was continued over 
night. The solvent was removed and the slightly yellow solution was separated between 5% 
aqueous NaHCO3 and CH2Cl2 and the aqueous layer was extracted two times with CH2Cl2. 
The combined organic layers were dried over Na2SO4 and the solvent was removed. The 
product was purified by flash chromatography on silica gel (CHCl3 : MeOH : NH3(aq) (25%) 
(10 : 1 : 0.1) and CHCl3 : MeOH : NH3(aq) (25%) (5 : 1 : 0.1)). After drying on HV, 89 mg 
(0.18 mmol) of 186 were obtained giving 54% yield related to the insert of Dde-OH 191 
respectively 32% related to the input of 178. 100 mg (0.27 mmol; 50%) of 178 were 
recovered and could be reused for further reactions.  
 
H2N N
N
H
N
OO
O O
O O
C28H46N4O6
1
2
3 4
5
6
7 8
9
10
11
12
13
14
15
13´
14´
16
17
16´
18
18´
19
19´
20
20´
21
21´
 
 
Rf = 0.46 (10 : 1 : 0.1 - CHCl3 : MeOH : NH3(aq) (25%)); 1H NMR (400 MHz, CD3OD) d 
5.94 (ddt, J1 = 17.3 Hz, J2 = 10.5 Hz, J3 = 5.4 Hz, 2 H, 20-H 20´-H), 5.29 (ddt, J1 = 17.3 Hz, 
J2 = 1.5 Hz, J3 = 1.4 Hz, 2 H, 21-Ha 21´-Ha), 5.20 (ddt, J1 = 10.5 Hz, J2 = 1.5 Hz, J3 = 1.4 Hz, 
2 H, 21-Hb 21´-Hb), 4.57 (dt, J1 = 5.4 Hz, J2 = 1.4 Hz, 4 H, 19-H 19´-H), 3.52 (t, J = 6.8 Hz, 
2 H, 10-H), 3.41 (t, J = 6.7 Hz, 2 H, 8-H), 3.37 – 3.25 (m, 6 H, 3-H 4-H 7-H), 2.65 (t, J = 7.0 
Hz, 2 H, 1-H), 2.55 (s, 3 H, 17-H), 2.37 (s, 4 H, 14-H 14´-H), 1.94 (tt, J1 = 6.8 Hz, J2 = 6.7 
Hz, 2 H, 9-H), 1.72 (tt, J1 = 7.1 Hz, J2 = 7.0 Hz, 2 H, 2-H), 1.57 (m, 4 H, 5-H 6-H), 0.91 (s, 6 
H, 16-H 16´-H); 13C NMR (75 MHz, CD3OD) d 199.7 (Cquart , C-13 C-13´), 175.4 (Cquart , 
C-11), 157.7, 157.6 (Cquart , C-18 C-18´), 134.3 (+, C-20, C-20´), 117.7 (–, C-21, C-21´, 
splitted and broadened signal), 108.7 (Cquart,  C-12), 67.0 (–,  C-19, C-19´), 53.4 (–,  C-14 
C-14´), 48.0 (–,  C-4 C-7), 46.1, 45.3 (–,  C-3 C-8), 42.1, 39.5 (–,  C-1 C-10, splitted and 
broadened signal), 31.0 (Cquart, C-15), 29.0, 28.7 (–, C-2 C-9, splitted and broadened signal), 
28.4 (+, C-16 C-16´), 26.7, 26.2 (–, C-5 C-6, splitted and broadened signal), 18.2 (+, C-17); 
FAB-MS: 699.3 (62) [M + Dde]+, 535.2 (100) [M + H]+, 371.2 (21) [M – Dde]+. 
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1-Amino-12-(2-nitrophenylsulfonamido)-4,9-bis-(allyloxycarbonyl)-4,9-diazadodecane 
(187) 
5,71 g (15.4 mmol; 1 equiv.) of 178 together with 2.06 mL (15.4 mmol; 1 equiv.) of 
collidine were dissolved in 100 mL CH2Cl2. 2.05 g (9.26 mmol; 0.6 equiv.) of 2-
nitrophenylsulfonylchloride in 50 mL CH2Cl2 were slowly added during 4 h and stirring was 
continued over night. The slightly yellow solution was washed three times with half 
concentrated hydrochloric acid to separate collidine and 178. The organic layer was quickly 
washed with 0.5 M NaOH and then dried over Na2SO4. The product was separated from its 
bis-nosylated by-product by filtration over a short pad of silica gel (CHCl3 and CHCl3 : 
MeOH : NH3(aq) (25%) (10 : 1 : 0.1)). The silicagel was removed by washing with 10 mL of 
water, the solvent was removed under reduced pressure, and the product was dried on HV. 
3.62 g (6.53 mmol) of 187 were obtained to give 71% yield related to the input of 2-
nitrophenylsulfonylchloride respectively 43% related to the insert of 178. Collidine and 178 
were recovered by increasing the pH of the acidic aqueous layer to 14 and extraction with 
CHCl3. Collidine was removed by heating under HV and 2.32 g (6.25 mmol; 41%) of 178 
were recovered for further reaction cycles.  
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Rf = 0.48 (CH2Cl2 : MeOH : NH3(aq) (25%) - 10 : 1 : 0.1); 1H NMR (400 MHz, CDCl3) d 
8.00 – 8.25 (m, 1 H, 13-H), 7.81 (m, 1 H, 16-H), 7.73 (m, 2 H, 14-H 15-H), 5.90 (ddt, J1 = 
17.2 Hz, J2 = 10.5 Hz, J3 = 5.5 Hz, 2 H, 19-H 19´-H), 5.27 (ddt, J1 = 17.2 Hz, J2 = 1.4 Hz, J3 
= 1.5 Hz, 2 H, 20-Ha 20´-Ha), 5.19 (ddt, J1 = 10.5 Hz, J2 = 1.4 Hz, J3 = 1.5 Hz, 2 H, 20-Hb 
20´-Hb), 4.57 (ddd, J1 = 5.5 Hz, J2 = 1.5 Hz, J3 = 1.5 Hz, 4 H, 18-H 18´-H), 3.37 (m, 2 H, 
3-H), 3.30 (m, 2 H, 8-H), 3.20 (m, 4 H, 4-H 7-H), 3.08 (t, J = 6.7 Hz, 2 H, 10-H), 2.98 (m, 2 
H, 1-H), 1.93 (m, 2 H, 2-H), 1.74 (m, 2 H, 9-H), 1.50 (m, 4 H, 5-H 6-H); 1H NMR (400 MHz, 
CD3OD / CDCl3) d 8.04 – 8.04 (m, 1 H, 13-H), 7.68 – 7.86 (m, 3 H, 14-H 15-H 16-H), 5.90 
(ddt, J1 = 17.2 Hz, J2 = 10.4 Hz, J3 = 5.3 Hz, 2 H), 5.28 (ddt, J1 = 17.2 Hz, J2 = 1.4 Hz, J3 = 
1.4 Hz, 1 H, 20-Ha), 5.25 (ddt, J1 = 17.2 Hz, J2 = 1.4 Hz, J3 = 1.4 Hz, 1 H, 20 -´Ha), 5.21 (ddt, 
J1 = 10.4 Hz, J2 = 1.4 Hz, J3 = 1.3 Hz, 1 H, 20-Hb), 5.17 (ddt, J1 = 10.4 Hz, J2 = 1.4 Hz, J3 = 
1.4 Hz, 1 H, 20´-Hb), 4.57 (ddd, J1 = 5.3 Hz, J2 = 1.5 Hz,  J3 = 1.3 Hz, 2 H, 18-H), 4.53 (d, 
J1 = 5.3 Hz, 2 H, 18´-H), 3.35 (t, J = 6.9 Hz, 2 H, 3-H), 3.18 – 3.30 (m, 6 H, 4-H 7-H 8-H), 
3.06 (t, J = 6.7 Hz, 2 H, 10-H), 2.87 (t, J = 6.4 Hz, 2 H, 1-H), 1.89 (tt, J1 = 6.9 Hz, J2 = 6.4 
Hz, 2 H, 2-H), 1.75 (m, 2 H, 9-H), 1.52 (m, 4 H, 5-H 6-H); 13C NMR (75 MHz, CDCl3) 
d 157.1, 156.5 (Cquart, C-17 C-17´), 147.9 (Cquart, C-12), 133.6 (Cquart, C-11), 132.5, 130.5, 
124.9 (+, 4 C, C-13 C-14 C-15 C-16)), 132.5, 132.6 (+, C-19, C-19´), 117.6 (–, C-20, C-20´), 
66.3, 66.0 (–, C-18, C-18´), 46.7 (–, C-4 C-7), 43.7, 44.2 (–, C-3 C-8), 40.6 (–, C-10), 36.8 (–, 
C-1), 28.6 (–, C-9), 25.4, 25.2, 24.9 (–, C-2 C-5 C-6, splitted and broadened signal); HRMS 
(EI) [M]+ calc. 555.2363, found 555.2354; FAB-MS: 556.3 (100) [M + H]+, 540.2 (5) [M – 
NH]+, 391.3 (49) [M – o-Nosyl + Na]+. 
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Figure 68 1H NMR and 13C NMR of 187, measured in CDCl3 / CD3OD. Some of the signals corresponding to 
the backbone methylene groups are splitted due to rotational isomerism of the tertiary carbamates. 
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Figure 69 1H-1H-COSY-Spectrum of 187, measured in CDCl3 / MeOH (1 : 5). The signal at 2.9 ppm 
corresponds to the methylene group 1. This is confirmed by the fact that solely this multiplet changes distinctly 
to lower field after protonation of the amino group in its trifluoroacetic acid salt. The identity of methylene 
groups 8 and 10 was allocated by comparison with the values of 3 / 3´in 178. 
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Figure 70 Section of the 1H-1H-COSY-Spectrum of 187, measured in CDCl3 / MeOH (1 : 5). The Aloc-groups 
show slightly different patterns. This differentiation is not present in the symmetrical molecule 178 and indicates 
affection by the o-Nosyl group. 
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Figure 71 2D-1H-13C HMQC-Spectrum of 187, measured in CDCl3 / MeOH (1 : 5). The signals of the 
13C NMR 
spectra are broadened / splitted. This is due to dynamic effects that result from hindered rotation along the bonds 
of the backbone. The Aloc groups show additional splitting, probably due to a long-range influence of the 
o-Nosyl group. 
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1-(2-Nitrophenylsulfonamido)-3-aminopropane  
5.63 mL (67.5 mmol; 1 equiv.) of 1,3-diaminopropane (24) were dissolved in 100 mL 
CH2Cl2 and 8.92 mL (67.5 mmol; 1 equiv.) of collidine were added in one portion. A solution 
of 8.86 g (40.0 mmol; 0.6 equiv.) of 2-nitrophenylsulfonylchloride in 50 mL CH2Cl2 was 
slowly added during 90 min and the solution was stirred for 18 h. The solution was three 
times washed with NaOH (1 M) and dried over Na2SO4. The solvent was removed and the 
product was purified by flash chromatography on silica gel (CHCl3 : MeOH (20 : 1) to CHCl3 
: MeOH : NH3 (25%) (1 : 1 : 0.1)). The silicagel was removed by washing with 10 mL of 
water, the solvent was removed under reduced pressure, and the product was dried on HV. 
4.86 g (18.8 mmol) of 188 were obtained to give 47% yield related to the insert of 2-
nitrophenylsulfonylchloride respectively 28% related to the input of diaminopropane (24). 
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Rf = 0.08 (CHCl3 : MeOH - 10 : 1); 1H NMR (400 MHz, CDCl3) d 8.08 (dd, J1 = 5.9 Hz, 
J2 = 3.3 Hz, 1 H, 6-H), 7.78 – 7.88 (m, 3 H, 7-H 8-H 9-H), 3.10 (t, J = 6.9 Hz, 2 H, 3-H), 2.71 
(t, J = 7.0 Hz, 2 H, 1-H), 1.68 (tt, J1 = 7.0 Hz, J2 = 6.9 Hz, 2 H, 2-H); HRMS (ESI) [M + H]+ 
calc. 260.0700, found 260.0704. 
 
2-(1-(3-Iodopropylamino)ethylidene)-5,5-dimethylcyclohexan-1,3-dione (193) 
 
2-(1-Hydroxyethylidene)-5,5-dimethylcyclohexan-1,3-dione (191) 
12.0 g (85.0 mmol; 1 equiv.) of dimedone (189) and 7.60 mL (94.2 mmol; 1.1 equiv.) of 
pyridine were dissolved in 250 mL CHCl3. The solution was cooled to 0 °C and 9.20 mL 
(128 mmol; 1.5 equiv.) of acetylchloride were added. The solution was stirred for 30 min and 
the organic layer was then washed with water, solutions of half-concentrated HCl, 
concentrated NaHCO3 and water. The organic layer was dried over Na2SO4 and 22.9 g 
(171 mmol; 2 equiv.) of AlCl3 were added. After stirring for 60 min the reaction mixture was 
given into 300 mL of a mixture of ice and concentrated hydrochloric acid (1 : 1). The aqueous 
layer was three times extracted with CHCl3. The combined organic layers were dried over 
Na2SO4 and the solvent was removed. A yellow solid was obtained. The product 191 was 
purified by flash chromatography on silica gel (cyclohexane : EtOAc (2 : 1)). A slightly 
yellow and highly viscose syrup was obtained that turns into a solid after drying on HV for 
2 d and storage for 10 h at –20 °C. 7.88 g (43.1 mmol) were achieved giving 51% yield over 
two steps. 
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Rf = 0.32 (CH2Cl2); 1H NMR (400 MHz, CDCl3) d 2.54 (s, 2 H, 2-Ha 2´-Ha); 2.50 (s, 2 H, 
2-Hb 2´-Hb); 2.32 (s, 3 H, 1-H); 1.04 (s, 6 H, 3-H 3´-H). 
 
2-(1-(3-Hydroxypropylamino)ethylidene)-5,5-dimethylcyclohexan-1,3-dione (192) 
7.88 g (43.3 mmol; 1 equiv.) of 191 were dissolved in 200 mL of MeOH. 9.06 mL 
(51.9 mmol; 1.2 equiv.) of DiPEA and 6.62 mL (86.5 mmol; 2.0 equiv.) of 3-amino-1-
propanol were added and the clear yellow solution was stirred for 6.5 h. The solvent was 
removed and the residue was dissolved in 150 mL of CH2Cl2. The organic layer was three 
times washed with half concentrated HCl and dried over Na2SO4. The solvent was removed 
and the remaining solid was dried on HV. 8.07 g (33.8 mmol) of a yellow solid 192 were 
obtained giving 78% yield. 
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Rf = 0.16 (cyc lohexane : EtOAc - 1 : 1); 1H NMR (400 MHz, CDCl3) d 13.40 (s, 1 H, 5-H, 
1-H); 3.74 (t, J1  = 5.9, 2 H, 2-H); 3.53 (dt, J1 = 5,7, J2 = 6.8, 2 H, 4-H); 2.53 (s, 4 H, 
6-H 6´-H); 2.32 (s, 3 H, 8-H); 1.89 (tt, J1 = 6.8, J2 = 5.9, 2 H, 3-H); 0.99 (s, 6 H, 7-H 7´-H); 
MS (ESI): 262.1 (100) [M + Na]+, 240.0 (100) [M + H]+. 
 
2-(1-(3-Iodopropylamino)ethylidene)-5,5-dimethylcyclohexan-1,3-dione (193) 
3.02 g (11.5 mmol; 1.1 equiv.) of PPh3 were dissolved in 5 mL CH2Cl2, cooled to 0 °C and 
stirred. Solutions of 999 mg (14.7 mmol; 1.4 equiv.) of imidazole in 9 mL CH2Cl2, 3.19 g 
(12.6 mmol; 1.2 equiv.) of iodine in 8 mL CH2Cl2 and 2.51 g (10.5 mmol; 1 equiv.) of 192 
were added and stirring was continued for 30 min. The reaction mixture was warmed to room 
temperature and the solvent was removed. The residue was purified by flash chromatography 
on silica gel (cyclohexane : EtOAc (2 : 1) to cyclohexane : EtOAc (1 : 1)). After drying on 
HV, 3.02 g (8.64 mmol) of a slightly yellow solid 193 were obtained giving 82% yield. 
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Rf = 0.39 (cyclohexane : EtOAc - 1 : 1); 1H NMR (400 MHz, CDCl3) d 3.47 (dt, J1 = 5.5 Hz, 
J2 = 6.7 Hz, 2 H, 3-H); 3.19 (t, J = 6.6 Hz, 2 H, 1-H); 2.52 (s, 3 H, 7-H); 2.29 (s, 4 H, 
5-H 5´-H); 2.09 (tt, J1 = 6.7 Hz, J2 = 6.6 Hz, 2 H, 2-H); 0.96 (s, 6 H, 6-H 6´-H). 
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N-Maleimidopropionylsuccinate (196) 
14 g (135 mmol; 1.2 equiv) of maleic anhydride were dissolved in 120 mL DMF. 10 g 
(112 mmol; 1 equiv.) of ß-alanine 194 in 20 mL DMF were added and stirred for 120 min. 
The reaction mixture was cooled to 0 °C and 55.5 g (269 mmol; 2.4 equiv.) of DCC and 
19.4 g (168 mmol; 1.5 equiv.) of HNS were added contemporaneously in two equimolar 
portions. The colour of the suspension turned to purple during further stirring at 0 °C for 
150 min. The suspension was filtered to remove residues of dicyclohexyl urea. The filtrate 
was partitioned between CH2Cl2 and water and the organic layer was washed with water 
(3 times), 5% NaHCO3 solution (three times) and concentrated NaCl solution (two times). 
The combined aqueous layers were re-extracted with a small amount of CH2Cl2 and the 
combined organic layers were dried over Na2SO4. 19.0 g (84.0 mmol) of a slightly purple 
solid 196 were obtained giving 75% yield. 
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Rf = 0.47 (cyclohexane : EtOAc - 1 : 1); 1H NMR (400 MHz, d6-DMSO) d 6.92 (s, 2 H, H-1, 
1-H 1´-H), 3.74 (t, J = 6.9 Hz, 2 H, 2-H), 3.32 (s, 4 H, 4-H 4´-H), 3.04 (t, J = 6.9 Hz, 2 H, 
3-H); FAB-MS: 289.2 (51) [M+ + Na]; 267.1 (100) [M+ + H]; 225.2 (31) [M+ + H –
 (COCH2)]Establishment of the solid phase methods 
 
6.4 Development of the solid phase methods 
6.4.1 Optimisation of loading conditions with building block 187 
100 mg (720 µmol; 1 equiv.) of inactivated alkoxytrityl resin were swollen in CH2Cl2 and 
5 µl (290 µmol; 4 equiv.) of SOCl2 were added. The suspension was agitated for 1 h and the 
resin was washed with CH2Cl2. A solution of base and building block 187 in CH2Cl2 was 
added and the suspension was agitated for 3 h. The resin was washed with CH2Cl2 / MeOH 
and CH2Cl2. The product was cleaved from the resin. The amount of attached material was 
calculated by the addition of dioxane as a quantitative NMR-standard. 
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1H NMR (400 MHz, CDCl3) d 8.08 (m, 1 H, 13-H), 7.82 (bs, 3 H, N-H), 7.73 (m, 3 H, 
14-H 15-H 16-H), 5.87 (ddt, J1 = 17.2 Hz, J2 = 10.5 Hz, J3 = 5.4 Hz, 2 H, 19-H 19´-H), 5.24 
(m, 2 H, 20-H), 5.18 (m, 2 H, 20 -´H), 4.55 (m, 4 H, 18-H 18´-H), 3.37 (m, 2 H, 3-H), 3.30 (m, 
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2 H, 8-H), 3.21 (m, 4 H, 4-H 7-H), 3.08 (t, J = 6.7 Hz, 2 H, 10-H), 3.01 (m, 2 H, 1-H), 1.93 
(m, 2 H, 2-H), 1.74 (m, 2 H, 9-H), 1.50 (m, 4 H, 5-H 6-H). 
 
General loading conditions 
The activated resin is swollen in CH2Cl2 and after removal of the solvent a solution of 
2.5 equiv. of DiPEA and 10 equiv. of the respective building block in CH2Cl2 is added. The 
suspension is agitated over night. 1 mL MeOH per 100 mg resin is added to the suspension to 
block the remaining binding sites and it is agitated for further 15 minutes. The resin is washed 
with CH2Cl2 / MeOH and CH2Cl2. After removal of the solvent and removal of DiPEA in HV 
the respective building block could be recovered for further reaction cycles. 
 
Introduction of Aloc group 
The resin is swollen in CH2Cl2 and after removal of the solvent a solution of 10 equiv. of 
allylchloroformate and 10 equiv. of Et3N in CH2Cl2 is added. The suspension is agitated over 
night, the solvent is removed, and the resin is washed with CH2Cl2 / MeOH and CH2Cl2. 
 
6.4.2 Exhaustive Aloc deprotection 
The following procedures were used for Entries of Table 6: 
(a) The resin 198 is swollen in THF and after removal of the solvent a solution of 10 – 
20 equiv. of pyrrolidine / 8 – 10 equiv. of dimedone and 1 – 50 mol% of Pd(PPh3)4 in 1.5 mL 
THF are added. The suspension is agitated for 0.5 – 21 h in the absence of light. The resin is 
washed with a solution of sodium-diethylaminodithiocarbamate in THF / MeOH, THF and 
CH2Cl2. The crude is cleaved from the resin. The drained cleavage mixture is combined with 
washings of CH2Cl2 and MeOH respectively. 
(b) The resin 198 is swollen in CH2Cl2 and after removal of the solvent a solution of 9 –
 20 equiv. phenylsilane / 8 – 10 equiv. of trimethylsillylazide and 1 – 20 mol% of Pd(PPh3)4 
in 1.5 mL CH2Cl2 are added. The suspension is agitated for 1.5 – 17 h in the absence of light. 
The resin is washed with a solution of sodium-diethylaminodithiocarbamate in THF / MeOH, 
THF and CH2Cl2. 
 
The successful procedure with N,N’-dimethylbarbituric acid was carried out as 
follows: 
The resin 198 was swollen in CH2Cl2 in a lock-up vial and 8 equiv. of N,N’-
dimethylbarbituric acid and 10 mol% of Pd(PPh3)4 in 1.5 mL CH2Cl2 are added. The 
suspension was agitated for 2 h at 35 °C in the absence of light. The resin is transferred to a 
glas frit, washed with a solution of sodium-diethylaminodithiocarbamate in CH2Cl2 / MeOH 
and CH2Cl2. After cleavage, 199 is obtained in high purity. 
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1H NMR (400 MHz, CD3OD) d 7.80 – 8.10 (m, 4 H, 13-H 14-H 15-H 16-H), 3.16 (t, 
J = 6.8 Hz, 2 H, 3-H), 3.00 – 3.15 (m, 10 H, 1-H 4-H 7-H 8-H 10-H), 2.09 (tt, J1 = 7.5, 
J2 = 7.7, 2 H, 9-H), 1.94 (tt, J1 = 7.4, J2 = 6.8, 2 H, 2-H), 1.79 (m, 4 H, 5-H 6-H); HRMS (EI) 
calc. 388.2013, found 388.2011. 
 
Introduction of o-Nosyl group 
The resin is swollen in CH2Cl2 and after removal of the solvent a solution of 10 equiv. of 
o-Nosyl chloride and 10 equiv. of collidine in CH2Cl2 is added. The suspension is agitated 
over night, the solvent is removed, and the resin is washed with CH2Cl2 / MeOH and CH2Cl2. 
 
o-Nosyl removal 
The resin is swollen in DMF and after removal of the solvent a solution 10 equiv. of 
b-mercaptoethanol and 5 equiv. of DBU in DMF are added. The suspension is agitated for 
1 h and the colour of the liquid turns to intensive yellow. After removal of solvent the resin is 
washed with DMF until the filtrate is colourless. The procedure is repeated in steps of 30 min 
until the supernatant stays colourless after the reaction. Usually the reaction is complete after 
2 h overall reaction time. Alternatively the resin is treated with 20 equiv. of mercaptoethanol 
and 20 equiv. of DBU overnight and subsequently washed with DMF until the filtrate is 
colourless. 
 
Dde removal 
The resin is swollen in DMF and after removal of the solvent a solution of 10 equiv. 
N2H4*H2O (80% in H2O) in DMF is added. In the presence of Aloc groups 100 equiv. of allyl 
alcohol are added. The suspension is agitated (1 * 30 min, 2 * 15 min) and after removal of 
the solvent the resin is washed with DMF in each case. 
 
Fmoc removal 
The resin is swollen in DMF and after removal of the solvent a solution of pyrrolidine / 
DMF (1 : 3) is added. The suspension is agitated (1 * 30 min, 2 * 15 min) and after removal 
of the solvent the resin is washed with DMF in each case. 
 
6.4.3 Versatility of the protection group strategy - synthesis of HO359b 
SP-bound-bis-Aloc-protected HO359b (201) 
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510 mg of 2-chlorotrityl resin were loaded with 187 under the conditions described above. 
Fifteen minutes prior termination of the reaction, 4 mL of MeOH were added to block the 
remaining binding sites on the resin. After drying 150 mg (82 µmol; 1 equiv.) of the resin 198 
were o-Nosyl deprotected. The cold Kaiser Test was positive. A solution of 55 mg 
(0.41 mmol; 5 equiv.) hydroxybenzotriazole and 72 mg (0.41 mmol; 5 equiv.) 3- indoleacetic 
acid in 1 mL DMF was added to resin 7 and the suspension was shortly agitated. 84 mg 
(0.41 mmol; 5 equiv.) dicyclohexylcarbodiimide in 1.7 mL were added and the suspension 
agitated for 4 h in the absence of light. The resin was washed with DMF, CH2Cl2 / MeOH and 
then with CH2Cl2. The Kaiser Test was negative. The product was cleaved from a small 
portion of the resin 201 and the crude product was analyzed by FAB-MS: 528.3 (100) [M + 
H]+. 
 
HO359b (203) 
Aloc-deprotection of 56 mg of resin 201 was carried out following the above described 
procedure with N,N’-dimethylbarbituric acid. The product was cleaved from the resin and 
after removal of the solvents, the crude product was purified by preparative HPLC (RP-18, 
H2O - MeCN - TFA (10 : 90 : 0.1 to 80 : 20 : 0.1)). 19.3 mg (27.5 µmol) of a yellow solid 
203, which changes into white foam after 4 d drying on HV were obtained. Yield: 90% 
calculated on the loading of resin 198. 
 
1
2
3 4
5
6
7 8
9
10
+H3N N
H2+
H2+
N
H
N
C26H36F9N5O7
3* CF3COO-
O NH
11 12 13
14
15 16
17
18
19
20
 
 
1H NMR (400 MHz, CD3OD) d 7.55 (d, J = 7.7 Hz, 1 H, 19-H), 7.37 (d, J = 7.9 Hz, 1 H, 
16-H), 7.21 (s, 1 H, 14-H), 7.11 (dt, J1 = 7.9 Hz, J2 = 0.7 Hz, 1 H, 17-H), 7.03 (dt, 
J1 = 7.7 Hz, J2 = 0.7 Hz, 1 H, 18-H), 3.68 (s, 2 H, 12-H), 3.30 (t, J = 6.7 Hz, 2 H, 10-H), 3.08 
(t, J = 7.7 Hz, 2 H, 4-H), 3.03 (t, J = 7.7 Hz, 2 H, 7-H), 2.96 (t, J = 7.9 Hz, 2 H, 3-H), 2.80 (t, 
J = 7.0 Hz, 2 H, 8-H), 2.78 (t, J = 7.7 Hz, 2 H, 1-H), 2.06 (tt, J1 = 7.9 Hz, J2 = 7.7 Hz, 2 H, 
2-H), 1.80 (tt, J1 = 7.0 Hz, J2 = 6.7 Hz, 2 H, 9-H), 1.70 (m, 2 H, 5-H), 1.61 (m, 2 H, 6-H); 
13C NMR (75 MHz, CD3OD) d 176.3 (Cquart , C-11), 138.1 (Cquart , C-15), 128.4 (Cquart , C-20), 
125.2, 122.7 (+, C-14 C-18), 120.1 (+, C-17), 119.3 (+, C-19), 112.6 (+, C-16), 109.4 (Cquart , 
C-13), 48.1, 47.9 (–, C-4 C-7), 46.0, 45.8 (–, C-3 C-8), 37.7, 36.8 (–, C-1 C-10), 33.9 (–, 
C-12), 27.4, 25.2 (–, C-2 C-9), 24.0 (–, C-5 C-6); HRMS (ESI) [M + H]+ calc. 360.2758, 
found 360.2755. 
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6.4.4 Investigation on Fukuyama alkylation  
 
General procedure with K2CO3 
1 equiv. of 198 and 13 equiv. of K2CO3 were suspended in DMF and after 5 min 13 equiv. 
of halide were added. The suspension is agitated at room temperature / 60°C for 18 h. The 
resin is washed with water, THF : MeOH (2 : 1) / MeOH and CH2Cl2. 
 
General procedure with DBU 
1 equiv. of 198 is swollen in DMF for 5 min and 6 equiv. of DBU and 6 equiv. of halide 
were added. The suspension is agitated at room temperature for 3, 5, 8, 18 or 30 h. The resin 
is washed with DMF, THF : MeOH (2 : 1) / MeOH and CH2Cl2. 
 
Purity determination 
Conversions were calculated by the purity of the crude products, which was determined by 
integration of the relative areas of RP-HPLC with UV-detection at 254 nm. The identity of the 
peaks was confirmed by HRMS. The crude product was purified by preparative HPLC and 
subsequently the 1H NMR spectra were measured in CDCl3 or CDCl3 / CD3OD (1 : 1). 
  
Analytical data of alkylation productsa 
Entry 1: 1H NMR (400 MHz, CDCl3) d 7.90 – 8.20 (m, 4 H, 13-H NH3), 7.60 – 7.80 (m, 3 
H, 14-H 15-H 16-H), 7.20 – 7.40 (m, 5 H, Arl-Hbenzy), 5.90 (ddt, J1 = 17.2 Hz, J2 = 10.5 Hz, 
J3 = 5.6 Hz, 2 H, 19-H 19´-H), 5.27 (dd, J1 = 17.2 Hz, J2 = 1.3 Hz, 2 H, 20-Ha 20´-Ha), 5.18 
(d, J = 10.5 Hz, 2 H, 20-Hb 20´-Hb), 4.40 – 4.80 (m, 6 H, 18-H 18´-H (CH2)benzyl), 3.39 (m, 
2 H, 3-H), 3.26 (m, J = 7.3 Hz, 8-H), 3.20 (m, 2 H, 10-H), 3.07 (m, 4 H, 4-H 7-H), 2.99 (m, 
2 H, 1-H), 1.93 (m, 2 H, 2-H), 1.63 (m, 2 H, 9-H), 1.43 (m, 4 H, 5-H 6-H); HRMS (ESI) 
[M + H]+ calc. 646.2905, found 646.2905. 
Entry 2: 1H NMR (400 MHz, CDCl3) d 8.17 (d, J = 8.6 Hz, 2 H, Ar-Hmeta-benzyl), 8.16 (m, 
3 H, NH3), 8.00 (d, J = 7.3 Hz, 1 H, 13-H), 7.60 – 7.80 (m, 3 H, 14-H 15-H 16-H), 7.47 (d, 
J = 8.6 Hz, 2 H, Ar -Hpara-benzyl), 5.90 (ddt, J1 = 17.2 Hz, J2 = 10.7 Hz, J3 = 5.5 Hz, 2 H, 
19-H 19´-H), 5.27 (dd, J1 = 17.2 Hz, J2 = 1.4 Hz, 2 H, 20-Ha 20´-Ha), 5.18 (d, J = 10.7, 2 H, 
20-Hb 20´-Hb), 4.40 – 4.70 (s, 6 H, 18-H 18´-H (CH2)benzyl), 3.38 (m, 2 H, 3-H), 3.28 (t, 
J = 7.0 Hz, 2 H, 8-H), 3.19 (m, 2 H, 10-H), 3.09 (m, 4 H, 4-H 7-H), 2.97 (m, 2 H, 1-H), 1.93 
(m, 2 H, 2-H), 1.64 (m, 2 H, 9-H), 1.43 (m, 4 H, 5-H 6-H); FAB-MS: 691.2 (100) [M + H]+, 
713.2 (6) [M + Na]+; HRMS (ESI) [M + H]+ calc. 691.2756, found 691.2753. 
Entry 3: 1H NMR (400 MHz, CDCl3) d 8.16 (bs, 3 H, NH3); 7.96 (m, 1 H, 13-H), 7.60 –
 7.80 (m, 3 H, 14-H 15-H 16-H), 7.56 (d, J = 7.9 Hz, 2 H, Ar-Hmeta-benzyl), 7.39 (d, J = 7.9 Hz, 
2 H, Ar-Hortho-benzyl), 5.90 (ddt, J1 = 17.3 Hz, J2 = 10.8 Hz, J3 = 5.6 Hz, 2 H, 19-H 19´-H), 5.27 
(dd, J1 = 17.3 Hz, J2 = 1.6 Hz, 2 H, 20-Ha 20´-Ha), 5.22 (d, J = 10.8 Hz, 2 H, 20-Hb 20´-Hb), 
4.55 (m, 4 H, 18-H 18´-H), 4.54 (s, 2 H, (CH2)benzyl), 3.39 (m, 2 H, 3-H), 3.28 (t, J = 7.1 Hz, 
2 H, 8-H), 3.20 (m, 2 H, 10-H), 3.08 (m, 4 H, 4-H 7-H), 2.98 (m, 2 H, 1-H), 1.93 (m, 2 H, 
2-H), 1.65 (m, 2 H, 9-H), 1.43 (m, 4 H, 5-H 6-H); HRMS (ESI) [M + H]+ calc. 714.2779, 
found 714.2769. 
Entry 4: 1H NMR (400 MHz, CDCl3) d 8.10 (m, 3 H, NH3), 7.95 (m, 1 H, 13-H), 7.69 (m, 
3 H, 14-H 15-H 16-H), 7.55 (d, J = 8.0 Hz, 2 H, Ar-Hmeta-benzyl), 7.39 (d, J = 8.0 Hz, 2 H, 
Ar-Hortho-benzyl), 5.88 (ddt, J1 = 17.3 Hz, J2 = 10.5 Hz, J3 = 5.5 Hz, 2 H, 19-H 19´-H), 5.27 (dd, 
J1 = 17.3 Hz, J2 = 1.5 Hz, 2 H, 20-Ha 20´-Ha), 5.22 (m, 2 H, 20-Hb 20´-Hb), 4.40 – 4.70 (m, 
6 H, 18-H 18´-H (CH2)benzyl), 3.38 (m, 2 H, 3-H), 3.27 (m, 2 H, 8-H), 3.20 (m, 2 H, 10-H), 
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3.07 (m, 4 H, 4-H 7-H), 2.97 (m, 2 H, 1-H), 1.92 (m, 2 H, 2-H), 1.64 (m, 2 H, 9-H), 1.43 (m, 
4 H, 5-H 6-H); HRMS (ESI) [M + H]+ calc. 692.2782, found 692.2799. 
Entry 5: 1H NMR (400 MHz, CDCl3) d 8.08 (bs, 3 H, NH3), 7.93 (d, J = 7.6 Hz, 1 H, 13-H), 
7.64 (m, 3 H, 14-H 15-H 16-H), 7.51 (d, J = 7.5 Hz, 1 H, Ar-Hbenzyl(3)), 7.42 (d, J = 7.5 Hz, 
1 H, Ar-Hbenzyl(6)), 7.25 (dd, J1 = 7.5 Hz, J2 = 7.4 Hz, 1 H, Ar-Hbenzyl(5)), 7.13 (dd, J1 = 7.5 Hz, 
J2 = 7.4 Hz, 1 H, Ar-Hbenzyl(4)), 5.90 (ddt, J1 = 17.3 Hz, J2 = 10.8 Hz, J3 = 5.4 Hz, 2 H, 
19-H 19´-H), 5.27 (dd, J1 = 17.3 Hz, J2 = 1.5 Hz, 2 H, 20-Ha 20´-Ha), 5.22 (d, J = 10.8, 2 H, 
20-Hb 20´-Hb), 4.40 – 4.70 (m, 6 H, 18-H 18´-H (CH2)benzyl), 3.37 (m, 2 H, 3-H), 3.33 (t, 
J = 7.5 Hz, 2 H, 8-H), 3.20 (m, 2 H, 10-H), 3.09 (m, 4 H, 4-H 7-H), 2.98 (m, 2 H, 1-H), 1.91 
(tt, J1 = 6.3 Hz, J2 = 6.2 Hz, 2 H, 2-H), 1.67 (m, 2 H, 9-H), 1.44 (m, 4 H, 5-H 6-H); HRMS 
(ESI) [M + H]+ calc. 724.2010, found 724.1997. 
Entry 6: 
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1H NMR (400 MHz, CDCl3) d 8.72 (s, 1 H, 19-H), 8.37 (d, J = 7.8, 1 H, 20-H), 8.14 (d, 
J = 7.9, 2 H, 21-H), 7.80 – 8.10 (bs, 3 H, NH3), 8.02 (d, J = 7.5, 1 H, 15-H), 7.79 (dd, 
J1 = 7.6, J2 = 7.6, 1 H, 13-H), 7.63 (dd, J1 = 7.6, J2 = 7.5, 1 H, 14-H), 6.91 (m, 1 H, 12-H), 
5.88 (ddt, J1 = 17.2 Hz, J2 = 10.5 Hz, J3 = 5.4 Hz, 2 H, 17-H 17´-H), 5.80 – 5.00 (bs, 3 H, 
11-H NH2), 5.26 (dd, J1 = 17.2 Hz, J2 = 1.4 Hz, 2 H, 18-Ha 18´-Ha), 5.20 (d, J = 10.5 Hz, 
2 H, 18-Hb 18´-Hb), 4.40 – 4.60 (m, 4 H, 16-H 16´-H), 3.97 (s, 3 H, 22-H), 3.44 (m, 2 H, 
8-H), 3.35 (m, 2 H, 3-H), 3.23 (m, 6 H, 4-H 7-H 10-H), 2.96 (m, 2 H, 1-H), 2.09 (tt, J1 = 6.0, 
J2 = 6.4, 2 H, 9-H), 1.91 (tt, J1 = 6.3, J2 = 6.3, 2 H, 2-H), 1.50 (m, 4 H, 5-H 6-H); HRMS 
(ESI) [M + H]+ calc. 685.3192, found 685.3188. 
Entry 7: 1H NMR (400 MHz, CDCl3) d 7.97 (m, 4 H, 13-H NH3), 7.60 – 7.80 (m, 3 H, 14-H 
15-H 16-H), 7.15 (d, J = 8.4 Hz, 2 H, Ar-Hmeta-benzyl), 6.81 (d, J = 8.4 Hz, 2 H, Ar-Hortho-benzyl), 
5.90 (ddt, J1 = 16.9 Hz, J2 = 10.7 Hz, J3 = 5.6 Hz, 2 H, 19-H 19´-H), 5.28 (dd, J1 = 16.9 Hz, 
J2 = 1.7 Hz, 2 H, 20-Ha 20´-Ha), 5.19 (d, J = 10.7 Hz, 2 H, 20-Hb 20´-Hb), 4.48 – 4.70 (m, 
4 H, 18-H 18´-H), 4.41 (s, 2 H, (CH2)benzyl), 3.78 (s, 3 H, CH3), 3.40 (m, 2 H, 3-H), 3.24 (m, 
4 H, 8-H 10-H), 3.08 (m, 4 H, 4-H 7-H), 3.01 (m, 2 H, 1-H), 1.94 (m, 2 H, 2-H), 1.64 (m, 2 H, 
9-H), 1.45 (m, 4 H, 5-H 6-H); HRMS (ESI) [M + H]+ calc. 676.3011, found 676.2997. 
Entry 8 / 9: 1H NMR (400 MHz, CDCl3) d 7.60 – 8.20 (m, 7 H, 13-H 14-H 15-H 16-H NH3), 
5.90 (ddt, J1 = 16.7 Hz, J2 = 10.9 Hz, J3 = 5.7 Hz, 2 H, 19-H 19´-H), 5.66 (ddt, J1 = 17.0 Hz, 
J2 = 10.2 Hz, J3 = 6.5 Hz, 1 H, CHallyl(2)), 5.12 – 5.35 (m, 6 H, 20-H 20´-H (CH2)allyl(3)), 4.58 
(d, J = 5.7 Hz, 2 H, 18-H), 4.56 (d, J = 5.7 Hz, 2 H, 18´-H), 3.91 (m, 2 H(CH2)allyl(1)), 3.40 (m, 
2 H, 3-H), 3.30 (t, J = 7.3 Hz, 2 H, 10-H), 3.22 (m, 6 H, 4-H 7-H 8-H), 3.01 (m, 2 H, 1-H), 
1.94 (m, 2 H, 2-H), 1.81 (m, 2 H, 9-H), 1.51 (m, 4 H, 5-H 6-H); MS (ESI): 596.3 (100) 
[M + H]+, 618.3 (2) [M + Na]+; HRMS (ESI) [M + H]+ calc. 596.2749, found 596.2749. 
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Entry 10: 1H NMR (400 MHz, CDCl3) d 7.60 – 8.20 (m, 7 H, 13-H 14-H 15-H 16-H NH3), 
5.90 (ddt, J1 = 17.1 Hz, J2 = 11.3 Hz, J3 = 5.7 Hz, 2 H, 19-H 19´-H), 5.85 (m, 1 H, 
(CH2)allyl(3)), 5.59 (d, J = 17.2 Hz, 1 H, (CH2)allyl(3)), 5.28 (d, J = 17.1 Hz, 2 H, 20-Ha 20´-Ha), 
5.20 (m, 2 H, 20-Hb 20´-Hb), 4.58 (d, J = 5.7 Hz, 2 H, 18-H), 4.56 (d, J = 5.7 Hz, 2 H, 
18´-H), 4.20 (s, 2 H, (CH2)allyl(1)), 3.37 (d, J = 5.8 Hz, 2 H, 3-H), 3.10 – 3.40 (m, 8 H, 4-H 
7-H, 8-H 10-H), 3.03 (m, 2 H, 1-H), 1.94 (m, 2 H, 2-H), 1.81 (m, 2 H, 9-H), 1.51 (m, 4 H, 
5-H 6-H); HRMS (ESI) [M + H]+ calc. 674.1854, found 674.1860. 
Entry 11: 1H NMR (400 MHz, CDCl3) d 7.60 – 8.20 (m, 7 H, 13-H 14-H 15-H 16-H NH3), 
5.91 (ddt, J1 = 17.1 Hz, J2 = 10.8 Hz, J3 = 5.8 Hz, 2 H, 19-H 19´-H), 5.28 (dd, J1 = 17.1 Hz, 
J2 = 6.2 Hz, 2 H, 20-Ha 20´-Ha), 5.22 (d, J  = 10.8 Hz, 2 H, 20-Hb 20´-Hb), 4.59 (d, 
J = 5.8 Hz, 2 H, 18-H), 4.57 (d, J = 5.8 Hz, 2 H, 18 -´H), 3.41 (m, 2 H, 3-H), 3.31 (t, J = 
7.7 Hz, 2 H, 10-H), 3.24 (m, 8 H, 4-H 7-H 8-H CH2(2)), 3.01 (m, 2 H, 1-H), 1.94 (m, 2 H, 
2-H), 1.82 (m, 2 H, 9-H), 1.52 (m, 6 H, 5-H 6-H CH2(2)), 1.10 – 1.40 (m, 22 H, CH2(3-13)), 
0.88 (t, J = 7.0 Hz, 3 H, CH3); HRMS (ESI) [M + H]+ calc. 752.4627, found 752.4624. 
Entry 12: 1H NMR (400 MHz, CDCl3) d 7.70 – 8.10 (m, 7 H, 13-H 14-H 15-H 16-H NH3), 
5.90 (ddt, J1 = 16.7 Hz, J2 = 10.7 Hz, J3 = 5.7 Hz, 2 H, 19-H 19´-H), 5.20 – 5.40 (m, 4 H, 
20-H 20´-H), 4.60 (m, 4 H, 18-H 18´-H), 3.42 (m, 2 H, 3-H), 3.37 (t, J = 6.3 Hz, 2 H, 
CH2(4)), 3.31 (m, 4 H, 10-H CH2(1)), 3.26 (m, 6 H, 4-H 7-H 8-H), 3.07 (m, 2 H, 1-H), 1.95 
(m, 2 H, 2-H), 1.81 (tt, J1 = 7.5 Hz, J2 = 6.3 Hz, 4 H, 9-H CH2(3)), 1.68 (tt, J1 = 7.5 Hz, 
J2 = 7.1 Hz, 2 H, CH2(2)), 1.54 (m, 4 H, 5-H 6-H); HRMS (ESI) [M + H]+ calc. 690.2167, 
found 690.2167. 
Entry 13: 1H NMR (400 MHz, CDCl3) d 8.25 (bs, 3 H, NH3), 7.78 (m, 1 H, 13-H), 7.60 – 
7.80 (m, 3 H, 14-H 15-H 16-H), 5.91 (ddt, J1 = 17.1 Hz, J2 = 10.6 Hz, J3 = 5.6 Hz, 2 H, 19-H 
19´-H), 5.15 – 5.30 (m, 4 H, 20-H 20´-H), 4.50 – 4.70 (m, 4 H, 18-H 18´-H), 3.42 (m, 2 H, 
3-H), 3.30 (t, J = 7.4 Hz, 2 H, CH2(1)), 3.20 – 3.35 (m, 8 H, 4-H 7-H 8-H 10-H), 2.99 (m, 
2 H, 1-H), 2.82 (t, J = 6.9, 2 H, CH2(4)), 2.31 (s, 3 H, CH3), 1.95 (m, 2 H, 2-H), 1.81 (m, 2 H, 
9-H), 1.45 – 1.64 (m, 8 H, 5-H 6-H CH2(2) CH2(3)); HRMS (ESI) [M + H]+ calc. 686.2881, 
found 686.2888. 
Entry 14: 1H NMR (400 MHz, CDCl3) d 8.12 (m, 3 H, NH3), 7.93 (m, 1 H, 13-H), 7.60 – 
7.75 (m, 3 H, 14-H 15-H 16-H), 7.10 – 7.35 (m, 5 H, Ar-Hphenyl), 5.90 (ddt, J1 = 17.1 Hz, 
J2 = 10.7 Hz, J3 = 5.5 Hz, 2 H, 19-H 19´-H), 5.10 – 5.40 (m, 4 H, 20-H 20´-H), 4.57 (m, 4 H, 
18-H 18´-H), 3.50 (t, J = 7.8 Hz, 2 H CH2(1)), 3.36 (t, J = 7.4 Hz, 2 H, 3-H), 3.30 – 3.45 (m, 
2 H, 10-H), 3.22 (m, 6 H, 4-H 7-H 8-H), 2.98 (m, 2 H, 1-H), 2.83 (t, J = 7.8 Hz, 2 H, CH2(2)), 
1.93 (m, 2 H, 2-H), 1.84 (m, 2 H, 9-H), 1.51 (m, 4 H, 5-H 6-H); FAB-MS: 660.3 (100) 
[M + H]+, 682.2 (22) [M + Na]+; HRMS (ESI) [M + H]+ calc. 660.3062, found 660.3041. 
Entry 15: 1H NMR (400 MHz, CDCl3 / CD3OD) d 7.78 (m, 1 H, 13-H), 7.40 – 7.60 (m, 3 H, 
14-H 15-H 16-H), 5.68 (ddt, J1 = 17.1 Hz,  J2 = 11.4 Hz, J3 = 5.7 Hz, 2 H, 19-H 19´-H), 4.90 
– 5.15 (m, 4 H, 20-H 20´-H), 4.20 – 4.40 (m, 4 H, 18-H 18´-H), 3.59 (m, 1 H, CH2(3)a), 3.31 
(m, 1 H, CH2(3)b), 3.27 (m, 2 H, 3-H), 3.23 (m, 1 H, CH), 2.90 – 3.20 (m, 10 H, 1-H 4-H 7-H 
8-H CH2(1)), 2.67 (t, J = 7.1 Hz, 2 H, 10-H), 1.66 (tt, J1 = 6.9 Hz, J2 = 6.9 Hz, 4 H, 2-H 9-H), 
1.30 (m, 4 H, 5-H 6-H); MS (ESI): 630.26 (100) [M + H]+. 
Entry 16: 1H NMR (400 MHz, CDCl3) d 7.90 – 8.20 (m, 4 H, 13-H NH3), 7.70 (m, 2 H, 
14-H 16-H), 7.63 (m, 1 H, 15-H), 5.90 (ddt, J1 = 17.0, J2 = 10.5, J3 = 5.4, 2 H, 19-H 19´-H), 
5.27 (dd, J1 = 17.0, J2 = 6.3, 2 H, 20-Ha 20´-Ha), 5.20 (d, J = 10.5, 2 H, 20-Hb 20´-Hb), 4.57 
(m, 4 H, 18-H 18´-H), 4.18 (s, 2 H, CH2), 3.65 (s, 3 H, CH3), 3.41 (m, 4 H, 3-H 10-H), 3.24 
(m, 6 H, 4-H 7-H 8-H), 3.01 (m, 2 H, 1-H), 1.95 (m, 2 H, 2-H), 1.82 (m, 2 H, 9-H), 1.52 (m, 
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4 H, 5-H 6-H); MS (ESI): 628.3 (100) [M + H]+, 650.2 (14) [M + Na]+; HRMS (ESI) 
[M + H]+ calc. 628.2647, found 628.2622. 
Entry 17: HRMS (ESI) calc. [M + H]+ 622.2905, found 622.2913. The amount of product 
from Entry 17 was too low for 1H NMR. 
Entry 19: 1H NMR (400 MHz, CDCl3 / CD3OD) d 7.85 (m, 1 H, 13-H), 7.50 – 7.70 (m, 3 H, 
14-H 15-H 16-H), 5.70 – 5.90 (m, 2 H, 19-H 19´-H), 5.04 – 5.20 (m, 4 H, 20-H 20´-H), 4.40 – 
4.50 (m, 4 H, 18-H 18´-H), 3.53 (m, 1 H, CH2(4)a), 3.10 – 3.40 (m, 14 H, 1-H 3-H, 4-H 
7-H 8-H CH2(1) CH(3) CH2(4)b), 2.78 (m, 2 H, 10-H), 1.77 (m, 4 H, 2-H 9-H), 1.61 (m, 1 H, 
CH2(2)a), 1.50 (m, 1 H, CH2(2)b), 1.40 (m, 4 H, 5-H 6-H); HRMS (ESI) [M + H]+ 
calc. 644.2960, found 644.2956. 
Entry 20: 1H NMR (400 MHz, CDCl3) d 7.50 – 8.20 (m, 7 H, 13-H 14-H 15-H 16-H NH3), 
5.89 (ddt, J1 = 16.9 Hz, J2 = 10.8 Hz, J3 = 5.6 Hz, 2 H, 19-H 19´-H), 5.28 (d, J = 16.9 Hz, 
2 H, 20-Ha 20´-Ha), 5.21 (d, J = 10.8 Hz, 2 H, 20-Hb 20´-Hb), 4.59 (d, J = 5.6 Hz, 4 H, 18-H 
18´-H), 3.54 (m, 2 H, CH2(3)), 3.42 (m, 4 H, 3-H 10-H), 3.32 (t, J = 7.1 Hz, 2 H, CH2(1)), 
3.25 (m, 6 H, 4-H 7-H  8-H), 3.09 (m, 2 H, 1-H), 2.54 (s, 3 H, CH3), 2.46 (s, 4 H, 
(CH2)cyclohexyl), 1.96 (m, 4 H, 2-H CH2(2)), 1.85 (m, 2 H, 9-H), 1.53 (m, 4 H, 5-H 6-H), 1.05 
(s, 6 H, 2 * CH3); HRMS (ESI) [M + H]+ calc. 777.3851, found 777.3847. 
a Numeral correlation of the protons is in analogy to compound 187. The substituents are 
described in the style CHx(y). 
 
 
6.5 Synthesis of polyamine conjugates 
6.5.1 Synthesis of spermidine derivatives 
 
[9-(2-{3-[4-(3-Amino-propylamino)-butylamino]-propylcarbamoyl}-phenyl)-6-
diethylamino-xanthen-3-ylidene]-diethyl-ammonium tetrakis-trifuoracetate (211) 
100 mg (45 µmol) of resin 198 were o-Nosyl deprotected. A solution of 110 mg 
rhodamine B 167 (230 µmol; 5 equiv.), 47 mg (230 µmol; 5 equiv.) of DCC, and 31 mg (230 
µmol; 5 equiv.) of HOBt in DMF was shortly agitated and added to the resin. The suspension 
was agitated for 16 h. After removal of the solvent the resin was washed with DMF, THF / 
H2O (10 : 1) / MeOH, and CH2Cl2. The colour of the resin turned to intensive pink and the 
Kaiser Test was negative. The resin was Aloc-deprotected with Pd(PPh3)4 / DMBA, treated 
with 10% TFA in CH2Cl2 and the crude product was purified by preparative HPLC 
(90% purity after cleavage from the resin, determined by UV detection at 254 nm). After 
removal of the solvent, the solid was dried on HV. 36 mg (34 µmol) of a pink solid were 
obtained giving 74% yield calculated on the loading of resin 198. 
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1H NMR (400 MHz, CD3OD) d 8.00 – 7.95 (m, 1 H, 11-H), 7.67 – 7.59 (m, 2 H, 13-H 
14-H), 7.52 – 7.46 (m, 2 H, 15-H 15´-H), 7.25 – 7.11 (m, 3 H, 12-H 16-H 16´-H), 6.99 – 6.91 
(m, 2 H, 17-H 17´-H), 3.64 (q, J = 7.0 Hz, 8 H, 18-H 18´-H 18´´-H 18´´´-H), 3.35 (t, J = 6.4 
Hz, 2 H, 3-H), 3.15 (t, J = 7.7 Hz, 2 H, 10-H), 3.12 – 2.98 (m, 6 H, 4-H 7-H 8-H), 2.92 (t, 
J = 6.5 Hz, 2 H, 1-H), 2.12 (tt, J1 = 7.7 Hz, J2 = 7.3 Hz, 2 H, 9-H), 1.88 – 1.78 (m, 4 H, 5-H 
6-H), 1.54 (tt, J1 = 6.8 Hz, J2 = 6.5 Hz, 2 H, 2-H), 1.30 and 1.16 (t, J = 7.0 Hz, 12 H, 19-H 
19´-H 19´´-H 19´´ -´H); HRMS (ESI) [M + H]+ calc. 627.4381, found 627.4362. 
 
[4-(3-Amino-propylamino)-butyl]-[3-(7-nitro-benzo[1,2,5]oxadiazol-4-ylamino)-
propyl]-ammonium tris-trifluoroacetate (212) 
100 mg (50 µmol) of resin 198 were o-Nosyl deprotected. The resin was washed with THF 
and a solution of 33 mg (170 µmol; 3.3 equiv.) of NBDCl 168 and 15 µl (84 µmol; 1.7 equiv.) 
of DiPEA in DMF was added to the resin. The suspension was agitated for 16 h. After 
removal of the solvent the resin was washed with THF / MeOH, and CH2Cl2. The colour of 
the resin turned to black. The resin was Aloc-deprotected with Pd(PPh3)4 / DMBA, treated 
with 10% TFA in CH2Cl2 and the crude product was purified by preparative HPLC 
(51% purity by UV detection). After removal of the solvent, the solid was dried on HV. 
29.7 mg (42 µmol) of a dark solid 212 were obtained giving 84% yield calculated on the 
loading of resin 198. 
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1H NMR (400 MHz, CD3OD) d 8.50 (d, J = 8.8 Hz, 1 H, 12-H), 6.39 (d, J = 8.8 Hz, 1 H, 
11-H), 3.74 – 3.64 (m, 2 H, 10-H), 3.20 (t, J = 7.9 Hz, 2 H, 3-H), 3.17 – 3.03 (m, 8 H, 1-H 
4-H 7-H 8-H), 2.18 (tt, J1 = 7.8 Hz, J2 = 7.4 Hz, 2 H, 9-H), 2.08 (tt, J1 = 7.8 Hz, J2 = 7.7 Hz, 
2 H, 2-H), 1.84 – 1.78 (m, 4 H, 5-H 6-H); HRMS (ESI) [M + H]+ calc. 366.2248, found 
366.2252. 
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[4-(3-Amino-propylamino)-butyl]-(3-{2-[1-(4-chloro-benzoyl)-5-methoxy-2-methyl-1H-
indol-3-yl]-acetylamino}-propyl)-ammonium tris-trifluoroacetate (213) 
100 mg (51 µmol) of resin 198 were o-Nosyl deprotected. A solution of 89 mg (250 µmol; 
5 equiv.) indomethacin 171, 51 mg (250 µmol; 5 equiv.) DCC, and 34 mg (250 µmol; 
5 equiv.) HOBt in DMF was shortly agitated and added to the resin. The suspension was 
agitated for 16 h. After removal of the solvent the resin was washed with DMF, THF : H2O 
(10 : 1) / MeOH, and CH2Cl2. The colour of the resin turned to orange and the Kaiser Test 
was negative. The resin was Aloc-deprotected with Pd(PPh3)4 / DMBA, treated with 
10% TFA in CH2Cl2 and the crude product was purified by preparative HPLC (74% purity by 
peak integration at 254 nm UV detection). After removal of the solvent, the solid was dried on 
HV. 43.3 mg (49 µmol) of a white solid 213 were obtained giving 97% yield calculated on the 
loading of resin 198. 
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1H NMR (400 MHz, CD3OD) d 7.69 (d, J = 8.4 Hz, 2 H, 23-H 23´-H), 7.55 (d, J = 8.4 Hz, 
2 H, 24-H 24-´H), 7.02 (d, J = 2.5 Hz, 1 H, 19-H), 6.94 (d, J = 9.0 Hz, 1 H, 16-H), 6.69 (dd, 
J1 = 9.0 Hz, J2 = 2.5 Hz, 1 H, 17-H), 3.80 (s, 3 H, 27-H), 3.65 (s, 2 H, 12-H), 3.32 (t, 
J = 6.7 Hz, 2 H, 3-H), 3.12 (t, J = 7.7 Hz, 2 H, 10-H), 3.06 (t, J = 7.8 Hz, 2 H, 8-H), 3.07 – 
3.00 (m, 4 H, 4-H 7-H), 2.95 (t, J = 7.1 Hz, 2 H, 1-H), 2.32 (s, 3 H, 26-H), 2.09 (tt, J1 = 
7.8 Hz, J2 = 7.7 Hz, 2 H, 9-H), 1.88 (tt, J1 = 7.1 Hz, J2 = 6.7 Hz, 2 H, 2-H), 1.81 – 1.67 (m, 
4 H, 5-H 6-H); 13C NMR (75 MHz, CD3OD) d 174.4 (Cquart, C-11), 170.0 (Cquart, C-21), 157.6 
(Cquart, C-18), 140.3 (Cquart, C-25), 137.3 (Cquart , C-14), 135.6 (Cquart, C-15), 132.3 (+, 
C-23a,b), 132.1 (Cquart, C-20), 130.2 (+, C-24a,b), 116.0 (1 C, C-17), 114.6 (1 C, C-16), 112.5 
(Cquart, C-13), 102.6 (+, C-19), 56.2 (+, C-27), 48.2, 48.0 (–, C-4 C-7), 46.3 (–, C-8), 45.8 (–, 
C-3), 37.8, 37.1 (–, 2 C, C-1 C-10), 32.3 (–, C-12), 27.5 (–, C-2), 25.3 (–, C-9), 24.2 (–, 3 C, 
C-5 C-6 C-9), 13.6 (+, C-26); HRMS (ESI) [M + H]+ calc. 542.2892, found 542.2890. 
 
[4-(3-Amino-propylamino)-butyl]-(3-{6-[4-(10,15,20-triundecyl-porphyrin-5-yl)-
benzoylamino]-hexanoylamino}-propyl)-ammonium tris-trifluoroacetate (217) 
123 mg (58 µmol) of resin 198 were o-Nosyl deprotected. A solution of 51 mg (140 µmol; 
3 equiv.) of N-Fmoc-aminocaproic acid, 67 mg (140 µmol; 3 equiv.) of PyBrOP, and 33 µl 
(190 µmol; 4 equiv.) of DiPEA in DMF / CH2Cl2 (1:1 (v/v)) was added to the resin. The 
suspension was agitated for 28 h. After removal of the solvent the resin was washed with 
DMF, THF : H2O (10 : 1) / MeOH, and CH2Cl2. The Kaiser Test was negative. The resin was 
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Fmoc deprotected. A solution of 81 mg (9.6 µmol; 2 equiv.) of carboxyporphyrin 215, 50 mg 
(240 µmol; 5 equiv.) of DCC, and 22 mg (190 µmol; 4 equiv.) of NHS in 3 mL DMF was 
shortly agitated and added to the resin. The resin was agitated for 3 d and after removal of the 
solvent the resin was washed with THF : H2O (10 : 1) / MeOH and with CH2Cl2 until the 
filtrate was clear. The colour of the resin had turned to black. The resin was Aloc-deprotected 
with Pd(PPh3)4 / DMBA and treated with 10% TFA in CH2Cl2. After removal of the solvent 
the solid was partitioned between an aqueous solution of K2CO3 (pH = 10) and CHCl3. The 
organic layer was successively washed with an aqueous solution of K2CO3 (pH = 10) and 
water. The combined aqueous layers were re-extracted with a small amount of CHCl3. The 
organic layers were dried over Na2SO4, the solvent was removed and the remaining solid was 
dried in HV. 70 mg (56 µmol) of a green solid were obtained giving 96% yield calculated on 
the loading of resin 198. The 1H NMR spectrum shows that the compound was pure. 
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1H NMR (400 MHz, CD3OD) d 9.64 (s, 4 H, 29-H 29´-H 30-H 30´-H), 9.56 (d, J = 4.9 Hz, 
2 H, 19-H 19´-H), 8.80 (d, J = 4.9 Hz, 2 H, 20-H 20´-H), 8.60 (d, J = 8.2 Hz, 2 H, 
25-H 25´-H), 8.44 (d, J = 8.2 Hz, 2 H, 24-H 24´-H), 5.10 (m, 6 H, 33-H 33´-H 33´´-H), 3.57 
(t, J = 7.1 Hz, 2 H, 16-H), 3.34 (t, J = 6.4 Hz, 2 H, 3-H), 3.16 (t, J = 7.7 Hz, 2 H, 10-H), 2.97 
– 3.11 (m, 8 H, 1-H 4-H 7-H 8-H), 2.50 – 2.60 (m, 6 H, 34-H 34´-H 34´´-H), 2.34 (t, 
J = 6.5 Hz, 2 H, 12-H), 2.10 (tt, J1 = 9.0 Hz, J2 = 6.4 Hz, 2 H, 2-H), 1.93 (tt, J1 = 6.9 Hz, 
J2 = 6.8 Hz, 2 H, 9-H), 1.73 – 1.86 (m, 10 H, 5-H 6-H 35-H 35´-H 35´´-H), 1.47 – 1.58 (m, 
8 H, 15-H 36-H 36´-H 36´ -´H), 1.20 – 1.38 (m, 40 H, 13-H 14-H (37-H to 42´´-H)), 0.87 (t, 
J = 7.0 Hz, 9 H, 43-H 43´-H 43´ -´H); 13C NMR (75 MHz, CD3OD) d 177.3 (Cquart, C-11), 
169.7 (Cquart,  C-17), 146.4, 146.1, 146.1, 145.6, 139.2, 137.1, 128.5, 128.3, 128.2, 121.0, 
115.9, 113.6 (Cquart and +, C-22 to C-32), 143.4 (Cquart, C-21), 130.5 (Cquart, C-18), 124.6, 
124.5 (+, C-19a C-19b C-20a C-20b), 48.3, 48.2 (–, C-4 C-7), 46.5, 45.9 (–, 2 C, C-3 C-8), 
41.2 (–, C-16), 37.8, 37.0 (–, 3 C, C-1 C-10 C-12), 33.1 (–, C-41 C-41´ C-41´´), 31.4, 31.3 (–, 
C-41 C-41´ C-41´´), 30.9, 30.8, 30.5, 30.4 (–, C-13 C-15 C-35 to C-44´´), 27.9 (–, C-34 C-34´ 
C-34´´), 26.8 (–, C33 C-33´ C-33´´), 27.8, 25.4 (–, 2 C, C-2 C-9), 24.4, 24.3 (–, C-5 C-6), 
23.8 (–, C-14 C-42 C-42´ C-42´´), 14.5 (+, C-43 C-43´ C-43´´); HRMS (ESI) [M + 2 H]2+ 
calc. 595.9816, found 595.9816. 
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6.5.2 Synthesis of spermine conjugates 
{9-[2-(3-{3-[4-(3-Amino-propylamino)-butylamino]-propylamino}-propylcarbamoyl)-
phenyl]-6-diethylamino-xanthen-3-ylidene}-diethyl-ammonium pentakis-trifluoroacetate 
(223) 
Resin 198 was alkylated with (N-Dde)-3-aminopropyliodide 193 as described in Entry 20 of 
the study on Fukuyama alkylation and then 72 mg (36 µmol) of the resin were Dde-
deprotected. A solution of 86 mg rhodamine B (180 µmol, equiv.), 24 mg HOBt (180 µmol, 5 
equiv.), and 66 mg DCC (320 µmol, 8.9 equiv.) in DMF was added to the resin and agitated 
for 16 h. After removal of the solvent the resin was washed with DMF, H2O / THF (1:10) / 
MeOH and CH2Cl2. The resin was Aloc-deprotected with Pd(PPh3)4 / DMBA, o-Nosyl-
deprotected treated with 10% TFA in CH2Cl2 and the crude product was purified by 
preparative HPLC (26% purity by UV detection). After removal of the solvent the solid was 
dried on HV. 13.5 mg (11 µmol) of a pink solid were obtained giving 31% yield calculated on 
the loading of resin 198. 
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1H NMR (400 MHz, CD3OD) d 7.97 – 7.92 (m, 1 H, 14-H), 7.65 – 7.59 (m, 2 H, 16-H 
17-H), 7.15 – 7.10 (s, 1 H, 15-H), 7.06 – 6.96 (m, 2 H, 18-H 18´-H), 6.83 – 6.76 (m, 2 H, 
19-H 19´-H), 6.71 – 6.65 (m, 2 H, 20-H 20´-H), 3.64 and 3.46 (q, J = 7.1 Hz, 8 H, 21-H 21´-H 
21´´-H 22´´´-H), 3.33 – 3.28 (m, 2 H, 3-H), 3.22 – 3.03 (m, 12 H, 4-H 7-H 8-H 10-H 11-H 
13-H), 2.89 (t, J = 6.7 Hz, 2 H, 1-H), 2.18 – 2.04 (m, 4 H, 9-H 12-H), 1.86 – 1.77 (m, 4 H, 
5-H 6-H), 1.54 – 1.45 (m, 2 H, 2-H), 1.31 and 1.17 (t, J = 7.2 Hz, 12 H, 22-H 22´-H 22´´-H 
22´´´-H); HRMS (ESI) [M + 2 H]2+ calc. 343.2553, found 343.2490. 
 
{3-[4-(3-Amino-propylamino)-butyl]-propylamino}-[3-(7-nitro-benzo[1,2,5]oxadiazol-
4-ylamino)-propyl]-ammonium tetrakis-trifluoroacetate (230) 
Resin 198 was alkylated with (N-Dde)-3-aminopropyliodide 193 as described in Entry 20 of 
the study on Fukuyama alkylation. On 100 mg (42 µmol) of the resin the o-Nosyl group was 
removed and Aloc was introduced instead. 100 mg of the resin (42 µmol) were Dde 
deprotected, washed with THF, and a solution of 33.5 mg NBDCl (168 µmol; 4 equiv.) and 
29 µl DiPEA (168 µmol; 4 equiv.) in THF was added to the resin. The suspension was 
agitated for 16 h. After removal of the solvent the resin was washed with THF / MeOH, and 
CH2Cl2. The colour of the resin turned to black. The resin was Aloc-deprotected with 
Pd(PPh3)4 / DMBA, o-Nosyl deprotected, treated with 10% TFA in CH2Cl2 and the crude 
product was purified by preparative HPLC (25% purity by UV detection). After removal of 
Experimental section 
 176
the solvent the solid was dried on HV. 8.8 mg (21 µmol) of a black solid were obtained giving 
24% yield calculated on the loading of resin 198. 
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1H NMR (400 MHz, CD3OD) d 8.53 (d, J = 8.7 Hz, 1 H, 15-H), 6.40 (d, J = 8.7 Hz, 1 H, 
14-H), 3.75 – 3.65 (m, 2 H, 13-H), 3.23 – 3.03 (m, 14 H), 2.17 (tt, J1 = 8.1 Hz, J2 = 6.9 Hz, , 
12-H), 2.19 – 2.11 (m, 2 H, 9-H), 2.08 (tt, J1 = 7.8 Hz, J2 = 7.8 Hz, 2 H, 2-H), 1.83 – 1.77 (m, 
4 H, 5-H 6-H); HRMS (ESI) [M + H]+ calc. 423.2827, found 423.2820. 
 
{3-[4-(3-Amino-propylamino)-butyl]-propylamino}-(3-{2-[1-(4-chloro-benzoyl)-5-
methoxy-2-methyl-1H-indol-3-yl]-acetylamino}-propyl)-ammonium tetrakis-
trifluoroacetate (229) 
The resin 198 was alkylated with (N-Dde)-3-aminopropyliodide 193 as described in 
Entry 20 of the study on Fukuyama alkylation. On 100 mg (43 µmol) of the resin the o-Nosyl 
group was removed and Aloc was introduced instead. After this the resin was washed with 
Dde deprotected and a solution of 75 mg indomethacin (210 µmol; 4.9 equiv.), 43 mg DCC 
(209 µmol; 4.9 equiv.), and 28 mg HOBt (207 µmol; 4.8 equiv.) in DMF was shortly agitated 
and added to the resin. The suspension was agitated for 16 h. After removal of the solvent the 
resin was washed with THF / MeOH, and CH2Cl2. The colour of the resin turned to orange. 
The resin was Aloc-deprotected with Pd(PPh3)4 / DMBA, treated with 10% TFA in CH2Cl2 
and the crude product was purified by preparative HPLC (67% purity by peak integration at 
254 nm UV detection). After removal of the solvent the solid was dried on HV. 43.9 mg 
(42 µmol) were obtained giving 99% yield calculated on the loading of resin 198. 
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1H NMR (400 MHz, CD3OD) d 7.67 (d, J = 8.4 Hz, 2 H, 26-H 26´-H), 7.54 (d, J = 8.4 Hz, 
2 H, 27-H 27´-H), 7.02 (d, J = 2.5 Hz, 1 H, 22-H), 6.92 (d, J = 9.0 Hz, 1 H, 19-H), 6.68 (dd, 
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J1 = 9.0 Hz, J2 = 2.5 Hz, 1 H, 20-H), 3.80 (s, 3 H, 30-H), 3.65 (s, 2 H, 15-H), 3.32 (t, 
J = 6.9 Hz, 2 H, 3-H), 3.14 (t, J = 7.7 Hz, 2 H, 13-H), 3.14 – 3.02 (m, 10 H, 4-H 7-H 8-H 
10-H 11-H), 2.98 (t, J = 7.1 Hz, 2 H, 1-H), 2.31 (s, 3 H, 29-H), 2.09 (tt, J1 = 7.7 Hz, 
J2 = 7.6 Hz, 4 H, 9-H 12-H), 1.89 (tt, J1 = 7.1 Hz, J2 = 6.9 Hz, 2 H, 2-H), 1.83 – 1.77 (m, 4 H, 
5-H 6-H); 13C NMR (75 MHz, CD3OD) d 174.5 (Cquart, C-14), 170.0 (Cquart, C-24), 157.7 
(Cquart, C-21), 140.4 (Cquart, C-28), 137.4 (Cquart , C-17), 135.6 (Cquart, C-18), 132.4 (+, 
C-26a,b), 132.2 (Cquart, C-23), 130.3 (+, C-27a,b), 116.1 (+, C-20), 114.7 (+, C-19), 112.6 
(Cquart, C-16), 102.7 (+, C-22), 56.3 (+, C-30), 48.3 (–, C-4 C-7), 46.6 (–, C-11), 45.9 (–, 2 C, 
C-8 C-10), 45.8 (–, C-3), 37.9, 37.2 (–, 2 C, C-1 C-13), 32.3 (–, C-15), 27.6 (–, C-2), 25.4 (–, 
C-12), 24.3, 24.2 (–, 3 C, C-5 C-6 C-9), 13.6 (+, C-29); HRMS (ESI) [M + H]+ 
calc. 599.3471, found 599.3465. 
  
6.5.3 Synthesis of lipophilic putrescine conjugates 
6.5.3.1 General procedures 
Alkylation with alkyliodide / K2CO3 
The resin is placed in a closed vial together with 13 equiv. of K2CO3. 3 mL of DMF are 
added and the suspension is shortly agitated. 13 equiv. of allyliodide are added, the vial is 
closed and the suspension is agitated at 40°C for xx h: The resin is washed with water, water / 
THF (1 : 10) and CH2Cl2. 
 
Alkylation with octylbromide / K2CO3 
The resin is placed in a closed vial together with 20 equiv. of K2CO3. 3 mL of DMF are 
added and the suspension is shortly agitated. 20 equiv. of octylbromide are added, the vial is 
closed and the suspension is agitated at 50°C for 72 h: The resin is washed with water, water / 
THF (1:10) and CH2Cl2. 
 
Alkylation with benzylbromide / K2CO3 
The resin is placed in a closed vial together with 10 equiv. of K2CO3. 3 mL of DMF are 
added and the suspension is shortly agitated. 10 equiv. of benzylbromide are added, the vial is 
closed and the suspension is agitated at 40°C for over night. The resin is washed with water, 
water / THF (1:10) and CH2Cl2. 
 
Alkylation with capronaldehyde / tetrabutylammonium borohydride  
The resin is placed in a frit with a plastic cap and 3 mL of 3% HOAc in DMF are added. 
The suspension is shortly agitated, heated to 40°C and 6 equiv. of capronaldehyde are added. 
The suspension is left for 30 min under occasional stirring and then 6 equiv. of 
tetrabutylammonium borohydride are added. The suspension is again left for 30 min under 
occasional stirring and is then cooled to room temperature. The resin is washed with DMF. 
The alkylation is twice repeated but in the last cycle reaction was left over night after the 
addition of tetrabutylammonium borohydride. The resin is washed with DMF, THF / MeOH 
and CH2Cl2. 
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6.5.3.2 Synthesis of the conjugates 
 
(4-{3-[(Adamantane-1-carbonyl)-amino]-propylamino}-butyl)-[3-(7-nitro-
benzo[1,2,5]oxadiazol-4-ylamino)-propyl]-ammonium bis-acetate (234) 
100 mg (41 µmol) of resin 198 were o-Nosyl deprotected. The resin was washed with DMF 
and a suspension of 59 mg (328 µmol; 8 equiv.) of adamantylcarboxylic acid, 69 mg 
(334 µmol; 8.2 equiv.) of DCC, and 24 mg (209 µmol; 5.1 equiv.) of NHS in 3 mL 
DMF : THF (1:1) was shortly agitated and added to the resin. The resin was washed with THF 
/ MeOH and CH2Cl2 and the resin was treated with 10% TFA in CH2Cl2. After removal of the 
solvents and drying on HV, 24 mg (120 µmol; 2.9 equiv.) of NBDCl, 17 mg (123 µmol; 
3 equiv.) of K2CO3, and 3 mL THF were added. The suspension was agitated for 18 h. The 
THF was removed in constant flow of N2 and the residue was partitioned between CHCl3 and 
water. The organic layer was three times washed with water. After removal of the solvent and 
drying on HV the solid was dissolved in CH2Cl2 and 62 mg (397 µmol; 9.7 equiv.) of 
N,N´-dimethylbarbituric acid and 4.6 mg (4 µmol; 0.1 equiv.) of Pd(PPh3)4 were added. The 
solution was stirred for 150 min at 40 °C under avoidance of light. 400 µl of acetic acid were 
added. The solvents were removed and the remaining solid was extracted with Et2O until the 
extract was colourless. The solid was dissolved in a solution of 3% HOAc in water and 
extracted three times with a solution of CH2Cl2 : Et2O (1:1). The water was removed and the 
solid was dried on HV. 14.3 mg (27 µmol) of a dark solid were obtained giving 66% yield 
calculated on the loading of resin 198. 
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1H NMR (400 MHz, CD3OD) d 8.46 (d, J = 8.8 Hz, 1 H, 12-H), 6.38 (d, J = 8.8 Hz, 1 H, 
11-H), 3.74 – 3.63 (m, 2 H, 10-H), 3.30 (t, J = 6.6 Hz, 2 H, 3-H), 3.22 (t, J = 7.2 Hz, 2 H, 
1-H), (3.12 (t, J = 7.1 Hz, 2 H) and 2.95 (t, J = 7.1 Hz, 2 H) 4-H and 7-H), 3.04 (t, J = 6.8 Hz, 
2 H, 8-H), 2.20 (tt, J1 = 7.8 Hz, J2 = 6.8 Hz, 2 H, 9-H), 2.03 – 1.98 (m, 3 H, 14-H 14´-H 
14´´-H), 1.88 (tt, J1 = 7.2 Hz, J2 = 6.6 Hz, 2 H, 2-H), 1.87 – 1.67 (m, 16 H, 5-H 6-H (13-H 
13´-H 13´´-H 15-H 15´-H 15´ -´H)); HRMS (ESI) [M + H]+ calc. 528.3293, found 528.3304. 
 
N1-Acetyl-N5,N10-bis-allyl-N12-(7-nitro-benzo[1,2,5]oxadiazol-4-ylamino)-4,9,12-
tetraazatetradecane bis-trifluoroacetate (239) 
50 mg (25 µmol) of resin 198 were swollen in CH2Cl2. After removal of the solvent a 
solution of 30 mg (0.025 mmol; 1 equiv.) of Pd(PPh3)4 and 0.7 µl (7.5 µmol; 0.3 equiv.) of 
allyliodide in CH2Cl2 were added. The suspension was agitated for 16 h and was then washed 
analogously to the procedure of Aloc protection. The resin was o-Nosyl deprotected and then 
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a solution of 9.5 µl (100 µmol; 4 equiv.) of acetic anhydride and 14 µl (100 µmol, 4 equiv.) of 
Et3N in DMF was added to the resin. The suspension was agitated for 16 h. After removal of 
the solvent the resin was washed with H2O / THF (1:10) / MeOH, and CH2Cl2. The resin was 
treated with 10% TFA in CH2Cl2 and the cleavage mixture was combined with washings of 
CH2Cl2 and MeOH. The solvents were removed and the solid was dried on HV to remove 
remains of TFA. 6.9 mg (50 µmol, 2 equiv.) of K2CO3 were added and it was suspended with 
a solution of 7.5 mg NBDCl (38 µmol, 1.5 equiv.) in 2 mL THF. The suspension was agitated 
for 18 h and THF was removed in a constant flow of N2. The remaining solid was purified by 
preparative HPLC (30% purity by UV detection at 254 nm). After removal of the solvent the 
solid was dried on HV. 4.7 mg (7 µmol) of a dark brown solid were obtained giving 27% 
yield calculated on the loading of resin 198. 
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1H NMR (400 MHz, CD3OD) d 8.56 – 8.50 (m, 1 H, 12-H), 6.41 (d, J = 8.6 Hz, 1 H, 11-H), 
5.97 (ddt, J1 = 17.1 Hz, J2 = 10.1 Hz, J3 = 7.2 Hz, 2 H, 14-H 14´-H), 5.68 – 5.58 (m, 4 H, 
15-H 15´-H), 3.87 (d, J = 7.2 Hz, 2 H, 13-H), 3.83 (d, J = 7.2 Hz, 2 H, 13 -´H), 3.73 – 3.66 (m, 
2 H, 10-H), 3.35 – 3.30 (m, 2 H, 3-H), (3.29 – 3.23 (m, 2 H) and 3.24 (t, J = 7.3 Hz, 2 H) 4-H 
and 7-H), 3.17 (t, J = 7.6 Hz, 2 H, 1-H), 3.15 (t, J = 8.3 Hz, 2 H, 8-H), 2.22 (tt, J1 = 8.3 Hz, 
J2 = 7.1 Hz, 2 H, 9-H), 1.97 (s, 3 H, 16-H), 1.93 (tt, J1 = 7.6 Hz, J2 = 6.8 Hz, 2 H, 2-H), 1.87 –
 1.78 (m, 4 H, 5-H 6-H); HRMS (ESI) [M + H]+ calc. 488,2980, found 488,2972. 
 
 
N1-Acetyl-N5,N10-bis-benzyl-N12-(7-nitro-benzo[1,2,5]oxadiazol-4-ylamino)-4,9,12-
tetraazatetradecane bis-trifluoroacetate (248) 
100 mg (40 µmol) of resin 198 were o-Nosyl deprotected. The resin was washed with DMF 
and a solution of 36 mg (200 µmol; 5 equiv.) adamantylcarboxylic acid, 23 mg (200 µmol, 
5 equiv.) NHS, and 41 mg (200 µmol; 5 equiv.) DCC in DMF was added to the resin. The 
suspension was agitated for 18 h. After removal of the solvent the resin was washed with H2O 
/ THF (1:10) / MeOH, and CH2Cl2. The resin was Aloc-deprotected with Pd(PPh3)4 / DMBA 
and the free secondary amines were partially alkylated with benzylbromide / K2CO3 in DMF. 
The Kaiser Test was still positive. The remaining secondary amines were expediently 
alkylated with benzaldehyde / tetrabutylammonium borohydride in 3% HOAc in DMF. Now 
the Kaiser Test was negative. The resin was treated with 10% TFA in CH2Cl2 and the 
cleavage mixture was combined with washings of CH2Cl2 and MeOH. The solvents were 
removed and the solid was dried on HV to remove remains of TFA. 39 mg (0.280 mmol, 
7 equiv.) of K2CO3 were added and it was suspended with a solution of 32 mg (0.160 mmol, 
4 equiv.) of NBDCl in THF. The suspension was agitated for 17 h and THF was removed in a 
constant flow of N2. The remaining solid was partitioned between CHCl3 and water and the 
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organic layer was twice washed with a solution of K2CO3 (pH 8.5). The combined aqueous 
layers were re-extracted with a small amount of CHCl3. The organic layers were combined 
and dried over Na2SO4. After removal of the solvent the solid was dried on HV. The ESI-MS 
showed the presence of minorities of a compound that had a molecular mass, which was 
consistent with the product. The product was purified by flash chromatography on silica gel. 
(CHCl3 : MeOH (20 : 1) to CHCl3 : MeOH (5 : 1). After removal of the solvent and drying on 
HV, no remains of product were obtained. 
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MS (ESI): 708.43 (10) [M + H]+. 
 
 
N1-Acetyl-N5,N10-bis-octyl-N12-(7-nitro-benzo[1,2,5]oxadiazol-4-ylamino)-4,9,12-
tetraazatetradecane (244) 
100 mg (40 µmol) of resin 198 were o-Nosyl deprotected. The resin was washed with DMF 
and a solution of 11.4 µl (200 µmol; 5 equiv.) of acetic acid, 23 mg (200 µmol, 5 equiv.) of 
NHS, and 41 mg (200 µmol; 5 equiv.) of DCC in DMF was added to the resin. The 
suspension was agitated for 16 h. After removal of the solvent the resin was washed with H2O 
/ THF (1:10) / MeOH, and CH2Cl2. The resin was Aloc-deprotected with Pd(PPh3)4 / DMBA 
and the free secondary amines were alkylated with octylbromide / K2CO3 in DMF. The resin 
was treated with 10% TFA in CH2Cl2 and the cleavage mixture was combined with washings 
of CH2Cl2 and MeOH. The solvents were removed and the solid was dried on HV to remove 
remains of TFA. 39 mg (280 µmol, 7 equiv.) of K2CO3 were added and it was suspended with 
a solution of 32 mg (160 µmol, 4 equiv.) of NBDCl in THF. The suspension was agitated for 
17 h and THF was removed in a constant flow of N2. The remaining solid was partitioned 
between CHCl3 and water and the organic layer was twice washed with a solution of K2CO3 
(pH 8.5). The combined aqueous layers were re-extracted with a small amount of CHCl3. The 
organic layers were combined and dried over Na2SO4. After removal of the solvent the solid 
was dried on HV. The product was purified by flash chromatography on silica gel. (CHCl3 : 
MeOH (19:1) to CHCl3 : MeOH (2:1)). 2.2 mg (3 µmol) of a dark brown solid were obtained 
giving 8% yield calculated on the loading of resin 198. 
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MS (ESI ): 632.50 [M+H]+. 
 
 
N1-adamantylcarbonyl-N5,N10-bis-hexyl-N12-(7-nitro-benzo[1,2,5]oxadiazol-4-ylamino)-
4,9,12-tetraazatetradecane (249) 
100 mg (40 µmol) of resin 198 were o-Nosyl deprotected. The resin was washed with THF 
and a solution of 56 mg 1-adamantylcarboxylic acid (312 µmol; 8 equiv.), 22 mg NHS 
(312 µmol, 8 equiv.), and 65 mg DCC (195 µmol; 5 equiv.) in DMF / THF (1:1) was added to 
the resin. The suspension was agitated for 24 h. After removal of the solvent the resin was 
washed with H2O : THF (1:10) / MeOH, and CH2Cl2. The resin was Aloc-deprotected with 
Pd(PPh3)4 / DMBA and the free secondary amines were alkylated with capronaldehyde / 
tetrabutylammonium borohydride in 3% HOAc in DMF. The resin was treated with 10% TFA 
in CH2Cl2 and the cleavage mixture was combined with washings of CH2Cl2 and MeOH. The 
solvents were removed and the solid was dried on HV to remove remains of TFA. 22 mg 
(160 µmol, 4 equiv.) of K2CO3 were added and it was suspended with a solution of 24 mg 
NBDCl (120 µmol, 3 equiv.) in THF. The suspension was agitated for 17 h and THF was 
removed in a constant flow of N2. The remaining solid was partitioned between CHCl3 and 
water and the organic layer was twice washed with a solution of K2CO3 (pH 8.5). The 
combined aqueous layers were re-extracted with a small amount of CHCl3. The organic 
layers were combined and dried over Na2SO4. After removal of the solvent the solid was dried 
on HV. The product was purified by flash chromatography on silica gel. (CHCl3 : MeOH 
(10 : 1) to CHCl3 : MeOH (5 : 1)). 14.6 mg (21 µmol) of a dark brown solid were obtained 
giving 53% yield calculated on the loading of resin 198. 
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1H NMR (400 MHz, CDCl3) d 8.38 – 8.30 (m, 1 H, 12-H), 6.71 (m, 1 H, 11-H), 3.75 – 3.62 
(m, 2 H, 10-H), 3.38 – 3.30 (m, 2 H, 1-H), 3.27 – 3.22 (m, 4 H, 16-H 16´-H), 3.16 – 2.94 (m, 
8 H, 3-H 4-H 7-H 8-H), 2.32 – 2.21 (m, 2 H, 9-H), 2.04 – 1.97 (m, 5 H, 2-H 14-H 14´-H 
14´´-H), 1.90 – 1.86 (m, 4 H, 17-H 17´-H), 1.85 – 1.81 (m, 4 H, 5-H 6-H), 1.76 – 1.60 (m, 
12 H, 13-H 13´-H 13´´-H 15-H 15´-H 15´´-H), 1.45 – 1.22 (m, 12 H, (18-H to 20´´-H)), 0.90 –
 0.81 (m, 6 H, 21-H 21´-H); HRMS (ESI) [M + H]+ calc. 696.5171, found 696.5167. 
 
 
((N-benzyl)-N1-docecanamidyl)-N4,N9-bis-hexyl-12-(7-nitro-benzo[1,2,5]oxadiazol-4-
ylamino)-4,9-diazadodecane bis-acetate (256) 
200 mg of resin 198 (71 µmol) were alkylated with benzylbromide / DBU according to 
Entry 1 of the study on Fukuyama alkylation. The resin was o-Nosyl deprotected. A solution 
of 254 µl (1.42 mmol, 20 equiv.) lauroyl chloride in 3 mL pyridine / CH2Cl2 (1:2) was added 
and the resin was agitated for 18 h. After removal of the solvent the resin was washed with 
CH2Cl2 / MeOH and CH2Cl2. The Kaiser Test was negative and the TLC showed only one 
spot. One third of the resin was treated with 10% TFA in CH2Cl2. The filtrate was collected 
and after removal of the solvents the remaining solid was analysed by 1H NMR spectroscopy. 
The spectrum showed that the lauroyl- and the benzyl moiety were expediently bound. The 
resin was Aloc-deprotected with Pd(PPh3)4 / DMBA and the free secondary amines were 
alkylated with capronaldehyde / tetrabutylammonium borohydride in 3% HOAc in DMF. The 
resin was treated with 10% TFA in CH2Cl2 and the cleavage mixture was combined with 
washings of CH2Cl2 and MeOH. The solvents were removed and the solid was dried on HV to 
remove remains of TFA. 26 mg (0.188 mmol, 4 equiv.) of K2CO3 were added and it was 
suspended with a solution of 28 mg NBDCl (0.141 mmol, 3 equiv.) in THF. The suspension 
was agitated for 17 h and THF was removed in a constant flow of N2. The remaining solid 
was partitioned between CHCl3 and water and the organic layer was twice washed with water. 
The combined aqueous layers were re-extracted with a small amount of CHCl3. The organic 
layers were combined and dried over Na2SO4. After removal of the solvent the solid was dried 
on HV. The product was purified by flash chromatography on silica gel. (CHCl3 : MeOH 
(15 : 1) to CHCl3 : MeOH (10 : 1). The product was converted to its bis-acetate salt by stirring 
it for 10 min in 5% HOAc in CHCl3. After removal of the solvent and drying on HV 40.0 mg 
(43.3 µmol) of a dark brown solid were obtained giving 91% yield calculated on the loading 
of resin 198. 
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1H NMR (400 MHz, CD3OD) d 8.42 (d, J = 8.7 Hz, 1 H, 12-H), 7.40 – 7.16 (m, 5 H, 14-H 
14´-H 15-H 15´-H 16-H), 6.29 (d, J = 8.7 Hz, 1 H, 11-H), 4.62 (s, 2 H, 13-H), 3.68 – 3.58 (m, 
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2 H, 10-H), 3.42 (t, J = 7.0 Hz, 2 H, 1-H), 3.12 – 2.84 (m, 12 H, 3-H 4-H 7-H 8-H 28-H 
28´-H), 2.40 (t, J = 7.6 Hz, 2 H, 17-H), 2.11 (tt, J1 = 7.1 Hz, J2 = 7.1 Hz, 2 H, 9-H), 1.89 (tt, J1 
= 7.3 Hz, J2 = 7.0 Hz, 2 H, 2-H), 1.77 – 1.69 (m, 4 H, 5-H 6-H), 1.69 – 1.52 (m, 6 H, 18-H 
29-H 29´-H), 1.35 – 1.19 (m, 28 H, (19-H to 26-H) (30-H to 32´-H)), 0.91 – 0.83 (m, 9 H, 
27-H 33-H 33´-H); HRMS (ESI) [M + H]+ calc. 806.6266, found 806.6249. 
 
 
N1-adamantylcarbonyl-N4-docecanoyl-N8,N13-bis-hexyl-N17-(7-nitro-
benzo[1,2,5]oxadiazol-4-ylamino)-1,4,8,13,17-pentaazaoctadecane bis-acetate (263) 
The resin 198 was alkylated with (N-Dde)-3-aminopropyliodid 193 as described in Entry 20 
of the study on Fukuyama alkylation. On 100 mg (43 µmol) of the resin the o-Nosyl group 
was removed. A solution of 203 µl (860 µmol; 20 equiv.) lauroyl chloride in pyridine / 
CH2Cl2 (1 : 2) was added and the resin was agitated for 51 h. The resin was washed with 
CH2Cl2 / MeOH and CH2Cl2. The Kaiser Test was negative. The resin was Dde deprotected 
and a solution of 56 mg adamantylcarboxylic acid (344 µmol; 8 equiv.), 65 mg DCC 
(215 µmol; 5 equiv.), and 22 mg NHS (344 µmol; 8 equiv.) in 2 mL DMF / THF (1 : 1) was 
shortly agitated and added to the resin. The suspension was agitated for 24 h. The Kaiser Test 
was negative. After removal of the solvent the resin was washed with H2O / THF (1 : 10) / 
MeOH, and CH2Cl2. The Kaiser Test was negative. The resin was Aloc-deprotected with 
Pd(PPh3)4 / DMBA and the free secondary amines were alkylated with capronaldehyde / 
tetrabutylammonium borohydride in 3% HOAc in DMF. Excess of 10 equiv. instead of 
6 equiv. of both, aldehyde and hydride were necessary to achieve saturation of all secondary 
amines. The resin was treated with 10% TFA in CH2Cl2 and the cleavage mixture was 
combined with washings of CH2Cl2 and MeOH. The solvents were removed and the solid was 
dried on HV to remove remains of TFA. A solution of 40 mg (200 µmol, 4.7 equiv.) of 
NBDCl and 28 µl Et3N (201 µmol, 4.7 equiv.) in DMF was added. The dark brown solution 
was agitated for 19 h, partitioned between CHCl3 and water, and the organic layer was three 
times washed with water. The combined aqueous layers were re-extracted with a small 
amount of CHCl3. The organic layers were combined and dried over Na2SO4. After removal 
of the solvent the solid was dried on HV until the last remains of DMF were removed. The 
product was purified by flash chromatography on silica gel. (CHCl3 : MeOH (15 : 1) to 
CHCl3 : MeOH : NH3(aq)(25%) (3 : 1 : 0.1)). 36 mg (38 µmol) of a dark brown solid were 
obtained giving 89% yield calculated on the loading of resin 198. The product was converted 
into its bis-acetate salt by treatment with 5% HOAc in CHCl3 for 10 min, subsequent removal 
of the solvent, and drying on HV. The spectra confirmed the identity of the compound but the 
ESI-MS spectra also showed a second compound with [M + 20]+ which could neither be 
separated nor be assigned to a suggestive structure consistent with the synthetic scheme. 
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1H NMR (400 MHz, CDCl3) d 8.44 – 8.33 (m, 1 H, 12-H), 6.31 – 6.26 (m, 1 H, 11-H), 
6.09 – 6.01 (m, 1 H), 3.66 – 3.54 (m, 2 H, 10-H), 3.42 – 3.34 (m, 2 H, 15-H), 3.34 – 3.22 (m, 
4 H, 1-H 13-H), 3.16 – 2.84 (m, 8 H, 3-H 4-H 7-H 8-H), 2.78 – 2.60 (m, 4 H, 30-H 30´-H), 
2.30 (t, J = 7.1 Hz, 2 H, 19-H), 2.22 – 2.15 (m, 2 H, 9-H), 2.08 – 1.96 (m, 7 H, 14-H 17-H 
17´-H 17´´-H), 1.88 – 1.81 (m, 6 H, 2-H 5-H 6-H), 1.72 – 1.66 (m, 6 H, 16-H 16´-H 16´´-H), 
1.66 – 1.50 (m, 12 H, 18-H 18´-H 18´ -´H 20-H 31-H 31´-H), 1.34 – 1.16 (m, 28 H, (21-H to 
28-H) (32-H to 34´-H)), 0.90 – 0.79 (m, 9 H, 29-H 35-H 35´-H); HRMS (ESI) [M + H]+ calc. 
935,7420, found 936.7415. 
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6.6 Development of coupling methods for the formation of 
sensitive polyamine-drug conjugates 
6.6.1 Establishment of the conditions for the Michael addition 
Introduction of a maleimide 
 
N13-(N-Maleimidopropionyl)-N4,N9-bis-allyloxycarbonyl-N1-amino-4,9,13-
triazatridecane trifluoroacetate (277) 
100 mg (42 µmol) of resin 198 were o-Nosyl deprotected. After this a solution of 94 mg 
(333 µmol, 8 equiv.) of 196 and 58 µl (333 µmol, 8 equiv.) of DiPEA in 2 mL DMF were 
added to the resin. The suspension was agitated for 16 h and the resin was washed with DMF, 
THF / MeOH and CH2Cl2. The resin was treated with 10% TFA in CH2Cl2 and the cleavage 
mixture was combined with washings of CH2Cl2 and MeOH. The solvents were removed and 
the solid was dried on HV to remove remains of TFA. 
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1H NMR (400 MHz, CDCl3) d 6.69 (s, 2 H, 15-H 15´-H), 5.89 (ddt, J1 = 17.1 Hz, 
J2 = 10.3 Hz, J3 = 5.5 Hz, 2 H, 18-H 18´-H), 5.28 (d, J = 17.1 Hz, 2 H, 19-Ha 19´-Ha), 5.23 
(d, J = 10.3 Hz, 2 H, 19-Hb 19´-Hb), 4.60 – 4.54 (m, 4 H, 17-H 17´-H), 3.82 (t, J = 6.8 Hz, 
2 H, 13-H), 3.44 – 3.37 (m, 2 H, 3-H), 3.32 – 3.16 (m, 8 H, 4-H 7-H 8-H 10-H), 3.08 – 3.01 
(m, 2 H, 1-H), 2.56 (t, J = 6.8 Hz, 2 H, 12-H), 1.99 – 1.91 (m, 2 H, 2-H), 1.75 – 1.64 (m, 2 H, 
9-H), 1.56 – 1.49 (m, 4 H, 5-H 6-H); 13C NMR (75 MHz, CDCl3) d 170.5 (Cquart, C-14 C-14´), 
157.5 (Cquart, C-16 C-16´), 134.2 (+, C-15 C-15´), 132.8 (+,  C-18 C-18´), 117.9 (–,  C-19 
C-19´), 67.0, 66.1 (–, C-17 C-17´), 46.9 (–, C-4 C-7), 44.4 (–, 2 C, C-3 C-8), 34.7 (–, C-1), 
34.3 (–,  C-10), 29.6 (–,  C-9), 25.7 (–, 3 C, C-2 C-5 C-6); HRMS (ESI) [M + H]+ calc. 
522.2922, found 522.2916; FAB: (70 eV) (m / z) (%) = 560.2 (10) [M + K]+, 544.3 (52) 
[M + Na]+; FAB-MS: 522.3 (13) [M + H]+, 459.3 (100) [M – 63]+. 
 
General procedure 
1 equiv. of resin 277 was swollen in DMF and the solvent was removed. In case of solid 
thiols, 1.5 or 5 equiv. of the respective thiol were weight in to the resin and 2 mL of DMF 
were added. In case of liquid thiols, the resin was suspended in 1 mL DMF, 1.5 equiv. of the 
thiol were added as 10% solution in DMF and the volume of the liquid phase was filled up to 
2 mL. The suspension was added for 3 h or 18 h and the resin was washed with DMF, 
THF : water (10 : 1) / MeOH, and CH2Cl2. The resin was treated with 10% TFA in CH2Cl2 
and the cleavage mixture was combined with washings of CH2Cl2 and MeOH. The solvents 
were removed and the solid was dried on HV to remove remains of TFA. Due to the 
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instability of some adducts during separation on RP-HPLC with gradients of water / MeCN / 
TFA, water / MeCN / HOAc, and water / MeCN, the crude products were interpreted from 
their 1H NMR spectra and the identity was additionally confirmed by ESI-HRMS. 
 
N1-{3-[3-(ethylthio)-2,5-dioxopyrrolidin-1-yl]propanoyl}-N4,N9-bis-allyloxycarbonyl-
spermine trifluoroacetate 
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1H NMR (400 MHz, CD3OD) d 5.89 (ddt, J1 = 17.3 Hz, J2 = 10.6 Hz, J3 = 5.3 Hz, 2 H, 
18-H 18´-H), 5.23 (d, J = 17.3 Hz, 2 H, 19-Ha 19´-Ha), 5.23 (d, J = 10.6 Hz, 2 H, 19-Hb 
19´-Hb), 4.57 (d, J = 5.3 Hz, 4 H, 17-H 17´-H), 3.79 (m, 2 H, 13-H), 3.76 (dd, J1 = 9.1 Hz, 
J2 = 3.7 Hz, 1 H, 15-H), 3.39 (m, 2 H, 3-H), 3.15 – 3.30 (m, 8 H, 4-H 7-H 8-H 10-H), 3.15 
(dd, J1 = 18.6 Hz, J2 = 9.1 Hz, 2 H), 3.01 (m, 2 H, 1-H, 15´-Ha), 2.90 and 2.87 (q, J = 7.3 Hz, 
1 H, 20-Ha), 2.77 and 2.73 (q, J = 7.3 Hz, 1 H, 20-Hb), 2.48 – 2.56 (m, 2 H, 12-H), 2.50 (dd, 
J1 = 18.6 Hz, J2 = 3.7 Hz, 1 H, 15´-Hb), 1.91 – 2.00 (m, 2 H, 2-H), 1.68 (tt, J1 = 6.0 Hz, 
J2 = 5.8 Hz, 2 H, 9-H), 1.48 – 1.58 (m, 4 H, 5-H 6-H), 1.29 (t, J = 7.3 Hz, 2 H, 21-H); HRMS 
(ESI) [M + H]+ calc. 584.3112, found 584.3100; FAB: 606.2 (13) [M+ + Na], 584.3 (100) 
[M+ + H]. 
 
 
N1-{3-[3-(2-hydroxyethylthio)-2,5-dioxopyrrolidin-1-yl]propanoyl}-N4,N9-bis-
allyloxycarbonyl-spermine trifluoroacetate 
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1H NMR (400 MHz, CDCl3 / CD3OD) d 5.84 (ddt, J1 = 17.2 Hz, J2 = 10.6 Hz, J3 = 5.8 Hz, 
2 H, 18-H 18´-H), 5.21 (d, J = 17.2 Hz, 2 H, 19-Ha 19´-Ha), 5.15 (d, J = 10.6 Hz, 2 H, 19-Hb 
19´-Hb), 4.50 (m, 4 H, 5-H 6-H), 3.81 (dd, J1 = 9.2 Hz, J2 = 3.8 Hz, 1 H, 15-H), 3.73 (t, 
J = 6.2 Hz, 2 H, 13-H), 3.62 – 3.70 (m, 2 H, 21-H), 3.32 – 3.24 (m, 2 H, 3-H), 3.22 – 3.13 (m, 
8 H, 4-H 7-H 8-H 10-H), 3.10 (dd, J1 = 18.8 Hz, J2 = 9.2 Hz, 1 H, 15´-Ha), 2.95 (dt, 
J1 = 14.1 Hz, J2 = 5.8 Hz, 1 H, 20-Ha), 2.83 (t, J = 6.4 Hz, 2 H, 1-H), 2.77 (dt, J1 = 14.1 Hz, 
J2 = 5.8 Hz, 1 H, 20-Hb), 2.50 (dd, J1 = 18.8 Hz, J2 = 3.8 Hz, 1 H, 15´-Hb), 2.40 (t, 
J = 6.2 Hz, 2 H, 12-H), 1.84 (tt, J1 = 6.7 Hz, J2 = 6.8 Hz, 2 H, 2-H), 1.57 – 1.68 (m, 2 H, 9-H), 
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1.42 – 1.48 (m, 4 H, 5-H 6-H); 1H NMR (400 MHz, CD3OD) d 5.94 (ddt, J1 = 17.2 Hz, 
J2 = 10.5 Hz, J3 = 5.4 Hz, 2 H, 18-H 18´-H), 5.30 (ddt, J1 = 17.2 Hz, J2 = 5.0 Hz, J3 = 1.5 Hz, 
2 H, 19-Ha 19´-Ha), 5.21 (ddt, J1 = 10.5 Hz, J2 = 4.5 Hz, J3 = 1.5 Hz, 2 H, 19-Hb 19´-Hb), 
4.58 (d, J = 5.4 Hz, 2 H, 17-H), 4.56 (d, J = 5.4 Hz, 2 H, 17´-H), 3.96 (dd, J1 = 9.1 Hz, 
J2 = 4.0 Hz, 1 H, 15-H), 3.76 (t, J = 6.7 Hz, 2 H, 13-H), 3.76 (m, 2 H, 21-H), 3.38 (t, 
J = 6.8 Hz, 2 H,  3-H), 3.34 – 3.25 (m, 6 H,  4-H 7-H 10-H), 3.19 (dd, J1 = 18.6 Hz, 
J2 = 9.1 Hz, 1 H, 15 -´Ha), 3.14 (t, J = 7.1 Hz, 2 H, 8-H), 3.04 (dt, J1 = 13.6 Hz, J2 = 6.2 Hz, 
1 H, 16-Ha), 2.94 (t, J = 7.2 Hz, 2 H, 1-H), 2.82 (dt, J1 = 13.6 Hz, J2 = 6.4 Hz, 1 H, 16-Hb), 
2.52 (dd, J1 = 18.6 Hz, J2 = 4.0 Hz, 1 H, 15 -´Hb), 2.46 (t, J = 6.7 Hz, 2 H, 12-H), 1.92 (tt, 
J1 = 7.2 Hz, J2 = 6.8 Hz, 2 H, 2-H), 1.68 – 1.78 (m, 2 H, 9-H), 1.52 – 1.59 (m, 4 H, 5-H 6-H); 
HRMS (ESI) [M + H]+ calc. 600.3062, found 600.3040; FAB-MS: 622.4 (10) [M + Na]+, 
600.4 (100) [M + H]+. 
 
 
N1-{3-[3-(2-aminoethylthio)-2,5-dioxopyrrolidin-1-yl]propanoyl}-N4,N9-bis-
allyloxycarbonyl-spermine bis-trifluoroacetate 
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1H NMR (400 MHz, CD3OD) d 5.96 (ddt, J1 = 17.1 Hz, J2 = 10.7 Hz, J3 = 5.5 Hz, 2 H, 
18-H 18´-H), 5.30 (ddt, J1 = 17.1 Hz, J2 = 5.0 Hz, J3 = 1.5 Hz, 2 H, 19-Ha 19´-Ha), 5.21 (ddt, 
J1 = 10.7 Hz, J2 = 5.3 Hz, J3 = 1.5 Hz, 2 H, 19-Hb 19´-Hb), 4.59 (d, J = 5.5 Hz, 2 H, 17-H), 
4.57 (dt, J1 = 5.5 Hz, J2 = 1.5 Hz, 2 H, 17´-H), 3.97 (dd, J1 = 9.3 Hz, J2 = 4.3 Hz, 1 H, 15-H), 
3.72 – 3.80 (m, 2 H, 13-H), 3.38 (t, J = 7.0 Hz, 2 H, 3-H), 3.26 – 3.34 (m, 6 H, 4-H 7-H 
10-H), 3.23 – 3.14 (m, 1 H, 21-H), 3.22 (dt, J1 = 18.5 Hz, J2 = 9.3 Hz, 1 H, 15´-Ha), 3.14 (t, 
J = 6.9 Hz, 2 H, 8-H), 3.04 (dt, J1 = 14.6 Hz, J2 = 6.5 Hz, 1 H, 20-Hb), 2.93 (t, J = 7.4 Hz, 
2 H, 1-H), 2.52 (dd, J1 = 18.5 Hz, J2 = 4.3 Hz, 1 H, 15 -´Hb), 2.45 – 2.50 (m, 2 H, 12-H), 1.91 
(tt, J1 = 7.4 Hz, J2 = 7.0 Hz, 2 H, 2-H), 1.70 – 1.78 (m, 2 H, 9-H), 1.53 – 1.59 (m, 4 H, 5-H 
6-H); HRMS (ESI) [M + H]+ calc. 599.3221, found 599.3215; FAB-MS: 621.4 (8) [M + Na]+, 
599.4 (100) [M + H]+. 
 
 
N1-(3-{3-[(R)-2-acetamido-3-methylpropanoyl-thio]-2,5-dioxopyrrolidin-1-
yl}propanoyl)- N4,N9-bis-allyloxycarbonyl-spermine trifluoroacetate 
 
(R)-methyl 2-acetamido-3-mercaptopropanoate 
300 mg (1.37 mmol) of N,S-diacetyl-L-cysteine methyl ester was dissolved in 14 ml MeOH 
and 96 mg (1.37 mmol, 1.0 equiv.) of sodium thiomethylate were added. The solution was 
stirred for 30 min and the reaction was terminated by addition of 20 mL of 0.1 M HCl. The 
aqueous solution was extracted with CH2C12. The combined organic layers are washed with 
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brine, dried over MgSO4, and filtered. After removal of the solvent, 238 mg (1.34 mmol) of 
the pure compound were obtained giving 98% yield.  
 
1
23
4
HS
NHAc
MeOOC
C6H11NO3S  
 
1H NMR (400 MHz, CD3OD) d 4.63 (dd, J1 = 6.8 Hz, J2 = 4.8 Hz, 1 H, 2-H), 3.75 (s, 3 H, 
3-H), 2.93 (dd, J1 = 13.9 Hz, J1 = 4.8 Hz, 1 H, 1-Ha), 2.85 (dd, J1 = 13.9 Hz, J1 = 6.8 Hz, 1 H, 
1-Hb), 2.02 (s, 3 H, 4-H); MS (EI): 177.0 (12) [M]+, 144.0 (4) [M – (SH)]+, 118.0 (38) [M – 
(COOMe)]+. 
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1H NMR (400 MHz, CD3OD) d 5.95 (ddt, J1 = 17.1 Hz, J2 = 10.5 Hz, J3 = 5.4 Hz, 2 H, 
18-H 18´-H), 5.30 (d, J = 17.1 Hz, 2 H, 19-Ha 19´-Ha), 5.21 (d, J = 10.5 Hz, 2 H, 
19-Hb 19´-Hb), 4.74 (m, 1 H, 21-H), 4.59 (d, J = 5.4 Hz, 2 H, 17-H), 4.57 (d, J1 = 5.4 Hz, , 
17´-H), 3.95 (dd, J1 = 9.1 Hz, J2 = 4.5 Hz, 1 H, 15-H), 3.76 (t, J = 7.1 Hz, 2 H, 13-H), 3.74 (s, 
3 H, 22-H), 3.39 (t, J = 6.8 Hz, 2 H, 3-H), 3.33 – 3.26 (m, 6 H, 4-H 7-H 10-H), 3.25 – 3.12 
(m, 3 H, 15-Ha 20-H), 2.94 (t, J = 7.2 Hz, 2 H, 1-H), 2.46 (t, J = 7.1 Hz, 2 H, 12-H), 2.41 – 
2.51 (m, 1 H, 15´-Hb), 2.00 (s, 3 H, 23-H), 1.91 (tt, J1 = 6.9 Hz, J2 = 6.8 Hz, 2 H, 2-H), 1.78 – 
1.70 (m, 2 H, 9-H), 1.60 – 1.52 (m, 4 H, 5-H 6-H); HRMS (ESI) [M + H]+ calc. 699.3382, 
found 699.3377; FAB-MS: 721.5 (15) [M + Na]+, 699.5 (100) [M + H]+. 
 
 
N1-(3-{3-[(R)-2-acetamido-3-propanoyl-thio]-2,5-dioxopyrrolidin-1-yl}propanoyl)-
N4,N9-bis-allyloxycarbonyl-spermine  
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1H NMR (400 MHz, CDCl3/CD3OD) d 5.88 (ddt, J1 = 17.1 Hz, J2 = 10.5 Hz, J3 = 5.5 Hz, 
2 H, 18-H 18´-H), 5.25 (d, J = 17.1 Hz, 2 H, 19-Ha 19´-H), 5.19 (d, J = 10.5 Hz, 2 H, 
19-Hb 19´-Hb), 4.74 – 4.69 (m, 1 H, 21-H), 4.57 – 4.51 (m, 4 H, 17-H 17´-H), (3.90 (dd, 
J1 = 9.2 Hz, J2 = 3.9 Hz) and 3.85 (dd, J1 = 9.2 Hz, J2 = 3.9 Hz) together 1 H, 15-H), 3.74 (t, 
J = 6.8 Hz, 2 H, 13-H), 3.35 – 3.30 (m, 2 H, 3-H), 3.26 – 3.19 (m, 6 H, 4-H 7-H 10-H), 3.19 – 
3.09 (m, 4 H, 8-H 20-H), 2.91 – 2.84 (m, 1H, 15´-Ha), 2.88 (t, J = 7.1 Hz, 2 H, 1-H), 2.47 – 
2.40 (m, 2 H, 12-H), 2.44 (dd, J1 = 18.6 Hz, J2 = 3.9 Hz, 1 H, 15´-Hb), 2.00 (s, 3 H, 22-H), 
1.87 (tt, J1 = 7.1 Hz, J2 = 6.8 Hz, 2 H, 2-H), 1.73 – 1.63 (m, 2 H, 9-H), 1.54 – 1.47 (m, 4 H, 
5-H 6-H); HRMS (ESI) [M + H]+ calc. 685.3225, found 685.3224. 
 
N1-(3-{3-[(R)-2-amino-3-methylpropanoyl-thio]-2,5-dioxopyrrolidin-1-yl}propanoyl)-
N4,N9-bis-allyloxycarbonyl-spermine bis-trifluoroacetate 
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1H NMR (400 MHz, CD3OD) d 5.96 (ddt, J1 = 17.1 Hz, J2 = 10.3 Hz, J3 = 5.7 Hz, 2 H, 
18-H 18´-H), 5.31 (ddt, J1 = 17.1 Hz, J2 = 5.3 Hz, J3 = 1.4 Hz, 2 H, 19-Ha 19´-Hb), 5.21 (ddt, 
J1 = 10.3 Hz, J2 = 5.3 Hz, J3 = 1.4 Hz, 2 H, 19-Hb 19´-Hb), 4.59 (d, J = 5.7 Hz, 2 H, 17-H), 
4.57 (d, J1 = 5.5 Hz, 2 H, 17´-H), (4.55 (dd, J1 = 8.6 Hz, J2 = 4.5 Hz) and 4.43 (dd, 
J1 = 8.6 Hz, J2 = 4.5 Hz) together 1 H, 21-H), 4.02 (dd, J1 = 9.3 Hz, J2 = 4.4 Hz, 1 H, 15-H), 
3.87 (s, 3 H, 22-H), 3.76 (t, J = 6.9 Hz, 2 H, 13-H), 3.38 (t, J = 7.0 Hz, 2 H, 3-H), 3.34 – 3.27 
(m, 8 H, 4-H 7-H  10-H 20-H), 3.21 (dd, J1 = 18.5 Hz, J2 = 9.3 Hz, 1 H, 15´-Ha), 3.14 (m, 
2 H, 8-H), 2.93 (t, J = 7.3 Hz, 2 H, 1-H), 2.52 (dd, J1 = 18.5 Hz, J2 = 4.4 Hz, 1 H, 15 -´Hb), 
2.52 – 2.45 (m, 2 H, 12-H), 1.91 (tt, J1 = 7.2 Hz, J2 = 7.0 Hz, 2 H, 2-H), 1.79 – 1.70 (m, 2 H, 
9-H), 1.60 – 1.52 (m, 4 H, 5-H 6-H); HRMS (ESI) [M + H]+ calc. 657.3276, found 657.3265. 
 
N1-(3-{3-[(R)-2-amino-3-propanoyl-thio]-2,5-dioxopyrrolidin-1-yl}propanoyl)-N4,N9-
bis-allyloxycarbonyl-spermine bis-trifluoroacetate 
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1H NMR (400 MHz, CD3OD) d 5.96 (ddt, J1 = 17.3 Hz, J2 = 10.6 Hz, J3 = 5.5 Hz, 2 H, 
18-H 18´-H), 5.30 (ddt, J1 = 17.3 Hz, J2 = 4.8 Hz, J3 = 1.4 Hz, 2 H, 19-Ha 19´-Ha), 5.22 (ddt, 
J1 = 10.6 Hz, J2 = 4.8 Hz, J3 = 1.4 Hz, 2 H, 19-Hb 19´-Hb), 4.59 (d, J = 5.5 Hz, 2 H, 17-H), 
4.57 (d, J1 = 5.3 Hz, 2 H, 17´-H), (4.45 (dd, J1 = 8.7 Hz, J2 = 4.3 Hz) and 4.33 (dd, J1 = 
8.7 Hz, J2 = 4.3 Hz) together 1 H, 21-H), 4.03 (dd, J1 = 9.1 Hz, J2 = 4.5 Hz, 1 H, 15-H), 
3.83 – 3.69 (m, 2 H, 13-H), 3.38 (t, J = 6.9 Hz, 2 H, 3-H), 3.34 – 3.26 (m, 8 H, 4-H 7-H  10-H 
20-H), 3.22 (dd, J1 = 18.6 Hz, J2 = 9.1 Hz, 1 H, 15´-Ha), 3.14 (t, J = 6.8 Hz, 2 H, 8-H), 2.93 
(t, J = 7.3 Hz, 2 H, 1-H), 2.53 (dd, J1 = 18.4 Hz, J2 = 4.5 Hz, 1 H, 15´-Hb), 2.52 – 2.45 (m, 
2 H, 12-H), 1.91 (tt, J1 = 7.3 Hz, J2 = 6.9 Hz, 2 H, 2-H), 1.78 – 1.70 (m, 2 H, 9-H), 1.60 – 
1.53 (m, 4 H, 5-H 6-H); HRMS (ESI) [M + H]+ calc. 643.3120 found 643.3117. 
 
 
N1-{3-[3-(phenylthio)-2,5-dioxopyrrolidin-1-yl]propanoyl}-N4,N9-bis-allyloxycarbonyl-
spermine trifluoroacetate 
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1H NMR (400 MHz, CDCl3 / CD3OD) d 7.50 – 7.46 (m, 2 H, 20-H 20´-H), 7.36 – 7.32 (m, 
3 H, 21-H 21´-H 22-H), 5.89 (ddt, J1 = 17.1 Hz, J2 = 10.6 Hz, J3 = 5.5 Hz, 2 H, 18-H 18´-H), 
5.28 (d, J = 17.1 Hz, 2 H, 19-Ha 19´-Hb), 5.23 (d, J = 10.6 Hz, 2 H, 19-Hb 19´-Hb), 4.60 –
 4.53 (m, 4 H, 17-H 17´-H), 4.07 (dd, J1 = 9.1 Hz, J2 = 3.8 Hz, 1 H), 3.69 (t, J = 6.8 Hz, 2 H, 
13-H), 3.43 – 3.35 (m, 2 H, 3-H), 3.32 – 3.15 (m, 8 H, 4-H 7-H 8-H 10-H), 3.17 (dd, 
J1 = 18.9 Hz, J2 = 9.1 Hz, 1 H, 15´-Ha), 3.06 – 2.99 (m, 2 H, 1-H), 2.68 (dd, J1 = 18.9 Hz, 
J2 = 3.8 Hz, 1 H, 15´-Hb), 2.43 (t, J = 6.8 Hz, 2 H, 12-H), 1.98 – 1.89 (m, 2 H, 2-H), 1.74 –
 1.62 (m, 2 H, 9-H), 1.55 – 1.48 (m, 4 H, 5-H 6-H); HRMS (ESI) [M + H]+ calc. 632.3112, 
found 632.3110. 
 
 
N1-(3-{3-[(R)-2-(e-glutamylamido)-3-glycinylpropanoyl-thio]-2,5-dioxopyrrolidin-1-
yl}propanoyl)-N4,N9-bis-allyloxycarbonyl-spermine bis-trifluoroacetate 
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1H NMR (400 MHz, CD3OD) d 5.96 (ddt, J1 = 17.3 Hz, J2 = 10.6 Hz, J3 = 5.4 Hz, 2 H, 
18-H 18´-H), 5.30 (ddt, J1 = 17.3 Hz, J2 = 5.0 Hz, J3 = 1.7 Hz, 2 H, 19-Ha 19´-Hb), 5.22 (ddt, 
J1 = 10.6 Hz, J2 = 5.0 Hz, J3 = 1.7 Hz, 2 H, 19-Hb 19´-Hb), 4.67 – 4.75 (m, 1 H, 21-H), 4.59 
(d, J = 5.4 Hz, 2 H, 17-H), 4.57 (dt, J1 = 5.4 Hz, J2 = 1.5 Hz, 2 H, 17´-H), 4.09 – 4.04 (m, 1 H, 
25-H), 4.01 (dd, J1 = 9.1 Hz, J2 = 3.9 Hz, 1 H, 15´-H), 3.94 (s, 2 H, 22-H), 3.76 (t, J = 6.8 Hz, 
2 H, 13-H), 3.39 (t, J = 6.8 Hz, 2 H, 3-H), 3.33 – 3.26 (m, 6 H, 4-H 7-H 10-H), 3.22 – 3.17 
(m, 1 H, 20-Ha), 3.21 (dd, J1 = 18.5 Hz, J2 = 9.1 Hz, 1 H, 15´-Ha), 3.14 (t, J = 6.8 Hz, 2 H, 
8-H), 2.94 (t, J = 7.4 Hz, 2 H, 1-H), 2.94 – 2.88 (m, 1 H, 20-Hb), 2.60 (t, J = 7.1 Hz, 2 H, 
12-H), 2.53 (dd, J1 = 18.5 Hz, J2 = 3.9 Hz, 1 H, 15´-Hb), 2.47 (t, J = 6.8 Hz, 2 H, 24-H), 
2.30 – 2.14 (m, 2 H, 23-H), 1.91 (tt, J1 = 7.4 Hz, J2 = 6.8 Hz, 2 H, 2-H), 1.79 – 1.68 (m, 2 H, 
9-H), 1.60 – 1.52 (m, 4 H, 5-H 6-H). 
 
6.6.2 Compatibility of maleimido-thiol coupling and Aloc protection 
strategy 
6.6.2.1 Removal of Aloc groups after coupling of maleimide and thiol 
 
N1-(3-{3-[(R)-2-acetamido-3-methylpropanoyl-thio]-2,5-dioxopyrrolidin-1-
yl}propanoyl)-spermine tris-trifluoroacetate (280) 
1 equiv. of resin 277 was swollen in DMF and the solvent was removed. 1.5 equiv. of N-
acetyl-L-cysteine methyl ester were added and the solids were suspended by 2 mL of DMF. 
The suspension was added for 3 h and the resin was washed with DMF, THF : water (10 : 1) / 
MeOH, and CH2Cl2. The resin 279 was Aloc-deprotected with N,N´-DMBA as described 
above. The resin was treated with 10% TFA in CH2Cl2 and the cleavage mixture was 
combined with washings of CH2Cl2 and MeOH. The solvents were removed and the solid was 
dried on HV to remove remains of TFA. The crude product was purified by RP-HPLC with a 
gradient of water / MeCN / HOAc. 
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1H NMR (400 MHz, CD3OD) d 4.77 – 4.70 (m, 1 H, 17-H), (3.98 (dd, J1 = 9.1 Hz, 
J2 = 3.7 Hz) and 3.97 (dd, J1 = 9.1 Hz, J2 = 3.7 Hz) together 1 H, 15-H), 3.78 (t, J = 6.9 Hz, 
2 H, 13-H), 3.75 (s, 3 H, 18-H), 3.31 – 2.90 (m, 15 H, 1-H 3-H 4-H 7-H 8-H 10-H 15 -´Ha 
16-H), 2.50 (t, J = 6.9 Hz, 2 H, 12-H), 2.48 (dd, J1 = 18.4 Hz, J2 = 3.7 Hz, 1 H, 15´-Hb), 2.14 
– 2.04 (m, 2 H, 2-H), 2.00 (s, 3 H, 19-H), 1.92 – 1.78 (m, 2 H, 9-H), 1.82 – 1.71 (m, 4 H, 5-H 
6-H); HRMS (ESI) [M + H]+ calc. 531,2959, found 531.2943. 
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6.6.2.2 Deprotection of Aloc in the presence of maleimides 
 
Investigation of maleimide stability 
 
N3-(3-N-maleimidopropionyl)-1,3-diaminopropane (281) 
900 mg (1.17 mmol) of 2-chlorotrityl resin (60) were swollen in CH2Cl2 and after removal 
of the solvent a solution of 4.50 g (17.4 mmol; 14.8 equiv.) of N3-(2-nitrophenylsulfonyl)-1,3-
diaminopropane (188) and 408 µl (2.34 mmol; 2 equiv.) of DiPEA in 30 mL CH2Cl2 was 
added. The suspension was agitated for 27 h and 10 mL of MeOH were added 15 min prior 
termination. The resin was washed with CH2Cl2 / MeOH and CH2Cl2. The resin was o-Nosyl 
deprotected. To 630 µmol of the resin was added a solution of 1.01 g (3.78 mmol; 6 equiv.) of 
3-N-maleimidopropionyl succinate 196 and 440 µl (2.53 mmol; 4 equiv.) of DiPEA in 12 mL 
DMF. The suspension was agitated for 17 h and was then washed with water : THF (1 : 10), 
THF / MeOH and CH2Cl2. 
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1H NMR (400 MHz, CDCl3) d 6.65 (s, 2 H, 6-H 6´-H), 3.75 (t, J = 6.8 Hz, 2 H, 5-H), 3.21 
(t, J = 6.3 Hz, 2 H, 3-H), 2.90 (t, J = 6.8 Hz, 2 H, 1-H), 2.45 (t, J = 6.8 Hz, 2 H, 4-H), 1.79 (tt, 
J1 = 6.8 Hz, J2 = 6.3 Hz, 2 H, 2-H) 
 
 
General procedure  
After swelling, 50 mg of the resin were treated with a solution of scavenger and Pd catalyst 
in the respective solvent. The suspension was agitated under avoidance of light and then the 
resin was washed with CH2Cl2 / MeOH and CH2Cl2. After cleavage from the resin, the 
product was analyzed by 1H NMR without further purification. 
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Table 14 Reaction conditions applied to resin 281. 
Scavenger 
Excess of 
scavenger in 
equiv. 
Amount of 
Pd(PPh3)4 in mol% 
Solvent 
Reaction 
time in 
min 
- - 4 / 10 / 40 THF 30 
- - 40 THF 120 
Pyrrolidine 10 20 THF 30 
Dimedone 8 10 THF 30 
N,N’-Dimethylbarbituric acid 10 15 CH2Cl2 60 
PhSiH3 6 10 THF 30 
Bu3SnH / HOAc 3 / 3 8 CH2Cl2 5 
Bu3SnH 7 20 CH2Cl2 30 
HOBt 6 10 DMF 30 
N-Hydroxysuccinimide 8 20 THF 30 
NaN3 5 10 DMF 30 
HOAc 20 20 THF 30 
Water 50 20 THF 30 
 
 
Synthesis of resin 285 
 
Na-Fluorenylmethyloxycarbonyl-Ne-allyloxycarbonyl-L-lysine resin 282 
340 mg (0.44 mmol) of 2-chlorotrityl resin (60) were swollen in CH2Cl2 and after removal 
of the solvent a solution of 1.00 g (2.20 mmol; 5 equiv.) of Na-fluorenylmethyloxycarbonyl-
Ne-allyloxycarbonyl-L- lysine and 116 µl (663 µmol; 1.5 equiv.) of DiPEA in 12 mL CH2Cl2 
was added. The suspension was agitated for 26 h and 4 mL of MeOH were added 15 min 
prior termination. The resin was washed with CH2Cl2 / MeOH and CH2Cl2. After drying on 
high vacuum, the product was cleaved from 50 mg of the resin 282 to confirm the identity of 
the immobilized substrate. The loading was determined to be approximately 0.4 mmol / g 
resin. 
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1H NMR (400 MHz, CDCl3) d 7.75 (d, J = 7.3 Hz, 2 H, 14-H 14´-H), 7.62 – 7.55 (m, 2 H, 
11-H 11´-H), 7.39 (ddd, J1 = 7.3, J2 = 7.0, J3 = 5.8, 2 H, 13-H 13´-H), 7.30 (ddd, J1 = 7.3, 
J2 = 7.0, J3 = 6.3, 2 H, 12-H 12´-H), 6.09 – 5.81 (m, 1 H, 2-H), 5.34 – 5.14 (m, 2 H, 1-H), 
4.66 – 4.59 (m, 1 H, 10-H), 4.59 – 4.48 (m, 2 H, 9-H), 4.40 (d, J = 5.8 Hz, 2 H, 3-H), 4.20 (t, 
J = 5.9 Hz, 1 H, 8-H), 3.24 – 3.10 (m, 2 H, 4-H), 1.96 – 1.81 (m, 1 H, 7-Ha), 1.81 – 1.69 (m, 
1 H, 7-Hb),  1.58 – 1.47 (m, 2 H, 5-H), 1.47 – 1.35 (m, 2 H, 6-H). 
 
Na-(3-N-Maleimidopropionl)-Ne-allyloxycarbonyl-L-lysine resin 284 
Resin 282 was Fmoc-deprotected. A solution 327 mg (1.02 mmol; 7.2 equiv.) of 
3-N-maleimido-propionyl succinate 196 and 118 µl (680 µmol; 4 equiv.) of DiPEA in 8 mL 
DMF were added to the resin and the suspension was agitated for 20 h. After washing with 
THF : MeOH (4 : 1) / MeOH and CH2Cl2 and drying in HV, a white resin was obtained. The 
product was cleaved from 50 mg of the resin to confirm the identity of the immobilized 
substrate. The loading was determined to be 0.41 mmol / g resin. 
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1H NMR (400 MHz, CDCl3) d 6.71 (s, 2 H, 11-H, 11´-H), 5.97 – 5.83 (m, 1 H, 2-H), 5.29  
(d, J = 17.1 Hz, 1 H, 1-Ha), 5.20  (d, J = 10.3 Hz, 1 H, 1-Hb), 4.63 – 4.57 (m, 1 H, 8-H), 4.57 
– 4.51 (m, 2 H, 3-H), 3.87 – 3.80 (m, 2 H, 10-H), 3.24 – 3.13 (m, 2 H, 7-H), 2.60 (t, 
J = 6.8 Hz, 2 H, 9-H), 1.92 – 1.80 (m, 1 H, 6-Ha), 1.80 – 1.68 (m, 1 H, 6-Hb), 1.52 (tt, 
J1 = 6.5 Hz, J2 = 6.5 Hz, 2 H, 5-H), 1.38 (tt, J1 = 6.8 Hz, J2 = 6.8 Hz, 2 H, 6-H); HRMS (ESI) 
[M + H]+ calc. 404,1428, found 404,1428. 
 
Aloc removal from resin 284 
 
General procedure  
The deprotection was carried out under the same conditions as described for the stability 
tests of the maleimide. However, due to the interaction of maleimide and catalyst, the amount 
of Pd(PPh3)4 was raised to 1.2 equiv. The successful experiment is described below. 
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Na-(3-N-maleimidopropiopnyl)-lysine 285 
50 mg (20 µmol) of the resin were swollen in THF and after removal of the solvent a 
solution of 43 µl (160 µmol; 8 equiv.) of tributyltinhydride and 28 mg (24 µmol; 1.2 equiv.) 
of Pd(PPh3)4 in 2 mL THF were added. The suspension was agitated for 5 h in the absence of 
light. The resin was washed with 10% HOAc in CH2Cl2 and CH2Cl2 / MeOH and the crude 
was cleaved from the resin with 10% TFA in CH2Cl2. The drained cleavage mixture was 
combined with washings of CH2Cl2 and MeOH and after removal of the solvent and drying 
on high vacuum the substance was purified by RP-HPLC (92% purity, detection at 214 nm). 
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HRMS (ESI) [M + H]+ calc. 298,1397, found 298,1397. 
 
 
 Aloc removal from resin 277 
General procedure  
The good procedure for the removal of the Aloc group from resin 284 was applied. 
Additional experiments were carried out as described below:  
Table 15 Conditions applied to resin 277. 
Scavenger 
Excess of 
scavenger in 
equiv. 
Amount of 
Pd(PPh3)4 in 
mol% 
Solvent 
Reaction 
time in 
min 
Formic acid / pyridine / 
N-hydroxysuccinimide 
8 / 8 / 8 80 THF 240 
HsnBu3 / DMBA 8 / 2 40 THF 240 
PhSiH3 / TmsCl 8 / 8 40 THF 240 
Dimedone 8 50 THF 960 
HOAc 40 4 * 110 CH2Cl2 300 
HOAc / N-ethylmorpholine 40 / 10 4 * 50 CH2Cl2 240 
HSnBu3 8 120 THF 180 
Tritylsulfide 4 120 THF 240 
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6.6.3 Application of 2-Iminothiolane for Polyamine-SPS 
6.6.3.1 Optimisation of the reaction 
 
Optimisation of solvent system 
500 mg of chlorotrityl resin (60) were loaded with 1-(2-nitrophenylsulfonamido)-1,3-
diaminopropane 188 and o-Nosyl deprotected. 50 mg (27 µmol) of the resin were swollen in 
the respective solvent. The solvent was removed and 7.5 mg (55 µmol; 2 equiv.) of 
2-iminothiolane (296) were added to the resin. 2 mL of the solvent or the solvent mixture 
were added and the suspension was agitated for 13 h. The solvent was removed and the resin 
was washed with water, THF / MeOH and CH2Cl2. The product was cleaved from the resin. 
After removal of the solvents and drying on HV the products were analyzed by 1H NMR. 
 
Optimisation of reaction protocol 
50 mg (34 µmol) of 155 were suspended in 1 mL THF. Ethylmaleimide and 2- iminothiolane 
(296) were dissolved in 0,5 mL THF or 200 µl water respectively and added to the suspension 
at the particular times and in the particular amounts. The volume was filled up to 2 mL 
solvent and the suspension was agitated for 15 h. After removal of the solvent, the resin was 
washed with water, THF / MeOH and CH2Cl2. The product was cleaved from the resin. After 
removal of the solvents and drying on HV the products were analyzed by 1H NMR and ESI-
MS. 
 
(E)-N1-(dihydrothiophen-2(3H)-ylidene)propane-1,3-diamine  bis-trifluoroacetate 301 
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1H NMR (400 MHz, CD3OD): d = 3.69 (t, J = 7.1 Hz, 2 H, 4-H), 3.65 (t, 2 H, J = 6.7 Hz, 
6-H), 3.26 (t, 2 H, J = 7.3 Hz, 3-H), 3.09 (t, 2 H, J = 7.5 Hz, 1-H), 2.44 (tt, 2 H, J1 = 7.1 Hz,  
J2 = 6.7 Hz, 5-H), 2.18 (tt, 2 H, J1 = 7.5 Hz, J2 = 7.3 Hz, 2-H); MS (ESI): 159.1 [M + H]+. 
 
3-(3-aminopropylamino)-1-ethylpyrrolidine -2,5-dione bis-trifluoroacetate 303 
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1H NMR (400 MHz, CD3OD): d = 4.45 (dd, J1 =9.2 Hz, J2 = 5.7 Hz, 1 H, 5-H), 3.57 (q, 
J = 7.3 Hz, 7-H), 3.16 (dd, J1 = 17.9 Hz, J2 = 9.2 Hz, 1 H, 6-Hb), 3.08 (t, J = 7.6 Hz, 2 H, 
3-H), 3.05 (t, J = 7.7 Hz, 2 H, 1-H), 2.91 (dd, J1 =17.9 Hz, J2 = 5.7 Hz, 1 H, 6-Hb), 2.13 (m, 
2 H, 2-H), 1.17 (t, J = 7.3 Hz, 8-H); HRMS (ESI) [M + H]+ calc. 200.1399, found 200.1406. 
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4-(1-ethyl-2,5-dioxopyrrolidin-3-ylthio)-N-(3-aminopropyl)butanamidine bis-
trifluoroacetate 304 
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1H NMR (400 MHz, CD3OD): d = 3.89 (dd, J1 = 9.1 Hz,  J2 = 3.3 Hz, 1 H, 7-H), 3.52 (q, 
J = 7.2 Hz, 2 H, 9-H), 3.38 (t, J = 7.1 Hz, 2 H, 3-H), 3.19 (dd, J1 = 18.5 Hz, J2 = 9.1 Hz, 1 H, 
8-Ha), 3.03 (t, J = 7.4 Hz, 2 H, 1-H), 2.97 (dd, J1 = 13.5 Hz, J2 = 7.1 Hz, 1 H, 6-Ha), 2.79 (dd, 
J1 = 13.5 Hz, J2 = 7.1 Hz, 1 H, 6-Hb), 2.61 (t, J = 7.5 Hz, 2 H, 4-H), 2.46 (dd, J1 = 18.6 Hz, 
J2 = 3.3 Hz, 1 H, 8-Hb), 2.08 (tt, J1 = 7.4 Hz, J2 = 7.1 Hz, 2 H, 2-H), 2.01 (tt, J1 = 7.5 Hz, 
J2 = 7.1 Hz, 2 H, 5-H), 1.13 (t, J = 7.2 Hz, 3 H, 10-H) – HRMS (ESI) [M + H]+ calc. 
301.1693 found 301.1686. 
 
 
6.6.3.2 Synthesis of maleimides 
 
N3-(3-N-maleimidopropionyl)-N1-(2-nitrophenylsulfonamido)-1,3-diaminopropane 
(309) 
308 mg (1.16 mmol; 3 equiv.) of 3-maleimidopropionic acid N-hydroxysuccinimide ester 
196 were dissolved in DMF and 100 mg (386 µmol; 1 equiv.) of 
1-(2-nitrophenylsulfonamido)-1,3-diaminopropane 188 and 162 µl (1.16 mmol; 3 equiv.) of 
Et3N were added in the same volume of THF. The suspension was stirred for 2 d and THF 
was removed in vacuum. The remaining suspension was partitioned between CHCl3 and water 
and the organic layer was three times washed with a solution of 1% HOAc in water. The 
organic layer was dried over Na2SO4 and the product was purified by flash chromatography 
on silica gel. (CHCl3 to CHCl3 : MeOH (5 : 1)). 74 mg of the product 309 were isolated giving 
47% yield. 
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1H NMR (400 MHz, CDCl3): d = 7.09 – 7.12 (m, 1 H, 11-H), 7.70 – 7.84 (m, 3 H, 12-H 
13-H 14-H), 6.73 (s, 2 H, 8-H 8´-H), 3.75 (t, J = 7.1 Hz, 2 H, 6-H), 3.17 (t, J = 6.7 Hz, 2 H, 
3-H) and 3.05 (t, J = 6.7 Hz, 2 H, 1-H), 2.43 (t, J = 7.1 Hz, 2 H, 5-H), 1.65 (tt, J1 = 6.7 Hz,  
J2 = 6.6 Hz, 2 H, 2-H); 13C NMR (75 MHz, CDCl3) d 172.3 (Cquart,  C-4), 171.5 (Cquart, 
C-7 C-7´), 148.8 (Cquart, C-10), 134.9 (+, C-8 C-8´), 134.4, 134.3, 133.2, 131.1, 125.6 (Cquart 
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and +, C-9 C-11 C-12 C-13 C-14), 41.3 (–, C-1), 36.9 (–, C-6), 35.3 (–, C-3), 29.8 (–, C-5, 
splitted and broadened signal), 26.1 (–, C-2); HRMS (ESI) [M + Na]+ calc. 433.0788, found 
433.0781.  
 
N4-Actyl-2´-deoxy-O5´-di-p-methoxytrityl cytidine (311) 
To a solution of 5.00 g 2´-deoxycytidine (19.0 mmol) (310) in 190 mL DMF was added 
1.80 mL acetic anhydride (19.00 mmol; 1 equiv) and 3.4 mL Et3N (38.0 mmol; 2 equiv.). 
After the mixture had been stirred at room temperature for 6 h, the solvent was removed under 
reduced pressure. The resulting residue was dissolved 20 mL pyridine and the solvent was 
removed by evaporation (two times). The crude product was dissolved in 180 mL pyridine 
and 8.37 g of 4,4’-dimethoxytritylchlorid (24.7 mmol; 1.3 equiv.) were added. The mixture 
was stirred at room temperature for 4 h and the solvent was evaporated. The remaining 
residue was partitioned between 100 mL CHCl3 and 100 mL of 5% aqueous NaHCO3. The 
aqueous phase was extracted three times with 35 mL CHCl3. The organic phase was dried 
over Na2SO4 and the solvent was removed in vacuum. The product was purified by flash 
chromatography on silica gel (CHCl3 to CHCl3 : MeOH (20 : 1)). 8.03 g of a yellow foam 
were obtained, giving 74% yield. 
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Rf = 0.31 (CHCl3 : MeOH - 11 : 1); 1H NMR (400 MHz, CDCl3) d 9.00 (bs, 1 H, OH), 8.22 
(d, 3J = 7.4 Hz, 1 H, 4-H), 7.39 (d, 3J = 7.4 Hz, 1 H, 3-H), 6.80 – 7.33 (m, 13 H, 
(8-H to 14´´´-H)), 6.27 (t, 3J = 5.8 Hz, 1 H, 1´-H), 4.50 (t, 3J = 5.3 Hz, 1 H, 3´-H), 4.13 (dt,  
3J = 3.6 Hz, 3J = 6.4 Hz, 1 H, 4´-H), 3.80 (s, 6 H, 16-H 16´-H), 3.49 (dd, 2J = 10.8 Hz, 
3J = 3.6 Hz, 1 H, 5´-Ha), 3.41 (dd, 2J = 10.8 Hz, 3J = 3.6 Hz, 1 H, 5´-Hb), 2.75 (ddd, 
2J = 13.6 Hz, 3J = 5.8 Hz, 3J = 5.3 Hz, 1 H, 2´-Ha), 2.23 (m, 1 H, 2´-Hb), 2.20 (s, 3 H, 6-H);  
13C NMR (100 MHz, CDCl3), d 170.67 (Cquart, C-5); 162.58 (+, C-1); 155.69 (Cquart, C-2); 
158.78, 144.75, 135.58, 135.44, 130.18, 130.15, 128.20, 128.14, 127.22, 113.43 (Cquart and +, 
18 C, C-8 C-9 C-9´ C-10 C-10´ C-11 C-12 C-12´ C-13 C-13´ C-13´´ C-13´´´ C-14 C-14´ 
C-14´´ C-14´´´ C-15 C-15´); 144.42 (+, C-4); 96.72 (+, C-3); 87.45 (+, C-4’); 87.03 (Cquart , 
C-7); 86.59 (+, C-1’); 71.02 (+, C 3’);  62.88 (–, C-5’); 55.30, 55.32 (+, C-16 C-16´); 42.16 (–
,  C-2’); 24.97 (+, C-6); MS (EI): 571.2 [M]+ (5), 528.2 [M-C2H3O]+ (5), 303.1 [DMTr]+ 
(100); FAB-MS: 572.2 [M+H]+ (61), 303.1 [DMTr]+ (100); 
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2´-Deoxy-O5´-di-p-methoxytrityl-cytidine (312) 
A solution of 1.00 g (1.76 mmol) of N4-Actyl-2´-deoxy-O5´-di-p-methoxytrityl cytidine 
(311) and 200 mg (1.45 mmol; 0.8 equiv.) of K2CO3 in 22 mL MeOH was stirred for 24 h. 
The colour of the solution turned to purple. The solvent was removed and the resulting yellow 
foam was partitioned between 30 mL CHCl3 and 20 mL 5% aqueous NaHCO3. The aqueous 
layer was extracted three times with 20 mL CHCl3. After removal of the solvent, the crude 
product was purified by flash chromatography on silica gel (CHCl3 : MeOH (25 : 1) to CHCl3 
: MeOH (10 : 1)). 730 mg of a white foam were obtained, giving 78% yield. 
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Rf = 0.30 (CHCl3 : MeOH - 10 : 1); FAB-MS: 303.0 [trityl]+(100), 530.1 [M + H]+ (56), 
552.1 [M + Na]+ (20), 1059.5 [2 M + H]+ (35). 
 
2´-Deoxy-O5´-di-p-methoxytrityl-N4-(3-N-maleimidopropionyl)-amino-cytidine (313) 
To a solution of 505 mg of 3-N-maleimidopropionic acid (2.99 mmol; 1.7 equiv.) in 18 mL 
CH2Cl2 was added 403 mg (2.99 mmol; 1.7 equiv.) of HOBt, 37 mg (299 µmol; 0.1 equiv.) of 
DMAP, and 616 mg (2.99 mmol; 1.7 equiv.) of 1,3-dicyclohexylcarbodiimide in 2 mL 
CH2Cl2. The solution was stirred for 2 h whereas the colour of the solution turns to red. The 
suspension was filtrated and the filtrate was directly passed into a solution of 930 mg 
(1.76 mmol; 1 equiv.) of 312 and 293 µl (2.90 mmol; 1.7 equiv.) of Et3N in 80 mL CH2Cl2. 
The red solution was stirred for 120 min and was then washed with brine. The aqueous layer 
was extracted three times with CH2Cl2 and the combined organic layers were dried over 
Na2SO4. The solvent was removed and the remaining solid was purified by flash 
chromatography on silica gel (CHCl3 : MeOH (15 : 1) to CHCl3 : MeOH (10 : 1)). 586 mg of 
a white foam were obtained, giving 49% yield. 
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Rf = 0.48 (CHCl3 : MeOH - 10 : 1); 1H NMR (400 MHz, CDCl3), d 9.70 (bs, 1 H, NH), 8.11 
(d, 3J = 7.5 Hz, 1 H, 4-H), 7.34 – 6.72 (m, 14 H, (3-H 11-H to 17´´ -´H)), 6.61 (s, 2 H, 9-H 
9´-H), 6.17 (t, 3J = 5.8 Hz, 1 H, 1´-H), 4.42 (dt, 3J = 4.5 Hz, 3J = 4.9 Hz, 1 H, 3´-H), 4.08 (dt, 
J1 = 4.5 Hz, J2 = 3.6 Hz,1 H, 4´-H), 3.80 (t, 3J = 7.1 Hz, 2 H, 7-H), 3.71 (s, 6 H, 19-H 19´-H), 
3.38 (dd, 2J = 10.7 Hz, 3J = 3.6 Hz, 1 H, 5´-Ha), 3.30 (dd, 2J = 10.7 Hz, 3J = 3.6 Hz, 1 H, 
5´-Hb), 2.94 – 2.84 (m, 1 H, 2´-Ha), 2.79 – 2.68 (m, 2 H, 6-H), 2.19 – 2.11 (m, 1 H, 2´-Hb); 
13C NMR (100 MHz, CDCl3) d 170.6 (Cquart , C-8 C-8´); 162.5 (Cquart , C-2); 158.8 (Cquart , 
C-18 C-18´); 155.7 (Cquart, C-1); 144.7 (Cquart, C-11), 144.4 (+, C-4); 134.4 (Cquart, 
C-15 C-15´); 130.1, 130.2, 128.2, 128.1, 127.2 (Cquart and +, 9 C, C-12 C-12´ C-13 C-13´ 
C-14 C-16 C-16´ C-16´´ C-16´´´); 135.7, 135.6 (+, C-9 C-9´); 113.5 (+, C-17 C-17´ 
C-17´´ C-17´´´ );  96.9 (+, C-3); 87.6 (+, C-4’); 87.0 (Cquart , C-10); 86.6 (+, C-1’); 71.0 (+, 
C 3’); 63.0 (–, C-5’); 55.4 (+, C-19 C-19´); 42.1 (–, C-2’); 35.8 (–, C-7); 33.6 (–, C-6); MS 
(ESI): 703.20 [M + Na]+ (100), 1383.43 [2 M + Na]+ (2). 
 
 
3´-Deoxy-3´-(3-N-maleimidopropylamido)-thymidine (319) 
57 mg (236 µmol) of aminothymidine 318 and 138 mg (523 µmol; 2.2 equiv.) of 196 were 
dissolved in 2 mL DMF and 91 µl of DiPEA were added under stirring. The solution was 
stirred for 16 h and the solvent was removed in HV. The mixture was purified by flash 
chromatography on silica gel. (CHCl3 : MeOH (10 : 1)) 32 mg of a white solid were obtained, 
giving 35% yield. 
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Rf = 0.31 (CHCl3 : MeOH - 10 : 1); 1H NMR (400 MHz, CD3OD), d 7.87 (s, 1 H, 2-H), 6.82 
(s, 2 H, 5-H 5´-H), 6.19 (t, J = 6.3 Hz, 1 H, 1´-H), 4.42 (ddd, J1 = 7.6 Hz, J2 = 6.0 Hz, 
J3 = 5.8 Hz, 1 H, 4´-H), 3.87 – 3.69 (m, 3 H, 3´-H 5´-H), 3.79 (t, J = 6.8 Hz, 2 H, 4-H), 2.47 
(t, J = 6.8 Hz, 2 H, 3-H), 2.35 – 2.20 (m, 2 H, 2´-H), 1.89 (s, 3 H, 1-H); HRMS (ESI) [M + 
H]+ calc. 393,1405 found 393,1401.  
 
 
6.6.3.3 Coupling of spermine and maleimides via 2-iminothiolane (296) 
Synthesis of non cross-linked spermine on alkoxytrityl resin 61 
1 g (0.7 mmol) of activated alkoxytrityl resin 61 were loaded with tris-Aloc-spermine 179 
and 100 mg portions were Aloc-deprotected with Pd(PPh3)4 and N,N´-DMBA. 
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The 1H NMR spectrum of the cleaved product was in accordance with those of protonated 
samples of commercially purchased spermine (16). 
 
General procedure 
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27 µmol of the resin 321 were swollen in 1 mL of THF for 10 min and 11 mg (81 µmol, 
3 equiv.) of 2- iminothiolane (296) in 200 µl of water were added. The suspension was 
agitated for 2 min. 2 equiv. of the respective maleimide in 800 µl THF were added and it was 
agitated for 1 h. The resin was washed with water, THF / MeOH and CH2Cl2. The crude 
product was cleaved from the resin with 1% TFA in CH2Cl2. The filtrate was combined with 
the drained washings of CH2Cl2 and MeOH. In Entry 5 the 5’-DMTr group was removed by 
quick treatment of the resin with 1% TFA in dichloromethane and subsequent washing of the 
polymer with a minimal amount of CH2Cl2 / Et2O (2 : 1) until the filtrate was clear. The 
product was washed from the resin with CH2Cl2 and MeOH. The solvents were removed and 
the remaining compound was purified by preparative HPLC on C18 column with gradients of 
eluant A (95% TEAA (0.01 M, pH 7.0) / 5% acetonitrile) and eluant B (5% TEAA (0.01 M, 
pH 7.0) / 95% acetonitrile) or with eluant A (95% water / 5% acetonitrile / 0.1% HOAc) and 
eluant B (5% water / 95% acetonitrile / 0.1% HOAc). 
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N1-(4-thio-S-(1-ethylpyrrolidine -2,5-dione-3-yl)-butyramidinyl)-spermine  
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1H NMR (400 MHz, CD3OD): d = 3.90 (dd, J1 = 9.1 Hz, J2 = 3.9 Hz, 1 H, 14-H) 3.53 (q, 
J = 7.3 Hz, 2 H, 16-H), 3.40 (t, J = 7.1 Hz, 2 H, 10-H), 3.19 (dd, 1 H, J1 = 18.5 Hz, 
J2 = 9.1 Hz, 15-Hb), 3.00 – 3.15 (m, 10 H, 1-H 3-H 4-H 7-H 8-H), 2.98 (dt, J1 = 13.6 Hz,  
J2 = 7.1 Hz, 1 H, 13-Ha), 2.80 (dt, J1 = 13.5 Hz, J2 = 7.1 Hz, 1 H, 13-Hb), 2.62 (t, J = 7.7 Hz, 
2 H, 11-H), 2.47 (dd, J1 = 18.5 Hz, J2 = 3.9 Hz, 1 H, 15-Hb), (2.13 (m, 2 H) and 2.06 (tt, 
J1 = 7.7 Hz, J2 = 7.1 Hz, 4 H, 12-H) and 2-H 9-H), 1.79 (m, 4 H, 5-H 6-H), 1.14 (t, 
J = 7.3 Hz, 3 H, 17-H); HRMS (ESI) [M + H]+ calc. 429.3006, found 429.3010.  
 
 
N1-(4-thio-S-(1-phenylpyrrolidine-2,5-dione-3-yl)-butyramidinyl)-spermine  
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1H NMR (400 MHz, CD3OD): d = 7.54 – 7.26 (m, 5 H, 16-H to 18-H), 4.10 (dd, 
J1 = 9.1 Hz, J2 = 3.8 Hz, 1 H, 14-H), 3.40 – 3.32 (m, 1 H, 15-Ha), 3.39 (t, J = 6.5 Hz, 2 H, 
10-H), 3.10 – 2.93 (m, 11 H, 1-H 3-H 4-H 7-H  8-H 15-Ha), 2.86 (dt, J1 = 13.6 Hz,  
J2 = 7.1 Hz, 1 H, 13-Hb), 2.70 – 2.60 (m, 3 H, 11-H 15-Hb), 2.14 – 1.96 (m, 6 H, 2-H 9-H 
12-H), 1.79 (bm, 4 H, 5-H 6-H); HRMS (ESI) [M + H]+ calc. 477.3006, found 477.3002.  
 
 
N1-(4-thio-S-(1-(3-carboxypropyl)-pyrrolidine-2,5-dione-3-yl)-butyramidinyl)-
spermine 
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HRMS (ESI) [M + H]+ calc. 473.2905, found 473.2907. 
 
Experimental section 
 203
N1-(4-thio-S-(1-(4-aza-3-oxyheptyl-7-o-Nosylsulfonamido)-pyrrolidine-2,5-dione-3-yl)-
butyramidinyl)-spermine  
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1H NMR (400 MHz, CD3OD): d = 8.11 – 7.80 (m, 4 H, 21-H 22-H 23-H 24-H), 3.90 (dd, 
J1 = 9.2 Hz,  J2 = 3.8 Hz, 1 H, 14-H), 3.83 – 3.68 (m, 2 H, 16-H), 3.42 (t, J = 7.1 Hz, 2 H, 
10-H), 3.04 – 3.24 (m, 15 H, 1-H 3-H 4-H 7-H 8-H 15-Ha 18-H 20-H), 2.93 (dt, J1 = 13.9 Hz,  
J2 = 6.9 Hz, 1 H, 13-Ha), 2.82 (dt, J1 = 13.9 Hz, J2 = 6.5 Hz, 1 H, 13-Hb), 2.70 – 2.44 (m, 
4 H, 11-H 17-H), 2.50 (dd, J1 = 17.9 Hz, J2 = 3.8 Hz, 1 H, 15-Hb), 2.14 – 2.00 (bum, 6 H, 2-H 
9-H 12-H), 1.88 – 1.73 (bum, 4 H, 5-H 6-H), 1.67 (tt; J1 = 6.7 Hz, J2 = 6.7 Hz, 2 H, 19-H); 
HRMS (ESI) [M + 2 H]2+ calc. 357.6749, found 357.6736.  
 
 
N1-(4-thio-S-(1-(3-oxy-3-(N4-(2´-deoxycytidine)-propyl)-pyrrolidine-2,5-dione-3-yl)-
butyramidinyl)-spermine  
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1H NMR (400 MHz, CD3OD): d = 8.39 (b, J = 7.8 Hz, 1 H, 19-H), 6.22 (m, 1 H, 20-H), 
6.09 (d, J = 7.8 Hz, 1 H, 18-H), 4.39 (dt, J1 = 6.8 Hz, J2 = 6.5 Hz, 1 H, 23-H), 4.03 (dt, 
J1 = 6.8 Hz, J2 = 3.5 Hz, 1 H,22-H), 3.93 (dd, J1 = 9.0 Hz,  J2 = 3.9 Hz, 1 H, 14-H), 3.90 – 
3.70 (m, 4 H, 16-H 24-H), 3.42 (t, J = 6.9 Hz, 2 H, 10-H), 3.30 – 3.00 (m, 12 H, 1-H 3-H 4-H 
7-H 8-H 13-Ha 15-Ha), 2.95 (dt, J1 = 13.1 Hz, J2 = 6.5 Hz, 1 H, 13-Hb), 2.81 (m, 2 H, 11-H), 
2.68 – 2.58 (m, 3 H, 15-Hb 17-H), 2.50 (m, 1 H, 21-Ha), 2.21 (m, 1 H, 21-Hb), 2.18 – 2.00 
(bum, 6 H, 2-H 9-H 12-H), 1.80 – 1.90 (m, 4 H, 5-H 6-H); MS (ESI): 682.36 [M + H]+, MS 
(FAB pos.): 682.4 [M + H]+. 
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N1-(4-thio-S-(1-(3-oxy-3-(3´-(3´-deoxy-3´-aminothymidine))-propyl)-pyrrolidine-2,5-
dione-3-yl)-butyramidinyl)-spermine  
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1H NMR (400 MHz, CD3OD): d = 7.87 (s, 1 H, 23-H), 6.21 (m, 1 H, 18-H), 4.42 (dt, 
J1 = 7.1 Hz, J2 = 6.4, 1 H, 19-H), 3.97 – 3.70 (m, 5 H, 16-H 18-H 20-H), 3.45 – 3.37 (m, 2 H, 
10-H), 3.28 – 2.91 (m, 12 H, 1-H 3-H 4-H 7-H 8-H 13-Ha 15-Ha), 2.81 (dt, J1 = 13.3 Hz, 
J2 = 7.2 Hz, 1 H, 13-Hb), 2.63 (t, J = 7.6 Hz, 2 H, 11-H), 2.55 – 2.45 (m, 3 H, 15-Hb 17-H), 
2.40 – 2.25 (m, 2 H, 21-H), 2.18- 2.00 (m, 6 H, 2-H 9-H 12-H), 1.89 (s, 3 H, 24-H), 1.85 – 
1.70 (m, 4 H, 5-H 6-H); HRMS (ESI) [M + H]+ calc. 696.3861, found 696.3859.  
 
 
´Radical scavenger´-adduct 
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Entry 7: MS (MALDI pos.): 1583.16 [M + H]+; HRMS (ESI) [M + 2 H]2+ calc. 791.8509, 
found 791.8456. 
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6.6.4 Preparation of polyamino-nucleotides 
 
6.6.4.1 Synthesis of maleimido modified 2´,3 -´deoxycytidine  
 
N4-Acetyl-2´deoxy-O5´-di-p-methoxytrityl-O3´-phenoxythiocarbonyl cytidine (327) 
To a solution of 8.03 g of 311 (14.1 mmol) in 145 mL CH3CN was added 2.65 g of DMAP 
(27.8 mmol; 2.0 equiv.) and 2.3 mL O-phenyl chlorothionoformiate (17.0 mmol; 1.2 equiv.). 
The solution was stirred for 20 h and the solvent was evaporated. The residue was partitioned 
between 90 mL CHCl3 and 100 mL 5% aqueous NaHCO3 and the aqueous layer was 
extracted three times with 70 mL CHCl3. The organic phase was dried over Na2SO4 and the 
solvent was removed under reduced pressure at temperatures lower than 32 °C. The crude 
product purified by flash chromatography on silica gel (CHCl3 to CHCl3 : MeOH (10 : 1)). 
3.23 g (4.56 mmol) of a yellow foam were obtained, giving 32% yield. 
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Rf = 0.57 (CHCl3 : MeOH - 25 : 1); 1H NMR (400 MHz, CDCl3), d (ppm) 8.02 (d, 
J = 7.6 Hz, 1 H, 4-H), 6.78 – 7.43 (m, 19 H, (3-H 8-H to 14´´´-H) (19-H to 21-H)), 6.32 (dd, 
3J = 7.7 Hz, 3J = 5.9 Hz, 1 H, 1´-H), 5.86 (d, 3J = 6.0 Hz, 1 H, 3´-H), 4.51 (m, 1 H, 4´-H), 3.75 
(s, 6 H, 16-H 16´-H), 3.57 (dd, 2J = 10.8 Hz, 3J = 3.4 Hz, 1 H, 5´-Ha), 3.49 (dd, 2J = 10.8 Hz, 
3J = 2.6 Hz, 1 H, 5´-Hb), 3.07 (dd, 2J = 14.7 Hz, 3J = 5.9 Hz, 1 H, 2´-Ha), 2.42 (m, 1 H, 2´-H), 
2.23 (s, 3 H, 6-H); 13C NMR (100 MHz, CDCl3), d 194.31 (Cquart , C-17); 170.74 (Cquart , C-5); 
162.74 (Cquart,  C-2); 155.23 (Cquart,  C-1); 158.86, 158.74, 144.40, 135.22, 135.08, 130.17, 
130.14, 129.26, 128.21, 128.13, 127.97, 127.90, 127.31, 127.19, 126.94, 113.53, 113.51, 
113.29 (Cquart and +, 19 C, C-8 C-9 C-9´ C-10 C-10´ C-11 C-12 C-12´ C-13 C-13´ C-13´´ 
C-13´´´ C-14 C-14´ C-14´´ C-14´´´ C-15 C-15´ C-18); 153.42, 129.78, 129.68, 121.93, 115.56 
(Cquart and +, 5 C, C-19 C-19´ C-20 C-20´ C-21); 144.14 (1 C, C-4); 96.79 (+, C-3); 87.58 (+, 
C-4´); 87.40 (Cquart, C-7); 84.87 (+, C-1´); 84.07 (+, C-3´); 63.69 (–, C-5´); 55.39 (+, C-16 
C-16´); 39.64 (–, C-2´); 25.09 (+, C-6); MS (ESI): 554.24 [M – (Base + Ac)]+ (9), 676.32 
[M – OCH3]+ (100), 730.23 [M + Na]+ (35), 1437.46 [2 M + Na]+ (3). 
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N4-Acetyl-2´,3´-dideoxy-O5´-di-p-methoxytrityl-cytidine (328) 
A solution of 1.00 g of 327 (1.41 mmol) in 190 mL anhydrous toluene was heated to reflux 
and a mixture of 1.15 mL (4.24 mmol; 3 equiv.) of tributyltinhydride in 2 mL toluene and 
89 mg (542 µmol; 0.4 equiv.) of 2,2’-azobisisobutylnitrile in 8 mL toluene was added drop 
wise during 10 min. After heating to reflux for 40 min, the solution was cooled down to room 
temperature and the solvent was removed. The resulting residue was partitioned between 
30 mL of CHCl3 and 30 mL of 5% aqueous NaHCO3. The aqueous phase was extracted three 
times with 30 mL CHCl3 and the organic phase was dried over Na2SO4. The solvent was 
removed and the supernatant liquid tinorganyles were removed from the precipitates by 
decantation. The remaining solid was purified by flash chromatography on silica gel (CHCl3 
to CHCl3 : MeOH (15 : 1)). 462 mg of a white foam were obtained, giving 59% yield. 
If both steps were carried out consecutively starting from 2.9 g of 311, the overall yield was 
46% over two steps. The intermediary thiocarbonate 327 was not purified by flash 
chromatography. However, the DMAP and the remains of 
O-phenyl chlorothionoformiate were removed by separating the crude product between 
solutions of dichloromethane and water. 
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Rf = 0.27 (CHCl3 : MeOH - 15 : 1); 1H NMR (400 MHz, CDCl3), d 9.59 (bs, 1 H, NH), 8.39 
(d, 3J = 7.5 Hz, 1 H, 4-H), 7.06 (d, 3J = 7.5 Hz, 1 H, 3-H), 6.75 – 7.37 (m, 13 H, (8-H to 
14´´´-H)), 6.02 (dd, 3J = 6.6 Hz, 3J = 1.6 Hz, 1 H, 1´-H), 4.21 (m, 1 H, 4´-H), 3.74 (s, 6 H, 
16-H 16´-H), 3.49 (dd, 2J = 11.0 Hz, 3J = 2.6 Hz, 1 H, 5´-Ha), 3.28 (dd, 2J = 11.0 Hz, 
3J = 3.9 Hz, 1 H, 5´-Hb), 2.43 (m, 1 H, 2´-Ha), 2.19 (s, 3 H, 6-H), 2.11 (m, 1 H, 2´-Hb), 1.87 
(m, 2 H, 3´-H); 13C NMR (100 MHz, CDCl3), d 170.83 (Cquart , C-5); 162.61 (Cquart , C-2); 
155.04 (Cquart, C-1); 158.79, 158.73, 144.47, 135.68, 135.53, 130.23, 130.19, 129.25, 128.27, 
128.12, 127.94, 127.89, 127.22, 127.16, 113.40, 113.26 (Cquart and +, 18 C, C-8 C-9 C-9  ´
C-10 C-10´ C-11 C-12 C-12´ C-13 C-13´ C-13´´ C-13´´´ C-14 C-14´ C-14´´ C-14´´´ C-15 
C-15´); 145.29 (+, C-4); 96.13 (+, C-3); 88.12 (+, C-1´); 86.91 (Cquart, C-7); 82.14 (+, C-4´); 
63.66 (–, C-5´); 55.37 (+, C-16 C-16´); 33.82 (–, C-2´); 24.99 (–, C-3´); 24.73 (+, C-6); MS 
(ESI): 425.17 [M – Base + Na]+ (24), 556.25 [M + H]+ (2), 578.21 [M + Na]+ (100), 1133.43 
[2 M + Na]+ (31). 
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2´,3´-Dideoxy-O5´-di-p-methoxytrityl-cytidine (329) 
A solution of 462 mg (832 µmol) 328 and 81 mg (582 µmol; 0.7 equiv.) of K2CO3 in 
10.4 mL MeOH was stirred for 18 h. The solvent was removed in vacuum and the resulting 
yellow foam was partitioned between CHCl3 and 5% aqueous NaHCO3. The aqueous layer 
was extracted three times with CHCl3 and the organic phase was dried over Na2SO4. After 
removal of the solvent, the crude product was purified by flash chromatography on silica gel 
(CHCl3 to CHCl3 : MeOH (1 : 1)). 830 mg of a white foam were obtained, giving 91% yield. 
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Rf = 0.36 (CHCl3 : MeOH - 15 : 1); 1H NMR (400 MHz, CDCl3), d 7.91 (bs, 1 H, NH), 7.57 
(d, 3J = 7.6 Hz, 1 H, 4-H), 6.64 – 7.34 (m, 13 H, (6-H to 12´´ -´H)), 6.09 (t, 3J = 6.1 Hz, 1 H, 
1´-H), 5.44 (d, 3J = 7.6 Hz, 1 H, 3-H), 4.36 (dt, 3J = 4.2 Hz, 3J = 5.6 Hz, 1 H, 3´-H), 3.93 (dt,  
3J = 4.2 Hz, 3J = 3.1 Hz, 1 H, 4´-H), 3.68 (s, 6 H, 14-H 14´-H), 3.28 (d, 3J = 3.1 Hz, 2 H, 
5´-H), 2.44 (ddd, 3J = 5.6 Hz, 3J = 6.1 Hz, 3J = 13.6 Hz, 1 H, 2´-Ha), 2.12 (ddd, 3J = 5.6 Hz, 
3J = 6.1 Hz, 3J = 13.6 Hz, 1 H, 2´-Hb); 13C NMR (100 MHz, CDCl3), d 165.78 (Cquart, C-2); 
158.70, 144.68, 135.80, 135.71 (Cquart, 5 C, C-13 C-13´ C-6 C-10 C-10´); 156.32 (Cquart, C-1); 
130.23, 128.30, 128.05, 127.09, 113.38 (+, 13 C, C-7 C-7´ C-8 C-8´ C-9 C-11 C-11´ C-11´´ 
C-11´´´ C-12 C-12´ C-12´´ C-12´´´); 141.28 (+, C-4); 94.68 (+, C-3); 86.79 (+, C-4´); 86.37 
(Cquart, C-5); 86.19 (+, C-1´); 71.52 (–, C-3´); 63.43 (–, C-5´); 55.47 (+, C-14 C-14´); 41.94 (–
, C-2´); MS (ESI): 530.2 [M + H]+ (100), 552.1 [M + Na]+ (100), 1059.6 [2 M + H]+ (24). 
 
 
2´,3´-Dideoxy-O5´-di-p-methoxytrityl-N4-(3-N-maleimidopropionyl)-amino-cytidine 
(330) 
To a solution of 213 mg of 3-N-maleimidopropionic acid (1.26 mmol; 1.7 equiv.) in 8 mL 
CH2Cl2 was added 170 mg (1.26 mmol; 1.7 equiv.) of HOBt, 15 mg (75 µmol; 0.2 equiv.) of 
DMAP, and 260 mg (1.13 mmol; 1.7 equiv.) of 1,3-dicyclohexylcarbodiimide. The solution 
was stirred for 30 min whereas the colour of the solution turns to pink. The suspension was 
filtrated and the filtrate was directly given into a solution of 380 mg (743 µmol; 1 equiv.) of 
329 and 17 µL (1.26 mmol; 1.7 equiv.) of Et3N in 12 mL CH2Cl2. The red solution was stirred 
for 90 min and was then washed with brine. The aqueous layer was extracted three times with 
CH2Cl2 and the combined organic layers were dried over Na2SO4. The solvent was removed 
and the remaining solid was purified by flash chromatography on silica gel 
(cyclohexane : EtOAc (3 : 1) to cyclohexane : EtOAc (1 : 1)). 335 mg of a white foam were 
obtained, giving 68% yield. 
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Rf = 0.13 (CHCl3 : MeOH - 20 : 1); 1H NMR (400 MHz, CDCl3), d 8.19 (d, 3J = 7.5 Hz, 
1 H, 4-H), 6.78 – 7.44 (m, 14 H, 3-H (11-H to 17´´´-H)), 6.69 (s, 2 H, 9-H 9´-H), 5.99 (t, 
3J = 5.8 Hz, 1 H, 1´-H), 4.44 (dt, 3J = 4.6 Hz, 3J = 5.1 Hz, 2 H, 3´-H), 4.11 (dt, J1 = 4.6 Hz, 
J2 = 3.6 Hz,1 H, 4´-H), 3.87 (t, 3J = 7.0 Hz, 2 H, 7-H), 3.79 (s, 6 H, 19-H 19´-H), 3.46 (dd, 
2J = 10.8 Hz, 3J = 3.6 Hz, 1 H, 5´-Ha), 3.37 (dd, 2J = 10.8 Hz, 3J = 3.6 Hz, 1 H, 5´-Hb), 2.77 
(m, 2 H, 6-H), 2.65 (ddd, 3J = 13.6, 3J = 5.8, 3J = 5.3, 1 H, 2´-Ha), 2.18 (dt, 3J = 13.6, 3J = 5.8, 
1 H, 2´-Hb); 13C NMR (100 MHz, CDCl3), d 162.49 (Cquart, C-2); 158.79, 144.39, 135.69, 
135.55 (Cquart, 5 C, C-18 C-18´ C-15 C-15´ C-11); 155.72 (Cquart ,  C-1); 130.18, 130.13, 
129.26, 128.26, 128.12, 127.20, 113.45 (+, 13 C, C-12 C-12´ C-13 C-13´ C-14 C-16 C-16´ 
C-16´´ C-16´´´ C-17 C-17´ C-17´´ C-17´´´); 144.74 (+, C-4); 134.39 (+, C-9 C-9´); 96.93 (+, 
C-3); 87.56 (+, C-4´); 87.00 (Cquart, C-10); 86.60 (+, C-1´); 71.07 (–, C-3´); 63.01 (–, C-5´); 
55.38 (+, C-19 C-19´); 42.12 (–,  C-2´); 35.77 (–,  C-7); 33.65 (–,  C-6); MS (ESI): 703.20 
[M + Na]+ (100), 1383.43 [2 M + Na]+ (24). 
 
 
2´,3´-Dideoxy- N4-(3-N-maleimidopropionyl)-cytidine (331) 
100 mg (152 µmol) of 330 were dissolved in 10 mL CH2Cl2 and during the addition of 0.1 
mL of TFA, the colour of the solution turns to red. Stirring was continued for 1 min and 4 mL 
of a 5% aqueous solution of NaHCO3 was added. The aqueous layer was six times extracted 
with CHCl3 and the solvent was removed in vacuum at temperature lower than 30 °C. The 
remaining foam was purified by flash chromatography on silica gel. (CHCl3 to 
CHCl3 : MeOH (10 : 1)) 42 mg of a white foam were obtained, giving 77% yield. Due to its 
instability the compound was only prepared in small amounts and quickly inserted into the 
next step. 
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Rf = 0.16 (CHCl3 : MeOH - 12 : 1); 1H NMR (400 MHz, CDCl3), d 8.47 (d, 3J = 7.4 Hz, 
1 H, 4-H), 7.33 (d, 3J = 7.4 Hz, 1 H, 3-H), 6.68 (s, 2 H, 9-H 9´-H), 6.03 (dd, 3J1 = 6.7 Hz,  
3J2 = 2.0 Hz, 1 H, 1´-H), 4.25 (ddt, 3J1 = 6.4 Hz, 3J2 = 6.4 Hz, 3J3 = 3.1 Hz, 1 H, 4´-H), 4.06 
(dd, J1 = 12.2 Hz, J2 = 3.1 Hz,1 H, 5´-Ha), 3.88 (t, 3J = 6.8 Hz, 2 H, 7-H), 3.77 (dd, 
2J = 12.2 Hz, 3J = 3.1 Hz, 1 H, 5´-Hb), 2.88 (t, J = 6.8 Hz, 2 H, 6-H), 2.56 – 2.44 (m, 1 H, 
2´-Ha), 2.23 – 2.15 (m, 1 H, 2´-Hb), 1.93 (dt, 3J = 6.4, 3J = 3.7, 1 H, 3´-H).  
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6.7 Solubility of spermine porphyrin 217 in aqueous media 
In order to probe whether unspecific aggregation occurs with the transporter, porphyrin 
solutions of different concentrations were studied both in freshly distilled methylene chloride 
(from calcium hydride) and in deionised water. The aqueous solution was prepared by 
dissolving 2.0 mg of construct 6 in 200 ± 10 µL 2-propanol and diluting it into 10 ml water. 
Short sonication yielded a transparent yellow-orange solution. 
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Figure 72 Absorption spectra in 2% (v / v) aqueous 2-propanol. Black trace was recorded in a 1 mm quartz 
cuvette, while the red traces present the same solution in a 1 cm quartz cuvette. The green and blue traces were 
obtained after approximately five time dilutions successively, respectively. Note that there are no changes in the 
blue shoulder of the Soret band or in the Q bands upon dilution indicating absence of aggregation. Absorption 
spectra were measured on a Cary 500 UV-NIR spectrometer at room temperature. 
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Figure 73 Stationary emission spectra in 2% (v / v) aqueous 2-propanol. The same solutions as in Figure 72 
were measured with the excitation wavelength fixed at the Soret maximum at 420 nm. Measurements were 
performed on a Cary Eclipse fluorimeter in a right angle geometry. Note that some concentration quenching 
occurs in the more concentrated solution (#2, red trace) in comparison to the more dilute solutions. 
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Figure 74 Comparison of the absorption spectrum of solution #2 from Figure 72 and the fluorescence excitation 
spectrum with emission monitored at 662 nm. Note that due to the absorption in the somewhat split Soret band, 
very little light passes through the sample to the detector. However in the Q band region, a perfect superposition 
of the absorption and fluorescence excitation spectrum is observed indicating a normal behaviour of the 
spermidine-porphyrin 217 in this solution. It was assumed that under physiological conditions and by using 
methanol instead of 2-propanol, a similar behaviour is encountered. 
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Figure 75 Absorption spectra in dry methylene chloride at three different concentrations. In the inset is 
presented the comparison between the absorption and the fluorescence excitation spectrum. As the emission was 
monitored at 652 n m, this explains the very intense last Q band. Note that apart from a slight blue shoulder of the 
Soret band, which also is less pronounced than in aqueous solution, there are no abnormal behaviours 
encountered.  
Experimental section 
 214
500 600 700 800
0
50
100
150
200
250
300
350
 Excitation @ 419 nm
 Excitation @ 519 nm
F
lu
or
es
ce
nc
e 
(a
.u
.)
Wavelength (nm)
 
Figure 76 Emission spectra in dry methylene chloride with the excitation wavelength set at the Soret and the Qx 
maxima, respectively. 
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6.8 Fluorescence microscopy 
6.8.1 Cell culture techniques for mammalian cells  
All procedures with mammalian cells are carried out under sterile conditions. 104 – 105 
HeLa (human cervix carcinoma) cells, COS-7 cells, human primary fibroblast were plated 
into each well of an 8-well Lab-Tek TM II chambered cover slide (Nalgene, Neerijse, 
Belgium) or 8-well slide from IBIDI, Germany, and cultured in 200 µl of Dulbecco’s 
modified Eagle’s medium, high glucose, (DMEM, Sigma Taufkirchen) supplemented with 
10% fetal calf serum (FCS, PAA), and 1 u / ml Penicillin / Streptomycin at 37 °C, 5% CO2.  
 
6.8.2 Treatment of adherent cells with fluorophore derivatives 
The spermine porphyrin 217 and the lipophilic NBD-derivatives were dissolved in methanol 
to yield a 20 mM / 10 mM stock solution and further diluted with 10% DMEM to yield the 
respective incubation media. To ensure equal incubation conditions, all dilutions contain 
equal amounts of methanol. The carboxyporphyrin 215 was dissolved in methanol to yield a 
stock solution of 18 µM and further diluted with 10% DMEM to yield the respective 
incubation media. The polar NBD- and rhodamine conjugates were dissolved in 50% EtOH in 
H2O to yield 1 mM stock solutions and were further diluted with 10% DMEM. 104 – 105 
HeLa (human cervix carcinoma) cells, HepG2 (human liver carcinoma) cells, COS-7 cells, 
and human primary fibroblast were plated into each well of an 8-well Lab-Tek TM II 
chambered cover slide (Nalge Nunc, Neerijse, Belgium) and cultured in 200 µl of Dulbecco’s 
modified Eagle’s medium, high glucose, (DMEM, Sigma Taufkirchen) supplemented with 
10% fetal calf serum (FCS, PAA), and 1% Penicillin / Streptomycin at 37 °C, 5% CO2. After 
the cells reach a confluency of about 80% the culture medium was removed and replaced by 
0.2 ml of the respective fluorophore supplemented media. Cellular uptake of all compounds, 
was measured by live cell imaging, since fixation would alter the intracellular distribution as 
described for other polycationic species.  
 
6.8.3 Fluorescence and confocal microscopy 
Cellular uptake of the conjugates was measured after incubation by live imaging using a 
fluorescence microscope (Zeiss Axiovert 35, filter: Bp 546 FT 580, LP 590). For confocal 
microscopy cellular uptake was visualized using a confocal microscope (Zeiss Axiovert 200) 
fitted with a Zeiss LSM 510 Laser Module (argon, 458 / 488 / 514 nm; HeNe, 543 / 633 nm). 
Images were collected with the AxioCam MRc and the images were visualized with the 
AxioVision 3.1 and the LSM imaging software as well as the LSM Image Browser software 
version 3.1.0.99. 
 
6.8.4 Fluorometric cellular uptake measurements 
HeLa cells were plated in black flat bottom 96 well plates at a density of 104 cells / well and 
incubated for 24 h at cell culture conditions. Eventually, the cells were treated with 0.5, 1, 5, 
and 10 µM of spermine porphyrin 217 and 5 µM of carboxy porphyrin 215 (final 
concentration in DMEM medium) and incubated for 4, 16, 24, and 48 h. After incubation, the 
medium was removed and the cells were washed with phosphate buffered saline (PBS). The 
Experimental section 
 216
cells were lysed with 100 µl of 1 * RIPA buffer (including Complete protease inhibitors, 
Roche, Mannheim) and the fluorescence was measured using a Thermo Scientific Varioskan 
plate reader at an excitation / emission wavelength of 420 / 650 nm. After the measurement, 
the protein concentration was quantified. 
 
6.8.5 Subcellular Localization 
For the intracellular localization of labelled conjugates, the cells were co- incubated with 
fluorescent probes (Molecular Probes, Karlsruhe) for different intracellular compartments: 
For endosomal / lysosomal labelling: 150 nM Lysotracker®Green DND 26 or 
Lysotracker®Red for 30 min, 4 h, and 24 h prior to examination; for mitochondria labelling: 
1 µM Mitotracker®Green FM for 1 h or 1 µM Mitotracker®Red FM for 30 min prior to 
examination; For Golgi apparatus: BSA complex of NBD-C6-ceramide (5 µM), For nucleus 
labelling: Hoechst 33342 (Invitrogen, Karlsruhe) according to the manufacturers manual.  
 
6.8.6 Colony-forming Assay 
The colony-forming assay was performed as it has been previously reported. After 
photo- irradiation or illumination of human primary fibroblasts, co-incubated with gram (-) 
and gram (+) bacteria 100 µl, aliquots were removed from the medium for the colony-forming 
assay, serially diluted, and streaked on agar plates as described in [416, 417]. The plates were 
incubated in the dark to avoid further photo- irradiation. Controls were bacteria treated with 
217 without illumination. The treatment with 1 µM of 217 and illumination for 15 min at 
650 nm revealed no colonies after 24 h. Likewise, 100 µl of fresh DMEM supplemented with 
10% fetal calf serum in absence of antibiotics were added to the cells to investigate the re-
growth of bacteria overnight. After 24 h – 72 h of co-incubation no re-growth of the bacteria 
could be observed, while the cells were proliferating.  
 
 
6.9 Toxicological assays 
6.9.1 Measurement of cell death rate after illumination at 650 – 660 nm 
HeLa (human cervix carcinoma) cells, COS-7 cells, and human primary fibroblast were 
plated into an 8-well Lab-Tek TM II chambered cover glass (104 – 105 cells / well) and 
incubated with 0,01, 0.1, 1, 5, 20, 50, 100 µM spermine porphyrin 217 and 5 µM 
carboxyporphyrin 215 in 200µl DMEM, high glucose, supplemented with 10% fetal calf 
serum (FCS, PAA), and 1% Penicillin / Streptomycin at 37 °C, 5% CO2 for 4 h and 24 h, 
respectively. Eventually, the cells were washed with PBS and the medium was replaced by 
DMEM, high glucose without phenol red (Sigma, Taufkirchen), supplemented with 10% fetal 
calf serum (FCS, PAA). To induce photodynamic destruction the cells were irradia ted with 
light of a 650 + / – 10 nm diode laser at a dose rate of 30 – 42 Mw / cm2 giving total fluency 
rate of 10 – 13 J / cm2. After exposure with light for 5 min, 10 min, 15 min, 30 min, 2 h, 4 h, 
respectively, the cells were stained with trypan blue and propidium iodide and visualized 
using a Zeiss Axiovert 35 (filter: Bp 546 FT 580, LP 590) microscope. Necrotic and dead 
cells were counted in comparison to intact cells.  
Experimental section 
 217
6.9.2 MTT-assay 
The dark toxicity was estimated indirectly by determination of the viability of the cells. 
HeLa cells and human primary fibroblasts were plated in a Greiner 96 well plate at a density 
of 3000 cells / well. The cells were incubated with increasing concentrations (1 – 100 µM) of 
the compounds at 37 °C and the viability was determined after 24, 48, and 72 h using the 
CellTiter96 viability test (Promega). It is performed by adding the premixed, Dye Solution to 
culture wells of a 96-well plate, containing various concentrations of test substance. During a 
4-hour incubation, living cells convert the MTT tetrazolium component of the Dye Solution 
into a formazan product. The Stop Solution is then added to the culture wells to solubilise the 
formazan product, and the absorbance at 570nm is recorded using a 96-well plate reader. The 
viability was measured by quantification of the absorbance at 570 nm using a Thermofisher 
Scientific Varioskan plate reader. The signal was normalized to 100% from untreated cells 
and 0% from lysed cells. 
 
6.9.3 Sulforhodamine B Test 
The test was executed in analogy to literature procedures.[411, 412] HT29 cells and A431 cells 
were plated in a 24 well plate at a density of 5000 HT29 cells / well or 12000 A431 cells / 
well, respectively. The cells were incubated with 213 and 229 in FKS-containing medium at 
37 °C and 5% CO2. A solution of 1% DMSO in FKS medium served as control experiment. 
After 72 h, 100 µl of 50% trichloracetic acid were added to stop the reaction. The cells were 
left for at least 1 h at 4 °C. All wells were washed four times with H2Obidest to remove cell 
rests and supernatant medium. The pates were dried and the cells were coloured by 30 min 
treatment with 250 µl of a 0.4% SRB solution. The cells were left under light exclusion for at 
least 30 min. The dye was removed from the cells with washings of H2Obidest and 1% acetic 
acid in H2O (two times each). After drying, the dye was dissolved in Tris (pH 10). The 
photometric measurement was carried out on a microplatereader Victor (3 / TM) Vat at 
570 nm wavelength. The absorption values were averaged and correlated to the median of the 
DMSO-control to give the T / C-value.  
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7 Abbreviations 
AA  amino acid 
Ac  acetyl 
ADDP 1,1'-(azodicarbonyl)dipiperidine 
ADP  adenosine diphosphate 
AIBN 2,2'-Azobis(isobutyronitrile) 
Ala  alanine 
AMD age-related macular degeneration 
AMPA 2-amino-3-(3-hydroxy-5-methyl-4-isooxazolyl)-propionic acid 
aq  aqueous 
ar  aromatic 
Arg  arginine 
ATP  adenosine triphosphate 
AzI  antizyme inhibitor 
BAL  Backbone Amide Linker 
Bn  benzyl 
Boc  tert-butyl oxycarbonyl 
BOP  (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 
BSA  N,O-bis(trimethylsilyl)acetamide 
Bu  butyl 
Bz  benzoyl 
c  cyclo 
Cbz  benzyloxycarbonyl 
Conc. concentrated 
COSY correlated spectroscopy 
COX  cyclooxygenase 
CPP  cell penetrating peptide 
Cy  cyclohexyl 
Cys  cysteine 
d  day 
DAPI 4',6-diamidino-2-phenylindole 
DBU  1,8-diazabicyclo[5.4.0]undec-7-ene 
DCC  N,N´-dicyclohexylcarbodiimid 
Dde  1-(4,4-Dimethyl-2,6-dioxacyclohex-1-yliden)ethyl 
DEAD Diethyl azodicarboxylate 
DFMO 2-difluoromethylornithine 
DIC  N,N´-diisopropylcarbodiimid 
DiPEA N,N-diisopropylethylamine 
DMAP N,N-dimethylamionopyridine 
DMBA N,N´-dimethylbarbituric acid  
DMF  N,N´-dimethylformamid 
DMSO dimethyl sulfoxide 
DMTr dimethoxytrityl 
DNA  deoxyribonucleic acid 
Dod  4,4´-dimethoxydityl 
ED50  50% effective dose 
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EDC  N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide 
eIF-5A eukaryotic translation initiation factor 
equiv. equivalents 
ESI  Electron Spray Ionisation 
Et  ethyl 
FACS Fluorescent-Activated Cell Sorting 
FAD  flavin adenine dinucleotide 
Fmoc 9H-fluoren-9-ylmethoxycarbonyl 
FMOP  4-formyl-3-methoxy-phenoxymethyl-polystyrol 
g  gram 
GABA g-aminobutyric acid 
GAD  glutamic acid decarboxylase 
Gln  glutamine 
Glu  glutamic acid 
Gly  glycine / glycyl 
h  hour  
HATU O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluroniumhexafluorophosphate 
HBTU O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 
HeLa Henrietta Lacks cells 
HepG2 human hepatocellular liver carcinoma cell line 
HIV  human immunodeficiency virus 
HOAc acetic acid 
HOAt 1-hydroxy-7-azabenzotriazole 
HOBt 1-hydroxybenzotriazole 
HODhbt  3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazin 
HPLC High Pressure (Performance) Liquid Chromatography 
HRMS High Resolution Mass Spectrometry 
HV  high vacuum 
Hz  Hertz 
IC50  50% inhibitory concentration 
IgluR ionotropic glutamate receptor 
LPS  lipopolysaccharide 
Lys  lysine 
m  meta 
M  molar 
MALDI Matrix-Associated Laser Desorption Ionisation 
Me  methyl 
Mesyl methylsulfonyl 
Met  methionine 
MGBG  methylglyoxal-bis(guanylhydrazone) 
MHz  megahertz 
min  minute 
Mmd  4-methoxydityl 
MMt  4-methoxytrityl 
MPS  N-maleimidopropionyl succinate 
MS  Mass Spectrometry 
MTT  3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
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n.d.  not determined 
NBDCl 7-nitro-1,2,3-benzoxadiazole-4-chloride 
NHS  N-hydroxysuccinimide 
NMDA N-methyl-D-aspartate 
NMP  N-methyl-pyrrollidone 
NMR Nuclear Magnetic Resonance 
Nosyl nitrophenylsulfonyl 
NPhTX nephilatoxin 
o  ortho 
ODC  ornithine decarboxylase 
PA  polyamine 
PAO  polyamine oxidase 
p  para 
PAMAM polyamidoamine dendrimers 
PAO  polyamine oxidase 
Paraquat  N,N´-dimethyl-4,4´-bipyridylium 
PDT  photodynamic therapy 
PEG  polyethylene glycole 
Pfp  pentafluorophenyl 
ph  phenylene 
Ph  phenyl 
Phe   phenylalanine 
Pht  phthaloyl 
PhTX philanthotoxin 
PLP  pyridoxal phosphate 
Pro  proline 
Prp  propyl 
PTD  protein transduction domain 
PTS  polyamine transport system 
PyBOP (benzotriazo l-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate 
PyBrOP bromotripyrrolidinophosphonium hexafluorophosphate 
Put  putrescine 
RNA  ribonucleic acid 
RP  Reversed Phase 
SD  standard deviation 
Spd  spermidine 
Spm  spermine 
SPOS Solid Phase Organic Synthesis 
SPPS Solid Phase Peptide Synthesis 
SPS  Solid Phase Synthesis 
Succ  succinimide 
TAT   transactivator of transcription 
TBP  tributyl phosphine 
TBAF tetrabutylammonium fluoride 
TEAA triethylammonium acetate 
Teoc  2-(trimethylsilyl)ethyl-oxycarbonyl 
Tfa  trifluoroacetyl 
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TFA  trifluoroacetic acid 
TFMSA trifluoromethylsulfonic acid 
THF  tetrahydrofuran 
TIS  triisopropyl silane 
TLC  Thin Layer Chromatography 
TMOF trimethyl orthoformiate 
TmsCl trimethylsilyl chloride 
Tox  toxicology 
Trp  tryptophane 
Trt  trityl 
Ts / Tosyl (4-methyl)-phenylsulfonyl 
Tyr  tyrosine / tyrosyl 
UV  ultraviolet 
Val  valine 
VLC  Vacuum Layer Chromatography 
Z  benzyloxycarbonyl 
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